<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML>
<HEAD>
<!-- Created by: EDGAR Online, Inc. EDGAR Filing HTML Converter, Version: 4.63, http://www.edgar-online.com -->
<TITLE> SIGNAL GENETICS, INC. (Form: 10-K, Received: 03/21/2016 16:41:22) </TITLE>
<META NAME="TABLES" CONTENT="FIS_FORM **FIS_PART_I **FIS_BUSINESS **FIS_RISK_FACTORS **FIS_UNRESOLVED_STAFF_COMMENTS **FIS_PROPERTIES **FIS_LEGAL_PROCEEDINGS **FIS_MINE_SAFETY_DISCLOSURE **FIS_PART_II **FIS_MARKET **FIS_FINANCIAL_DATA **FIS_MANAGEMENTS_DISCUSSION **FIS_RESULTS_OF_OPERATIONS **FIS_LIQUIDITY_CAPITAL **FIS_MARKET_RISK **FIS_FINANCIAL_STATEMENTS **FIS_ACCOUNTING_CHANGES **FIS_CONTROL_AND_PROCEDURES **FIS_OTHER_INFORMATION **FIS_PART_III **FIS_DIRECTORS_AND_OFFICERS **FIS_NAME_AND_TITLE **FIS_COMPENSATION **FIS_COMPENSATION_TABLE **FIS_SECURITY_OWNERS **FIS_BENEFICIAL_OWNERS **FIS_OFFICER_TRANSACTIONS **FIS_ACCOUNTANT_FEES **FIS_PART_IV **FIS_EXHIBITS **FIS_SIGNATURES **FIS_AUDITORS_OPINION **FIS_BALANCE_SHEET **FIS_INCOME_STATEMENT **FIS_STOCKHOLDERS_EQUITY **FIS_CASH_FLOW **FIS_NOTES_TO_FINANCIAL_STATEMENT FIS_EXHIBIT_10 FIS_EXHIBIT_23 **FIS_EXPERTS_CONSENT FIS_EXHIBIT_31 **FIS_CERTIFICATION FIS_EXHIBIT_31_2 **FIS_CERTIFICATION_2 FIS_EXHIBIT_32 **FIS_CERTIFICATION_3 ">
<META NAME="DETECTED PAGES" CONTENT="103">
<STYLE TYPE="text/css">
<!--
	body          { background-color: white; color: black }
	.eolNewPage   { page-break-after: always; line-height: 0; height: 0; margin: 0; padding: 0 }
	.eolLeftAlign { text-align: left; margin-left: auto; margin-right: auto }
	.eolCenter    { text-align: center }
	a:link        { color: blue }
	a:active      { color: red }
	a:visited     { color: purple }
	
	@media print
	{
		@page           { margin: 0.25in }
		body            { font-size: 10pt }
		a               { text-decoration: none }
		thead           { display: table-header-group }
		tfoot           { display: table-footer-group }
		hr.eolPageBreak { display: none }
		.eolPrint50pt   { font-size: 5pt }
		.eolPrint55pt   { font-size: 5.5pt }
		.eolPrint60pt   { font-size: 6pt }
		.eolPrint65pt   { font-size: 6.5pt }
		.eolPrint70pt   { font-size: 7pt }
		.eolPrint75pt   { font-size: 7.5pt }
		.eolPrint80pt   { font-size: 8pt }
		.eolPrint85pt   { font-size: 8.5pt }
		.eolPrint90pt   { font-size: 9pt }
		.eolPrint95pt   { font-size: 9.5pt }
	}
-->
</STYLE>
</HEAD>
<BODY>
<A NAME="eolPage1"></A>
<A NAME="FIS_TOP_OF_DOCUMENT"></A>

<A NAME="F10K_032116P_HTM"></A>
<EFX_FORM>
<A NAME="FIS_FORM"></A>
<P STYLE="MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 18PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	UNITED STATES
</B>
</P>
<P STYLE="FONT-SIZE: 18PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	SECURITIES AND EXCHANGE COMMISSION
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	WASHINGTON, D.C. 20549
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 18PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0 0PT 4.4PT">
<B>
	FORM 10-K
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 4.4PT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 4.4PT; TEXT-INDENT: 0.5IN">
<B>
	(Mark One)
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT; WIDTH: 5%">
<FONT STYLE="FONT-FAMILY: WINGDINGS; FONT-SIZE: 12PT">
	x
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; WIDTH: 95%">
<FONT STYLE="FONT-SIZE: 12PT">
<B>
	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
	EXCHANGE ACT OF 1934
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-LEFT: 10PT">
<B>
	For the fiscal year ended December&nbsp;31, 2015
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 26.65PT; MARGIN: 0PT 0 0PT 10.1PT">
<B>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<B>
	OR
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT; WIDTH: 5%">
<FONT STYLE="FONT-FAMILY: WINGDINGS; FONT-SIZE: 12PT">
	o
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; WIDTH: 95%">
<FONT STYLE="FONT-SIZE: 12PT">
<B>
	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
	EXCHANGE ACT OF 1934
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-LEFT: 10PT">
<B>
	For the transition period from &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
	&nbsp;&nbsp; to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 26.4PT; MARGIN: 0PT 0 0PT 9.9PT">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0 0PT 9.9PT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<B>
	Commission File Number: 001-36483
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0 0PT 242PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE"></A>
<P STYLE="FONT-SIZE: 24PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0 0PT 4.4PT">
<B>
	SIGNAL GENETICS, INC.
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	(Exact name of registrant as specified in its charter)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="FONT-SIZE: 10PT; WIDTH: 70%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: CENTER; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Delaware
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: CENTER; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	47-1187261
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 1.1PT 0PT 3.3PT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	(State or
	other jurisdiction of
</B>
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 1.1PT 0PT 3.3PT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	incorporation
	or organization)
</B>
</FONT>
</P>
</TD>
<TD>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 1.1PT 0PT 3.3PT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	(I.R.S. Employer
</B>
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 1.1PT 0PT 3.3PT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	Identification
	Number)
</B>
</FONT>
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: CENTER; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	5740 Fleet Street, Carlsbad, California
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 50%; TEXT-ALIGN: CENTER; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	92008
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	(Address of principal executive offices)
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	(Zip Code)
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0 0PT 9.9PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0 0PT 9.9PT">
<B>
	Registrant's telephone number, including area code:
	(760) 537-4100
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0 0PT 3.3PT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0 0PT 3.3PT">
<B>
	Securities registered pursuant to Section&nbsp;12(b)
	of the Act:
</B>
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 50%; TEXT-DECORATION: UNDERLINE; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<U>
	Title of each class
</U>
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 50%; TEXT-DECORATION: UNDERLINE; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
<U>
	Name of each exchange on which registered
</U>
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Common Stock, $0.01 par value
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER; FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	The NASDAQ Capital Market
</B>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0 0PT 3.3PT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0 0PT 3.3PT">
<B>
	Securities registered pursuant to Section&nbsp;12(g)
	of the Act: None
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0 0PT 242PT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 19.8PT; MARGIN: 0PT 0 6PT 3.3PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Indicate by check mark if
	the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	o
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 19.8PT; MARGIN: 0PT 0 6PT 3.3PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Indicate by check mark if
	the registrant is not required to file reports pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	o
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 19.8PT; MARGIN: 0PT 0 6PT 3.3PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Indicate by check mark whether
	the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act
	of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and
	(2)&nbsp;has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
	&nbsp;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	o
</FONT>
	&nbsp;&nbsp;No
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 19.8PT; MARGIN: 0PT 0 6PT 3.3PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Indicate by check mark whether
	the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required
	to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months
	(or for such shorter period that the registrant was required to submit and post such files).&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
	&nbsp;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	o
</FONT>
	&nbsp;&nbsp;No
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 19.8PT; MARGIN: 0PT 0 0PT 3.3PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Indicate by check mark if
	disclosure of delinquent filers pursuant to Item&nbsp;405 of Regulation S-K is not contained herein, and will not be contained,
	to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of
	this Form&nbsp;10-K or any amendment to this Form 10-K.&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1.1PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage2"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 19.8PT; MARGIN: 0PT 0 6PT 3.3PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Indicate by check mark whether
	the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See
	definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221;
	in Rule 12b-2 of the Exchange Act.
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="WIDTH: 15%">
<FONT STYLE="FONT-SIZE: 8PT">
	Large&nbsp;accelerated&nbsp;filer
</FONT>
</TD>
<TD STYLE="WIDTH: 50%">
<FONT STYLE="FONT-FAMILY: WINGDINGS; FONT-SIZE: 8PT">
	o
</FONT>
</TD>
<TD STYLE="WIDTH: 25%">
<FONT STYLE="FONT-SIZE: 8PT">
	Accelerated&nbsp;filer
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: WINGDINGS; FONT-SIZE: 8PT">
	o
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	Non-accelerated filer
</FONT>
</TD>
<TD NOWRAP>
<FONT STYLE="FONT-FAMILY: WINGDINGS; FONT-SIZE: 8PT">
	o
</FONT>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;&nbsp;(Do not check if
	a smaller reporting company)
</FONT>
</TD>
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 8PT">
	Smaller&nbsp;reporting&nbsp;company&nbsp;filer
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: WINGDINGS; FONT-SIZE: 8PT">
	x
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 19.8PT; MARGIN: 6PT 0 6PT 3.3PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Indicate by check mark whether
	the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	o
</FONT>
	&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;
<FONT STYLE="FONT-FAMILY: WINGDINGS">
	x
</FONT>
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 19.8PT; MARGIN: 0PT 0 6PT 3.3PT">
<FONT STYLE="FONT-SIZE: 8PT">
	The aggregate market value
	of the voting stock held by non-affiliates of the registrant, based upon the closing sale price of the Common Stock on June&nbsp;30,
	2015 as reported on The NASDAQ Capital Market, was $11.6 million. Shares of Common Stock held by each executive officer and director
	and by each person who owns 10% or more of the outstanding Common Stock have been excluded in that such persons may be deemed
	to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes.
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 19.8PT; MARGIN: 0PT 0 0PT 3.3PT">
<FONT STYLE="FONT-SIZE: 8PT">
	As of March 15, 2016, there
	were 10,709,080 shares of the registrant's Common Stock outstanding.
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 19.8PT; MARGIN: 0PT 0 0PT 3.3PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0 0PT 6.6PT">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	DOCUMENTS INCORPORATED
	BY REFERENCE
</B>
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 19.8PT; MARGIN: 0PT 0 0PT 3.3PT">
<FONT STYLE="FONT-SIZE: 8PT">
	None.
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 100%; BORDER-BOTTOM: BLACK 2.25PT DOUBLE">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage3"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	SIGNAL GENETICS, INC.
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	INDEX
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT">
<B>
</B>
</P>
<TABLE BORDER="0" CELLPADDING="3" CELLSPACING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 82%">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1.1PT SOLID; TEXT-ALIGN: CENTER; WIDTH: 8%">
<FONT STYLE="FONT-SIZE: 8PT">
	Page&nbsp;No.&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	PART I
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F10K_032116P_HTM_A_001">
	ITEM 1.
</A>
</TD>
<TD>
<A HREF="#F10K_032116P_HTM_A_001">
	BUSINESS
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<A HREF="#F10K_032116P_HTM_A_001">
	1
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F10K_032116P_HTM_A_002">
	ITEM 1A.
</A>
</TD>
<TD>
<A HREF="#F10K_032116P_HTM_A_002">
	RISK FACTORS
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<A HREF="#F10K_032116P_HTM_A_002">
	14
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F10K_032116P_HTM_A_003">
	ITEM 1B.
</A>
</TD>
<TD>
<A HREF="#F10K_032116P_HTM_A_003">
	UNRESOLVED STAFF COMMENTS
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<A HREF="#F10K_032116P_HTM_A_003">
	38
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F10K_032116P_HTM_A_004">
	ITEM 2.
</A>
</TD>
<TD>
<A HREF="#F10K_032116P_HTM_A_004">
	PROPERTIES
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<A HREF="#F10K_032116P_HTM_A_004">
	38
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F10K_032116P_HTM_A_005">
	ITEM 3.
</A>
</TD>
<TD>
<A HREF="#F10K_032116P_HTM_A_005">
	LEGAL PROCEEDINGS
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<A HREF="#F10K_032116P_HTM_A_005">
	38
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F10K_032116P_HTM_A_006">
	ITEM 4.
</A>
</TD>
<TD>
<A HREF="#F10K_032116P_HTM_A_006">
	MINE SAFETY DISCLOSURES
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<A HREF="#F10K_032116P_HTM_A_006">
	38
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	PART II
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F10K_032116P_HTM_A_007">
	ITEM 5.
</A>
</TD>
<TD>
<A HREF="#F10K_032116P_HTM_A_007">
	MARKET FOR REGISTRANT'S COMMON EQUTY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<A HREF="#F10K_032116P_HTM_A_007">
	39
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F10K_032116P_HTM_A_008">
	ITEM 6.
</A>
</TD>
<TD>
<A HREF="#F10K_032116P_HTM_A_008">
	SELECTED FINANCIAL DATA
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<A HREF="#F10K_032116P_HTM_A_008">
	40
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F10K_032116P_HTM_A_010">
	ITEM 7.
</A>
</TD>
<TD>
<A HREF="#F10K_032116P_HTM_A_010">
	MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<A HREF="#F10K_032116P_HTM_A_010">
	41
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F10K_032116P_HTM_A_011">
	ITEM 7A.
</A>
</TD>
<TD>
<A HREF="#F10K_032116P_HTM_A_011">
	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<A HREF="#F10K_032116P_HTM_A_011">
	48
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F10K_032116P_HTM_A_012">
	ITEM 8.
</A>
</TD>
<TD>
<A HREF="#F10K_032116P_HTM_A_012">
	FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<A HREF="#F10K_032116P_HTM_A_012">
	48
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F10K_032116P_HTM_A_013">
	ITEM 9.
</A>
</TD>
<TD>
<A HREF="#F10K_032116P_HTM_A_013">
	CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<A HREF="#F10K_032116P_HTM_A_013">
	48
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F10K_032116P_HTM_A_014">
	ITEM 9A.
</A>
</TD>
<TD>
<A HREF="#F10K_032116P_HTM_A_014">
	CONTROLS AND PROCEDURES
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<A HREF="#F10K_032116P_HTM_A_014">
	49
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F10K_032116P_HTM_A_015">
	ITEM 9B.
</A>
</TD>
<TD>
<A HREF="#F10K_032116P_HTM_A_015">
	OTHER INFORMATION
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<A HREF="#F10K_032116P_HTM_A_015">
	49
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	PARTIII
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F10K_032116P_HTM_A_016">
	ITEM 10.
</A>
</TD>
<TD>
<A HREF="#F10K_032116P_HTM_A_016">
	DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<A HREF="#F10K_032116P_HTM_A_016">
	50
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F10K_032116P_HTM_A_017">
	ITEM 11.
</A>
</TD>
<TD>
<A HREF="#F10K_032116P_HTM_A_017">
	EXECUTIVE COMPENSATION
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<A HREF="#F10K_032116P_HTM_A_017">
	55
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F10K_032116P_HTM_A_018">
	ITEM 12.
</A>
</TD>
<TD>
<A HREF="#F10K_032116P_HTM_A_018">
	SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<A HREF="#F10K_032116P_HTM_A_018">
	63
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F10K_032116P_HTM_A_019">
	ITEM 13.
</A>
</TD>
<TD>
<A HREF="#F10K_032116P_HTM_A_019">
	CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<A HREF="#F10K_032116P_HTM_A_019">
	64
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F10K_032116P_HTM_A_020">
	ITEM 14.
</A>
</TD>
<TD>
<A HREF="#F10K_032116P_HTM_A_020">
	PRINCIPAL ACCOUNTING FEES AND SERVICES
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<A HREF="#F10K_032116P_HTM_A_020">
	65
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
	PART IV
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: TOP">
<A HREF="#F10K_032116P_HTM_A_021">
	ITEM 15.
</A>
</TD>
<TD>
<A HREF="#F10K_032116P_HTM_A_021">
	EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<A HREF="#F10K_032116P_HTM_A_021">
	66
</A>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="2">
<A HREF="#F10K_032116P_HTM_A_022">
	SIGNATURES
</A>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<A HREF="#F10K_032116P_HTM_A_022">
	69
</A>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT">
<B>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 3 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage4"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	FORWARD-LOOKING STATEMENTS
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	All statements included in this Annual Report on Form 10-K (this
	&#8220;Annual Report&#8221;) that are not historical are forward-looking statements within the meaning of Section 21E of the Securities
	Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). These forward-looking statements can generally be identified
	as such because the context of the statement will include words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;intend,&#8221;
	&#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221;
	&#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;opportunity,&#8221; &#8220;goals,&#8221; or &#8220;should,&#8221; the negative
	of these words or words of similar import. Similarly, statements that describe our future plans, strategies, intentions, expectations,
	objectives, goals, or prospects are also forward-looking statements. These forward-looking statements are or will be, as applicable,
	based largely on our expectations and projections about future events and future trends affecting our business, and so are or will
	be, as applicable, subject to risks and uncertainties including but not limited to the risk factors discussed in this report, that
	could cause actual results to differ materially from those anticipated in the forward-looking statements. We caution investors
	that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested
	in such forward-looking statements. The forward-looking statements included in this Annual Report speak only as of the date of
	this Annual Report. Our views and the events, conditions and circumstances on which these future forward-looking statements are
	based, may change. We do not assume any obligation to update or revise any forward-looking statements, whether as a result of new
	information, future events or developments, or otherwise, except as may be required by the securities laws, and we caution you
	not to rely on them unduly. All forward-looking statements are qualified in their entirety by this cautionary statement.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_PART_I>
<A NAME="FIS_PART_I"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	PART I
</B>
</P>
<EFX_BUSINESS>
<A NAME="FIS_BUSINESS"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<A NAME="F10K_032116P_HTM_A_001">
</A>
	Item 1. Business
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We were founded in New York as a Delaware limited liability company
	in January 2010 under the name Myeloma Health LLC. Signal Genetics LLC was formed as a Delaware limited liability company in December
	2010. Effective January 1, 2011, substantially all of the member interests in Myeloma Health LLC were exchanged for member interests
	in Signal Genetics LLC and Myeloma Health LLC became a subsidiary of the Company. Immediately prior to the pricing of our initial
	public offering, on June 17, 2014, Signal Genetics LLC converted from a Delaware limited liability company to a Delaware corporation
	(the &#8220;Corporate Conversion&#8221;). In connection with the Corporate Conversion, each unit of Signal Genetics LLC was converted
	into a share of common stock of Signal Genetics, Inc., the members of Signal Genetics LLC became stockholders of Signal Genetics,
	Inc. and Signal Genetics, Inc. succeeded to the business of Signal Genetics LLC and its consolidated subsidiaries. As used in this
	report, the words &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; the &#8220;Company,&#8221; and &#8220;Signal Genetics&#8221;
	refer to Signal Genetics, Inc. and its wholly-owned subsidiaries.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Overview
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We are a commercial stage, molecular genetic diagnostic company
	focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of
	their patients suffering from cancer. Our mission is to develop, validate and deliver innovative diagnostic services that enable
	better patient-care decisions. The patient-care decisions we impact include the field of personalized medicine, wherein diagnostic
	tests guide treatment decisions with genetically-targeted therapies as well as traditional chemotherapy regimens. We hold an exclusive
	license in our licensed field to the intellectual property stemming from the renowned research on multiple myeloma (&#8220;MM&#8221;),
	performed at the University of Arkansas for Medical Sciences (&#8220;UAMS&#8221;).
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	MM is a hematologic, or blood, cancer that develops in the bone
	marrow and specifically affects the plasma cells of the bone marrow. Normal plasma cells produce immunoglobulins, otherwise known
	as antibodies, which help the body fight infection and disease. In MM, the normal plasma cells become malignant and inhibit the
	production of normal blood cells and antibodies, including red blood cells, white blood cells and blood platelets, and crowd the
	bone marrow with malignant plasma cells, which produce an abnormal antibody called a monoclonal protein (&#8220;M protein&#8221;).
	The hallmark characteristic of MM is a high level of M protein in the blood. MM can also cause soft spots in the bone known as
	osteolytic lesions. MM is the second most common blood cancer after non-Hodgkin&#8217;s lymphoma (&#8220;NHL&#8221;) and represents
	approximately 15% of all hematomalignancies. According to the American Cancer Society and the National Cancer Institute, approximately
	26,850 new cases of MM were expected to be diagnosed in the United States in 2015 and approximately 11,240 deaths from MM were
	expected to occur in the United States in 2015. More Americans were expected to die from MM in 2015 than from any other blood cancer.
	Although a relatively rare disease, MM is responsible for 2% of all cancer deaths in the United States each year and will kill
	more Americans than melanoma, the deadliest form of skin cancer. There are an estimated 89,658 people currently living with MM
	in the United States. The five-year survival rate for people with MM is about 47%. The American Cancer Society estimates that the
	lifetime risk in the United States of getting MM is 1 in 143.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 4; OPTIONS: NEWSECTION; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	1
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage5"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	To date, there are no known causes of MM. The most significant risk
	factor for developing MM is age. According to Nature: International Weekly Journal of Science&#8217;s supplement on MM published
	on December 15, 2011 in volume 480, page S-33 through S-80, or Nature&#8217;s MM supplement, 96% of MM cases are diagnosed in people
	older than 45 years of age, and more than 63% are diagnosed in people older than 65 years of age. There are usually no early stage
	symptoms of MM and a suspicion of a MM diagnosis is often made incidentally through routine blood tests which reveal low numbers
	of red blood cells and high levels of protein. Once diagnosed, MM is classified into one of three categories in a process known
	as staging. Staging is the process of determining how widespread or advanced the cancer is. Under the International Staging System
	(&#8220;ISS&#8221;), MM is classified into three stages based upon the presence of serum beta-2 microglobulin and serum albumin,
	which are blood proteins that are measured through a blood test. Staging is the key factor in a physician&#8217;s choice of treatment
	for a patient and that patient&#8217;s outlook or prognosis, often framed as progression free survival (&#8220;PFS&#8221;) or overall
	survival (&#8220;OS&#8221;). Prognosis is typically based on the existence of different signs, symptoms and circumstances. Certain
	laboratory and clinical findings, or prognostic indicators, provide important information for MM, including when treatment should
	begin and what treatments to use, based upon a patient&#8217;s individual prognosis and risk for relapse. However, the experts
	caring for MM patients have been burdened by a staging system that predates and thus fails to capture the rich body of new genomic
	information that has been shown to assist in the staging process. Similar genetic information has proven transformational in a
	number of solid tumor types, including breast, colon and lung cancer. In each case, specific genetic determinants enable doctors
	to identify patients who are likely to respond to genetically targeted therapies, resulting in better outcomes for these patients,
	including a higher rate of survival. According to the National Cancer Institute, these benefits have not yet been recognized in
	MM treatment. The traditional approach in MM treatment which utilizes cytogenetic techniques, such as karyotyping and fluorescent
	in-situ hybridization (&#8220;FISH&#8221;), for staging may not accurately stage MM patients or accurately assess the risk of relapse.
	Perhaps the greatest shortcoming of the current staging system for MM is its inability to classify MM patients into high and low
	risk prognosis groups. A tool that can further define risk-stratification by classifying MM patients in this manner would better
	inform physicians when to treat and what drugs to treat patients with, potentially improving health outcomes in MM patients. We
	believe a more comprehensive, systematic approach utilizing current genetic technologies is necessary to meet this unmet medical
	need.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Our flagship diagnostic service is the Myeloma Prognostic Risk Signature,
	or MyPRS
<SUP>
	&#174;
</SUP>
	test. The MyPRS
<SUP>
	&#174;
</SUP>
	test is a microarray-based gene expression profile (&#8220;GEP&#8221;),
	assay that measures the expression level of specific genes and groups of genes that are designed to predict an individual&#8217;s
	long-term clinical outcome/prognosis, giving a basis for personalized treatment options and helping physicians classify MM patients
	into either high or low risk groups. The MyPRS
<SUP>
	&#174;
</SUP>
	test provides a whole-genomic expression profile of a patient&#8217;s
	MM. The GEP is a genetic fingerprint of a cancer, with each cancer being unique, just as each fingerprint is unique. Many recent
	studies show that the GEP of cancerous tumors makes personalized treatment possible, and our MyPRS
<SUP>
	&#174;
</SUP>
	test is the
	first genetic test to be developed specifically for MM according to the 2007 John Shaughnessy paper in the journal Blood (A validated
	gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Mar
	15;109(6):2276-84. Epub 2006 Nov 14). MyPRS
<SUP>
	&#174;
</SUP>
	is designed to be used at the time of initial MM diagnosis and also
	when the patient has experienced a relapse as an aid to physicians in selecting the optimal treatment regimen for each patient&#8217;s
	unique condition. Specifically, the test helps allow:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<UL STYLE="MARGIN-TOP: 0IN; LIST-STYLE-TYPE: DISC">
<LI STYLE="MARGIN: 0PT 0; FONT-SIZE: 10PT">
	risk stratification to help distinguish patients with indolent MM that may not need
	treatment from those patients with aggressive MM that requires more aggressive treatment; and
</LI>
<LI STYLE="MARGIN: 5PT 0; FONT-SIZE: 10PT">
	identification of important genomic alterations that allow for MM sub-classification
	that may affect the therapy selection, and potentially enable a personalized medicine approach.
</LI>
</UL>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Our Services
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We offer our MyPRS
<SUP>
	&#174;
</SUP>
	test in our approximately 2,800
	square foot state-of-the-art laboratory located in Little Rock, Arkansas, which is certified under the Clinical Laboratory Improvement
	Amendments of 1988 (&#8220;CLIA&#8221;) and accredited by the College of American Pathologists (&#8220;CAP&#8221;), to perform
	high complexity testing. We are licensed to sell our test in all 50 states. We are dedicated to making our extensively validated
	diagnostic services available to all patients who need them.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	In addition, we are exploring, and peer-review studies are being
	conducted on, the use of our MyPRS
<SUP>
	&#174;
</SUP>
	test as an indicator of progression to MM in patients with either smoldering
	multiple myeloma (&#8220;SMM&#8221;), or monoclonal gammopathies of unknown significance (&#8220;MGUS&#8221;), the precursor conditions
	to MM. There is, however, currently no projected timeline for our use of MyPRS
<SUP>
	&#174;
</SUP>
	in these patients. For a discussion
	of MyPRS
<SUP>
	&#174;
</SUP>
	in these patients see &#8220;&#8212; Market Opportunities,&#8221; below.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Over the next 12 to 18 months, we intend to expand our test menu
	by adding tests that are used to help manage MM patients. There is a broad array of molecular and cytogenetic testing modalities
	that are utilized in the management of patients with MM, such as conventional cytogenetics, FISH, molecular tests, M protein serum
	test and flow cytometry (especially in the context of minimum residual disease testing for MM therapy response). During 2015, we
	launched both RNA sequencing and next generation DNA sequencing services for research use only to assist our research collaborators,
	including pharmaceutical companies, in further characterizing their MM patients enrolled in clinical trials.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Market Opportunities
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Over the past several decades, improved awareness and diagnostic
	testing technologies have led to an increase in the early diagnosis of cancer. Although the goals of these efforts were to decrease
	cancer mortality, national data demonstrate significant increases in early-stage disease, without a proportional decline in later-stage
	disease. What has emerged amongst clinicians and researchers has been an appreciation of the complexity of cancer. Cancers are
	heterogeneous and do not follow a uniform course. In some cases, cancer can lead to severe disease and death, while in other cases
	it is indolent. Unfortunately, identifying those patients who will likely succumb to non-cancer related causes, or comorbidities,
	is difficult.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 5; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage6"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Before 1990, treatment of MM was limited to the use of melphalan
	(a chemotherapeutic agent) and prednisone (a steroid), which were of marginal effectiveness. In 1986, high dose dexamethasone (a
	corticosteroid), which is used to induce plasma cell lysis, was introduced and in the early 1990s, induction therapy with vincristine,
	doxorubicin (a chemotherapeutic agent) and dexamethasone, followed by stem cell transplant after high dose melphalan was introduced
	and resulted in longer term remissions but patients always relapsed. Then, in 1999, thalidomide was added to existing regimens
	for MM. The first clinicians to attempt the use of thalidomide in the treatment of MM were at the UAMS. The initial use of thalidomide
	ultimately led to the development of Revlimid
<SUP>
	&#174;
</SUP>
	, Celgene&#8217;s blockbuster drug that is now part of most front-line
	therapies for the treatment of MM. In 2006, Velcade
<SUP>
	&#174;
</SUP>
	was approved and added to existing regimens. Thalomid
<SUP>
	&#174;
</SUP>
	,
	Revlimid
<SUP>
	&#174;
</SUP>
	and Velcade
<SUP>
	&#174;
</SUP>
	are now considered cornerstones of therapy in addition to stem cell transplant
	after bone marrow ablation.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Although new treatments for patients with MM have become available
	over the last 10 years, we do not believe that these treatments have provided any significant benefits in overall survival &#8212;
	especially in the high risk patient population. In part, this is because MM is a disease with significant tumor heterogeneity at
	the genetic level. Specialists in MM have long recognized the need for diagnostic tests that accurately identify the mutations
	and overarching genotype of each patient to inform risk stratification, prognosis and choice of therapy. Because it is impossible
	to use classic staging modalities such as clinical factors and cell morphology (the microscopic review of tumor material by a pathologist)
	to classify MM, physicians use plasma cell labeling indices, chemical markers, imaging studies and genetic abnormalities at the
	chromosomal level (e.g., cytogenetics) to better predict prognosis. Unfortunately, these tests provide limited information as to
	a particular MM patient&#8217;s prognosis and response to treatment. With the use of MyPRS
<SUP>
	&#174;
</SUP>
	GEP, it has become possible
	to go beyond morphological and chromosomal level analysis and identify the individual MM genomic profile of each individual patient.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Like many forms of cancer, MM can present as asymptomatic, even
	in advanced stages. MM begins as the precursor condition, MGUS. It is estimated that more than 3% of the population of the United
	States 50 years of age or older have MGUS. Characterized by an excess of particular immunoglobulins or M proteins in the serum
	or urine with less than 10% plasma cells in the bone marrow, MGUS is not itself harmful to health. But every year, 1% of MGUS patients
	will progress to MM.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Aside from the precursor condition, MGUS, MM exists on a spectrum
	from asymptomatic or SMM to full-blown MM. Collectively, these precursor conditions, MGUS and SMM, are referred to as AMG. Preventative
	treatment of every AMG patient is not a viable option. As noted in The Disperenzieri paper (Blood October 2013), along with the
	prohibitive expense, many doctors worry that they could do more harm than good if they treat otherwise healthy people, the vast
	majority of whom will never develop MM. A 1988 clinical study discussed in Nature&#8217;s MM supplement, using the best treatments
	available at the time, concluded that treating patients even at the smoldering stage caused unnecessary side effects with no survival
	benefit.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The applicability of our test for use in predicting MM progression
	from AMG could create a substantial increase in the potential patient population eligible for MyPRS
<SUP>
	&#174;
</SUP>
	testing and
	as such represents an important pillar of our growth strategy. We estimate the total potential MM testing market in the United
	States at approximately 40,000 patients per year, including newly diagnosed and relapsed patients. We believe we currently service
	just over 3% of this market. We estimate that the addition of an AMG progression indication feature for the MyPRS
<SUP>
	&#174;
</SUP>
	test could expand the MyPRS
<SUP>
	&#174;
</SUP>
	addressable market in the United States to more than 140,000 patients per year. As
	a specialty focused diagnostic laboratory company, we hope for such opportunities to expand our service offerings for the benefit
	and convenience of physicians and patients.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Our Competitive Strengths
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Differentiated value proposition of the MyPRS
<SUP>
	&#174;
</SUP>
	test
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We believe the MyPRS
<SUP>
	&#174;
</SUP>
	test is one of the most extensively
	validated molecular prognostic assays on the market today. There are more than 30 peer-reviewed scientific publications that substantiate
	the clinical validity and utility of the MyPRS
<SUP>
	&#174;
</SUP>
	test. MyPRS
<SUP>
	&#174;
</SUP>
	is the only GEP-based prognostic assay
	commercially available in the United States which may be used to determine which patients have a high-risk form of MM.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Additionally, the MyPRS
<SUP>
	&#174;
</SUP>
	test provides oncologists
	with the molecular subtype of each patient&#8217;s particular form of MM. Molecular subtypes can be used to further stratify the
	level of risk severity of a patient&#8217;s MM as well as assist the physician in choosing the most appropriate therapy while potentially
	avoiding therapies that may be less beneficial or harmful.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Furthermore, MyPRS
<SUP>
	&#174;
</SUP>
	provides a virtual karyotype
	(a characterization of the chromosomal complement of an individual or a species, including number, form and size of the chromosomes),
	that can identify cytogenetic abnormalities in patients with MM. The accuracy of this method was validated against a range of conventional
	cytogenetic techniques and was shown to have a concordance of 89%. Certain cytogenetic abnormalities are commonly used, along with
	clinical and cell biology parameters in the traditional work up of MM patients for determining disease stage and to help guide
	therapy decisions for patients. The virtual karyotype algorithm in MyPRS
<SUP>
	&#174;
</SUP>
	was designed to be an alternative to conventional
	methods that can be time consuming, expensive, subjective and can often fail to provide results due to the difficulties encountered
	when attempting to culture myeloma cells.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 6; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage7"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Pharmaceutical Services
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	There are currently over 300 new therapies in development for MM.
	Many of the pharmaceutical and large biotechnology companies have ongoing development programs for new compounds and combinations
	of existing drugs including Celgene, Takeda, Novartis, Karyopharm, Pharmacyclics, Janssen and Roche.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We believe that MyPRS
<SUP>
	&#174;
</SUP>
	offers an attractive value
	proposition for companies developing therapies for MM by its ability to stratify high-risk patients likely refractory to current
	standard of care and to identify a patient&#8217;s molecular subtype which assists physicians in determining the most appropriate
	therapy or class of drugs for each patient. In addition, we have analyzed over 20,000 patients with MyPRS
<SUP>
	&#174;
</SUP>
	and have
	the gene expression data available to assist companies in identifying the appropriate patient population for new compounds and
	combination therapies.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	We executed master service agreements with two leading pharmaceutical companies in 2015.
	Under these agreements, MyPRS
<SUP>
	&#174;
</SUP>
	is being run across multiple clinical trials in connection with the development of
	novel treatments for patients with MM.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Relationship with University of Arkansas, leader in the study and treatment of
	MM
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We are the exclusive licensee to the intellectual property developed
	at UAMS&#8217;s Myeloma Institute (&#8220;MI&#8221;), in our licensed field. MI is one of the largest centers in the world dedicated
	solely to MM and related diseases as well as to prevention and management of treatment-related consequences, including myelodysplastic
	syndrome (&#8220;MDS&#8221;) and acute myelogenous leukemia (AML). UAMS developed a novel &#8220;Total Therapy&#8221; approach,
	designed as a first line treatment for MM that includes a full array of treatment modalities. This approach is considered, by many
	in the oncology community, to have achieved positive results, particularly in patients diagnosed with low-risk MM who are treated
	at UAMS MI. A number of treatment improvements for MM patients were first discovered at MI. The physicians at MI routinely utilize
	our MyPRS
<SUP>
	&#174;
</SUP>
	test to identify patients who may be eligible for the provision of &#8220;Total Therapy.&#8221;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We are the exclusive provider of GEP-based testing to UAMS. UAMS
	has a thirty-year history of clinical and research knowledge and experience. UAMS has treated more than 10,000 patients since the
	program&#8217;s inception in 1989. UAMS has amassed more than 10,000 gene array samples, many of which were used to discover and
	validate the MyPRS
<SUP>
	&#174;
</SUP>
	test. More than 90% of patients who are treated at UAMS continue to be actively followed by
	UAMS over the course of their lifetime &#8212; many patients have been followed for more than 20 years.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Because of our exclusive relationship with UAMS, we are uniquely
	positioned to benefit from the breadth of clinical research and expertise developed at UAMS. We intend to continue to use this
	relationship to improve our MyPRS
<SUP>
	&#174;
</SUP>
	test and develop additional indications for the MyPRS
<SUP>
	&#174;
</SUP>
	test, as
	well as additional tests. Our relationship with UAMS also provides us with credibility within the oncology community beyond that
	related to the MyPRS
<SUP>
	&#174;
</SUP>
	validation we have received in published articles, and we benefit from this association in
	our pursuit of additional collaborations with leading universities and research institutions.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Revenue sourced from or through UAMS accounted for 54% and 84% of
	our net revenue for the years ended December 31, 2015 and 2014, respectively. The decrease is due to the decrease in research funds
	available at UAMS for such programs. We expect continued declining revenue from the UAMS research programs.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Our substantial proprietary estate that protects our exclusive access to the MyPRS
<SUP>
	&#174;
</SUP>
	test
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We use our trademark of Signal Genetics, Inc.
<SUP>
	TM
</SUP>
	and our
	registered trademark MyPRS
<SUP>
	&#174;
</SUP>
	in this Annual Report. This report may also refer to trade names and trademarks of other
	organizations.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We currently license, or own outright, 14 issued patents (12 issued
	U.S. patents, one issued European patent validated in 9 countries: Switzerland, Germany, Denmark, Spain, France, United Kingdom,
	Italy, Netherlands, and Sweden, and one issued Japanese patent with various expiration dates ranging from 2022 to 2030) and 11
	pending patent applications, many of which protect and defend our exclusive ability to market the MyPRS
<SUP>
	&#174;
</SUP>
	test as
	well as additional proprietary tests and treatments. We also have six registered U.S. trademarks to further differentiate our products
	and services in the marketplace.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	There are two issued U.S. patents related to the MyPRS
<SUP>
	&#174;
</SUP>
	test, which form the basis of our right to exclude others from practicing the MyPRS
<SUP>
	&#174;
</SUP>
	test. The patents claim methods
	of gene expression-based classification for MM using RNA from plasma cells, methods of identifying groups of genes that can distinguish
	normal and MM plasma cells by isolating RNA from CD138 positive plasma cells and identifying differentially expressed genes, methods
	of diagnosing MM by examining mRNA levels or chromosomal translocations of particular genes from plasma cells, methods of determining
	the prognosis of a human multiple myeloma patient by measuring gene expression levels of multiple genes from plasma cells, and
	methods of determining the prognosis of a MM patient by determining the copy number of the CKS1B gene in plasma cells. CKS1B is
	one of the genes in the 70 gene signature.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 7; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage8"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	In addition to the issued U.S. patents, we have one issued Japanese
	patent and several pending patent applications in the United States and abroad directed to other aspects of the MyPRS
<SUP>
	&#174;
</SUP>
	test. For example, the Japanese patent provides methods for examining the susceptibility of a subject for transformation from a
	low-risk to a high-risk MM by measuring gene expression levels of multiple genes expressed from plasma cells isolated from the
	subject. A Canadian application and an issued European counterpart patent of one of the five issued U.S. patents (U.S. Patent No.
	8,843,320) describe the full 70 gene signature used in the MyPRS
<SUP>
	&#174;
</SUP>
	test. Another pending U.S. application provides
	methods of prognosing subjects with MGUS using the 70 gene signature. We expect that additional advances will come out of our ongoing
	work and form the basis of additional intellectual property to protect and refine the MyPRS
<SUP>
	&#174;
</SUP>
	test, through new patent
	filings, trademarks, trade secrets, and copyrights.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Focus on the leading academic hospitals in the United States where a large portion
	of MM patients are treated
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We currently focus our sales efforts exclusively on leading academic
	research hospitals and clinics throughout the United States. Given our limited selling and marketing capabilities, focusing our
	sales efforts on these academic research hospitals and clinics provides an efficient way to reach the largest segment of MM patients
	with our limited resources. Selling into academic research hospitals and clinics is a complex process that requires technical knowledge
	and the ability to engage in discourse to convince technical and administrative stakeholders to adopt new diagnostic tests or therapies.
	Our current commercial team is well versed in the science and technology behind our MyPRS
<SUP>
	&#174;
</SUP>
	test. We will continue
	to grow our commercial organization with expertise necessary to interface successfully with these institutions.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The extensive scientific evidence that substantiates the MyPRS
<SUP>
	&#174;
</SUP>
	test is a key enabler for our sales effort that affords us access to the thought leaders within these institutions. The relationships
	that we build with the thought leaders at leading academic hospitals is a direct result of the quality of our science and the quality
	of our services and helps to secure continued access to these accounts and the MM patients they treat. It also affords us the opportunity
	to expand our offerings as we add additional services to our test menu.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Early success in establishing positive reimbursement coverage for MyPRS
<SUP>
	&#174;
</SUP>
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We successfully obtained a positive Local Coverage Determination
	(&#8220;LCD&#8221;), for MyPRS
<SUP>
	&#174;
</SUP>
	in March 2011 from the Arkansas Medicare Administrative Contractor (&#8220;MAC&#8221;),
	which at the time was Pinnacle Medical Services. The current MAC is Novitas Health Solutions. We have also received reimbursement
	approval from Blue Cross Blue Shield of Arkansas and we are an in-network provider to their patient population. We anticipate that
	our managed care team, which includes our recently added Chief Medical Officer, as of September 2015, and the continued development
	of our clinical validity and utility dossier, we will be able to achieve positive coverage determinations from a number of the
	major third-party payors in the United States. However, those efforts may take quite some time and may not be successful. In the
	meantime, we have executed agreements with eleven Preferred Provider Networks (&#8220;PPO Networks&#8221;) to facilitate our reimbursement
	from third-party payors.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Experienced oncology-centered laboratory
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Our specimens are tested and interpreted by highly qualified oncology-focused
	laboratory professionals with more than 70 years of cumulative experience with gene expression-based diagnostic testing technology.
	Because our clinical staff is highly specialized in oncology, we believe we are better positioned to consult with our oncologist
	customers to help them derive maximum value from the diagnostic and prognostic data generated by our tests.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Our Growth Strategy
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Our goal is to deliver innovative diagnostic services that enable
	physicians to make better-informed treatment decisions regarding the care of their cancer patients. We intend to do this by:
</P>
<UL STYLE="MARGIN-TOP: 0IN; LIST-STYLE-TYPE: DISC">
<LI STYLE="MARGIN: 5PT 0; FONT-SIZE: 10PT">
	Expanding the U.S. market penetration of our MyPRS
<SUP>
	&#174;
</SUP>
	test by increasing
	the geographic coverage of our commercial organization,;
</LI>
<LI STYLE="MARGIN: 0PT 0; FONT-SIZE: 10PT">
	Broadening the base of health care insurance companies that have approved reimbursements
	for MyPRS
<SUP>
	&#174;
</SUP>
	;
</LI>
<LI STYLE="MARGIN: 5PT 0; FONT-SIZE: 10PT">
	Expanding the diagnostic indications for MyPRS
<SUP>
	&#174;
</SUP>
	to include AMG, the precursor
	conditions to MM;
</LI>
<LI STYLE="MARGIN: 0PT 0; FONT-SIZE: 10PT">
	Pursuing additional collaborations with pharmaceutical companies who focus on developing
	therapies to treat MM and its precursor disease;
</LI>
<LI STYLE="MARGIN: 5PT 0; FONT-SIZE: 10PT">
	Expanding our information technology infrastructure to further improve our customer
	service experience;
</LI>
<LI STYLE="MARGIN: 0PT 0; FONT-SIZE: 10PT">
	Continuing to leverage our relationship with UAMS via our exclusive license agreement;
</LI>
<LI STYLE="MARGIN: 5PT 0; FONT-SIZE: 10PT">
	Expanding our test offering with the addition of other molecular tests useful to physicians
	who care for MM patients;
</LI>
<LI STYLE="MARGIN: 0PT 0; FONT-SIZE: 10PT">
	Expanding and leveraging our capabilities into additional blood cancer indications;
</LI>
<LI STYLE="MARGIN: 5PT 0; FONT-SIZE: 10PT">
	Pursuing additional collaborations, mergers and acquisitions, and in-licensing to expand
	our service offering; and
</LI>
<LI STYLE="MARGIN: 0PT 0; FONT-SIZE: 10PT">
	Continuing to reduce the costs associated with the development, manufacture and interpretation
	of our proprietary genomic tests and services.
</LI>
</UL>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 8; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage9"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Competition
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The primary competition for our MyPRS
<SUP>
	&#174;
</SUP>
	test stems
	from the use of older diagnostic technologies to assess patient prognosis and to define high risk and low risk MM patients. These
	older technologies include various serum markers, karyotype analysis and FISH probes. Several independent groups have assessed
	the use of GEP versus various conventional methodologies and these studies have been published in peer-reviewed journals. For a
	select list of these publications, please visit our website at www.signalgenetics.com in the &#8220;Publications&#8221; section
	under the &#8220;Physician Resources&#8221; tab. It is our experience that whenever MyPRS
<SUP>
	&#174;
</SUP>
	is compared to conventional
	techniques, the MyPRS
<SUP>
	&#174;
</SUP>
	test shows superior ability to predict patient outcome. We believe that an active educational-based
	marketing campaign and additional sales personnel to deliver the message to potential new clients is needed to drive MyPRS
<SUP>
	&#174;
</SUP>
	adoption by educating physicians as to the limitations of conventional testing modalities and the added benefits of MyPRS
<SUP>
	&#174;
</SUP>
	testing. Additionally, there are a number of independent clinical studies that are underway that continue to compare our MyPRS
<SUP>
	&#174;
</SUP>
	test to various conventional techniques, and we believe these new studies will also demonstrate the superiority of our MyPRS
<SUP>
	&#174;
</SUP>
	test to predict patient prognosis. However, we cannot be sure that the data will support the superiority of MyPRS
<SUP>
	&#174;
</SUP>
	and even if there is support, physicians may not adopt use of MyPRS
<SUP>
	&#174;
</SUP>
	by incorporating it in to their molecular diagnostic
	work up of MM or AMG patients.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Another source of competition for our MyPRS
<SUP>
	&#174;
</SUP>
	test
	stems from other scientific teams attempting to develop GEP signatures utilizing other genes or a subset of the genes utilized
	in the MyPRS
<SUP>
	&#174;
</SUP>
	test. Two signatures of note include the French IFM-15 gene signature and the Netherlands EMC-92 gene
	signature which have been studied by independent groups and compared to the UAMS GEP test, MyPRS
<SUP>
	&#174;
</SUP>
	. Based on previous
	head-to-head comparisons, we believe that the MyPRS
<SUP>
	&#174;
</SUP>
	test is a superior predictor of patient outcome compared to
	any other published gene expression signature. However, there is no guarantee that in the future a GEP will not be commercially
	available that is superior to MyPRS
<SUP>
	&#174;
</SUP>
	. If that happens, our commercialization efforts could be severely hampered.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We are not currently aware of any company attempting to bring GEP
	based tests into the U.S. market. Additionally, we believe our intellectual property portfolio will provide protection for our
	exclusive ability to market GEP tests for MM in the U.S. Our success to date in establishing reimbursement coverage for our MyPRS
<SUP>
	&#174;
</SUP>
	test may provide an additional competitive barrier to any new U.S. market entrant attempting to use GEP to predict prognosis in
	MM patients. This is because we believe any such test would have to be supported by evidence showing clinical validity and clinical
	utility that is of the same strength as the evidence supporting MyPRS
<SUP>
	&#174;
</SUP>
	. Lastly, we are not aware of any pending
	clinical research utilizing a GEP to predict conversion from AMG to MM other than the SWOG study that used the MyPRS
<SUP>
	&#174;
</SUP>
	test. However, there may be other academic or industry based scientists who are developing new genetic expression based predictive
	assays or other novel technology based assays that will be superior to MyPRS
<SUP>
	&#174;
</SUP>
	test in predicting risk in patients
	with MM and/or AMG.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We compete largely on the basis of the quality of our tests, the
	significant number of peer-reviewed scientific publications that support the clinical validity and utility of our MyPRS
<SUP>
	&#174;
</SUP>
	test, our turnaround time, the convenience of ordering our tests and the innovation of our results delivery platform.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We provide services in a segment of the health care industry that
	is highly fragmented and extremely competitive. Any failure to respond to technological advances and emerging industry standards
	could impair our ability to attract and retain clients. This industry is characterized by rapid technological change. Our actual
	and potential competitors in the United States and abroad may include biotechnology, genomic and diagnostic companies such as Novartis,
	Cancer Genetics, Inc. and NeoGenomics, Inc., large clinical laboratories, universities and other research institutions. Many of
	our potential competitors have considerably greater financial, technical, marketing, research and other resources than we do, which
	may allow these competitors to discover important information and develop technology before we do. It is anticipated that competition
	will continue to increase due to such factors as the potential for commercial applications of biotechnology and the continued availability
	of investment capital and government funding for cancer-related research. Our competitors may succeed in developing diagnostic
	products that are superior to our tests and technologies, including our pipeline products. Also, our competitors may succeed in
	developing technologies, products or services that are more effective than those that will be developed by us or that would render
	our technology or product candidates less competitive or obsolete.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	In addition, our goal is to develop diagnostic tests and other services
	that impact the treatment of MM and other cancers. If those treatments change, it is possible that the demand for our services
	and products could significantly decline or cease altogether. The development of new or superior competing technologies, products
	or services, or a change in the treatment of MM and other cancers, could affect our competitive position and harm our business.
	Moreover, these competitors may offer broader services and/or product lines and have greater name recognition than us and may offer
	discounts as a competitive tactic.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Additionally, competitors may succeed in developing products and/or
	services that are approved by the FDA and/or they may market technologies, products or services that are more effective or commercially
	attractive than our tests and services or that render our technologies and current or potential tests and other services obsolete.
	Competitors may also develop proprietary positions that may prevent us from commercializing, or continue to commercialize current
	and future product candidates.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 9; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage10"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We also face competition from companies such as Genoptix, Inc. (a
	Novartis AG company), Neogenomics, Inc., Cancer Genetics, Inc., Bio-Reference Laboratories (a division of OPKO Health, Inc.).,
	Integrated Genetics (a LabCorp Specialty Testing Group) and Foundation Medicine, Inc., which offer products or services or have
	conducted research to develop genetic profiles, or genetic or protein biomarkers for various cancers. Additionally, projects related
	to cancer genomics have received increased government funding, both in the United States and internationally. As more information
	regarding cancer genomics becomes available to the public, we anticipate that more products aimed at predicting patient outcome
	as well as identifying targeted treatment options will be developed and that these products may compete with ours. In addition,
	competitors may develop their own versions of our tests in countries where we did not apply for patents or where our patents have
	not issued and compete with us in those countries, including promoting the use of their test(s) by physicians or patients in other
	countries.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Research and Development Program
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Research and development is crucial to our ongoing growth as we
	seek to expand our series of diagnostic tests for use by physicians that treat MM and other cancer patients. Our research and development
	expenses were $1.0 million and $347,000 for the years ended December 31, 2015 and 2014, respectively, representing 39% and 8% of
	our net revenue for the years ended December 31, 2015 and 2014, respectively. Major components of our research and development
	expenses include supplies and reagents for our research activities, personnel costs, occupancy costs, equipment warranties and
	service, insurance, consulting, and clinical research sponsorship. We are also investing in clinical research studies to further
	validate the clinical utility of MyPRS
<SUP>
	&#174;
</SUP>
	to predict the risk that a patient with AMG would progress to developing
	MM and to facilitate the development and clinical utility validation of additional genetic characterization of MM patients. We
	expect research and development expenses to increase as we work to develop additional diagnostic tests and services or add indications,
	including new testing modalities, and to study additional diagnostic and prognostic indicators for patients suffering from MM and
	its precursor conditions AMG, as well as other hematomalignancies. In the future, we expect research and development expenses to
	increase as we work to develop additional tests and services and add indications to our MyPRS
<SUP>
	&#174;
</SUP>
	test. We cannot estimate
	the amounts we will need to invest in order to achieve the new indications or new services, nor do we know if we will be successful
	in these endeavors.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Governmental Regulation
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Our business is subject to extensive laws and regulations, the most
	significant of which are summarized below.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Clinical Laboratory Improvement Amendments
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We are subject to CLIA, which is administered by CMS, and extends
	federal oversight to virtually all clinical laboratories by requiring certification by the federal government or by a federally-approved
	accreditation agency.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Under CLIA, a laboratory is defined as any facility which performs
	laboratory testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment
	of disease, or the impairment of, or assessment of health. CLIA requires that we hold a certificate applicable to the type of work
	we perform and comply with certain standards. CLIA further regulates virtually all clinical laboratories by requiring compliance
	with various operational, personnel, facilities, administration, quality and proficiency requirements intended to ensure that their
	clinical laboratory testing services are accurate, reliable and timely. CLIA certification is a prerequisite to being eligible
	to bill for services provided to governmental payor program beneficiaries. CLIA is user-fee funded. Therefore, all costs of administering
	the program must be covered by the regulated facilities, including certification and survey costs.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	CLIA has specific conditions for certification. CLIA is intended
	to ensure the quality and reliability of clinical laboratories, including the accuracy, reliability and timeliness of patient test
	results performed in clinical laboratories in the United States, by mandating specific standards in the areas of personnel qualification,
	administration participation in proficiency testing, patient test management, quality control, quality assurance and inspections.
	CLIA regulations contain guidelines for the qualification, responsibilities, training, working conditions and oversight of clinical
	laboratory employees. In addition, specific standards are imposed for each type of test that is performed in a laboratory. The
	categorization of commercially marketed in vitro diagnostic tests under CLIA is the responsibility of the FDA. The FDA will assign
	commercially marketed test systems into one of three CLIA regulatory categories based on their potential risk to public health.
	Tests will be designated as waived, of moderate complexity or of high complexity. CLIA and the regulations promulgated thereunder
	are enforced through quality inspections of test methods, equipment, instrumentation, materials and supplies on a periodic basis.
	The sanction for failure to comply with CLIA requirements may be suspension, revocation or limitation of a laboratory&#8217;s CLIA
	certificate, which is necessary to conduct business, as well as significant fines and/or criminal penalties. If a laboratory is
	certified as &#8220;high complexity&#8221; under CLIA, the laboratory is permitted to obtain analyte specific reagents, or ASRs,
	which are commercially marketed products that function as the building blocks of in vitro diagnostic tests and in-house diagnostic
	tests known as &#8220;home brews.&#8221; We received our CLIA certificate as a &#8220;high complexity&#8221; laboratory in 2011.
	Our current CLIA certificate renewal period began April 14, 2015 and will expire on April 13, 2017. Loss of our CLIA certification,
	change in CLIA or CLIA regulations or in the interpretation thereof, could have a material adverse effect on our business.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 10; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage11"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	New York State Laboratory Licensing
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	New York state laws and regulations also establish standards for
	the day-to-day operations of clinical laboratories, including physical facility requirements and equipment and quality control.
	New York standards include proficiency testing requirements, even for a laboratory not located within the state. In addition, the
	New York Department of Health separately approves certain LDTs offered in New York State. In June 2014, following our initial public
	offering, we obtained the requisite approvals for our LDTs in New York. Such license expires in June 2016. We expect to renew the
	license before expiration.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Other States&#8217; Laboratory Testing
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	In addition to New York, certain other states, including California,
	Florida, Maryland, Pennsylvania, and Rhode Island require that we hold licenses to test specimens from patients residing in those
	states even though we are physically located in Arkansas. We have obtained licenses in these states and believe we are in material
	compliance with their applicable licensing laws, and will continue to pursue license renewals, as required.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	From time to time, other states may require out of state laboratories
	to obtain licensure in order to accept specimens from such state. If we identify any other state with such requirements or if we
	are contacted by any other state advising us of such requirements, we intend to follow instructions from the state regulators as
	to how we should comply with such requirements.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Other Laboratory Regulations
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Our clinical operations are also subject to regulation under state
	laws that may be more stringent than CLIA. State clinical laboratory laws generally require that laboratories and/or laboratory
	personnel meet certain qualifications. State clinical laboratory laws also generally require laboratories to specify certain quality
	controls and maintain certain records. For example, California requires that we maintain a state issued license and comply with
	California standards for our laboratory operations, including the standards for laboratory personnel and quality control. Additional
	states may require similar licenses in the future. Potential sanctions for violation of these state requirements include significant
	fines and the suspension or loss of various licenses, certificates and authorizations, which could adversely affect our business
	and results of operations. Finally, we may be subject to regulation in foreign jurisdictions, including in Europe and Asia, if
	we expand offering of our tests or distribution of our tests internationally.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	HIPAA Compliance and Privacy Protection and the HITECH Act
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	HIPAA and its implementing regulations established comprehensive
	federal protection for the privacy and security of health information. The HIPAA standards apply to three types of organizations,
	or &#8220;Covered Entities&#8221;: health plans, health care clearing houses, and health care providers who conduct certain health
	care transactions electronically, or Standard Transactions. Covered Entities must have in place administrative, physical and technical
	safeguards to protect against the misuse of individually identifiable health information, or PHI. Additionally, some state laws
	impose privacy and security protections more stringent than HIPAA&#8217;s and some states impose privacy and security obligations
	specifically applicable to clinical laboratories. Additionally, many states have implemented data breach laws requiring additional
	security measures for certain types of PHI and also public notification of the theft, breach or other loss of personal information.
	There are also international privacy laws, such as the European Data Directive and various national laws implementing the Data
	Directive, that impose restrictions on the access, use, and disclosure of health information and other types of identifiable personal
	information. All of these laws may impact our business. We are a Covered Entity subject to the HIPAA regulations because our testing
	services are reimbursable by insurance payors and we conduct Standard Transactions. We have an active program designed to address
	HIPAA regulatory compliance. This program will likely require periodic updating to comply with amendments to HIPAA. Regardless
	of our own Covered Entity status, HIPAA presently applies to many of the facilities and physicians with whom we do business and
	controls the ways in which we may obtain tissue specimens and associated clinical information from those facilities and physicians.
	We believe we have taken the steps required for us to comply with applicable health information privacy and confidentiality statutes
	and regulations under both federal and applicable state jurisdictions. However, we may not be able to maintain compliance in all
	jurisdictions where we do business. Our failure to comply with these privacy laws or significant changes in the laws restricting
	our ability to obtain tissue specimens and associated patient information could significantly impact our business and our future
	business plans.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Additionally, the HITECH Act and the regulations promulgated thereunder
	by the HHS require HIPAA covered entities, including clinical laboratories, to provide notification to affected individuals and
	to the Secretary of HHS, following discovery of a breach of unsecured PHI. In some cases, the HITECH Act requires covered entities
	to provide notification to the media of breaches. In the case of a breach of unsecured PHI at or by a business associate of a covered
	entity, the HITECH Act requires the business associate to notify the covered entity of the breach. The HITECH Act requires the
	Secretary of HHS to post on the HHS website a list of covered entities that experience breaches of unsecured PHI involving more
	than 500 individuals. The HITECH Act made other changes relating to the HIPAA privacy and security rules, including, among others,
	establishing that, effective February 17, 2010, the HIPAA security and certain privacy regulations apply directly to business associates
	and, consequently, that a business associate&#8217;s violation of the HIPAA regulations may result in government enforcement action
	directly against the business associate or the covered entity with whom the business associate contracts depending upon the nature
	of that business relationship. We contract with business associates to provide certain services regulated by the HIPAA regulations
	and therefore must comply with the HIPAA regulations governing those business relationships.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 11; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage12"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	In summary, we are required to comply with laws governing the transmission,
	security and privacy of health information that require significant compliance costs, and any failure to comply with these laws
	could result in material criminal and civil penalties.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Federal and State Physician Self-referral Prohibitions
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We are subject to the Stark Law, and restrictions under California&#8217;s
	Physician Ownership and Referral Act, or PORA. These restrictions prohibit us from billing a patient or any governmental or private
	payor for any test when the physician ordering the test, or any member of such physician&#8217;s immediate family, has an investment
	interest in or compensation arrangement with us, unless the arrangement meets an exception to the prohibition.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Both the Stark Law and PORA contain an exception for referrals made
	by physicians who hold investment interests in a publicly traded company that has stockholders&#8217; equity exceeding $75 million
	at the end of its most recent fiscal year or on average during the previous three fiscal years, and which satisfies certain other
	requirements. In addition, both the Stark Law and PORA contain an exception for compensation paid to a physician for personal services
	rendered by the physician. In the future we may develop compensation arrangements with other physicians for personal services.
	We will structure these arrangements with terms intended to comply with the requirements of the personal services exception to
	Stark Law and PORA and other applicable laws.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	However, we cannot be certain that regulators would find these arrangements
	to be in compliance with Stark Law, PORA or similar state laws. If we are deemed out of compliance by the applicable regulators,
	we would be required to refund any payments we receive pursuant to a referral prohibited by these laws to the patient, the payor
	or the Medicare program, as applicable.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Penalties for a violation of the Stark Law include: refunds of amounts
	collected by an entity in violation of the Stark Law, denial of payment for the services provided in violation of the prohibition,
	and civil penalties of up to $15,000 per service arising out of the prohibited referral. Additionally, a person who engages in
	a scheme to circumvent the Stark Law&#8217;s prohibition may be subject to a civil penalty of up to $100,000. A violation of PORA
	is a misdemeanor and could result in civil penalties and criminal fines.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Other states have self-referral restrictions with which we have
	to comply that differ from those imposed by federal and California law.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	While we have attempted to comply with these laws, it is possible
	that some of our financial arrangements with pathologists and other physicians could be subject to regulatory scrutiny at some
	point in the future, and we cannot provide assurance that we will be found to be in compliance with these laws following any such
	regulatory review.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Federal, State and Foreign Fraud and Abuse Laws
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The federal Anti-Kickback Statute prohibits, among other things,
	knowingly and willfully offering, paying, soliciting or receiving remuneration to induce or in return for purchasing, leasing,
	ordering or arranging for the purchase, lease or order of any health care item or service reimbursable under a governmental payor
	program. The definition of &#8220;remuneration&#8221; has been broadly interpreted to include anything of value, including gifts,
	discounts, credit arrangements, payments of cash, waivers of co-payments, ownership interests and providing anything at less than
	its fair market value. Recognizing that the Anti-Kickback Statute is broad and may technically prohibit many innocuous or beneficial
	arrangements within the health care industry, the HHS has issued a series of regulatory &#8220;safe harbors.&#8221; These safe
	harbor regulations set forth certain provisions, which, if met, will assure health care providers and other parties that they will
	not be prosecuted under the federal Anti-Kickback Statute. Although full compliance with these provisions ensures against prosecution
	under the federal Anti-Kickback Statute, the failure of a transaction or arrangement to fit within a specific safe harbor does
	not necessarily mean that the transaction or arrangement is illegal or that prosecution under the federal Anti-Kickback Statute
	will be pursued. For further discussion of the impact of federal and state health care fraud and abuse laws and regulations on
	our business, see the section entitled &#8220;Risk Factors &#8212; Risks Related to Our Business &#8212; We are subject to federal
	and state health care fraud and abuse laws and regulations and could face substantial penalties if we are unable to, or if a tribunal
	has determined that we do not fully comply with such laws.&#8221;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	In addition to the administrative simplification regulations discussed
	above, HIPAA also created two new federal crimes: health care fraud and false statements relating to health care matters. The health
	care fraud statute prohibits knowingly and willfully executing a scheme to defraud any health care benefit program, including private
	payors. A violation of this statute is a felony and may result in fines, imprisonment or exclusion from federal health care programs
	such as the Medicare and Medicaid programs. The false statements statute prohibits knowingly and willfully falsifying, concealing
	or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery
	of or payment for health care benefits, items or services. A violation of this statute is a felony and may result in fines, imprisonment
	or exclusion from federal health care programs.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 12; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage13"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Finally, another development affecting the health care industry
	is the increased enforcement of the federal False Claims Act and, in particular, actions brought pursuant to the False Claims Act&#8217;s
	&#8220;whistleblower&#8221; or &#8220;qui tam&#8221; provisions. The False Claims Act imposes liability on any person or entity
	that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal governmental
	payor program. The qui tam provisions of the False Claims Act allow a private individual to bring actions on behalf of the federal
	government alleging that the defendant has defrauded the federal government by submitting a false claim to the federal government
	and permit such individuals to share in any amounts paid by the entity to the government in fines or settlement. In addition, various
	states have enacted false claim laws analogous to the federal False Claims Act, many of which apply where a claim is submitted
	to any third-party payor and not merely to a governmental payor program. When an entity is determined to have violated the False
	Claims Act, it may be required to pay up to three times the actual damages sustained by the government, plus civil penalties ranging
	from $5,500 to $11,000 for each false claim.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Additionally, in Europe various countries have adopted anti-bribery
	laws providing for severe consequences, in the form of criminal penalties and/or significant fines, for individuals and/or companies
	committing a bribery offence. Violations of these anti-bribery laws, or allegations of such violations, could have a negative impact
	on our business, results of operations and reputation. For instance, in the United Kingdom, under the Bribery Act 2010, which went
	into effect in July 2011, a bribery occurs when a person offers, gives or promises to give a financial or other advantage to induce
	or reward another individual to improperly perform certain functions or activities, including any function of a public nature.
	Bribery of foreign public officials also falls within the scope of the Bribery Act 2010. Under the new regime, an individual found
	in violation of the Bribery Act 2010, faces imprisonment of up to 10 years. In addition, the individual can be subject to an unlimited
	fine, as can commercial organizations for failure to prevent bribery.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	There are federal and state laws prohibiting fraudulent billing
	and providing for the recovery of non-fraudulent overpayments, as a large number of laboratories have been forced by the federal
	and state governments, as well as by private payors, to enter into substantial settlements under these laws. In particular, if
	an entity is determined to have violated the federal False Claims Act, it may be required to pay up to three times the actual damages
	sustained by the government, plus civil penalties ranging from $5,500 to $11,000 for each separate false claim. While there are
	many potential bases for liability under the federal False Claims Act, such liability primarily arises when an entity knowingly
	submits, or causes another to submit, a false claim for reimbursement to the federal government. Submitting a claim with reckless
	disregard or deliberate ignorance of its validity could result in substantial civil liability. A current trend within the health
	care industry is the increased use of the federal False Claims Act and, in particular, actions under the False Claims Act&#8217;s
	&#8220;whistleblower&#8221; or &#8220;qui tam&#8221; provisions to challenge providers and suppliers. Those provisions allow a
	private individual standing to bring actions on behalf of the government, alleging that the defendant has submitted a fraudulent
	claim for payment to the federal government. The government may join in the lawsuit, but if the government declines to do so, the
	individual may choose to pursue the lawsuit alone. The government must be kept apprised of the progress of the lawsuit. Whether
	or not the federal government intervenes in the case, it will receive the majority of any recovery. In addition, various states
	have enacted laws modeled after the federal False Claims Act.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Even though we believe we are in material compliance with these
	laws and regulations, it is possible the government may determine that we are not in compliance, in which case we could be subject
	to civil and criminal penalties.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	The Physician Payment Sunshine Act
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The Physician Payment Sunshine Act, or the Sunshine Act, which was
	enacted as part of the ACA, requires applicable manufacturers of drugs, devices, biologicals, or medical supplies covered under
	Medicare, Medicaid or the Children&#8217;s Health Insurance Program, to report annually to HHS payments or other transfers of value
	made by that entity, or by a third party as directed by that entity, to physicians and teaching hospitals, or to third parties
	on behalf of physicians or teaching hospitals, during the course of the preceding calendar year. Similar reporting requirements
	have also been enacted on the state level in the United States, and an increasing number of countries worldwide either have adopted
	or are considering similar laws requiring transparency of interactions with health care professionals. In addition, some states
	such as Massachusetts and Vermont impose an outright ban on certain gifts to physicians.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The final rule implementing the Sunshine Act, published on February
	8, 2013, requires data collection on payments to begin on August 1, 2013. Failure to comply with the reporting requirements can
	result in significant civil monetary penalties ranging from $1,000 to $10,000 for each payment or other transfer of value that
	is not reported (up to a maximum per annual report of $150,000) and from $10,000 to $100,000 for each knowing failure to report
	(up to a maximum per annual report of $1 million). We believe that our laboratory is not an &#8220;applicable manufacturer&#8221;
	as that term is defined in the final rule implementing the Sunshine Act, and, therefore, we are not required to collect data on
	and report these payments. However, we cannot be certain that regulators will agree with our position. If we are deemed to be an
	applicable manufacturer subject to the Sunshine Act, we could be subject to civil monetary penalties for failing to comply with
	the requirements.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	These laws could affect our promotional activities by limiting the
	kinds of interactions we could have with hospitals, physicians or other potential purchasers or users of our tests. Both the disclosure
	laws and gift bans could impose administrative, cost and compliance burdens on us.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 13; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage14"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	New Medicare Reimbursement Methodology Under PAMA
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The Protecting Access to Medicare Act (&#8220;PAMA&#8221;), which
	became law on April 1, 2014, significantly reforms the way in which the Medicare program will pay for clinical laboratory services
	going forward. Under PAMA, starting in 2017, CMS will be required to base its payments to clinical laboratories for diagnostic
	tests on the amounts that that are being paid by commercial health insurance plans for such tests. On October 1, 2015, CMS issued
	a proposed rule to implement PAMA that would require applicable laboratories to begin reporting the amounts that they are paid
	for their clinical laboratory tests by private health insurers to CMS, beginning in the first quarter of 2016. Based on the data
	reported, CMS would, in general, calculate weighted median payments for each test, and use these amounts as new Clinical Laboratory
	Fee Schedule (&#8220;CLFS&#8221;) rates beginning in 2017. PAMA provides that, for the first two years, (that is, 2017 through
	2019), a payment price cannot be reduced by more than 10 percent per year and thereafter, through 2022, a test payment cannot be
	reduced by more than 15 percent per year. PAMA authorizes CMS to impose civil monetary penalties of up to $10,000 per day for each
	failure to report or each misrepresentation or omission in reporting applicable information to CMS. Because no final rule has yet
	been published, the ultimate impact of PAMA and its implementing regulations on our business remains unclear.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Food and Drug Administration
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The FDA regulates the sale or distribution in interstate commerce,
	of medical devices, including in vitro diagnostic test kits. The information that must be submitted to the FDA in order to obtain
	clearance or approval to market a new medical device varies depending on how the medical device is classified by the FDA. Medical
	devices are classified into one of three classes on the basis of the controls deemed by the FDA to be necessary to reasonably ensure
	their safety and effectiveness. Class I devices are subject to general controls, including labeling, listing, registration, and
	reporting. It may also include pre-market notification and adherence to the FDA&#8217;s quality system regulation, which are device-specific
	good manufacturing practices. Class II devices are subject to general controls and special controls, such as performance standards
	and post-market surveillance. Class III devices are subject to most of the previously identified requirements as well as to PMA.
	Most in vitro diagnostic kits are regulated as Class I or Class II devices. Entities that fail to comply with FDA requirements
	can be liable for criminal or civil penalties, recalls, seizures, orders to cease manufacturing and restrictions on labeling and
	promotion.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The FDA presently requires clearance or approval of diagnostic test
	kits that are sold to laboratories, hospitals and doctors, considering them to be medical devices. However, diagnostic tests that
	are developed and performed by a CLIA-certified reference laboratory, known as &#8220;home-brew,&#8221; &#8220;in-house&#8221;
	or LDTs have not been regulated by FDA to date. The FDA has stated that it has the power to regulate LDTs such as the ones that
	we develop. Nevertheless, it has exercised enforcement discretion and not regulated most LDTs performed by high complexity CLIA
	certified laboratories. It is possible, perhaps likely, that FDA will decide to more actively regulate LDTs, which could lead to
	pre-market and post-market obligations. Section 1143 of the Food and Drug Administration Safety and Innovation Act, signed by the
	President on July 9, 2012, requires FDA to notify Congress at least 60 days prior to issuing a draft or final guidance regulating
	LDTs and provide details of the anticipated action.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Class II devices are subject to FDA&#8217;s general controls, and
	any other special controls as deemed necessary by FDA to provide reasonable assurance of the safety and effectiveness of the device.
	Pre-market review and clearance by FDA for Class II devices are generally accomplished through the 510(k) pre-market notification
	procedure. Pre-market notification submissions are subject to user fees, unless a specific exemption applies. To obtain 510(k)
	clearance for a medical device (or for certain modifications to devices that have received 510(k) clearance), a manufacturer must
	submit a pre-market notification demonstrating that the proposed device is substantially equivalent to a previously cleared 510(k)
	device or to a pre-amendment device that was in commercial distribution before May 28, 1976, or a predicate device, for which FDA
	has not yet called for the submission of a PMA application. In making a determination that the device is substantially equivalent
	to a predicate device, FDA compares the proposed device to the predicate device or predicate devices and assesses whether the subject
	device is comparable to the predicate device or predicate devices with respect to intended use, technology, design and other features
	which could affect the safety and effectiveness. If FDA determines that the subject device is substantially equivalent to the predicate
	device or predicate devices, the subject device may be cleared for marketing. FDA&#8217;s 510(k) clearance pathway generally takes
	from three to twelve months from the date the application is completed, but can take significantly longer. Moreover, in January
	2011, FDA announced twenty-five specific action items it intended to take to improve transparency and predictability of the 510(k)
	program. We anticipate that the changes may also result in additional requirements with which manufacturers will need to comply
	in order to obtain or maintain 510(k) clearance for their devices. These additional requirements could increase the costs or time
	for manufacturers&#8217; seeking marketing clearances through the 510(k) process. Moreover, the 510(k) process could result in
	a not-substantially equivalent determination, in which case the device would be regulated as a Class III device, discussed below.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Class III devices are those devices which are deemed by FDA to pose
	the greatest risk, such as life-sustaining, life-supporting or implantable devices, have a new intended use, or use advanced technology
	that is not substantially equivalent to that of a legally marketed device. Reasonable assurance of the safety and effectiveness
	of Class III devices cannot be assured solely by the general controls and the other requirements described above. These devices
	are required to undergo the PMA process in which the manufacturer must demonstrate reasonable assurance of the safety and effectiveness
	of the device to FDA&#8217;s satisfaction. A PMA application must provide extensive preclinical and clinical trial data and also
	information about the device and its components regarding, among other things, device design, manufacturing and labeling. PMA applications
	(and supplemental PMA applications) are subject to significantly higher user fees than are 510(k) pre-market notifications. After
	approval of a PMA, a new PMA or PMA supplement is required in the event of a modification to the device, it&#8217;s labeling or
	it&#8217;s manufacturing process. The PMA process, including the gathering of clinical and nonclinical data and the submission
	to and review by FDA, can take several years.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 14; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage15"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	A clinical trial may be required in support of a 510(k) submission
	and generally is required for a PMA application. These trials generally require an effective Investigational Device Exemption from
	FDA for a specified number of patients, unless the product is exempt from Investigational Device Exemption requirements or deemed
	a non-significant risk device eligible for more abbreviated Investigational Device Exemption requirements. The Investigational
	Device Exemption application must be supported by appropriate data, such as animal and laboratory testing results. Clinical trials
	may begin 30 days after the submission of the Investigational Device Exemption application unless FDA or the appropriate institutional
	review boards at the clinical trial sites place the trial on clinical hold.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	After a device is placed on the market, regardless of the classification
	or pre-market pathway, it remains subject to significant regulatory requirements. Even if regulatory approval or clearance of a
	medical device is granted, FDA may impose limitations or restrictions on the uses and indications for which the device may be labeled
	and promoted. Medical devices may be marketed only for the uses and indications for which they are cleared or approved. Device
	manufacturers must also establish registration and device listings with FDA. A medical device manufacturer&#8217;s manufacturing
	processes and those of its suppliers are required to comply with the applicable portions of the Quality Systems Regulations, which
	cover the methods and documentation of the design, testing, production, processes, controls, quality assurance, labeling, packaging
	and shipping of medical devices. Domestic facility records and manufacturing processes are subject to periodic unscheduled inspections
	by FDA. FDA also may inspect foreign facilities that export products to the United States.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Failure to comply with applicable regulatory requirements can result
	in enforcement action by FDA, which may include any of the following sanctions: warning letters, fines, injunctions, civil or criminal
	penalties, recall or seizure of current or future products, operating restrictions, partial suspension or total shutdown of production,
	denial of 510(k) clearance or PMA applications for new products, or challenges to existing 510(k) clearances or PMA applications.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	If they become regulated by FDA, we believe that our LDTs would
	likely be regulated as either Class II or Class III devices. It is also possible that some may fall into one Class and some into
	the other. Accordingly, some level of pre-market review &#8212; either a 510(k) or a PMA &#8212; would likely be required for each
	test. While the data requirements are typically greater for Class III devices, the data required for Class II devices has increased,
	and it is likely that some amount of clinical data (retrospective or prospective or both) would be required for either type of
	submission. Currently, FDA is undertaking a review of the adequacy of the 510(k) process. It is difficult to predict what changes
	may result, but it should be assumed that any changes will increase, not decrease, the regulatory requirements.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	If the FDA decides to regulate MyPRS
<SUP>
	&#174;
</SUP>
	or any future
	test of ours, it could classify the test as a Class II or Class III device. This would mean that we would have to invest substantial
	time and resources into obtaining FDA approval and we might have to withdraw the applicable test from the market. This could adversely
	affect our operations, revenues and our potential to be a profitable or viable entity.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The FDA has stated that it intends to regulate some LDTs as devices.
	On October 3, 2014, the FDA published a proposed risk-based framework for LDTs, which are tests that are designed, manufactured,
	and used within a single laboratory. This draft guidance indicates that FDA would like to establish an LDT oversight framework,
	including premarket review for higher-risk LDTs, such as those that have the same intended use as FDA-approved or cleared companion
	diagnostics currently on the market. FDA&#8217;s notice states that FDA does not consider devices to be LDTs if they are designed
	or manufactured completely, or partly, outside of the laboratory that offers and uses them. The degree to which in-house tests
	are regulated by the FDA has also been the focus of recent Congressional attention, and Congress is considering the introduction
	of legislation that would subject at least some such tests to pre-market review or approval by the FDA.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	MyPRS
<SUP>
	&#174;
</SUP>
	and the other tests being developed by the
	Company include the use of genes and determine whether a patient falls into a high or low risk for disease recurrence or response
	to a particular chemotherapy. The Company plans to continue to develop and offer these tests as LDTs unless it becomes clearer
	that these tests are subject to regulation by the FDA. We will continue to monitor both the FDA and Congress and we intend to comply
	with any new requirements that may apply.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Good Laboratory Practice (&#8220;GLP&#8221;)
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We are subject to various regulatory requirements designed to ensure
	the quality and integrity of our non-clinical testing processes. Our standard operating procedures are written in accordance with
	applicable regulations and guidelines for operating in the United States. The industry standards for conducting preclinical laboratory
	testing are embodied in GLP regulations promulgated by the FDA. In the United States, non-clinical studies intended for FDA submission
	must be conducted in accordance with GLP regulations; foreign governments may require our North American clients to comply with
	certain regulatory requirements of other countries (in order to gain approval within these countries), such as regulations promulgated
	by the Japanese Ministry of Health, Labor and Welfare and Ministry of Agriculture, Forestry and Fisheries, and in Europe, the Organization
	for Economic Co-operation and Development. GLP regulations specify requirements for facilities, equipment, and professional staff
	and standardized procedures for conducting studies, including procedures for recording and reporting data and for managing study
	materials and records. We have established a required quality assurance program that monitors ongoing compliance with GLP regulations
	by auditing test data and reporting and conducting inspections of testing procedures.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 15; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage16"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Our business is also subject to regulation under state and federal
	laws regarding environmental protection and hazardous substances control, such as the Federal Occupational Safety and Health Act,
	or OSHA, the Environmental Protection Act, and the Toxic Substances Control Act. These regulations, among other things, require
	work practice controls, protective clothing and equipment, training and other measures designed to minimize exposure to chemicals
	and transmission of pathogens. We believe that we are in compliance with these and other applicable laws and that the costs of
	our ongoing compliance will not have a material adverse effect on our business. However, it is possible that the government will
	find that we are not in compliance with these requirements, which could have an adverse effect on our business and subject us to
	regulatory sanctions. In addition, statutes and regulations applicable to our business may be adopted which impose substantial
	costs to assure compliance or otherwise materially adversely affect our operations.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Regulation of Reimbursement and Coverage
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Revenues for clinical laboratory testing services come from a variety
	of sources and depend significantly on the availability of third-party reimbursement, including from the Medicare and Medicaid
	programs, commercial insurers and managed care organizations. We are currently a Medicare laboratory services provider and intend
	to become a Medicaid laboratory services provider. We also receive reimbursement from third-party payors for our testing services.
	As is the case with health care services generally, the majority of payors pay for our testing services at varying levels that
	may be significantly lower or otherwise differ from our list prices. Obtaining reimbursement from third-party payors is both time
	consuming and expensive. Payment from third-party payors may not be sufficient to allow us to sell our services on a profitable
	and competitive basis.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Corporate Practice of Medicine
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Numerous states have enacted laws prohibiting business corporations,
	such as us, from practicing medicine and employing or engaging physicians to practice medicine, generally referred to as the prohibition
	against the corporate practice of medicine. These laws are designed to prevent interference in the medical decision-making process
	by anyone who is not a licensed physician. Violation of these laws may result in civil or criminal fines, as well as sanctions
	imposed against us and/or the professional through licensure proceedings.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Other Regulatory Requirements
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Our laboratory is subject to federal, state and local regulations
	relating to the handling and disposal of regulated medical waste, hazardous waste and biohazardous waste, including chemical, biological
	agents and compounds, blood and bone marrow samples and other human tissue. Typically, we use outside vendors who are contractually
	obligated to comply with applicable laws and regulations to dispose of such waste. These vendors are licensed or otherwise qualified
	to handle and dispose of such waste.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	OSHA has established extensive requirements relating to workplace
	safety for health care employers, including requirements to develop and implement programs to protect workers from exposure to
	blood-borne pathogens by preventing or minimizing any exposure through needle stick or similar penetrating injuries.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Employees
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	As of March 15, 2016, we have 32 employees, all of whom are full
	time employees. None of our employees is represented by a labor union, and we consider our relationship with our employees to be
	good.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Available Information
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We file our annual reports on Form 10-K, quarterly reports on Form
	10-Q, current reports on Form 8-K, amendments to those reports, and other information with the U.S. Securities and Exchange Commission
	(&#8220;SEC&#8221;). We will supply a copy of any document we file with the SEC, without charge. To request a copy, please contact
	Investor Relations, Signal Genetics, Inc., 5740 Fleet Street, Carlsbad, CA 92008, USA. The public may also read and copy any document
	we file with the SEC at its public reference facilities at 100 F Street NE, Washington, D.C. 20549, or by calling the SEC at 1-800-SEC-0330,
	or by accessing the SEC's website at www.sec.gov, where the SEC maintains reports, proxy and information statements and other information
	regarding us and other issuers that file electronically with the SEC. In addition, as soon as reasonably practicable after such
	materials are filed with or furnished to the SEC, we make copies available to the public free of charge through our website at
	www.signalgenetics.com. We also regularly post on our corporate website copies of our press releases as well as additional information
	about us.
<BR CLEAR="ALL">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 16; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_BUSINESS>
<A NAME="eolPage17"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<EFX_RISK_FACTORS>
<A NAME="FIS_RISK_FACTORS"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<A NAME="F10K_032116P_HTM_A_002">
</A>
	Item 1A. Risk Factors
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
<I>
	The business, financial condition and operating results of the
	Company may be affected by a number of factors, whether currently known or unknown, including but not limited to those described
	below. Any one or more of such factors could directly or indirectly cause the Company&#8217;s actual results of operations and
	financial condition to vary materially from past or anticipated future results of operations and financial condition. Any of these
	factors, in whole or in part, could materially and adversely affect the Company&#8217;s business, financial condition, results
	of operations and stock price. The following information should be read in conjunction with Part II, Item 7, &#8220;Management&#8217;s
	Discussion and Analysis of Financial Condition and Results of Operations&#8221; and the consolidated financial statements and related
	notes in Part II, Item 8, &#8220;Financial Statements and Supplementary Data&#8221; of this Annual Report.
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Risks Related to our Financial Condition
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	We are an early stage company with a limited commercial history and a history of
	net losses; we expect to incur net losses in the future, and we may never achieve sustained profitability.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We have a limited commercial history. Substantially all of our revenue
	has been derived from our MyPRS
<SUP>
	&#174;
</SUP>
	testing services, which were launched in 2011. We have historically incurred substantial
	net losses. We incurred losses attributable to stockholders of Signal Genetics, Inc. (or members of Signal Genetics LLC, as applicable)
	of $11.3 million and $7.9 million during the years ended December 31, 2015 and 2014, respectively. Losses are continuing through
	the date of this Annual Report. We expect our losses to continue as a result of ongoing research and development expenses, increased
	selling and marketing costs and increased general and administrative costs to support our planned growth. These losses have had,
	and will continue to have, an adverse effect on our working capital, total assets and stockholders&#8217; equity. Because of the
	numerous risks and uncertainties associated with our research, development and commercialization efforts, we are unable to predict
	when we will become profitable, and we may never become profitable. Even if we do achieve profitability, we may not be able to
	sustain or increase profitability on a quarterly or annual basis. Our inability to achieve and then maintain profitability would
	negatively affect our business, financial condition, results of operations and cash flows.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	We will need to raise additional capital.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Although we are forecasting continued losses and negative cash flows
	as we continue to fund our selling and marketing activities and research and development programs, we expect that we will have
	sufficient cash and cash equivalents on hand to support operations for the next 12 to 15 months. We will need to secure additional
	financing in order to support our future operations. We can provide no assurances that any additional sources of financing will
	be available to us on favorable terms, if at all. Our forecast of the period of time through which our current financial resources
	will be adequate to support our operations and the costs to support our general and administrative, selling and marketing and research
	and development activities are forward-looking statements and involve risks and uncertainties.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We will also need to raise additional capital to expand our business
	to meet our long-term business objectives. Additional financing, which is not in place at this time, may be from the sale of equity
	or convertible or other debt securities in a public or private offering, from an additional credit facility or strategic partnership
	coupled with an investment in us or a combination of both.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	If events or circumstances occur such that we are unable to obtain
	additional funding, we will most likely be required to reduce our plans and/or certain discretionary spending, which could have
	a material adverse effect on our ability to achieve our intended business objectives. For further discussion of our liquidity requirements
	as they relate to our long-term plans, see the section entitled &#8220;Liquidity and Capital Resources&#8221;.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Risks Related to our Business
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	If we are unable to obtain adequate coverage and reimbursement for our tests, it
	is unlikely that our tests will gain widespread acceptance.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Maintaining and growing revenues from MyPRS
<SUP>
	&#174;
</SUP>
	depends
	on the availability of adequate coverage and reimbursement for our tests from third-party payors, including government programs
	such as Medicare and Medicaid, private insurance plans and managed care programs. Health care providers that order diagnostic services
	such as MyPRS
<SUP>
	&#174;
</SUP>
	generally expect that those diagnostic services are covered and reimbursed by third-party payors
	for all or part of the costs and fees associated with the diagnostic tests they order. If such diagnostic tests are not covered
	and reimbursed then their patients may be responsible for the entire cost of the test, which can be substantial. Therefore, health
	care providers generally do not order tests that are not covered and reimbursed by third-party payors in order to avoid subjecting
	their patients to such financial liability. The existence of adequate coverage and reimbursement for the procedures performed with
	MyPRS
<SUP>
	&#174;
</SUP>
	by government and private insurance plans is central to the acceptance of MyPRS
<SUP>
	&#174;
</SUP>
	and any future
	services we provide. During the past several years, third-party payors have undertaken cost-containment initiatives including different
	payment methods, monitoring health care expenditures, and anti-fraud initiatives. For example, the Centers for Medicare &amp; Medicaid
	Services (&#8220;CMS&#8221;), which administers the Medicare program, has taken the position that the algorithm portion of multi-analyte
	algorithmic assays (&#8220;MAAAs&#8221;), such as MyPRS
<SUP>
	&#174;
</SUP>
	, is not a clinical laboratory test and is therefore not
	reimbursable under the Medicare program. Although this position is only applicable to tests with a CMS determined national payment
	amount, it is possible that the local MACs, who make coverage and payment determinations for tests like MyPRS
<SUP>
	&#174;
</SUP>
	may
	adopt this policy and reduce payment for MyPRS
<SUP>
	&#174;
</SUP>
	. If that were to happen, reimbursement might be made for each gene
	used in the MyPRS
<SUP>
	&#174;
</SUP>
	test and coverage and the amount of reimbursement for the genes we use in MyPRS
<SUP>
	&#174;
</SUP>
	would be uncertain. We may not be able to achieve or maintain profitability if third-party payors deny coverage or reduce their
	current levels of payment, or if our costs of production increase faster than increases in reimbursement levels. For some governmental
	programs, such as Medicaid, coverage and reimbursement differ from state to state, and some state Medicaid programs may not pay
	an adequate amount for MyPRS
<SUP>
	&#174;
</SUP>
	or may make no payment at all. As the portion of the U.S. population over the age
	of 65 and eligible for Medicare continues to grow, we may be more vulnerable to coverage and reimbursement limitations imposed
	by CMS. Furthermore, the health care industry in the United States has experienced a general trend toward cost containment as government
	and private insurers seek to control health care costs through various mechanisms, including imposing limitations on payment rates
	and negotiating reduced contract rates with service providers, among other things. Therefore, we cannot be certain that our services
	will be reimbursed at a level that is sufficient to meet our costs.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 17; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage18"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	A small number of test ordering sites account for most of the sales of our tests
	and services. If any of these sites orders fewer tests from us for any reason, our revenues could decline.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Due to the early stage nature of our business and our limited selling
	and marketing activities to date, we have historically derived a significant portion of our revenue from a limited number of test
	ordering sites. In particular, the most significant portion of our revenue is generated from our MyPRS
<SUP>
	&#174;
</SUP>
	test services
	provided at our clinical laboratory in Little Rock, Arkansas for UAMS. Revenue sourced either from or through UAMS accounted for
	54% and 84% of our revenue for the years ended December 31, 2015 and 2014, respectively. Accounts receivable from UAMS at December
	31, 2015 and 2014 accounted for 19% and 42%, respectively. The aforementioned decrease in revenue is due to the decrease in research
	funds available at UAMS for such programs. We expect continued declining revenue from the UAMS research programs.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	In addition, approximately 10% of our net revenue for the year ended
	December 31, 2015 was sourced through H. Lee Moffitt Cancer Center and Research Institute (&#8220;Moffitt&#8221;).
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Our test ordering sites are largely hospitals and cancer centers.
	Oncologists and pathologists at these sites order the tests on behalf of their oncology patients or as part of a clinical trial
	sponsored by a pharmaceutical company in which the patient is enrolled. We generally do not enter into formal written agreements
	with such test ordering sites and, as a result, we may lose the business of any of these test ordering sites at any time.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	There is a scarcity of experienced professionals in our industry. If we are not
	able to retain and recruit personnel with the requisite technical skills, we may be unable to successfully execute our business
	strategy.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The specialized nature of our industry results in an inherent scarcity
	of experienced personnel in the field. Our future success depends upon our ability to attract and retain highly skilled personnel
	(including medical, scientific, technical, commercial, business, regulatory and administrative personnel) necessary to support
	our anticipated growth, develop our business and perform certain contractual obligations. Given the scarcity of professionals with
	the scientific knowledge that we require and the competition for qualified personnel among life science businesses, we may not
	succeed in attracting or retaining the personnel we require to continue and grow our operations. The loss of a key employee, the
	failure of a key employee to perform in his or her current position or our inability to attract and retain skilled employees could
	result in our inability to continue to grow our business or to implement our business strategy.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	We will need to generate significant revenues to become and remain profitable.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We intend to increase our operating expenses substantially as we
	add sales representatives to increase our geographic sales coverage, increase our marketing capabilities, conduct clinical trials
	and increase our general and administrative functions to support our growing operations. We will need to generate significant sales
	to achieve and maintain profitability and we might not be able to do so. Even if we do generate significant sales, we might not
	be able to become profitable or sustain or increase profitability on a quarterly or annual basis in the future. If our sales grow
	more slowly than we anticipate or if our operating expenses exceed our expectations, our financial performance will likely be adversely
	affected.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	If we are unable to increase sales of our laboratory tests and services or to successfully
	develop and commercialize other indications for our proprietary tests, our revenues will be insufficient for us to achieve profitability.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Our revenue is derived primarily from our laboratory testing services.
	We currently offer our MyPRS
<SUP>
	&#174;
</SUP>
	test through our state-of the-art CLIA-certified, CAP-accredited and state licensed
	laboratory in Little Rock, Arkansas. MyPRS
<SUP>
	&#174;
</SUP>
	is not assigned a specific CPT code, but our local MAC and Blue Cross
	Blue Shield (&#8220;BCBS&#8221;), of Arkansas have established a specific payment amount for the test, which is billed under a
	nonspecific code. We are in varying stages of research and development for other diagnostic tests that we may offer. We do not
	currently offer any other testing services. If we are unable to increase sales of MyPRS
<SUP>
	&#174;
</SUP>
	or to successfully develop
	and commercialize other diagnostic tests, we will not produce sufficient revenues to become profitable. Our laboratory testing
	services are expensive and may be a negative factor for gaining routine reimbursement.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 18; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage19"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	If pathologists and oncologists decide not to order our diagnostic tests, we may
	be unable to generate sufficient revenue to sustain our business.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	To increase awareness and adoption of our molecular diagnostic tests
	and services, we will need to educate oncologists and pathologists on the clinical utility, benefits and value of each type of
	test we provide through published papers, presentations at scientific conferences and one-on-one education sessions by members
	of our commercial team. In addition, we will need to assure oncologists and pathologists of our ability to obtain and maintain
	adequate reimbursement coverage from third-party payors. We may need to hire additional commercial, scientific, technical, selling
	and marketing and other personnel to support this process. If our educational efforts fail and medical practitioners do not order
	our diagnostic tests or other tests we may develop, utilization of our tests in sufficient volume for us to achieve sustained profitability
	or, perhaps, viability may not be possible.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Our business depends on our ability to successfully develop and commercialize novel
	cancer diagnostic tests and services, which is time consuming and complex, and our development efforts may fail.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Our current business strategy focuses on discovering, developing
	and commercializing molecular diagnostic tests and services. We believe the success of our business depends on our ability to fully
	commercialize our existing diagnostic tests and services and to develop and commercialize new diagnostic tests. In particular,
	it is essential to our business strategy that we expand the indications for use of MyPRS
<SUP>
	&#174;
</SUP>
	. The first additional
	indications for which we hope MyPRS
<SUP>
	&#174;
</SUP>
	will be used include MGUS and SMM. Collectively, these precursor conditions
	are referred to as AMG. However, we may be unsuccessful and MyPRS
<SUP>
	&#174;
</SUP>
	may never be used for these indications. We may
	not succeed because it may never be accepted by the oncologist community, third-party payors may not pay for it, and the recent
	peer-reviewed publication that could support these indications for MyPRS
<SUP>
	&#174;
</SUP>
	may not be sufficient to drive adoption
	support coverage and reimbursement and the results may not be duplicated in additional studies.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	In addition, prior to commercializing our diagnostic tests, we must
	undertake time-consuming and costly development activities, sometimes including clinical studies, and may be required to obtain
	regulatory clearance or approval, which may be denied. This development process involves a high degree of risk, substantial expenditures
	and will occur over several years. Our development efforts may fail for many reasons, including:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<UL STYLE="MARGIN-TOP: 0IN; LIST-STYLE-TYPE: DISC">
<LI STYLE="MARGIN: 0PT 0; FONT-SIZE: 10PT">
	failure of the tests at the research or development stage;
</LI>
<LI STYLE="MARGIN: 5PT 0; FONT-SIZE: 10PT">
	difficulty in accessing archival tissue samples, especially tissue samples with known
	clinical results; or
</LI>
<LI STYLE="MARGIN: 0PT 0; FONT-SIZE: 10PT">
	lack of clinical validation data to support the effectiveness of the test.
</LI>
</UL>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Tests that appear promising in early development may fail to be
	validated in subsequent studies, and even if we achieve positive results, we may ultimately fail to obtain the necessary regulatory
	clearances, approvals or coverage and reimbursement. There is substantial risk that our research and development projects will
	not result in commercially viable tests, and that success in early clinical trials will not be replicated in later studies. At
	any point, we may abandon development of a test or be required to expend considerable resources repeating clinical trials, which
	would adversely impact our ability to generate revenues from that test. In addition, as we develop tests, we will have to make
	significant investments in research, development and marketing resources. If a clinical validation study of a particular test fails
	to meet its endpoint, we might choose to abandon the development of that test. Further, our ability to develop and launch diagnostic
	tests will likely depend on our receipt of additional funding beyond that obtained through our public offerings. If our discovery
	and development programs yield fewer commercial tests than we expect, we may be unable to execute our business plan, which may
	adversely affect our business, financial condition and results of operations.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	We may acquire other businesses or form joint ventures or make investments in other
	companies or technologies that could harm our operating results, dilute our stockholders&#8217; ownership, increase our debt or
	cause us to incur significant expense.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	As part of our business strategy, we may pursue acquisitions of
	businesses and assets. We also may pursue strategic alliances and joint ventures that leverage our core technology and industry
	experience to expand our offerings or distribution. For example, we may seek to purchase or license proprietary tests for other
	cancer indications or tests that complement our current offering for MM patients. We have limited experience with acquiring other
	companies and limited experience with forming strategic alliances and joint ventures. We may not be able to find suitable partners
	or acquisition candidates, and we may not be able to complete such transactions on favorable terms, if at all. If we make any acquisitions,
	we may not be able to integrate these acquisitions successfully into our existing business, and we could assume unknown or contingent
	liabilities. Any future acquisitions also could result in significant write-offs or the incurrence of debt and contingent liabilities,
	any of which could have a material adverse effect on our financial condition, results of operations and cash flows. Integration
	of an acquired company also may disrupt ongoing operations and require management resources that would otherwise focus on developing
	our existing business. We may experience losses related to investments in other companies, which could have a material negative
	effect on our results of operations. We may not identify or complete these transactions in a timely manner, on a cost-effective
	basis, or at all, and we may not realize the anticipated benefits of any acquisition, technology license, strategic alliance or
	joint venture.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 19; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage20"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	To finance any acquisitions or joint ventures, we may choose to
	issue shares of our common stock as consideration, which would dilute the ownership of our stockholders. If the price of our common
	stock is low or volatile, we may not be able to acquire other companies or fund a joint venture project using our stock as consideration.
	Alternatively, it may be necessary for us to raise additional funds for acquisitions through public or private financings. Additional
	funds may not be available on terms that are favorable to us, or at all.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	If we are unable to obtain regulatory clearance or approvals in the United States
	or if we experience delays in receiving clearance or approvals, our growth strategy may not be successful and our business may
	not be viable.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We currently offer our proprietary laboratory services in our CLIA-certified
	and CAP-accredited laboratory. Because we currently offer these tests and services solely for use within our laboratory, we believe
	we may market the tests as LDTs. Under current FDA enforcement policies and guidance, LDTs generally do not require FDA pre-market
	clearance or approval before commercialization, and we have marketed our LDTs on that basis. The FDA may, in the future, change
	this regulatory policy and require pre-market approvals (&#8220;PMAs&#8221;), for LDTs. We may be unable to obtain PMAs for our
	tests, which could make it impossible for us to legally market our services, which would mean that our business may not be viable.
	See the risk factor below &#8212; &#8220; If the FDA were to begin requiring approval or clearance of our tests, we could incur
	substantial costs and time delays associated with meeting requirements for pre-market clearance or approval or we could experience
	decreased demand for, or reimbursement for our tests .&#8221;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	If we are unable to execute our marketing strategy for our cancer diagnostic tests
	and are unable to gain acceptance in the market, we may be unable to generate sufficient revenue to sustain our business.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We are an early-stage company and have engaged in only limited selling
	and marketing activities for MyPRS
<SUP>
	&#174;
</SUP>
	. There is not currently widespread awareness or adoption of our MyPRS
<SUP>
	&#174;
</SUP>
	testing system. Although we believe that MyPRS
<SUP>
	&#174;
</SUP>
	represents a promising commercial opportunity, it may never gain
	significant acceptance in the marketplace and therefore may never generate substantial revenue or profits for us. This is also
	true for any additional diagnostic tests we may market. We will need to establish a market for our diagnostic tests and build that
	market through physician education and awareness programs. Gaining acceptance in medical communities requires publication in leading
	peer-reviewed journals of results from studies using our tests. The process of publication in leading medical journals is subject
	to a peer review process and peer reviewers may not consider the results of our studies sufficiently novel or worthy of publication.
	Failure to have our studies published in peer-reviewed journals would limit the adoption of our tests and future coverage and reimbursement
	decisions for our tests could be negatively affected.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Our ability to successfully market the diagnostic tests that we
	may develop will depend on numerous factors, including:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<UL STYLE="MARGIN-TOP: 0IN; LIST-STYLE-TYPE: DISC">
<LI STYLE="MARGIN: 0PT 0; FONT-SIZE: 10PT">
	whether health care providers believe our diagnostic tests are clinically useful;
</LI>
<LI STYLE="MARGIN: 5PT 0; FONT-SIZE: 10PT">
	whether the medical community accepts that our diagnostic tests are sufficiently sensitive
	and specific to be meaningful in patient care and treatment decisions; and
</LI>
<LI STYLE="MARGIN: 0PT 0; FONT-SIZE: 10PT">
	whether health insurers, government health programs and other third-party payors will
	cover and pay for our diagnostic tests and, if so, whether they will adequately reimburse us.
</LI>
</UL>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	If any of these do not occur, we could fail to achieve widespread
	market acceptance of our diagnostic tests and our business would be materially harmed, as would our financial condition and results
	of operations.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	If we cannot develop tests to keep pace with rapid advances in technology, medicine
	and science, our operating results and competitive position could be harmed.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	In recent years, there have been numerous advances in technologies
	relating to the diagnosis and treatment of cancer. There are several new cancer drugs under development that may increase patient
	survival time. There have also been advances in methods used to analyze very large amounts of genomic information.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We must continuously develop new tests and enhance our existing
	tests to keep pace with evolving standards of care. Our tests could become obsolete unless we continually innovate and expand them
	to demonstrate benefit in patients treated with new therapies. New cancer therapies typically have only a few years of clinical
	data associated with them, which limits our ability to perform clinical studies and correlate sets of genes to a new treatment&#8217;s
	effectiveness. We plan to use a portion of our cash resources to fund continued clinical development of new products and services.
	We may experience research and development, regulatory, market or other difficulties that could delay or prevent our introduction
	of new or enhanced tests. The research and development process generally takes a significant amount of time from design stage to
	product launch, and we may have to abandon a test in which we have devoted substantial resources and time. We cannot be certain
	that any tests we seek to develop will prove to be effective; that we will be able to obtain, in a timely manner or at all, necessary
	regulatory approvals; that the tests we develop can be provided at acceptable costs, with appropriate quality or that they will
	be covered or reimbursed; or that, if developed, these tests will be successfully marketed and achieve community acceptance. If
	we cannot adequately demonstrate the applicability of our tests to new treatments, sales of our tests and services could decline,
	which would have a material adverse effect on our business, financial condition and results of operations.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 20; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage21"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	If our tests do not continue to perform as expected, our operating results, reputation
	and business will suffer.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Our success depends on the market&#8217;s confidence that we can
	continue to provide reliable, high-quality diagnostic tests. We believe that our customers are likely to be particularly sensitive
	to test defects and errors, such as false positive or false negative results which could affect the patient&#8217;s eventual diagnosis
	and/or treatment. As a result, the failure of our tests or services to perform as expected would significantly impair our reputation
	and the public image of our tests and services, and we may be subject to legal claims arising from any defects or errors.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	We may implement a product recall or voluntary market withdrawal of MyPRS
</I>
<SUP>
	&#174;
</SUP>
<I>
	due to test defects or enhancements and modifications, which would significantly increase our costs.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The marketing of MyPRS
<SUP>
	&#174;
</SUP>
	and any future diagnostic
	tests that we may develop involves an inherent risk that such tests may prove to be defective. In that event, we may voluntarily
	implement a market withdrawal of such tests or may be required to do so by a regulatory authority. A recall of MyPRS
<SUP>
	&#174;
</SUP>
	or one of our future diagnostic tests, or a similar product or service offered by another provider, could impair sales of the services
	we market as a result of confusion concerning the scope of the recall or as a result of the damage to our reputation for quality
	and safety.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	We rely on a limited number of third parties for manufacture and supply of all
	of our laboratory instruments, tests and materials, and we may not be able to find replacement suppliers or manufacturers in a
	timely manner in the event of any disruption, which could adversely affect our business.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We rely on third parties for the manufacture and supply of all of
	our laboratory instruments, equipment and materials, such as reagents, microarray chips and disposable test kits, that we need
	to perform our specialized diagnostic services, and rely on a limited number of suppliers for certain laboratory materials and
	some of the laboratory equipment with which we perform our diagnostic services. We do not have long-term contracts with our suppliers
	and manufacturers that commit them to supply equipment and materials to us. Certain of our suppliers provide us with analyte specific
	regents (&#8220;ASRs&#8221;), which serve as building blocks in the diagnostic tests we conduct in our laboratory. These suppliers
	are subject to regulation by the FDA, and must comply with federal regulations related to the manufacture and distribution of ASR
	products. Because we cannot ensure the actual production or manufacture of such critical equipment and materials, or the ability
	of our suppliers to comply with applicable legal and regulatory requirements, we may be subject to significant delays caused by
	interruption in production or manufacturing. If any of our third-party suppliers or manufacturers were to become unwilling or unable
	to provide this equipment or these materials in required quantities or on our required timelines, we would need to identify and
	acquire acceptable replacement sources on a timely basis. While we have developed alternate sourcing strategies for the equipment
	and materials we use, we cannot be certain that these strategies will be effective and even if we were to identify other suppliers
	and manufacturers for the equipment and materials we need to perform our specialized diagnostic services, there can be no assurance
	that we will be able to enter into agreements with such suppliers and manufacturers or otherwise obtain such items on a timely
	basis or on acceptable terms, if at all. If we encounter delays or difficulties in securing necessary laboratory equipment or materials,
	including consumables, we would face an interruption in our ability to perform our specialized diagnostic services and experience
	other disruptions that would adversely affect our business, results of operations and financial condition.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	If our sole laboratory facility becomes damaged or inoperable, or we are required
	to vacate the facility, our ability to provide services and pursue our research and development efforts may be jeopardized.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We currently derive substantially all of our revenues from our laboratory
	testing services. We do not have any clinical reference laboratory facilities other than our facility in Little Rock, Arkansas.
	Our facilities and equipment could be harmed or rendered inoperable by natural or man-made disasters, including fire, flooding
	and power outages, which may render it difficult or impossible for us to perform our tests or provide laboratory services for some
	period of time. The inability to perform our tests or the backlog of tests that could develop if our facility is inoperable for
	even a short period of time may result in the loss of customers or harm to our reputation or relationships with collaborators,
	and we may be unable to regain those customers or repair our reputation in the future. Furthermore, our facilities and the equipment
	we use to perform our research and development work could be costly and time-consuming to repair or replace, which could further
	delay our ability to provide our testing services.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Additionally, a key component of our research and development process
	involves using biological samples and the resulting data sets and medical histories, as the basis for our diagnostic test development.
	In some cases, these samples are difficult to obtain. If the parts of our laboratory facility where we store these biological samples
	are damaged or compromised, our ability to pursue our research and development projects, as well as our reputation, could be jeopardized.
	We carry insurance for damage to our property and the disruption of our business, but this insurance may not be sufficient to cover
	all of our potential losses and may not continue to be available to us on acceptable terms, if at all.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 21; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	18
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage22"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Further, if our laboratory became inoperable, we may not be able
	to license or transfer our proprietary technology to a third party, with established state licensure and CLIA certification under
	the scope of which our diagnostic tests could be performed following validation and other required procedures, to perform the tests.
	Even if we find a third party with such qualifications to perform our tests, such party may not be willing to perform the tests
	for us on commercially reasonable terms. We may have to reapply for state licensure and CLIA certification if we are unable to
	find a third party with such qualifications.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	If we fail to properly manage our anticipated growth, our business could suffer.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Our growth has placed, and will continue to place, a significant
	strain on our management and on our operational and financial resources and systems. Failure to manage our growth effectively could
	cause us to over-invest or under-invest, and result in losses or weaknesses. Additionally, our anticipated growth will increase
	the demands placed on our suppliers, resulting in an increased need for us to carefully monitor for quality assurance. Any failure
	by us to manage our growth effectively could have an adverse effect on our ability to achieve our development and commercialization
	goals.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Fluctuations in insurance cost and availability could adversely affect our profitability
	or our risk management profile.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We hold a number of insurance policies, including product liability
	insurance, property insurance, workers&#8217; compensation insurance, and directors&#8217; and officers&#8217; liability insurance.
	If the costs of maintaining adequate insurance coverage increase significantly in the future, our operating results and cash flow
	could be materially adversely affected. Likewise, if any of our current insurance coverage should become unavailable to us or become
	economically impractical, we would be required to operate our business without indemnity from commercial insurance providers. If
	we operate our business without insurance, we could be responsible for paying claims or judgments against us that would have otherwise
	been covered by insurance, which could adversely affect our results of operations or financial condition.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	If we cannot compete successfully with our competitors, we may be unable to increase
	or sustain our revenues or achieve and sustain profitability.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Our principal competition comes from the existing mainstream diagnostic
	methods that pathologists and oncologists use and have used for many years. It may be difficult to change the methods or behavior
	of the referring pathologists and oncologists to incorporate our molecular diagnostic testing in their practices. However, we believe
	that we can introduce our diagnostic tests successfully due to their clinical utility and the desire of pathologists and oncologists
	to find solutions for more accurate diagnosis, prognosis and personalized treatment options for MM and AMG patients. But this is
	not certain and if the health care providers who are in a position to order our tests do not adopt them, it could adversely affect
	our business.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We also face competition from companies that currently offer or
	are developing products to profile genes, gene expression or protein biomarkers in various cancers. Personalized genetic diagnostics
	is a new area of science, and we cannot predict what tests others will develop that may compete with or provide results superior
	to the results we are able to achieve with the tests we develop. Our competitors include public companies such as NeoGenomics,
	Inc., Quest Diagnostics, Abbott Laboratories, Inc., Johnson &amp; Johnson, Roche Molecular Systems, Inc., bioTheranostics, Inc.,
	Genomic Health, Inc., Myriad Genetics Inc., Qiagen N.V., Foundation Medicine, Inc., Cancer Genetics, Inc., and many private companies,
	including Agendia B.V. Another source of competition comes from other scientific teams attempting to develop GEP signatures utilizing
	other genes or a subset of the genes utilized in our MyPRS
<SUP>
	&#174;
</SUP>
	test. Two groups of note include the French IFM-15 gene
	signature and the Netherlands EMC-92 gene signature which have been studied by independent groups and compared to the UAMS GEP
	test, or MyPRS
<SUP>
	&#174;
</SUP>
	.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We provide services in a segment of the health care industry that
	is highly fragmented and extremely competitive. Any failure to respond to technological advances and emerging industry standards
	could impair our ability to attract and retain clients. This industry is characterized by rapid technological change. It is anticipated
	that competition will continue to increase due to such factors as the potential for commercial applications of biotechnology and
	the continued availability of investment capital and government funding for cancer-related research. Our competitors may succeed
	in developing diagnostic tests and/or services that are superior to our tests and technologies, including our pipeline tests. This
	could render our tests obsolete and, as a result, they might not be ordered, thus impairing the viability of our business.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We expect that pharmaceutical and biopharmaceutical companies will
	increasingly focus attention and resources on the personalized diagnostic sector as the potential and prevalence increases for
	molecularly targeted oncology therapies approved by the FDA along with companion diagnostics. For example, the FDA has approved
	two such agents &#8212; Xalkori crizotinib from Pfizer Inc. along with its companion anaplastic lymphoma kinase FISH test from
	Abbott Laboratories, Inc. and Zelboraf vemurafenib from Genentech USA Incorporated and Daiichi-Sankyo Inc. along with its companion
	B-RAF kinase V600 mutation test from Roche Molecular Systems, Inc. These two FDA approvals are the second and third instances of
	simultaneous approvals of a drug and companion diagnostic, the first being the 1998 approval of Genentech, Inc.&#8217;s Herceptin
	trastuzumab for HER2 positive breast cancer along with the HercepTest from partner Dako A/S.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We also face competition from companies such as Genoptix, Inc. (a
	Novartis AG company), Neogenomics, Inc., Cancer Genetics, Inc., Bio-Reference Laboratories, Inc. (a division of OPKO Health, Inc.),
	Intergrated Genetics (a LabCorp Specialty Testing Group) and Foundation Medicine, Inc., which offer products or services or have
	conducted research to develop genetic profiles, or genetic or protein biomarkers for various cancers. Additionally, projects related
	to cancer genomics have received increased government funding, both in the United States and internationally. As more information
	regarding cancer genomics becomes available to the public, we anticipate that more products and services aimed at predicting patient
	outcome as well as identifying targeted treatment options will be developed and that these products and services may compete with
	the services we offer. In addition, competitors may develop their own versions of our tests in countries where we did not apply
	for patents or where our patents have not issued and compete with us in those countries, including promoting the use of their test(s)
	by physicians or patients in other countries.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 22; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	19
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage23"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Many of our present and potential competitors have widespread brand
	recognition and substantially greater financial and technical resources and development, production and marketing capabilities
	than we do. Others may develop lower-priced, less complex tests that payors, pathologists and oncologists could view as functionally
	equivalent to our tests, which could force us to lower the list price of our tests and impact our operating margins and our ability
	to achieve profitability. In addition, technological innovations that result in the creation of enhanced diagnostic tools may enable
	other clinical laboratories, hospitals, physicians or medical providers to provide specialized diagnostic services similar to ours
	in a more patient-friendly, efficient or cost-effective manner than is currently possible. If we cannot compete successfully against
	current or future competitors, we may be unable to increase market acceptance and sales of our tests, which could prevent us from
	increasing or sustaining our revenues or achieving or sustaining profitability.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	We expect to continue to incur significant expenses to develop and market our diagnostic
	tests, which could make it difficult for us to achieve and sustain profitability.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	In recent years, we have incurred significant costs in connection
	with the development of our diagnostic tests. For the year ended December 31, 2015, our research and development expenses were
	$1.0 million, or 39% of our net revenue, and our selling and marketing expenses were $2.6 million, or 101% of our net revenue.
	For the year ended December 31, 2014, our research and development expenses were $347,000, or 8% of our net revenue, and our selling
	and marketing expenses were $717,000, or 17% of net revenue. We expect our expenses to continue to increase, in absolute dollars,
	for the foreseeable future as we seek to expand the clinical utility of our diagnostic tests, and work to drive adoption of and
	reimbursement for our diagnostic tests and develop new tests. As a result, we will need to generate significant revenues in order
	to achieve sustained profitability.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	We depend on third parties for the supply of certain tissue samples and biological
	materials that we use in our research and development efforts. If these costs increase or our third party collaborators terminate
	their relationship with us, our business may be materially harmed.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Under standard clinical practice in the United States, tumor biopsies
	removed from patients are chemically preserved, embedded in paraffin wax and stored. Our clinical development relies on our ability
	to access these archived tumor biopsy samples, as well as information pertaining to their associated clinical outcomes. Other companies
	often compete with us for access. Additionally, the process of negotiating access to archived samples is lengthy, because it typically
	involves numerous parties and approvals to resolve complex issues such as usage rights, institutional review board approval, privacy
	rights, publication rights, intellectual property ownership and research parameters.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	UAMS and other institutions provide us with tissue samples and other
	biological materials that we use in developing and validating our tests. We do not have written agreements with some of these third
	parties, and, in many of the cases in which the agreements are in writing, our relationships with such third parties are terminable
	on 30 days&#8217; notice or less. Disagreements or disputes might cause delays or termination of the research, development or commercialization
	of testing systems or additional test indications, might lead to additional responsibilities or costs to us or might result in
	litigation or arbitration, any of which could divert management attention and resources and be time-consuming and expensive. If
	one or more of these suppliers terminate their relationship with us, we will need to identify other third parties to provide us
	with tissue samples and biological materials, which could result in a delay in our research and development activities and negatively
	affect our business. In addition, as we grow, research and academic institutions may begin to seek financial contributions from
	us, which may negatively affect our results of operations. Potential suppliers may elect not to work with us based on their assessment
	of our financial, regulatory or intellectual property position. Even if we establish new agreements, this may not result in the
	successful development of future testing systems or additional test indications.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	The loss of our Chairman or key members of our executive management team could
	adversely affect our business.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Our success in implementing our business strategy depends largely
	on the skills, experience and performance of the Chairman of our board of directors, Bennett S. LeBow, key members of our executive
	management team and others in key management positions, including Samuel D. Riccitelli, our President and Chief Executive Officer,
	and Tamara A. Seymour, our Chief Financial Officer. The collective efforts of each of these persons working as a team are critical
	to us as we continue to develop our technologies, tests and research and development and sales programs. As a result of the difficulty
	in locating qualified new management, the loss or incapacity of existing members of our executive management team could adversely
	affect our operations. If we were to lose one or more of these key employees, we could experience difficulties in finding qualified
	successors, competing effectively, developing our technologies and implementing our business strategy. Our President and Chief
	Executive Officer, Samuel D. Riccitelli, our Chief Financial Officer, Tamara A. Seymour, our Chief Commercial Officer, Michael
	C. Cerio, our Chief Medical Officer, Richard A. Bender, M.D., FACP, our Chief Information Officer, Sudipto Sur, Ph.D., and our
	Vice President of Research and Operations, Ryan Van Laar, Ph.D. each have employment agreements with us. However, the existence
	of an employment agreement does not guarantee retention of members of our executive management team or our key employees and we
	may not be able to retain those individuals for the duration of or beyond the end of their respective terms.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 23; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	20
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage24"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	In addition, we rely on consultants and advisors, including scientific
	and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants
	and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other
	entities that may limit their availability to us.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Our inability to attract, hire and retain a sufficient number of qualified sales
	professionals would hamper our ability to increase demand for our tests, to expand geographically and to successfully commercialize
	any other diagnostic tests or products we may develop.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Our success in selling our clinical laboratory services, diagnostic
	tests and any other tests or products that we are able to develop will require us to expand our sales force in the United States
	by recruiting additional sales representatives with extensive experience in oncology and close relationships with medical oncologists,
	surgeons, pathologists and other hospital personnel. To achieve our marketing and sales goals, we will need to substantially expand
	our sales and commercial infrastructure, with which to date we have had little experience. Sales professionals with the necessary
	technical and business qualifications are in high demand, and there is a risk that we may be unable to attract, hire and retain
	the number of sales professionals with the right qualifications, scientific backgrounds and relationships with decision-makers
	at potential customers needed to achieve our sales goals. We may face competition from other companies in our industry, some of
	whom are much larger than us and who can pay greater compensation and benefits than we can, in seeking to attract and retain qualified
	selling and marketing employees. If we are unable to hire and retain qualified selling and marketing personnel, our business will
	suffer.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Some of our future contract manufacturers and distributors may be located outside
	of the United States, which may subject us to increased complexity and costs.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	In the future we may need to rely on manufacturing or laboratory
	facilities located outside the United States for our tests. Our MyPRS
<SUP>
	&#174;
</SUP>
	and future test sales may be subject to certain
	risks, including:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<UL STYLE="MARGIN-TOP: 0IN; LIST-STYLE-TYPE: DISC">
<LI STYLE="MARGIN: 0PT 0; FONT-SIZE: 10PT">
	difficulty in obtaining, maintaining or enforcing intellectual property rights in some
	countries;
</LI>
<LI STYLE="MARGIN: 5PT 0; FONT-SIZE: 10PT">
	local business and cultural factors that differ from our normal standards and practices;
</LI>
<LI STYLE="MARGIN: 0PT 0; FONT-SIZE: 10PT">
	foreign currency exchange fluctuations;
</LI>
<LI STYLE="MARGIN: 5PT 0; FONT-SIZE: 10PT">
	additional U.S., and new foreign regulatory requirements;
</LI>
<LI STYLE="MARGIN: 0PT 0; FONT-SIZE: 10PT">
	impediments to the flow of foreign exchange capital payments and receipts due to exchange
	controls instituted by certain foreign governments and the fact that local currencies of some countries are not freely convertible;
</LI>
<LI STYLE="MARGIN: 5PT 0; FONT-SIZE: 10PT">
	geopolitical and economic instability and military conflicts;
</LI>
<LI STYLE="MARGIN: 0PT 0; FONT-SIZE: 10PT">
	difficulties in managing international partners;
</LI>
<LI STYLE="MARGIN: 5PT 0; FONT-SIZE: 10PT">
	burdens of complying with a variety of foreign laws and treaties and changes in local
	laws and regulations, including tax laws;
</LI>
<LI STYLE="MARGIN: 0PT 0; FONT-SIZE: 10PT">
	increased financial accounting and reporting burdens;
</LI>
<LI STYLE="MARGIN: 5PT 0; FONT-SIZE: 10PT">
	difficulty in enforcing agreements, judgments and arbitration awards in foreign jurisdictions;
	and
</LI>
<LI STYLE="MARGIN: 0PT 0; FONT-SIZE: 10PT">
	adverse economic conditions in any jurisdiction.
</LI>
</UL>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	These factors could harm our business or results of operations.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	If we were sued for product liability or professional liability, we could face
	substantial liabilities that exceed our resources.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The marketing, sale and use of our tests could lead to the filing
	of product liability claims were someone to allege that our tests failed to perform as designed. We may also be subject to liability
	for errors in the test results we provide to pathologists and oncologists or for a misunderstanding of, or inappropriate reliance
	upon, the information we provide. A product liability or professional liability claim could result in substantial damages and be
	costly and time-consuming for us to defend.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Although we believe that our existing product and professional liability
	insurance is adequate, our insurers may fail to defend us or our insurance may not fully protect us from the financial impact of
	defending against product liability or professional liability claims. Any product liability or professional liability claim brought
	against us, with or without merit, could increase our insurance rates or prevent us from securing insurance coverage in the future.
	Additionally, any product liability lawsuit could damage our reputation, or cause current clinical partners and collaborators to
	terminate existing agreements and potential clinical partners to seek other partners, cause customers to terminate their relationship
	with us and potential customers to seek alternative testing solutions, any of which could impact our results of operations.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 24; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	21
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage25"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	If we use biological and hazardous materials in a manner that causes injury, we
	could be liable for damages.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Our activities currently require the controlled use of potentially
	harmful biological materials and hazardous materials and chemicals. We cannot eliminate the risk of accidental contamination or
	injury to employees or third parties from the use, storage, handling or disposal of these materials. In the event of contamination
	or injury, we could be held liable for any resulting damages, and any liability could exceed our resources or any applicable insurance
	coverage we may have. Additionally, we are subject to, on an ongoing basis, federal, state and local laws and regulations governing
	the use, storage, handling and disposal of these materials and specified waste products. The cost of compliance with these laws
	and regulations may become significant and could have a material adverse effect on our financial condition, results of operations
	and cash flows. In the event of an accident or if we otherwise fail to comply with applicable regulations, we could lose our permits
	or approvals or be held liable for damages or penalized with fines.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	If we cannot support demand for our tests, including successfully managing the
	evolution of our technology and manufacturing platforms, our business could suffer.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	As our test volume grows, we will need to increase our testing capacity,
	implement increases in scale and related processing, customer service, billing, collection and systems process improvements and
	expand our internal quality assurance program and technology to support testing on a larger scale. We will also need additional
	certified laboratory scientists and other scientific and technical personnel to process these additional tests. Any increases in
	scale, related improvements and quality assurance may not be successfully implemented and appropriate personnel may not be available.
	As additional tests are commercialized, we will need to bring new equipment on line, implement new systems, technology, controls
	and procedures and hire personnel with different qualifications. Failure to implement necessary procedures or to hire the necessary
	personnel could result in a higher cost of processing or an inability to meet market demand. We cannot assure that we will be able
	to perform tests on a timely basis at a level consistent with demand, that our efforts to scale our commercial operations will
	not negatively affect the quality of our test results or that we will respond successfully to the growing complexity of our testing
	operations. If we encounter difficulty meeting market demand or quality standards for our tests, our reputation could be harmed
	and our future prospects and business could suffer, which may have a material adverse effect on our financial condition, results
	of operations and cash flows.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Declining general economic or business conditions may have a negative impact on
	our business.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Continuing concerns over United States health care reform legislation
	and energy costs, geopolitical issues, the availability and cost of credit and government stimulus programs in the United States
	and other countries have contributed to increased volatility and diminished expectations for the global economy. These factors,
	combined with low business and consumer confidence and high unemployment, precipitated an economic slowdown and recession. If the
	economic climate does not improve or deteriorates, our business, including our access to patient samples and the addressable market
	for diagnostic tests that we may successfully develop, as well as the financial condition of our suppliers and our third-party
	payors, could be adversely affected, resulting in a negative impact on our business, financial condition and results of operations.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	We depend on our information technology and telecommunications systems, and any
	failure of these systems could harm our business.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We depend on information technology and telecommunications systems
	for significant aspects of our operations. In addition, our third-party billing and collections provider depends upon telecommunications
	and data systems provided by outside vendors and information we provide on a regular basis. These information technology and telecommunications
	systems support a variety of functions, including test processing, sample tracking, quality control, customer service and support,
	billing and reimbursement, research and development activities and our general and administrative activities. Information technology
	and telecommunications systems are vulnerable to damage from a variety of sources, including telecommunications or network failures,
	malicious human acts and natural disasters. Moreover, despite network security and back-up measures, some of our systems are potentially
	vulnerable to physical or electronic break-ins, computer viruses and similar disruptive problems. Despite the precautionary measures
	we have taken to prevent unanticipated problems that could affect our information technology and telecommunications systems, failures
	or significant downtime of our information technology or telecommunications systems or those used by our third-party service providers
	could prevent us from processing tests, providing test results to pathologists, oncologists, billing payors, processing reimbursement
	appeals, handling patient or physician inquiries, conducting research and development activities and managing the administrative
	aspects of our business. Any disruption or loss of information technology or telecommunications systems on which critical aspects
	of our operations depend could have an adverse effect on our business. Furthermore, we depend on FedEx as our courier. Any disruption
	in any of our mail services or transportation logistics could result in spoiled or lost samples, which could reduce revenue. Moreover,
	we are required to comply with laws governing the transmission, security and privacy of health information that require significant
	compliance costs, and any failure to comply with these laws could result in material criminal and civil penalties and civil liabilities.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 25; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	22
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage26"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	We license our billing and collections web-based software platform from a third-party
	provider. Our provider may fail in its obligations to maintain the system and thereby reduce our cash collections and harm our
	business.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Billing for laboratory tests is complicated and is subject to extensive
	and non-uniform rules and administrative requirements. Missing or incorrect information on requisitions adds complexity to and
	slows the billing process, creates backlogs and increases the aging of accounts receivable and bad debt expenses. Failure to timely
	or correctly bill may lead to our not being reimbursed for our services or an increase in aging of our accounts receivable. In
	addition, failure to comply with applicable federal and state laws relating to billing, including, but not limited, to the federal
	False Claims Act may lead to various penalties including civil and criminal fines and penalties, recoupment efforts, and exclusion
	from participation in Medicare and other federal health care programs. We rely heavily on a single third party to provide us with
	key software for our billing. If that third party is unable or unwilling to provide these software systems to us for any reason,
	or violates the law, we may not be able to submit claims promptly or at all and we may be subject to an investigation and potential
	civil and criminal penalties. Delays in invoicing can lead to delays in collections, and inaccuracies in our billing could result
	in lost revenue. If we fail to adapt quickly and effectively to changes affecting our costs, pricing and billing, our profitability
	and cash flow will be adversely affected.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Regulatory Risks Relating to Our Business
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Our business may be adversely impacted by sequestration in the United States.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	On March 1, 2013, most agencies of the federal government automatically
	reduced their budgets according to an agreement made by Congress in 2012 known as &#8220;sequestration.&#8221; Originally devised
	as an incentive to force Congressional agreement on budget issues, the sequestration order was approved on March 1, 2013 by the
	President of the United States. Reimbursement under the CLFS continues to be reduced by 2% as a result of federal government sequestration.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Health care policy changes, including legislation reforming the U.S. health care
	system and other legislative initiatives, may have a material adverse effect on our financial condition, results of operations
	and cash flows.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Government payors, such as Medicare and Medicaid, have taken steps
	and can be expected to continue to take steps to control the cost, utilization and delivery of health care services, including
	clinical laboratory test services.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	For example, in March 2010, U.S. President Barack Obama signed the
	Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the
	ACA, which made a number of substantial changes in the way health care is financed by both governmental and private insurers.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	While the ultimate impact of the ACA remains unclear, it is likely
	to be extensive and may result in significant changes to coverage and reimbursement of our tests. Congress has also proposed a
	number of legislative initiatives in response to the ACA, including possible repeal of the ACA. At this time, it remains unclear
	whether there will be any changes made to the ACA, whether to certain provisions or its entirety.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The ACA, among other things, imposed cuts to Medicare reimbursement
	for clinical laboratories. Medicare updates laboratory payment rates for inflation based on the CPI. The ACA included a &#8220;productivity
	adjustment&#8221; to reduce the CPI update. For 2015, the productivity adjustment for the CLFS was -0.6 percent. In addition, the
	ACA included an additional 1.75 percent reduction in the CPI update for clinical laboratories for the years 2011 through 2015.
	The annual update for 2015 in CLFS rates following the productivity adjustment and reduction of 1.75 percentage points was -0.3
	percent.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	In addition, on February 22, 2012, the President signed the Middle
	Class Tax Relief and Job Creation Act of 2012 (&#8220;MCTRJCA&#8221;), which, among other things, mandated an additional change
	in Medicare reimbursement for clinical laboratory services. This legislation required the Center for Medicare and Medicaid Services
	(&#8220;CMS&#8221;) to rebase payment amounts under the Medicare CLFS, reducing them by 2% in 2013. The reduced 2013 amount served
	as the base for payment rates in 2014, and subsequent years.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Such legislative changes have negatively impacted payments for clinical
	laboratory services since 2012. MACs have the authority to apply these cuts to locally determined payments for tests, such as MyPRS
<SUP>
	&#174;
</SUP>
	,
	that are reported using unlisted CPT codes. Thus, even though we use an unlisted CPT code to bill for MyPRS
<SUP>
	&#174;
</SUP>
	and
	reimbursement is determined by the local MAC, such legislative changes could affect our reimbursement. The full impact on our business
	of such legislative initiatives is uncertain.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	In addition, many of the CPT codes that we may use to bill our tests
	in the future are periodically revised by the AMA. The adoption of analyte specific codes allows payors to better identify tests
	being performed, resulting in potential changes to coverage and reimbursement. In the 2014 Final Medicare CLFS Rule, CMS announced
	that it will keep the new molecular codes on the CLFS. CMS also announced that it would price the new codes using a &#8220;gapfilling&#8221;
	process by which it refers the codes to the MACs to allow them to determine an appropriate price. In addition, CMS also stated
	that it would not separately reimburse the algorithm portion of certain of the new codes for MAAAs, because it does not believe
	the algorithm qualifies as a clinical laboratory test. Thus, payment levels and the methodology for determining payment by Medicare
	and commercial health plans remain largely unresolved. Furthermore, CMS has the authority to revise payment rates for all tests
	paid under the CLFS, including imposing payment reductions. Even though we use an unlisted CPT code to bill for MyPRS
<SUP>
	&#174;
</SUP>
	and reimbursement is determined by the local MAC, our future reimbursement could be adversely affected by any number of CMS policy
	or payment changes. For example, if CMS reduces reimbursement for new test codes or does not pay for the algorithmic portion of
	our MAAA tests, then our revenues will be adversely affected. Whether Medicare and other payors will establish positive or adequate
	coverage policies or reimbursement rates remains uncertain.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 26; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	23
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage27"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The &#8220;Protecting Access to Medicare Act of 2014&#8221; (&#8220;PAMA&#8221;),
	which was signed into law on April 1, 2014, contained provisions that significantly affect Medicare payment for tests that are
	reimbursed under the CLFS. PAMA states that, starting in 2017, Medicare payment for each test will be based on the amount of payment
	being made by private payors for that test. Private payor payment amounts, adjusted for discounts and other price concessions,
	will be collected by certain laboratories, starting in 2016, and submitted to CMS so that market-based payment rates can be calculated.
	PAMA further states that, beginning in 2017, the Medicare payment rate for each clinical diagnostic lab test will be equal to the
	weighted median amount for the test from the most recent data collection period. New tests will generally be paid using the crosswalk
	or gapfilling methodology described elsewhere in this Annual Report. However, some new tests, termed Advanced Diagnostic Laboratory
	Tests, will be paid based on the laboratory&#8217;s actual list charge for a brief period of time until private payor payment data
	is available. Furthermore, in order to facilitate implementation of the new payment methodology, starting in 2016, CMS is required
	to assign specific billing codes to many CLFS tests existing at the time of enactment and to all new CLFS tests. The Secretary
	of HHS published a proposed rule that would implement these PAMA reforms on October 1, 2015. The timing and content of a final
	rule remain highly uncertain. Under the proposed rule, reporting by &#8220;applicable laboratories&#8221; would begin on January
	1, 2016, and would include private pay rate and volume data for the last two calendar quarters of 2015. We expect that we will
	likely be considered an &#8220;applicable laboratory.&#8221; Although the new reimbursement methodology established by PAMA is
	expected to generally result in relatively lower Medicare reimbursement for clinical diagnostic laboratory tests than has been
	historically available under the CLFS, the impact of this law and implementing regulations, if any, on Medicare payment for MyPRS
<SUP>
	&#174;
</SUP>
	or any test we might develop and commercialize in the future remains unclear. .
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We cannot predict whether future health care initiatives will be
	implemented at the federal or state level, or how any future legislation or regulation may affect us, but they may reduce our profits
	and have a materially adverse effect on our business, financial condition, results of operations and cash flows. We expect continuing
	efforts on the part of payors to reduce reimbursement, to impose more stringent cost controls, and to reduce utilization of clinical
	test services.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Our commercial success could be compromised if third-party payors, including managed
	care organizations and Medicare, do not provide coverage and reimbursement, breach, rescind or modify their contracts or reimbursement
	policies or delay payments for our molecular diagnostic tests.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Pathologists and oncologists may not order our molecular diagnostic
	tests unless third-party payors, such as managed care organizations and government payors such as Medicare and Medicaid, pay a
	substantial portion of the test price. Coverage and reimbursement by a third-party payor may depend on a number of factors, including
	a payor&#8217;s determination that tests using our technologies are:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<UL STYLE="MARGIN-TOP: 0IN; LIST-STYLE-TYPE: DISC">
<LI STYLE="MARGIN: 0PT 0; FONT-SIZE: 10PT">
	experimental or investigational;
</LI>
<LI STYLE="MARGIN: 5PT 0; FONT-SIZE: 10PT">
	not medically necessary;
</LI>
<LI STYLE="MARGIN: 0PT 0; FONT-SIZE: 10PT">
	not appropriate for the specific patient;
</LI>
<LI STYLE="MARGIN: 5PT 0; FONT-SIZE: 10PT">
	not cost-effective;
</LI>
<LI STYLE="MARGIN: 0PT 0; FONT-SIZE: 10PT">
	not supported by peer-reviewed publications; and/or
</LI>
<LI STYLE="MARGIN: 5PT 0; FONT-SIZE: 10PT">
	not included in clinical practice guidelines.
</LI>
</UL>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Uncertainty surrounds third-party payor reimbursement of any test
	incorporating new technology, including tests developed using microarrays. Technology assessments of new medical tests and devices
	conducted by research centers and other entities may be disseminated to interested parties for informational purposes. Third-party
	payors and health care providers may use such technology assessments as grounds to deny coverage for a test or procedure. To our
	knowledge, no technology assessments have been performed on our tests to date. However, if any technology assessments on our tests
	are performed, they could conclude that our tests are not clinically useful and this could result in payor non-coverage decisions,
	which would adversely affect our business.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Because each payor generally determines for its own enrollees or
	insured patients whether to cover or otherwise establish a policy to reimburse our diagnostic tests, seeking coverage and reimbursement
	is a time-consuming and costly process. We cannot be certain that coverage for our tests will be provided in the future by additional
	third-party payors or that existing contracts, agreements or policy decisions or reimbursement levels will remain in place or be
	fulfilled under existing terms and provisions. If we cannot obtain coverage and reimbursement from private and governmental payors
	such as Medicare and Medicaid for our current tests, or new tests or test enhancements that we may develop in the future, our ability
	to generate revenues could be limited, which may have a material adverse effect on our financial condition, results of operations
	and cash flow. Further, we have experienced in the past, and will likely experience in the future, delays and temporary interruptions
	in the receipt of payments from third-party payors due to missing documentation and other issues, which could cause delay in collecting
	our revenue.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 27; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	24
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage28"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	We depend on Medicare and a limited number of private payors for a significant
	portion of our revenues and if these or other payors stop providing reimbursement or decrease the amount of reimbursement for our
	tests, our revenues could decline.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	During the years ended December 31, 2015 and 2014, respectively,
	we derived 19% and 7% of our total revenue from private insurance, including managed care organizations and other health care insurance
	providers, 31% and 17% from government payor programs, most of which was derived from Medicare, and 50% and 76% from direct-bill
	customers, including hospitals and other laboratories. Medicare and other third-party payors may withdraw their coverage policies
	or cancel their contracts with us at any time, review and adjust the rate of reimbursement or stop paying for our tests altogether,
	which would reduce our total revenues.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We face efforts by payors to control the cost, utilization and delivery
	of health care services including clinical laboratory tests. In the past, measures have been undertaken to reduce payment rates
	for and decrease utilization of the clinical laboratory industry generally. Because of the cost-trimming trends, third-party payors
	that currently cover and provide reimbursement for our tests may suspend, revoke or discontinue coverage at any time, or may reduce
	the reimbursement rates payable to us. Any such action could have a negative impact on our revenues, which may have a material
	adverse effect on our financial condition, results of operations and cash flows.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	In some circumstances, being contracted with private third-party payors may limit
	the amount of reimbursement.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We are currently considered a &#8220;non-contracted provider&#8221;
	by a number of private third-party payors because we have not entered into a specific contract to provide our specialized diagnostic
	services to their insured patients at specified rates of reimbursement. If we were to become a contracted provider in the future,
	the amount of overall reimbursement we would receive may decrease because we could be reimbursed less at a contracted rate than
	we would be at a non-contracted rate, which could have a negative impact on our revenues. Further, we may be unable to collect
	payments from patients beyond that which is paid by their insurance and may experience lost revenue as a result.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Because of certain Medicare billing rules, we may not receive reimbursement for
	all tests provided to Medicare patients.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Under current Medicare billing rules, claims for our tests performed
	on Medicare beneficiaries who were hospital patients when the tumor tissue samples were obtained and whose tests were ordered less
	than 14 days from discharge must be included in the payment that the hospital receives for the patient services provided. Accordingly,
	we must bill individual hospitals for tests performed on Medicare beneficiaries during these timeframes in order to receive payment
	for our tests. Because we generally do not have a written agreement in place with these hospitals that purchase these tests, we
	may not be paid for our tests or may have to pursue payment from the hospital on a case-by-case basis. This could be especially
	problematic for us if the hospital does not receive separate payment from Medicare for our test.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Because a portion of our revenues is from third-party payors with whom we are not
	currently contracted, we may be required to make positive or negative adjustments to accounting estimates with respect to contractual
	allowances, which may adversely affect our results of operations, our credibility with financial analysts and investors, and our
	stock price.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We record revenues net of contractual allowances. We estimate contractual
	allowances for non-contracted insurance companies based on our historical collection experience for each type of payor. In the
	event that the actual amount of payment received differs from the previously recorded estimate, an adjustment to revenue is made
	in the current period at the time of final collection and settlement. Our estimates of net revenue for non-contracted insurance
	companies are subject to change based on the contractual status and payment policies of the third-party payors with whom we deal.
	We regularly refine our estimates in order to make our estimated revenue as accurate as possible based on our most recent collection
	experience with each third-party payor. There can be no assurances that we will not be required to make similar adjustments to
	estimates with respect to contractual allowances in the future, which could adversely affect our results of operations, our credibility
	with financial analysts and investors, and our stock price.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Complying with numerous regulations pertaining to our business is an expensive
	and time-consuming process, and any failure to comply could result in substantial penalties.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We are subject to CLIA, a federal law regulating clinical laboratories
	that perform testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or
	treatment of disease. Our clinical laboratory must be certified under CLIA in order for us to perform testing on human specimens.
	In addition, our proprietary tests must also be categorized as part of our CLIA certification so that we can offer them in our
	laboratory. CLIA is intended to ensure the quality and reliability of clinical laboratories in the United States by mandating specific
	standards in the areas of personnel qualifications, administration, and participation in proficiency testing, patient test management,
	quality control, quality assurance and inspections. We have a current certificate under CLIA to perform high complexity testing.
	To renew this certificate, we are subject to survey and inspection every two years. Moreover, CLIA inspectors may make periodic
	inspections of our clinical reference laboratory outside of the renewal process. Because we are also CAP-accredited, we are subject
	to published accreditation standards to which we must conform in order to maintain our accreditation, and subject to periodic unannounced
	laboratory audits.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 28; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	25
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage29"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The law also requires us to maintain a state laboratory license
	to conduct testing. Our laboratory is located in Arkansas and must have an Arkansas state license. Arkansas laws establish standards
	for day-to-day operation of our clinical reference laboratory, including the training and skills required of personnel and quality
	control. In addition, several other states require that we hold licenses to test specimens from patients in those states. Other
	states may have similar requirements or may adopt similar requirements in the future. Finally, we may be subject to regulation
	in foreign jurisdictions as we seek to expand international distribution of our tests.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	If we were to lose our CLIA certificate or Arkansas laboratory license,
	whether as a result of a revocation, suspension or limitation, we would no longer be able to offer our tests, which would limit
	our revenues and harm our business. If we were to lose our license in other states where we are required to hold licenses, we would
	not be able to test specimens from those states.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	If the FDA were to begin requiring approval or clearance of our tests, we could
	incur substantial costs and time delays associated with meeting requirements for pre-market clearance or approval or we could experience
	decreased demand for, or reimbursement for our tests.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Although the FDA maintains that it has authority to regulate the
	development and use of LDTs, such as ours, as medical devices, it has not exercised its authority with respect to most LDTs as
	a matter of enforcement discretion. The FDA does not generally extend its enforcement discretion to reagents or software provided
	by third parties used to perform LDTs, and therefore these products must typically comply with the FDA medical device regulations,
	which are wide-ranging and govern, among other things: product design and development, product testing, product labeling, product
	storage, pre-market clearance or approval, advertising and promotion and product sales and distribution.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We believe that our MyPRS
<SUP>
	&#174;
</SUP>
	test, as utilized in our
	laboratory testing, is an LDT. As a result, we believe that pursuant to the FDA&#8217;s current policies and guidance that the
	FDA does not currently require that we obtain regulatory clearances or approvals for our LDT. The container we provide for collection
	and transport of tumor samples from a pathology laboratory or hospital to our clinical reference laboratory may be a medical device
	subject to the FDA regulation but is currently exempt from pre-market review by the FDA. While we believe that we are currently
	in material compliance with applicable laws and regulations, we cannot be sure that the FDA or other regulatory agencies would
	agree with our determination, and a determination that we have violated these laws, or a public announcement that we are being
	investigated for possible violations of these laws, could adversely affect our business, prospects, and the results of operations
	or financial condition.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Moreover, FDA guidance and policy pertaining to diagnostic testing
	is continuing to evolve and is subject to ongoing review and revision. A significant change in any of the laws, regulations or
	policies may require us to change our business model in order to maintain regulatory compliance. At various times since 2006, the
	FDA has issued guidance documents or announced draft guidance regarding initiatives that may require varying levels of FDA oversight
	of our tests. For example, in June 2010, the FDA announced a public meeting to discuss the agency&#8217;s oversight of LDTs prompted
	by the increased complexity of LDTs and their increasingly important role in clinical decision-making and disease management, particularly
	in the context of personalized medicine. The FDA indicated that it was considering a risk-based application of oversight to LDTs
	and that, following public input and discussion, it might issue separate draft guidance on the regulation of LDTs, which ultimately
	could require that we seek and obtain either pre-market clearance or approval of LDTs, depending upon the risk-based approach the
	FDA adopts. The public meeting was held in July 2010 and further public comments were submitted to the FDA through September 2010.
	The FDA has stated it is continuing to develop draft guidance in this area.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	On July 31, 2014, the FDA notified Congress (as required by Section
	1143 of the Food and Drug Administration Safety and Innovation Act, signed by the U.S. President on July 9, 2012) of its intent
	to publish a proposed risk-based framework for LDTs, which are designed, manufactured, and used within a single laboratory. The
	notice to Congress provides the anticipated details of the draft guidance through which the FDA would propose to establish an LDT
	oversight framework, including premarket review for higher-risk LDTs, such as those that have the same intended use as FDA-approved
	or cleared companion diagnostics currently on the market. On October 3, 2014, the FDA published a proposed risk-based framework
	for LDTs, which are tests that are designed, manufactured, and used within a single laboratory. This draft guidance indicates that
	FDA would like to establish an LDT oversight framework, including premarket review for higher-risk LDTs, such as those that have
	the same intended use as FDA-approved or cleared companion diagnostics currently on the market. FDA&#8217;s notice states that
	FDA does not consider devices to be LDTs if they are designed or manufactured completely, or partly, outside of the laboratory
	that offers and uses them. Such guidance, if and when finalized, may significantly impact the sales of our products and how customers
	use our products, and may require us to change our business model in order to maintain compliance with these laws. We cannot predict
	the ultimate timing or form of any FDA guidance or regulation on LTDs.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 29; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	26
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage30"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Additionally, on November 25, 2013, the FDA issued Final Guidance
	&#8220;Distribution of In Vitro Diagnostic Products Labeled for Research Use Only.&#8221; The guidance emphasizes that the FDA
	will review the totality of the circumstances when it comes to evaluating whether equipment and testing components are properly
	labeled as research use only. The final guidance states that merely including a labeling statement that the product is for research
	purposes only will not necessarily render the device exempt from the FDA&#8217;s clearance, approval, and other regulatory requirements
	if the circumstances surrounding the distribution of the product indicate that the manufacturer knows its product is, or intends
	for its product to be, offered for clinical diagnostic uses. These circumstances may include written or verbal marketing claims
	or links to articles regarding a product&#8217;s performance in clinical applications and a manufacturer&#8217;s provision of technical
	support for clinical applications. If the FDA imposes significant changes to the regulation of LDTs, it could reduce our revenue
	or increase our costs and adversely affect our business, prospects, results of operations or financial condition.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We may be required to proactively achieve compliance with certain
	FDA regulations and to conform our diagnostic service operations to the FDA&#8217;s good manufacturing practice regulations for
	medical devices, known as the Quality System Regulation (&#8220;QSR&#8221;). In addition, we may voluntarily seek to conform our
	diagnostic service operations to QSR requirements. For clinical diagnostic products that are regulated as medical devices, the
	FDA enforces the QSR through pre-approved inspections and periodic unannounced inspections of registered manufacturing facilities.
	If we are subject to QSR requirements, the failure to comply with those requirements or take satisfactory corrective action in
	response to an adverse QSR inspection could result in enforcement actions, including a public warning letter or an untitled letter,
	a delay in approving or clearing, or a refusal to approve or clear, our products, a shutdown of diagnostic service operations,
	a product recall, civil or criminal penalties or other sanctions, which could in turn cause our sales and business to suffer.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We cannot provide any assurance that FDA regulation, including pre-market
	review, will not be required in the future for our tests, whether through final guidance issued by the FDA, new enforcement policies
	adopted by the FDA or new legislation enacted by Congress. We believe it is possible that legislation will be enacted into law
	or a final guidance could be issued by the FDA which may result in increased regulatory burdens for us to continue to offer our
	tests or to develop and introduce new tests. Given the attention Congress continues to give to these issues, legislation affecting
	this area may be enacted into law and may result in increased regulatory burdens on us as we continue to offer our tests and to
	develop and introduce new tests.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	In addition, the Secretary of the U.S. Department of HHS, requested
	that its Advisory Committee on Genetics, Health and Society make recommendations about the oversight of genetic testing. A final
	report was published in April 2008. If the report&#8217;s recommendations for increased oversight of genetic testing were to result
	in further regulatory burdens, they could negatively affect our business and delay the commercialization of tests in development.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Any requirement of pre-market review could negatively affect our
	business until such review is completed and clearance to market or approval is obtained. The FDA could require that we stop selling
	our tests pending pre-market clearance or approval. If the FDA allows our tests to remain on the market but there is uncertainty
	about the validity of our tests, if they are labeled investigational by the FDA or if the labeling claims the FDA allows us to
	make are very limited, orders or reimbursement may decline. The regulatory approval process may involve, among other things, successfully
	completing additional clinical trials and making a 510(k) submission, or filing a PMA application with the FDA. If the FDA requires
	pre-market review, our tests may not be cleared or approved on a timely basis, if at all. We may also decide voluntarily to pursue
	FDA pre-market review of our tests if we determine that doing so would be appropriate.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Additionally, should future regulatory actions affect any of the
	reagents we obtain from vendors and use in conducting our tests, our business could be adversely affected in the form of increased
	costs of testing or delays, limits or prohibitions on the purchase of reagents necessary to perform our testing.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	If we were required to conduct additional clinical trials prior to continuing to
	offer our proprietary MyPRS
</I>
<SUP>
	&#174;
</SUP>
<I>
	test or any other tests that we may develop as LDTs, those trials could lead
	to delays or failure to obtain necessary regulatory approval, which could cause significant delays in commercializing any future
	products and harm our ability to achieve sustained profitability.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	If FDA decides to require that we obtain clearance or approvals
	to commercialize our proprietary genetic-based tests, we may be required to conduct additional pre-market clinical testing prior
	to submitting a regulatory notification or application for commercial sales. Clinical trials must be conducted in compliance with
	FDA regulations or FDA may take enforcement action or reject the data. The data collected from these clinical trials may ultimately
	be used to support market clearance or approval for our tests. Even if our clinical trials are completed as planned, we cannot
	be certain that their results will support our test claims or that FDA or foreign authorities will agree with our conclusions regarding
	our test results. Success in early clinical trials does not ensure that later clinical trials will be successful, and we cannot
	be sure that the later trials will replicate the results of prior trials and studies. If we are required to conduct pre-market
	clinical trials, whether using prospectively acquired samples or archival samples, delays in the commencement or completion of
	clinical testing could significantly increase our test development costs and delay commercialization. Many of the factors that
	may cause or lead to a delay in the commencement or completion of clinical trials may also ultimately lead to delay or denial of
	regulatory clearance or approval. The commencement of clinical trials may be delayed due to insufficient patient enrollment, which
	is a function of many factors, including the size of the patient population, the nature of the protocol, the proximity of patients
	to clinical sites and the eligibility criteria for the clinical trial. Moreover, the clinical trial process may fail to demonstrate
	that our tests are effective for the proposed indicated uses, which could cause us to abandon a test candidate and may delay development
	of other tests.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 30; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	27
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage31"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We may find it necessary to engage contract research organizations
	to perform data collection and analysis and other aspects of our clinical trials, which might increase the cost and complexity
	of our trials. We may also depend on clinical investigators, medical institutions and contract research organizations to perform
	the trials properly. If these parties do not successfully carry out their contractual duties or obligations or meet expected deadlines,
	or if the quality, completeness or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our
	clinical protocols or for other reasons, our clinical trials may have to be extended, delayed or terminated. Many of these factors
	would be beyond our control. We may not be able to enter into replacement arrangements without undue delays or considerable expenditures.
	If there are delays in testing or approvals as a result of the failure to perform by third parties, our research and development
	costs would increase, and we may not be able to obtain regulatory clearance or approval for our tests. In addition, we may not
	be able to establish or maintain relationships with these parties on favorable terms, if at all. Each of these outcomes would harm
	our ability to market our tests or to achieve sustained profitability.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	We are subject to federal and state health care fraud and abuse laws and regulations
	and could face substantial penalties if we are unable to fully comply with such laws.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We are subject to health care fraud and abuse regulation and enforcement
	by both the federal government and the states in which we conduct our business. These health care laws and regulations include,
	for example:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<UL STYLE="MARGIN-TOP: 0IN; LIST-STYLE-TYPE: DISC">
<LI STYLE="MARGIN: 0PT 0; FONT-SIZE: 10PT">
	the federal Anti-Kickback Statute, which prohibits, among other things, persons or entities
	from soliciting, receiving, offering or providing remuneration, directly or indirectly, in return for, to induce or to arrange
	for the referral of an individual for, or the purchase, order or recommendation of, any items or services for which payment may
	be made under a federal health care program such as the Medicare and Medicaid programs;
</LI>
<LI STYLE="MARGIN: 5PT 0; FONT-SIZE: 10PT">
	the federal physician self-referral prohibition, commonly known as the Stark Law, which
	prohibits physicians from referring Medicare or Medicaid patients to providers of &#8220;designated health services&#8221; with
	whom the physician or a member of the physician&#8217;s immediate family has an ownership interest or compensation arrangement,
	unless a statutory or regulatory exception applies;
</LI>
<LI STYLE="MARGIN: 0PT 0; FONT-SIZE: 10PT">
	the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;),
	which establishes federal crimes for knowingly and willfully executing a scheme to defraud any health care benefit program or making
	false statements in connection with the delivery of or payment for health care benefits, items or services;
</LI>
<LI STYLE="MARGIN: 5PT 0; FONT-SIZE: 10PT">
	the federal False Claims Act, which prohibits, among other things, individuals or entities
	from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors
	that are false or fraudulent;
</LI>
<LI STYLE="MARGIN: 0PT 0; FONT-SIZE: 10PT">
	the federal Physician Payment Sunshine Act requirements under the ACA, which require
	manufacturers of drugs, devices, biologics and medical supplies to report to HHS information related to payments and other transfers
	of value made to or at the request of covered recipients, such as physicians and teaching hospitals, and physician ownership and
	investment interests in such manufacturers. Payments made to physicians and research institutions for clinical trials are included
	within the ambit of this law; and
</LI>
<LI STYLE="MARGIN: 5PT 0; FONT-SIZE: 10PT">
	state law equivalents of each of the above federal laws, which may apply more broadly,
	contain additional restrictions, or carry different types of penalties.
</LI>
</UL>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We seek to comply with these laws. However, it is possible that
	we could be the subject of a government investigation regarding our compliance with these or other laws and that the government
	could take the position that we are not in compliance with one or more of them. In such case, we may be judged to be in violation
	of those laws and subject to civil and criminal penalties. In addition, many of these laws and regulations are vague or indefinite
	and have not been interpreted by the courts or regulatory agencies. These laws and regulations may be interpreted or applied by
	a prosecutorial, regulatory or judicial authority in a manner that could subject us to liability and/or require us to make changes
	in our operations.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We believe that federal and state governments continue to strengthen
	their enforcement efforts against health care fraud. In addition, the ACA increases the funding, power, penalties and remedies
	to pursue suspected cases of fraud and abuse and provides the government with expanded opportunities to pursue actions under the
	federal Anti-Kickback Statute, the False Claims Act, and the Stark Law. For example, the ACA narrowed the public disclosure bar
	under the False Claims Act, allowing increased opportunities for whistleblower litigation. In addition, the legislation modified
	the intent standard under the federal Anti-Kickback Statute, making it easier for prosecutors to prove that alleged violators had
	met the requisite knowledge requirement. The ACA and final regulations promulgated thereunder also require Medicare Part A and
	B providers and suppliers to report and return Medicare overpayments by the later of 60 days after the date on which the overpayment
	was identified or, if applicable, the date any corresponding cost report is due. Overpayments are considered to be &#8220;identified&#8221;
	when the provider or supplier has or should have, through the exercise of reasonable diligence, determined that it has received
	an overpayment, and quantified the amount of the overpayment. The ACA also provides that claims that include items or services
	resulting from a violation of the Anti-Kickback Statute constitutes a false or fraudulent claims for purposes of the False Claims
	Act. Any action brought against us for violation of these laws or regulations, even if we successfully defend against it, could
	cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. If
	our operations are found to be in violation of any of these laws and regulations, we may be subject to any applicable penalty associated
	with the violation, including civil and criminal penalties, damages and fines, and/or exclusion from participation in Medicare,
	Medicaid or other state or federal health care programs, we could be required to refund payments received by us, and we could be
	required to curtail or cease our operations. Any of the foregoing consequences could seriously harm our business, our financial
	condition and results of operations.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 31; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	28
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage32"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<I>
	Anti-Kickback Statutes
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The federal Anti-Kickback Statute establishes criminal prohibitions
	against and civil penalties for the knowing and willful solicitation, receipt, offer or payment of any remuneration, whether direct
	or indirect, in return for, to induce, or to arrange for the referral of patients or the ordering or purchasing of items or services
	payable in whole or in part under Medicare, Medicaid or other federal health care programs. Sanctions for violations of the Anti-Kickback
	Statute include criminal and civil penalties, such as imprisonment and/or criminal fines of up to $25,000 per violation, and civil
	penalties of up to $50,000 per violation and up to three times the amount received from the health care program, and exclusion
	from the Medicare, Medicaid and other federal health care programs.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The Office of Inspector General (&#8220;OIG&#8221;) has the authority
	to promulgate regulations referred to as &#8220;safe harbors&#8221; that define certain business relationships and arrangements
	that would not be subject to civil sanction or criminal enforcement under the Anti-Kickback Statute. Failure to comply with a safe
	harbor provision does not make the activity illegal. Rather, the safe harbors set forth specific criteria that, if fully met, will
	assure the entities involved of not being prosecuted criminally or civilly for the arrangement under the Anti-Kickback Statute.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Many states also have enacted statutes similar to the Anti-Kickback
	Statute, which may include criminal penalties, applicable to referrals of patients regardless of payor source, and may contain
	exceptions different from state to state and from the exceptions to the federal Anti-Kickback Statute.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<I>
	False Claims Act and Related Criminal Provisions
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The False Claims Act imposes civil penalties for knowingly making
	or causing to be made false claims with respect to governmental programs, such as Medicare and Medicaid, for services billed but
	not rendered, or for misrepresenting actual services rendered, in order to obtain higher reimbursement. Under the interpretation
	of certain courts, claims submitted for services furnished in violation of the Anti-Kickback Statute or Stark Law could also violate
	the False Claims Act. Moreover, private individuals may bring qui tam or &#8220;whistle blower&#8221; suits against providers under
	the False Claims Act, which authorizes the payment of a portion of any recovery to the individual bringing suit. Such actions are
	initially required to be filed under seal pending their review by the Department of Justice. The False Claims Act generally provides
	for the imposition of civil penalties of $5,500 to $11,000 per claim and for treble damages, resulting in the possibility of substantial
	financial penalties for small billing errors that are replicated in a large number of claims, as each individual claim could be
	deemed to be a separate violation of the False Claims Act. Some states also have enacted statutes similar to the False Claims Act
	which may include criminal penalties, substantial fines, and treble damages. The Social Security Act provides financial incentives
	to states that enact state false claims acts that meet specified requirements. The OIG, in consultation with the Attorney General
	of the United States and the Department of Justice, determines whether a state false claims act meets these enumerated requirements
	to qualify for the added financial incentive.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<I>
	Civil Monetary Penalties Law
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Individuals or entities who have among other things (1) directly
	submitted, or caused to be submitted, claims which are improper or false; (2) arranged or contracted with an individual or entity
	that the person knows or should know is excluded from participation in federal health care programs; or (3) offered or received
	kickbacks may also be subject to monetary penalties or exclusion under the Civil Monetary Penalties Law (&#8220;CMPL&#8221;), at
	the discretion of the OIG. Penalties are generally not more than $10,000 for each item or service. However, under the CMPL, violators
	of the federal Anti-Kickback Statute provisions may also be subject to additional civil money penalties of $50,000 per violation.
	Violators are also subject to an assessment of up to three times the amount claimed for each item or service in lieu of damages
	sustained by the United States or a state agency because of such claim, or damages of up to three times the total amount of remuneration
	offered, paid, solicited, or received. In addition, any person or entity who violates this section may be excluded from participation
	in federal and state health care programs.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<I>
	Stark Law
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The original Ethics in Patient Referrals Act of 1989, commonly referred
	to as the Stark Law, was enacted as part of the Omnibus Budget Reconciliation Act (&#8220;OBRA&#8221;), of 1989, and prohibited
	a physician from referring Medicare patients for clinical laboratory services to entities with which the physician (or an immediate
	family member) has a financial relationship, unless an exception applies. Sanctions for violations of the Stark Law may include
	denial of payment, refund obligations, civil monetary penalties and exclusion of the provider from the Medicare and Medicaid programs.
	In addition, the Stark Law prohibits the entity receiving the referral from filing a claim or billing for services arising out
	of the prohibited referral.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 32; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	29
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage33"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Provisions of OBRA 1993, known as &#8220;Stark II,&#8221; amended
	the Stark Law to revise and expand upon various statutory exceptions, expanded the services regulated by the statute to a list
	of &#8220;Designated Health Services,&#8221; and expanded the reach of the statute to the Medicaid program. Although CMS published
	Phase III of the Stark regulations on September 5, 2007, intending Phase III to be the final phase of the Stark rulemaking process,
	CMS continues to address the Stark Law as part of its annual rulemaking process for reimbursement under the Medicare Part B Physician
	Fee Schedule or under the Inpatient Prospective Payment System.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Finally, many states in which we operate have enacted self-referral
	statutes similar to the Stark Law. Such state self-referral laws may apply to referrals of patients regardless of payor source
	and may contain exceptions different from each other and from those contained in the Stark Law.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<I>
	The Health Insurance Portability and Accountability Act of 1996
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	HIPAA expanded federal fraud and abuse laws by increasing their
	reach to all federal health care programs, establishing new bases for exclusions and mandating minimum exclusion terms, creating
	an additional statutory exception to the Anti-Kickback Statute for risk-sharing arrangements, requiring HHS to issue advisory opinions,
	increasing civil money penalties to $10,000 per item or service and assessments to three times the amount claimed, creating a specific
	health care fraud offense and related health fraud crimes, and expanding investigative authority and sanctions applicable to health
	care fraud. HIPAA also prohibits a provider from offering anything of value which the provider knows or should know would be likely
	to induce a federal health care program beneficiary to select or continue with the provider.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	HIPAA includes a health care fraud provision prohibiting knowingly
	and willfully executing a scheme or artifice to defraud any &#8220;health care benefit program,&#8221; which includes any public
	or private plan or contract affecting commerce under which any medical benefit, item, or service is provided to any individual,
	and includes any individual or entity who is providing a medical benefit, item, or service for which payment may be made under
	the plan or contract. Penalties for violating this statute include criminal penalties, exclusion from the Medicare and Medicaid
	programs, freezing of assets and forfeiture of property traceable to commission of a health care fraud.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<I>
	Other Fraud and Abuse Laws
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Our operations are also subject to a variety of other federal and
	state fraud and abuse laws, principally designed to ensure that claims for payment to be made with public funds are complete, accurate
	and fully comply with all applicable program rules, and to prevent remuneration in exchange for referrals or purchases of items
	which may be reimbursed by the government or which may lead to overutilization, corruption of health care provider judgment, or
	a lack of transparency in costs or charges. Failure to remain in compliance with any of these rules could result in a material
	adverse effect on our business, financial condition or results of operations.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	We are required to comply with laws governing the transmission, security and privacy
	of health information that require significant compliance costs, and any failure to comply with these laws could result in material
	criminal and civil penalties.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Under the administrative simplification provisions of HIPAA, HHS
	has issued regulations which establish uniform standards governing the conduct of certain electronic health care transactions and
	protecting the privacy and security of Protected Health Information (&#8220;PHI&#8221;), used or disclosed by health care providers
	and other covered entities. Three principal regulations with which we are currently required to comply have been issued in final
	form under HIPAA: privacy regulations, security regulations and standards for electronic transactions.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The privacy regulations cover the use and disclosure of PHI by health
	care providers. It also sets forth certain rights that an individual has with respect to his or her PHI maintained by a health
	care provider, including the right to access or amend certain records containing PHI or to request restrictions on the use or disclosure
	of PHI. We have also implemented policies, procedures and standards to comply appropriately with the final HIPAA security regulations,
	which establish requirements for safeguarding the confidentiality, integrity and availability of PHI, which is electronically transmitted
	or electronically stored. The HIPAA privacy and security regulations establish a uniform federal &#8220;floor&#8221; and do not
	supersede state laws that are more stringent or provide individuals with greater rights with respect to the privacy or security
	of, and access to, their records containing PHI. As a result, we are required to comply with both HIPAA privacy regulations and
	varying state privacy and security laws. Almost all U.S. states now require notification to affected individuals and state authorities,
	as well as the media in certain cases, in the event of a breach of the security of personal information (including PHI in a few
	states), often with significant financial penalties for noncompliance.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 33; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	30
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage34"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The Health Information Technology for Economic and Clinical Health
	Act (the &#8220;HITECH Act&#8221;), enacted pursuant to the American Recovery and Reinvestment Act of 2009 (&#8220;ARRA&#8221;),
	made sweeping changes to the health information privacy and security regulations of HIPAA by expanding the scope and application
	of the statute. These changes include, among other things, (1) establishing an affirmative obligation to provide patient data breach
	notification in the event of the unauthorized acquisition, access, use or disclosure of unsecured PHI; (2) elaborating upon the
	standard for &#8220;minimum necessary&#8221; uses and disclosures of PHI by a covered entity; (3) restricting certain uses of PHI
	for marketing purposes (by expanding the definition of marketing activities requiring authorization); (4) prohibiting certain sales
	of PHI; (5) establishing an affirmative obligation to provide an accounting of disclosures made for payment, treatment and health
	care operations (up to three years made through an electronic health record); (6) requiring covered entities to agree to individuals&#8217;
	requests to restrict disclosure of PHI in certain circumstances; (7) applying the security regulations and certain provisions of
	the privacy regulations to business associates; and (8) modifying an individuals&#8217; right to access PHI in an electronic format.
	HHS issued modifications to the HIPAA Regulations, effective March 26, 2013, implementing some of these changes including the obligation
	to provide patient data breach notifications, which subject the Company to additional administrative requirements in the U.S. With
	regard to the accounting of disclosures, the HITECH Act provides for removing the exception in the existing HIPAA privacy regulations&#8217;
	accounting of disclosures of PHI requirement for disclosures of PHI for payment, treatment, and health care operations purposes
	made through an electronic health record (within the past three years). HHS issued proposed regulations to implement this provision
	of the HITECH Act in May 2011, but those regulations have not been finalized.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The HITECH Act also implemented measures to strengthen enforcement
	of HIPAA and increased applicable penalties for HIPAA violations. Penalties are now tiered and range from $100 to $50,000 per violation
	with an annual cap for the same violations of $25,000 to $1,500,000. The Office for Civil Rights of the HHS (&#8220;OCR&#8221;)
	has increased enforcement activities and has recently levied large penalties for violations. In addition, as mandated by the HITECH
	Act, OCR has begun an audit program to assess compliance by covered entities and their business associates with the HIPAA privacy
	and security rules and breach notification standards.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We seek to comply with HIPAA privacy regulations and state privacy
	laws. In addition, we are in the process of taking necessary steps to comply with HIPAA&#8217;s standards for electronic transactions,
	which establish standards for common health care transactions. Given the complexity of HIPAA, the HITECH Act and state privacy
	restrictions, the possibility that the regulations may change, and the fact that the regulations are subject to changing and potentially
	conflicting interpretation, our ability to comply with HIPAA, the HITECH Act and state privacy requirements is uncertain and the
	costs of compliance are significant. To the extent that we or our third-party billing company submit electronic health care claims
	and payment transactions that do not comply with the electronic data transmission standards established under HIPAA and the HITECH
	Act, payments to us may be delayed or denied. Additionally, the costs of complying with any changes to HIPAA, the HITECH Act and
	state privacy restrictions may have a negative impact on our operations. We could be subject to criminal penalties and civil sanctions
	for failing to comply with HIPAA, the HITECH Act and state privacy restrictions, which could result in the incurrence of significant
	monetary penalties.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Intellectual Property Risks Related to Our Business
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	If we are unable to maintain intellectual property protection, our competitive
	position could be harmed.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Our ability to protect our proprietary discoveries and technologies
	affects our ability to compete and to achieve sustained profitability. Currently, we rely on a combination of issued U.S. patents,
	U.S. and foreign patent applications, copyrights, trademarks and trademark applications, confidentiality or non-disclosure agreements,
	material transfer agreements, licenses, work-for-hire agreements and invention assignment agreements to protect our intellectual
	property rights. We also maintain certain company know-how, trade secrets and technological innovations designed to provide us
	with a competitive advantage in the market place as trade secrets.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Currently, we are the worldwide exclusive licensee, in our licensed
	field, and the owner of 14 issued patents (12 issued U.S. patents, one issued European patent validated in nine countries: Switzerland,
	Germany, Denmark, Spain, France, United Kingdom, Italy, Netherlands, and Sweden, and one issued Japanese patent) and 11 pending
	patent applications, which include both U.S. and foreign patent applications, relating to various aspects of our technology. Of
	the 11 pending patent applications, two are owned outright by Signal Genetics, Inc. Our exclusive field of use covers, inter alia,
	therapeutic, diagnostic, prognostic, and personalized medicine applications worldwide, excluding applications using FISH and some
	claims directly covering DKK1 inhibitors and their uses.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	While we intend to pursue additional patent applications, it is
	possible that our pending patent applications and any future applications may not result in issued patents. Even if patents are
	issued, third parties may independently develop similar or competing technology that avoids the claims of our patents or may challenge
	the validity of our patents. Further, we cannot be certain that the steps we have taken will prevent the misappropriation of our
	trade secrets and other confidential information as well as the misuse of our patents and other intellectual property, particularly
	in foreign countries where we have not filed for patent protection.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 34; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	31
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage35"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	From time to time the U.S. Supreme Court, other federal courts,
	the U.S. Congress or the U.S. Patent and Trademark Office (the &#8220;USPTO&#8221;), as well as counterpart agencies and bodies
	in corresponding foreign jurisdictions, may change the standards of patentability and any such changes could have a negative impact
	on our business.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	For instance, on October 30, 2008, the Court of Appeals for the
	Federal Circuit issued a decision that methods or processes cannot be patented unless they are tied to a machine or involve a physical
	transformation. The U.S. Supreme Court later reversed that decision in Bilski v. Kappos (&#8220;Bilski&#8221;), finding that the
	&#8220;machine-or-transformation&#8221; test is not the only test for determining patent eligibility. The Court, however, declined
	to specify how and when processes are patentable. On March 20, 2012, in Mayo v. Prometheus (&#8220;Mayo&#8221;), the U.S. Supreme
	Court reversed the Federal Circuit&#8217;s application of Bilski and invalidated a patent focused on a diagnostic process because
	the patent claim embodied a law of nature. On July 30, 2012, the USPTO released a memorandum entitled &#8220;2012 Interim Procedure
	for Subject Matter Eligibility Analysis of Process Claims Involving Laws of Nature&#8221;, with guidelines for determining patentability
	of diagnostic or other processes in line with the Mayo decision. On June 13, 2013, in Association for Molecular Pathology v. Myriad
	Genetics (&#8220;Myriad&#8221;), the Supreme Court held that a naturally occurring DNA segment is a product of nature and not patent
	eligible merely because it has been isolated, but cDNA is patent eligible because it is not naturally occurring. The Supreme Court&#8217;s
	decision reversed in part and affirmed in part the earlier decision of the Federal Circuit that both isolated genes and cDNA were
	patent eligible, however, the Supreme Court specifically did not address the patentability of any method claims involving the use
	of such isolated genes. On March 4, 2014, the USPTO released a memorandum entitled &#8220;2014 Procedure For Subject Matter Eligibility
	Analysis Of Claims Reciting Or Involving Laws Of Nature/Natural Principles, Natural Phenomena, And/Or Natural Products,&#8221;
	which we refer to as the March 4, 2014 memorandum. This memorandum provides guidelines for the USPTO&#8217;s new examination procedure
	for subject matter eligibility under 35 U.S.C. &#167;101 for claims embracing natural products or natural principles. On December
	16, 2014, the USPTO issued a &#8220;2014 Interim Guidance on Patent Subject Matter Eligibility,&#8221; which we refer to as the
	2014 Interim Guidance, for use by USPTO personnel in determining subject matter eligibility in view of recent decisions by the
	U.S. Supreme Court, which superseded the March 4, 2014 memorandum. On July 2015, the USPTO published an updated guidance document
	entitled &#8220;July 2016 Update on Subject Matter Eligibility&#8221; that includes new examples and discussion of relevant issues.
	Although the guidelines do not have the force of law, patent examiners have been instructed to follow them.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Some aspects of our technology involve products and/or processes
	that may be subject to this evolving standard and we cannot guarantee that any of our pending claims will be patentable as a result
	of such evolving standards or that issued patents will be held valid, if challenged under these changing standards.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	In addition, on February 5, 2010, the Secretary&#8217;s Advisory
	Committee on Genetics, Health and Society voted to approve a report entitled &#8220;Gene Patents and Licensing Practices and Their
	Impact on Patient Access to Genetic Tests.&#8221; That report defines &#8220;patent claims on genes&#8221; broadly to include claims
	to isolated nucleic acid molecules as well as methods of detecting particular sequences or mutations. The report also contains
	six recommendations, including the creation of an exemption from liability for infringement of patent claims on genes for anyone
	making, using, ordering, offering for sale or selling a test developed under the patent for patient care purposes, or for anyone
	using the patent-protected genes in the pursuit of research. The report also recommended that the Secretary should explore, identify
	and implement mechanisms that will encourage more voluntary adherence to current guidelines that promote nonexclusive in-licensing
	of diagnostic genetic and genomic technologies. It is unclear whether the HHS will act upon these recommendations, or if the recommendations
	would result in a change in law or process that could negatively impact our patent portfolio or future research and development
	efforts.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Our rights to use technologies licensed from third parties are not fully within
	our control, and we may not be able to sell our products if we lose our existing rights or cannot obtain new rights on reasonable
	terms.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Our ability to market certain of our tests and services, domestically
	and/or internationally, is in part derived from licenses to intellectual property which is owned by third parties. As such, we
	may not be able to continue selling our tests and services if we lose our existing licensed rights or sell new tests and services
	if we cannot obtain such licensed rights on reasonable terms. In particular, we in-license a portfolio of issued U.S. and foreign
	patents, and pending U.S. and foreign patent applications as the worldwide exclusive licensee in our licensed field from UAMS.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We may also need to license other technologies to commercialize
	future diagnostic tests that we may offer. As may be expected, our business may suffer if, for example, (1) these licenses terminate;
	(2) if the licensors fail to abide by the terms of the license, properly maintain the licensed intellectual property or fail to
	prevent infringement of such intellectual property by third parties; (3) if the licensed patents or other intellectual property
	rights are found to be invalid or (4) if we are unable to enter into necessary licenses on reasonable terms or at all. In return
	for the use of a third party&#8217;s technology, we may agree to pay the licensor royalties based on sales of our products as well
	as other fees. Such royalties and fees are a component of cost of product revenues and will impact the margins on our tests.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	We may face intellectual property infringement claims that could be time-consuming
	and costly to defend, and could result in our loss of significant rights and the assessment of treble damages.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	From time to time we may face intellectual property infringement,
	misappropriation, or invalidity/non-infringement claims from third parties. Some of these claims may lead to litigation. The outcome
	of any such litigation can never be guaranteed, and an adverse outcome could affect us negatively. For example, were a third party
	to succeed on an infringement claim against us, we may be required to pay substantial damages (including up to treble damages if
	such infringement were found to be willful). In addition, we could face an injunction, barring us from conducting the allegedly
	infringing activity. The outcome of the litigation could require us to enter into a license agreement which may not be under acceptable,
	commercially reasonable, or practical terms or we may be precluded from obtaining a license at all.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 35; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	32
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage36"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	It is also possible that an adverse finding of infringement against
	us may require us to dedicate substantial resources and time in developing non-infringing alternatives, which may or may not be
	possible. In the case of diagnostic tests, we would also need to include non-infringing technologies which would require us to
	re-validate our tests. Any such re-validation, in addition to being costly and time consuming, may be unsuccessful.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Finally, we may initiate claims to assert or defend our own intellectual
	property against third parties. If one or more of our patents were held to be invalid or not infringed, we might not be able to
	exclude others from offering similar or identical tests to ours. Any intellectual property litigation, irrespective of whether
	we are the plaintiff or the defendant, and regardless of the outcome, is expensive and time-consuming, and could divert our management&#8217;s
	attention from our business and negatively affect our operating results or financial condition.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	We may be subject to claims by third parties asserting that our employees or we
	have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Although we try to ensure that we, our employees, and independent
	contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that
	we, our employees, or independent contractors have used or disclosed intellectual property in violation of others&#8217; rights.
	These claims may cover a range of matters, such as challenges to our trademarks, as well as claims that our employees or independent
	contractors are using trade secrets or other proprietary information of any such employee&#8217;s former employer or independent
	contractors.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	In addition, while it is our policy to require our employees and
	independent contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual
	property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property
	that we regard as our own. Our and their assignment agreements may not be self-executing or may be breached, and we may be forced
	to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard
	as our intellectual property.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	If we fail in prosecuting or defending any such claims, in addition
	to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in prosecuting
	or defending against such claims, litigation could result in substantial costs and be a distraction to management.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	We or our suppliers and/or manufacturers may be subject to litigation relating
	to, among other things, payor and customer disputes, regulatory actions, professional liability, intellectual property, employee-related
	matters, product liability and other potential claims, which could adversely affect our business.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We or our suppliers and/or manufacturers may become subject in the
	ordinary course of business to material litigation related to things, payor or customer disputes, professional liability, regulatory
	actions, intellectual property, employee-related matters, product liability and other potential claims, as well as investigations
	by governmental agencies and governmental payors relating to the specialized diagnostic services we provide. Responding to these
	types of claims, regardless of their merit, could result in significant expense and divert the time, attention and resources of
	our management. Legal actions could result in substantial monetary damages as well as significant harm to our reputation with our
	oncologist customers and with payors, which could adversely affect our business, financial condition and results of operations.
	Our laboratory directors and other laboratory professionals may be sued, or may be added as an additional party, under physician
	liability or other liability law for acts or omissions by our lab directors, laboratory personnel, and other employees and consultants,
	including but not limited to being sued for misdiagnoses or liabilities arising from the professional interpretations of test results.
	We may periodically become involved as defendants in medical malpractice and other lawsuits, and are subject to the attendant risk
	of substantial damage awards, in particular in connection with our MyPRS
<SUP>
	&#174;
</SUP>
	test. Our laboratory directors are insured
	for medical malpractice risks on a claims-made basis under traditional professional liability insurance policies. We also maintain
	general liability insurance that covers certain claims to which we may be subject. Our general insurance does not cover all potential
	liabilities that may arise, including governmental fines and penalties that we may be required to pay, liabilities we may incur
	under indemnification agreements and certain other uninsurable losses that we may suffer. It is possible that future claims will
	not be covered by or will exceed the limits of our insurance coverage or that our insurers will refuse to defend us against claims.
	The suppliers and manufacturers of the diagnostic tests we perform, which are critical to the performance of our specialized diagnostic
	services, may be exposed to, or threatened with, future litigation by third parties having patent or other intellectual property
	rights alleging that their diagnostic tests infringe the intellectual property rights of these third parties. In such event, we
	could no longer have access to, or we may be prohibited from marketing or performing, such diagnostic tests unless we obtained
	a license from such third party. A license may not be available to us on acceptable terms, if at all. If we are unable to license
	diagnostic tests that are important to our specialized diagnostic services, our business, financial condition and results of operations
	may be adversely affected.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 36; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	33
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage37"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Risks Related to our Common Stock
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Provisions in our corporate charter documents and under Delaware law could make
	an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders
	to replace or remove our current management.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Provisions in our corporate charter and our bylaws may discourage,
	delay or prevent a merger, acquisition or other change in control of our company that stockholders may consider favorable, including
	transactions in which you might otherwise receive a premium for your shares. These provisions could also limit the price that investors
	might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock.
	In addition, because our board of directors is responsible for appointing the members of our management team, these provisions
	may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult
	for stockholders to replace members of our board of directors. Among other things, these provisions state that:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<UL STYLE="MARGIN-TOP: 0IN; LIST-STYLE-TYPE: DISC">
<LI STYLE="MARGIN: 0PT 0; FONT-SIZE: 10PT">
	the authorized number of directors can be changed only by resolution of our board of
	directors;
</LI>
<LI STYLE="MARGIN: 5PT 0; FONT-SIZE: 10PT">
	our bylaws may be amended or repealed by our board of directors or our stockholders;
</LI>
<LI STYLE="MARGIN: 0PT 0; FONT-SIZE: 10PT">
	stockholders may not call special meetings of the stockholders or fill vacancies on
	the board of directors;
</LI>
<LI STYLE="MARGIN: 5PT 0; FONT-SIZE: 10PT">
	our board of directors will be authorized to issue, without stockholder approval, preferred
	stock, the rights of which will be determined at the discretion of the board of directors and that, if issued, could operate as
	a &#8220;poison pill&#8221; to dilute the stock ownership of a potential hostile acquirer to prevent an acquisition that our board
	of directors does not approve;
</LI>
<LI STYLE="MARGIN: 0PT 0; FONT-SIZE: 10PT">
	our stockholders do not have cumulative voting rights, and therefore our stockholders
	holding a majority of the shares of common stock outstanding will be able to elect all of our directors; and
</LI>
<LI STYLE="MARGIN: 5PT 0; FONT-SIZE: 10PT">
	our stockholders must comply with advance notice provisions to bring business before
	or nominate directors for election at a stockholder meeting.
</LI>
</UL>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Moreover, because we are incorporated in Delaware, we are governed
	by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of
	our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in
	which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed
	manner.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Our failure to meet the continued listing requirements of The NASDAQ Capital Market
	could result in a delisting of our common stock.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT">
	The listing standards of NASDAQ provide,
	among other things, that a company may be delisted if the bid price of its stock drops below $1.00 for a period of 30 consecutive
	business days. The bid price of our stock has been below $1.00 for a period of greater than 30 consecutive business days. As such,
	on November 24, 2015, we received a
</FONT>
	&nbsp;
<FONT STYLE="FONT-SIZE: 10PT">
	notice
</FONT>
	&nbsp;
<FONT STYLE="FONT-SIZE: 10PT">
	from
	the
</FONT>
	&nbsp;
<FONT STYLE="FONT-SIZE: 10PT">
	NASDAQ
</FONT>
	&nbsp;
<FONT STYLE="FONT-SIZE: 10PT">
	Listing Qualifications Department
	informing us that we must regain compliance with listing
</FONT>
	&nbsp;
<FONT STYLE="FONT-SIZE: 10PT">
	requirements
</FONT>
	&nbsp;
<FONT STYLE="FONT-SIZE: 10PT">
	or
	face
</FONT>
	&nbsp;
<FONT STYLE="FONT-SIZE: 10PT">
	delisting. In order to regain compliance, at any time before May 23, 2016, the bid
	price of our common stock must close at a price of at least $1.00 per share for a minimum of 10 consecutive business days. The
</FONT>
	&nbsp;
<FONT STYLE="FONT-SIZE: 10PT">
	notice
</FONT>
	&nbsp;
<FONT STYLE="FONT-SIZE: 10PT">
	states
	that
</FONT>
	&nbsp;
<FONT STYLE="FONT-SIZE: 10PT">
	NASDAQ
</FONT>
	&nbsp;
<FONT STYLE="FONT-SIZE: 10PT">
	will provide us with written notification
	when our common stock has regained compliance.
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	If compliance cannot be demonstrated by May 23, 2016, then
	NASDAQ will decide whether we meet all applicable standards for initial listing on the Capital Market (except the bid price
	requirement) based on our most recent public filings and market information. The notice states that, if we meet these
	standards, then we are eligible to have an additional 180 calendar day compliance period. NASDAQ can deny the extension if it
	does not appear to them that it is possible for us to cure the deficiency. In addition, if we fail to satisfy the continued
	listing requirements of The NASDAQ Capital Market, such as the corporate governance requirements or the minimum
	shareholders&#8217; equity, publicly held shares or market value of publicly held shares requirements, NASDAQ may take steps
	to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock and
	would impair your ability to sell or purchase our common stock when you wish to do so. In the event of a delisting, we would
	take actions to restore our compliance with NASDAQ&#8217;s listing requirements, but we can provide no assurance that any
	such action taken by us would allow our common stock to become listed again, stabilize the market price or improve the
	liquidity of our common stock, prevent our common stock from dropping below the NASDAQ minimum bid price requirement or
	prevent future non-compliance with NASDAQ&#8217;s listing requirements. Further, if we were to be delisted from The NASDAQ
	Capital Market, our common stock would cease to be recognized as covered securities and we would be subject to regulation in
	each state in which we offer our securities.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Delisting from NASDAQ could adversely affect our ability to raise
	additional financing through the public or private sale of equity securities, would significantly affect the ability of investors
	to trade our securities and would negatively affect the value and liquidity of our common stock. Delisting could also have other
	negative results, including the potential loss of confidence by employees, the loss of institutional investor interest and fewer
	business development opportunities.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 37; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	34
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage38"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	If our shares become subject to the penny stock rules, this may make it more difficult
	to sell our shares.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The SEC has adopted rules that regulate broker-dealer practices
	in connection with transactions in penny stocks. Penny stocks are generally equity securities with a price of less than $5.00 (other
	than securities registered on certain national securities exchanges or authorized for quotation on certain automated quotation
	systems, provided that current price and volume information with respect to transactions in such securities is provided by the
	exchange or system). The OTCBB does not meet such requirements and if the price of our common stock remains less than $5.00 and
	we are no longer listed on a national securities exchange, our common stock may be deemed a penny stock. The penny stock rules
	require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from those rules, to deliver a standardized
	risk disclosure document containing specified information. In addition, the penny stock rules require that prior to effecting any
	transaction in a penny stock not otherwise exempt from those rules, a broker-dealer must make a special written determination that
	the penny stock is a suitable investment for the purchaser and receive: (1) the purchaser&#8217;s written acknowledgment of the
	receipt of a risk disclosure statement; (2) a written agreement to transactions involving penny stocks; and (3) a signed and dated
	copy of a written suitability statement. These disclosure requirements may have the effect of reducing the trading activity in
	the secondary market for our common stock, and therefore stock holders may have difficulty selling their shares.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	An active trading market for our common stock may not develop.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Prior to our initial public offering in June 2014, there was no
	public market for our common stock. The listing of our common stock on the NASDAQ Capital Market does not assure that a meaningful,
	consistent and liquid trading market exists. Although our common stock is listed on The NASDAQ Capital Market, trading volume in
	our common stock has been limited and an active trading market for our shares may never develop or be sustained. If an active market
	for our common stock does not develop, it may be difficult for investors to sell their shares without depressing the market price
	for the shares or at all.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	The price of our common stock may be volatile and fluctuate substantially, which
	could result in substantial losses for our stockholders.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Our stock price is likely to be volatile. The stock market in general
	and the market for smaller diagnostic services companies in particular have experienced extreme volatility that has often been
	unrelated to the operating performance of particular companies. As a result of this volatility, our stockholders may not be able
	to sell their common stock at or above the price they paid for it. The market price for our common stock may be influenced by many
	factors, including:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<UL STYLE="MARGIN-TOP: 0IN; LIST-STYLE-TYPE: DISC">
<LI STYLE="MARGIN: 0PT 0; FONT-SIZE: 10PT">
	issuances of new equity securities pursuant to a future offering, including issuances
	of preferred stock;
</LI>
<LI STYLE="MARGIN: 5PT 0; FONT-SIZE: 10PT">
	the success of competitive products, services or technologies;
</LI>
<LI STYLE="MARGIN: 0PT 0; FONT-SIZE: 10PT">
	regulatory or legal developments in the United States and other countries;
</LI>
<LI STYLE="MARGIN: 5PT 0; FONT-SIZE: 10PT">
	developments or disputes concerning patent applications, issued patents or other proprietary
	rights;
</LI>
<LI STYLE="MARGIN: 0PT 0; FONT-SIZE: 10PT">
	the recruitment or departure of key personnel;
</LI>
<LI STYLE="MARGIN: 5PT 0; FONT-SIZE: 10PT">
	actual or anticipated changes in estimates as to financial results, development timelines
	or recommendations by securities analysts;
</LI>
<LI STYLE="MARGIN: 0PT 0; FONT-SIZE: 10PT">
	variations in our financial results or those of companies that are perceived to be similar
	to us;
</LI>
<LI STYLE="MARGIN: 5PT 0; FONT-SIZE: 10PT">
	changes in the structure of health care payment systems;
</LI>
<LI STYLE="MARGIN: 0PT 0; FONT-SIZE: 10PT">
	market conditions in the diagnostic services sector;
</LI>
<LI STYLE="MARGIN: 5PT 0; FONT-SIZE: 10PT">
	general economic, industry and market conditions; and
</LI>
<LI STYLE="MARGIN: 0PT 0; FONT-SIZE: 10PT">
	the other factors described in this &#8220;Risk Factors&#8221; section.
</LI>
</UL>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Reports published by securities or industry analysts, including projections in
	those reports that exceed our actual results, could adversely affect our common stock price and trading volume.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Securities research analysts may establish and publish their own
	periodic projections for our business. These projections may vary widely from one another and may not accurately predict the results
	we actually achieve. Our stock price may decline if our actual results do not match securities research analysts&#8217; projections.
	Similarly, if one or more of the analysts who writes reports on us downgrades our stock or publishes inaccurate or unfavorable
	research about our business, our stock price could decline. If one or more of these analysts ceases coverage of our company or
	fails to publish reports on us regularly, our stock price or trading volume could decline. While we expect securities research
	analyst coverage, if no securities or industry analysts begin to cover us, the trading price for our stock and the trading volume
	could be adversely affected.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 38; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	35
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage39"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Future sales of our common stock, or the perception that future sales may occur,
	may cause the market price of our common stock to decline, even if our business is doing well.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Sales of substantial amounts of our common stock in the public market,
	or the perception that these sales may occur, could materially and adversely affect the price of our common stock and could impair
	our ability to raise capital through the sale of additional equity securities. We maintain a shelf registration statement on Form
	S-3 with the SEC pursuant to which we may, from time to time, sell up to an aggregate of $50 million of our common stock, preferred
	stock, debt securities, warrants, rights and units. We have established an &#8220;at-the-market&#8221; offering pursuant to which
	we may offer and sell shares of our common stock, if and when our public float increases. Sales of securities under the registration
	statement will result in dilution of our stockholders and could cause our stock price to fall.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	We are an &#8220;emerging growth company,&#8221; and the reduced disclosure requirements
	applicable to emerging growth companies may make our common stock less attractive to investors.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We are an &#8220;emerging growth company,&#8221; as defined in the
	JOBS Act, and may remain an emerging growth company for up to five years. For so long as we remain an emerging growth company,
	we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies
	that are not emerging growth companies. These exemptions include:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<UL STYLE="MARGIN-TOP: 0IN; LIST-STYLE-TYPE: DISC">
<LI STYLE="MARGIN: 0PT 0; FONT-SIZE: 10PT">
	being permitted to provide only two years of audited financial statements, in addition
	to any required unaudited interim financial statements, with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis
	of Financial Condition and Results of Operations&#8221; disclosure;
</LI>
<LI STYLE="MARGIN: 5PT 0; FONT-SIZE: 10PT">
	not being required to comply with the auditor attestation requirements in the assessment
	of our internal control over financial reporting;
</LI>
<LI STYLE="MARGIN: 0PT 0; FONT-SIZE: 10PT">
	not being required to comply with any requirement that may be adopted by the Public
	Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing
	additional information about the audit and the financial statements;
</LI>
<LI STYLE="MARGIN: 5PT 0; FONT-SIZE: 10PT">
	reduced disclosure obligations regarding executive compensation; and
</LI>
<LI STYLE="MARGIN: 0PT 0; FONT-SIZE: 10PT">
	exemptions from the requirements of holding a non-binding advisory vote on executive
	compensation and stockholder approval of any golden parachute payments not previously approved.
</LI>
</UL>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We have taken advantage of reduced reporting burdens in this Annual
	Report. In particular, we have not included all of the executive compensation related information that would be required if we
	were not an emerging growth company. We cannot predict whether investors will find our common stock less attractive if we rely
	on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market
	for our common stock and our stock price may be more volatile.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	We have elected to avail ourselves of the extended transition period for adopting
	new or revised accounting standards available to emerging growth companies under the JOBS Act and will, therefore, not be subject
	to the same new or revised accounting standards as other public companies that are not emerging growth companies, which could make
	our common stock less attractive to investors.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The JOBS Act provides that an emerging growth company can take advantage
	of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company
	to delay the adoption of these accounting standards until they would otherwise apply to private companies. The Company has elected
	to avail itself of this extended transition period for adopting new or revised accounting standards and therefore, we will not
	be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. As
	a result of this election, our financial statements may not be comparable to companies that comply with public company effective
	dates.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We cannot predict whether investors will find our stock less attractive
	as a result of this election. If some investors find our common stock less attractive as a result of this election, there may be
	a less active trading market for our common stock and our stock price may be more volatile.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Since our initial public offering in June 2014, we have incurred significantly
	increased costs and our management has had to devote substantial time as a result of operating as a public company; and such costs
	are expected to further increase after we are no longer an &#8220;emerging growth company.&#8221;
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	As a public company, we incur significant legal, accounting and
	other expenses that we did not incur as a private company. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and
	Consumer Protection Act, the listing requirements of The NASDAQ Capital Market and other applicable securities rules and regulations
	impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial
	controls and corporate governance practices. Our management and other personnel have had to devote a substantial amount of time
	to these compliance initiatives since becoming a public company. Moreover, these rules and regulations have increased our legal
	and financial compliance costs and have made certain activities more time-consuming and costly.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 39; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	36
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage40"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Because we only recently became a public company, we cannot yet
	predict or estimate the costs we may incur in the future with respect to these compliance initiatives or the timing of such costs.
	In addition, these rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity,
	and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies.
	This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to
	disclosure and governance practices.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002 (&#8220;Section
	404&#8221;), we will be required to furnish a report by our management on our internal control over financial reporting with our
	second annual report to be filed with the SEC in 2016. However, while we remain an emerging growth company, we will not be required
	to include an attestation report on internal control over financial reporting issued by our independent registered public accounting
	firm. To achieve compliance with Section 404 within the prescribed period, we will be engaged in a process to document and evaluate
	our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to
	dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy
	of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing
	that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over
	financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe
	or at all, that our internal control over financial reporting is effective as required by Section 404. If we identify one or more
	material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability
	of our financial statements.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Because we do not anticipate paying any cash dividends on our capital stock in
	the foreseeable future, capital appreciation, if any, will be your sole source of gain.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We do not anticipate paying future dividends on our capital stock.
	We currently intend to retain all of our future earnings, as applicable, to finance the growth and development of our business.
	In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation,
	if any, of our common stock will be your sole source of gain for the foreseeable future.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Certain of our net operating loss carryforwards have been limited.
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Net operating losses incurred by the Company as of June 17, 2014
	and prior to the Corporate Conversion of Signal Genetics LLC into Signal Genetics, Inc. have been used by the members of Signal
	Genetics LLC to offset gains on other interests and are therefore not able to be carried forward to the Company. The net operating
	loss carryforward for federal tax purposes held by Signal Genetics, Inc. after the Corporate Conversion through December 31, 2015
	totaled $10.6 million.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 40; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	37
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_RISK_FACTORS>
<A NAME="eolPage41"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNRESOLVED_STAFF_COMMENTS>
<A NAME="FIS_UNRESOLVED_STAFF_COMMENTS"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<A NAME="F10K_032116P_HTM_A_003">
</A>
	Item 1B. Unresolved Staff Comments
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	None.
</P>
</EFX_UNRESOLVED_STAFF_COMMENTS>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_PROPERTIES>
<A NAME="FIS_PROPERTIES"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<A NAME="F10K_032116P_HTM_A_004">
</A>
<B>
	Item 2. Properties
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We currently lease 5,560 square feet of office space in Carlsbad,
	California, for our corporate headquarters. This lease expires in October 2017. We also lease 2,800 square feet of space in Little
	Rock, Arkansas for use as a clinical reference laboratory. This lease expires in March 2017. Based on our current operational needs,
	we believe that our office space and laboratory facilities are adequate for our operations for the near future and do not anticipate
	any difficulty securing alternative or additional space, as needed, on terms acceptable to us.
</P>
</EFX_PROPERTIES>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_LEGAL_PROCEEDINGS>
<A NAME="FIS_LEGAL_PROCEEDINGS"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<A NAME="F10K_032116P_HTM_A_005">
</A>
	Item 3. Legal Proceedings
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We are not currently a party to any legal proceedings.
</P>
</EFX_LEGAL_PROCEEDINGS>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_MINE_SAFETY_DISCLOSURE>
<A NAME="FIS_MINE_SAFETY_DISCLOSURE"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<A NAME="F10K_032116P_HTM_A_006">
</A>
	Item 4. Mine Safety Disclosures
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Not applicable.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 41; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	38
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_MINE_SAFETY_DISCLOSURE>
</EFX_PART_I>
<A NAME="eolPage42"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_PART_II>
<A NAME="FIS_PART_II"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	PART II
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_MARKET>
<A NAME="FIS_MARKET"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<A NAME="F10K_032116P_HTM_A_007">
</A>
	Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and
	Issuer Purchases of Equity Securities
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Market Information
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Prior to our initial public offering, no public trades occurred
	in our common stock. Since June 18, 2014, our common stock has been listed on The NASDAQ Capital Market. The following table sets
	forth, for the periods indicated, our high and low sales prices on The NASDAQ Capital Market.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_2"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	High
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Low
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Year Ended December 31, 2015:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 64%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Fourth Quarter
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 14%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1.24
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 14%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.66
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Third Quarter
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2.73
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.88
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Second Quarter
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2.94
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1.42
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	First Quarter
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3.97
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1.76
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Year Ended December 31, 2014:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Fourth Quarter
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5.00
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2.11
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Third Quarter
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	9.05
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4.12
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Second Quarter
<SUP>
	(1)
</SUP>
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	9.99
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7.05
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1.1PT SOLID; WIDTH: 15%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)
</TD>
<TD>
	From June 18, 2014 through June 30, 2014.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Holders
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	As of March 15, 2016, we had nine registered holders of record of
	our common stock. A substantially greater number of holders of our common stock are &#8220;street name&#8221; or beneficial holders,
	whose shares of record are held by banks, brokers, other financial institutions, and registered clearing agencies.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Dividend Policy
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We do not anticipate paying dividends on our common stock. We currently
	intend to retain all of our future earnings, as applicable, to finance the growth and development of our business. We are not subject
	to any legal restrictions respecting the payment of dividends, except that we may not pay dividends if the payment would render
	us insolvent. Any future determination as to the payment of cash dividends on our common stock will be at our board of directors&#8217;
	discretion and will depend on our financial condition, operating results, capital requirements and other factors that our board
	of directors considers to be relevant.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Use of Proceeds
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	As noted above, on June 23, 2014, we completed our IPO pursuant to
	which we offered and sold 850,000 shares of our common stock at a public offering price of $10.00 per share (for an aggregate offering
	price of $8,500,000), pursuant to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-194668), which was declared
	effective by the Securities and Exchange Commission (&#8220;SEC&#8221;) on June 17, 2014. After deducting underwriting discounts
	and commissions of approximately $595,000, and other offering expenses payable by us of approximately $1,761,000, the Company received
	approximately $6,144,000 in net cash proceeds. Aegis Capital Corp. acted as the sole book-running manager for the offering.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	From the closing date of our IPO through September 30, 2015, we used
	$323,000 to purchase property and equipment, and $5.8 million to fund our cash losses from operations. Therefore, our net cash
	proceeds from our IPO were expended as of September 30, 2015. No payments were made by us to directors, officers or persons owning
	ten percent or more of our common stock or to their associates, or to our affiliates, other than payments in the ordinary course
	of business to officers for salaries and directors for board of directors&#8217; fees.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.5IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Securities Authorized for Issuance Under Equity Compensation Plans
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The information included in Part III, Item 12 under the heading
	&#8220;Securities Authorized for Issuance Under Equity Compensation Plans&#8221; is hereby incorporated by reference into this
	Item 5.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 42; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	39
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_MARKET>
<A NAME="eolPage43"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<EFX_FINANCIAL_DATA>
<A NAME="FIS_FINANCIAL_DATA"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<A NAME="F10K_032116P_HTM_A_008">
</A>
	Item 6. Selected Financial Data
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The following selected consolidated financial data is derived from
	our audited consolidated financial statements and should be read in conjunction with the consolidated financial statements and
	the notes to such statements and &#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations&#8221;
	included elsewhere in this report. Historical results are not necessarily indicative of the results to be expected in the future.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_3"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Years Ended December 31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-STYLE: ITALIC">
	(in thousands, except share and per share data)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<B>
	2014
<SUP>
	(1)(2)
</SUP>
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Consolidated statements of operations data
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 68%; FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Net revenue
<SUP>
	(3)
</SUP>
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,538
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,320
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Operating expenses:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; PADDING-LEFT: 10PT">
	Cost of revenue
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,472
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,366
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Research and development
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,002
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	347
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Selling and marketing
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,559
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	717
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	General and administrative
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7,692
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,857
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 10PT">
	Gain on legal settlement
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(100
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 20PT">
	Total operating expenses
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	13,725
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	11,187
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT">
	Loss from operations
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(11,187
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(6,867
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 10PT">
	Interest expense
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(141
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(1,023
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT">
	Net loss attributable to stockholders of Signal Genetics, Inc./members of Signal Genetics LLC
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(11,328
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(7,890
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT">
	Net loss per common share, basic and diluted
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(1.40
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(3.50
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Weighted-average number of shares outstanding, basic and diluted
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8,091,899
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,255,864
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	As of December 31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; FONT-STYLE: NORMAL; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; FONT-STYLE: NORMAL; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2014
<FONT STYLE="FONT-SIZE: 10PT; FONT-STYLE: NORMAL">
<B>
<SUP>
	(1)(2)
</SUP>
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	Consolidated balance sheet data
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 68%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Cash and cash equivalents
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	10,832
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,119
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Total assets
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	12,902
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8,089
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Note payable &#8211; related party
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,105
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Total liabilities
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,492
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,098
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Total stockholders&#8217; equity
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	10,410
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,991
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1.1PT SOLID; WIDTH: 15%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)
</TD>
<TD>
	On June 17, 2014, we completed the Corporate Conversion whereby Signal Genetics LLC converted from a limited liability company
	to a Delaware corporation. Immediately prior to the Corporate Conversion, $27.3 million of our note payable &#8212; related party
	was converted into 2,732,629 newly authorized Class C units (the &#8220;Debt Conversion&#8221;). In connection with the Corporate
	Conversion, all outstanding Class A and C units of Signal Genetics LLC were converted into an aggregate of 2,932,629 shares of
	common stock of the Company, the members of Signal Genetics LLC became stockholders of the Company and the Company succeeded to
	the business of Signal Genetics LLC and its consolidated subsidiaries.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT; MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(2)
</TD>
<TD>
	On June 23, 2014, we completed our initial public offering of 850,000 shares of our common stock, at $10.00 per share, for
	net cash proceeds of $6.1 million, which is net of $2.4 million in underwriter commissions and offering expenses.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(3)
</TD>
<TD>
	During the year ended December 31, 2015, net unfavorable changes in estimates were recorded to revenue related to non-contracted
	revenues recorded in the prior year of $193,000. During the year ended December 31, 2014, net unfavorable changes in estimates
	were recorded to revenue related to non-contracted revenues recorded in prior years of $380,000, of which $106,000 and $274,000
	related to revenues previously recorded during 2012 and 2013, respectively.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 43; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	40
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_FINANCIAL_DATA>
<A NAME="eolPage44"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<EFX_MANAGEMENTS_DISCUSSION>
<A NAME="FIS_MANAGEMENTS_DISCUSSION"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<A NAME="F10K_032116P_HTM_A_010">
</A>
	Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results
	of Operations
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Introduction
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The following discussion and analysis should be read together with
	our financial statements and the related notes appearing elsewhere in this report. This discussion contains forward-looking statements
	reflecting our current expectations that involve risks and uncertainties. See &#8220;Forward-Looking Statements&#8221; for a discussion
	of the uncertainties, risks and assumptions associated with these statements. Actual results and the timing of events could differ
	materially from those discussed in our forward-looking statements as a result of many factors, including those set forth under
	&#8220;Risk Factors&#8221; and elsewhere in this report.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	All references to 2015 and 2014 refer to our calendar years ended
	December 31, 2015 and 2014, respectively.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Overview
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We are a commercial stage, molecular genetic diagnostic company
	focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of
	their patients suffering from cancer. Our mission is to develop, validate and deliver innovative diagnostic services that enable
	better patient-care decisions.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We were founded in January 2010 and hold an exclusive license to
	the intellectual property stemming from the renowned research on MM performed at UAMS. Our flagship service offering is the MyPRS
<SUP>
	&#174;
</SUP>
	test, which is a microarray-based Gene Expression Profiling (&#8220;GEP&#8221;) assay that tests for the presence of specific groups
	of genes that can predict low or high level risk of early relapse in patients suffering from MM. The information provided by our
	MyPRS
<SUP>
	&#174;
</SUP>
	test aids physicians in selecting the optimal treatment regimen for each patient&#8217;s unique MM condition.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	To our knowledge, we are the only company marketing a GEP test for
	assessing the status of MM in the United States. The MyPRS
<SUP>
	&#174;
</SUP>
	test is protected by a substantial patent portfolio
	of issued and pending patents.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Our growth strategy includes the following key elements:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<UL STYLE="MARGIN-TOP: 0IN; LIST-STYLE-TYPE: DISC">
<LI STYLE="MARGIN: 0PT 0; FONT-SIZE: 10PT">
	Expanding the U.S. market penetration of our MyPRS
<SUP>
	&#174;
</SUP>
	test by increasing
	the geographic coverage of our commercial organization.
</LI>
<LI STYLE="MARGIN: 5PT 0; FONT-SIZE: 10PT">
	Broadening the base of health care insurance companies that have approved reimbursements
	for MyPRS
<SUP>
	&#174;
</SUP>
	.
</LI>
<LI STYLE="MARGIN: 0PT 0; FONT-SIZE: 10PT">
	Expanding the diagnostic indications for MyPRS
<SUP>
	&#174;
</SUP>
	to include asymptomatic
	monoclonal gammopathy (&#8220;AMG&#8221;), the precursor conditions to MM.
</LI>
<LI STYLE="MARGIN: 5PT 0; FONT-SIZE: 10PT">
	Pursuing additional collaborations with pharmaceutical companies who focus on developing
	therapies to treat MM and its precursor disease.
</LI>
<LI STYLE="MARGIN: 0PT 0; FONT-SIZE: 10PT">
	Expanding our information technology infrastructure to further improve our customer
	service experience.
</LI>
<LI STYLE="MARGIN: 5PT 0; FONT-SIZE: 10PT">
	Continuing to leverage our relationship with UAMS via our exclusive license agreement.
</LI>
<LI STYLE="MARGIN: 0PT 0; FONT-SIZE: 10PT">
	Expanding our test offering with the addition of other molecular tests useful to physicians
	who care for MM patients.
</LI>
<LI STYLE="MARGIN: 5PT 0; FONT-SIZE: 10PT">
	Expanding and leverage our capabilities into additional blood cancer indications.
</LI>
<LI STYLE="MARGIN: 0PT 0; FONT-SIZE: 10PT">
	Pursuing additional collaborations, mergers and acquisitions, and in-licensing to expand
	our service offering.
</LI>
<LI STYLE="MARGIN: 5PT 0; FONT-SIZE: 10PT">
	Continuing to reduce the costs associated with the development, manufacture and interpretation
	of our proprietary genomic tests and services.
</LI>
</UL>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We believe a key challenge to achieving our growth strategy will
	be our ability to become contracted with additional payors beyond Medicare and Arkansas Blue Cross Blue Shield (&#8220;AR-BCBS&#8221;).
	In order to broaden our coverage policy approval to include a number of the major health care insurance providers in the United
	States, we have developed a clinical validity and utility dossier and health economic model to present to third-party payors that
	supports their reimbursement approval. MyPRS
<SUP>
	&#174;
</SUP>
	has been studied extensively and there are more than 30 peer-reviewed
	scientific publications that describe the validity and utility of the test. MyPRS
<SUP>
	&#174;
</SUP>
	is one of the most extensively
	validated genomic assays available today. Further, the MyPRS
<SUP>
	&#174;
</SUP>
	assay has been validated on patient cohorts totaling
	over 4,500 patients, detailed in 17 peer-reviewed publications. Please visit our website at www.signalgenetics.com in the &#8220;Publications&#8221;
	section under the &#8220;Physician Resources&#8221; tab for a list of these publications. These publications were used to help
	create the aforementioned clinical utility dossier that justifies reimbursement approval by the majority of health care payors.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Other challenges to our growth strategy include: (1) if medical
	oncologists do not adopt the use of MyPRS
<SUP>
	&#174;
</SUP>
	to evaluate the risk of developing MM in patients with AMG, our growth
	strategy could be adversely affected, (2) if other tests that more accurately predict the severity of MM, the risk of progression
	of AMG to MM or the likelihood of response to therapy, are developed, physicians could stop ordering MyPRS
<SUP>
	&#174;
</SUP>
	, adversely
	affecting our ability to generate revenue, and (3) if payors, including our currently contracted payors, decide to reduce payment
	for MyPRS
<SUP>
	&#174;
</SUP>
	.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 44; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	41
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage45"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We operate in only one segment and, currently, have no operations
	outside of the United States.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	2015 Highlights
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<UL STYLE="MARGIN-TOP: 0IN; LIST-STYLE-TYPE: DISC">
<LI STYLE="MARGIN: 0PT 0; FONT-SIZE: 10PT">
	In February 2015, we completed a follow-on offering of 3,696,427 shares of our common
	stock, including the underwriters&#8217; overallotment, at $2.80 per share, for net cash proceeds of $9.1 million, which is net
	of $1.3 million in underwriter commissions and estimated offering expenses.
</LI>
<LI STYLE="MARGIN: 5PT 0; FONT-SIZE: 10PT">
	During September 2015, we sold 2,734,983 shares of common stock pursuant to a shelf
	registration through an &#8220;at-the-market&#8221; equity offering program (the &#8220;ATM program&#8221;) for total cash proceeds
	of $4.0 million, which is net of $429,000 in sales agent&#8217;s commissions and offering expenses. Due to the size of our public
	float, the current ATM program has been completed, unless and until our public float increases.
</LI>
<LI STYLE="MARGIN: 0PT 0; FONT-SIZE: 10PT">
	In June 2015 we executed a Master Service Agreement (&#8220;MSA&#8221;) with a leading
	pharmaceutical company. Under the MSA, our proprietary MyPRS
<SUP>
	&#174;
</SUP>
	genetic test will be run across multiple clinical
	trials in connection with the development of novel treatments for patients with multiple myeloma. During 2015, we began the first
	of four studies as part of the MSA. Under the agreement, MyPRS
<SUP>
	&#174;
</SUP>
	will help inform patterns of response to novel therapy
	regimens with the aim of enabling physicians to better manage multiple myeloma patients based on their specific genetic profile.
</LI>
<LI STYLE="MARGIN: 5PT 0; FONT-SIZE: 10PT">
	In August 2015, we announced that we executed an agreement with America&#8217;s Choice
	Provider Network (&#8220;ACPN&#8221;). Under the terms of the agreement, our MyPRS
<SUP>
	&#174;
</SUP>
	assay will be offered through
	ACPN&#8217;s proprietary network which covers over 22 million patients across the United States. We expect increased reimbursement
	support for our assay through agreements such as this to have a positive impact on our revenue generation over the long term.
</LI>
<LI STYLE="MARGIN: 0PT 0; FONT-SIZE: 10PT">
	In September 2015, we announced that we executed a master services agreement (&#8220;MSA&#8221;)
	with a leading biopharmaceutical company. The first two projects under this MSA, which commenced during 2015, will deploy our proprietary
	MyPRS
<SUP>
	&#174;
</SUP>
	test to inform the customers&#8217; clinical stage development program of a novel treatment, including potential
	combination therapies with current drugs, for patients with multiple myeloma.
</LI>
<LI STYLE="MARGIN: 5PT 0; FONT-SIZE: 10PT">
	During the fourth quarter of 2015 we executed agreements with additional preferred provider
	organizations (&#8220;PPO&#8221;). Under the terms of the agreements, our MyPRS
<SUP>
	&#174;
</SUP>
	assay will be offered through additional
	PPO networks including the Stratose, USA Managed Care Organization, and Evolutions Healthcare Systems PPO networks. Together with
	the PPO agreement we announced in August 2015 and our other payor relationships with Medicare and Blue Cross Blue Shield of Arkansas,
	the covered lives within our universe has increased to over 155 million patients in the United States.
</LI>
<LI STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT">
	In November 2015
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	a peer-reviewed paper
	highlighting the clinical utility of MyPRS
<SUP>
	&#174;
</SUP>
	was published on-line in the journal
<I>
	Leukemia.
</I>
	In the paper,
	titled &#8220;The Clinical Value of Molecular Subtyping Multiple Myeloma Using Gene Expression Profiling&#8221;, authored by N.
	Weinhold
<I>
	et al
</I>
	., researchers examined a dataset of 1,217 multiple myeloma patients treated at UAMS to gauge the impact of
	novel therapies on molecular and risk subgroups. As part of the research, MyPRS
<SUP>
	&#174;
</SUP>
	(also known as the GEP70 test)
	was used to classify patients into risk categories and molecular subtypes. The outcome of this research demonstrates the importance
	of classifying the risk category and subtype of a patient&#8217;s cancer in order to appropriately manage the course of treatment.
</FONT>
</LI>
</UL>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Sources of Revenues and Expenses
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Revenues
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We generate revenues primarily from the completion of tests processed
	through our CAP-accredited and CLIA certified laboratory when test results are delivered to ordering physicians. During 2015 and
	2014, we had two major customers, UAMS and Moffitt. Revenue sourced either from or through UAMS accounted for 54% and 84% of our
	net revenue during 2015 and 2014, respectively. Revenue sourced through Moffitt accounted for approximately 10% and 9% of our net
	revenue during 2015 and 2014, respectively.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	A significant portion of our revenues consist of payments or reimbursements
	received from various payors, including Medicare, contracted insurance companies, directly billed customers (UAMS, pharmaceutical
	companies, reference laboratories and hospitals) and non-contracted insurance companies. We report revenues from contracted payors
	and directly billed customers based on the contractual rate. Medicare reimburses MyPRS
<SUP>
	&#174;
</SUP>
	based on the local coverage
	determination at approximately $1,900 per test and AR-BCBS reimburses MyPRS
<SUP>
	&#174;
</SUP>
	based on the contractual rate of approximately
	$2,000 per test. Revenues from non-contracted payors are reported based on the amount expected to be collected, which is based
	on the historical collection experience of each payor or payor group, as appropriate. Our estimates of net revenue are subject
	to change based on the contractual status and payment policies of third-party payors with whom we deal as well as anticipated changes
	in the healthcare industry and related legislation. We regularly refine our estimates in order to make our estimated revenue as
	accurate as possible based on our most recent collection experience with each third-party payor.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 45; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	42
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage46"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Cost of Revenue
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Our cost of revenue consists primarily of the cost of materials
	and supplies, labor, and other costs associated with processing specimens including pathological review, quality control analyses,
	delivery charges necessary to render an individualized test result, depreciation, amortization and royalty expense. Costs associated
	with performing tests are recorded as the tests are processed.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Research and Development Expenses
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Our research and development expenses primarily include personnel
	costs, laboratory supplies, reagents, consulting costs associated with developing and validating new testing services and sponsored
	research agreements with leading academic institutions for clinical trials and other studies to further validate the use of MyPRS
<SUP>
	&#174;
</SUP>
	for MM and AMG.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Selling and Marketing Expenses
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Our selling and marketing expenses consist primarily of sales commissions
	and support costs, salaries and related employee benefits, travel, and marketing costs for our commercial, business development
	and managed care functions.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	General and Administrative Expenses
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Our general and administrative expenses consist primarily of personnel
	costs, professional service fees and other costs related to our being a publicly-traded company.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Interest Expense
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Interest expense primarily reflects interest on our notes payable
	- related party.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Critical Accounting Policies and Estimates
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The preparation of financial statements in conformity with U.S.
	generally accepted accounting principles requires the use of estimates and assumptions that affect the reported amounts of assets
	and liabilities, revenues and expenses, and related disclosures in the financial statements. Critical accounting policies are those
	accounting policies that may be material due to the levels of subjectivity and judgment necessary to account for highly uncertain
	matters or the susceptibility of such matters to change, and that have a material impact on financial condition or operating performance.
	While we base our estimates and judgments on our experience and on various other factors that we believe to be reasonable under
	the circumstances, actual results may differ from these estimates under different assumptions or conditions. We believe the following
	critical accounting policies used in the preparation of our financial statements require significant judgments and estimates. For
	additional information relating to these and other accounting policies, see Note 2 to our audited financial statements, appearing
	elsewhere in this report.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Revenue Recognition
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We recognize revenue from testing services in accordance with the
	Financial Accounting Standards Board Accounting Standards Codification (&#8220;FASB ASC&#8221;), 605, Revenue Recognition, which
	requires that four basic criteria be met before revenue can be recognized: (1) persuasive evidence that an arrangement exists;
	(2) delivery has occurred and title and the risks and rewards of ownership have been transferred to the client or services have
	been rendered; (3) the price is fixed or determinable; and (4) collectability is reasonably assured.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Revenues are recorded on an accrual basis when the contractual obligations
	are completed as tests are processed through our laboratory and test results are delivered to ordering physicians. Revenues are
	billed to various payors, including Medicare, contracted insurance companies, directly billed customers (UAMS, pharmaceutical companies,
	reference laboratories and hospitals) and non-contracted insurance companies. Revenues from Medicare, contracted insurance companies
	and directly billed customers are reported based on the contractual rate. The difference between the amounts billed and the contractual
	rates from Medicare and contracted insurance companies are recorded as contractual allowances at the same time the revenue is recognized,
	to arrive at reported net revenue. The contractual rate is based on established agreed upon rates between us and the respective
	payor. Directly billed customers are invoiced at the contractual rate by us. Revenues from non-contracted insurance companies are
	reported based on the amount expected to be collected, which is based on the historical collection experience of each payor or
	payor group, as appropriate, and anticipated effects of changes in the healthcare industry, if any. The difference between the
	amount billed and the amount estimated to be collected from non-contracted insurance companies is recorded as a contractual allowance
	at the same time the revenue is recognized, to arrive at reported net revenue. We do not record revenue from individuals for billings
	until cash is collected; as collectability is not assured at the time services are provided, therefore there are no accounts receivable
	from self-payors. Gross revenues from individuals have been immaterial to date.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Our estimates of net revenue for non-contracted insurance companies
	are subject to change based on the contractual status and payment policies of the third-party payors with whom we deal. We regularly
	refine our estimates in order to make estimated revenue as accurate as possible based on its most recent collection experience
	with each third-party payor. We regularly review our historical collection experience for non-contracted payors and anticipated
	changes in the healthcare industry and adjust expected revenues for current and subsequent periods accordingly, including previously
	recorded revenues related to outstanding accounts receivable for such non-contracted payors. During 2015, net unfavorable changes
	in estimates were recorded to revenue related to non-contracted revenues recorded in the prior year of $193,000 and represented
	32% of the total non-contracted revenues for 2014. Although we regularly refine our estimates to reflect recent historical collection
	experience, if we have a similar percentage reduction of 32% in our estimated amount to be collected from non-contracted payors
	on the uncollected accounts receivable from non-contracted payors at December 31, 2015 of $131,000, this could result in a $42,000
	unfavorable change in our financial position and results of operations.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 46; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	43
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage47"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Accounts Receivable, Contractual Allowances and Allowance for Doubtful Accounts
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We record accounts receivable net of contractual allowances and
	an allowance for doubtful accounts. At December 31, 2015 and 2014, contractual allowances were $2.1 million and $1.5 million, respectively.
	We estimate an allowance for doubtful accounts based on the aging of the accounts receivable and the historical collection experience
	for each of our contracted payors. When the amounts are determined to be uncollectible, they are expensed as bad debt and subsequently
	charged-off against the allowance. During 2015 and 2014, we recognized $33,000 and $177,000 in bad debt expense, respectively.
	At December 31, 2015 and 2014, there were no allowances for doubtful accounts. Uncollectability of accounts receivable for a non-contracted
	payor is typically a reflection of an estimate in excess of actual collections and is adjusted in the period of collection as a
	change in estimate resulting in an increase in contractual allowances and, therefore, a reduction in current period net revenue.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The following tables present our gross accounts receivable from
	customers outstanding by aging category reduced by total contractual allowances to arrive at the net accounts receivable balance
	at December 31, 2015 and 2014. Other than our direct bill customers, all of our receivables were pending approval by third-party
	payors as of the date that the receivables were recorded:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_4"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="19" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	December 31, 2015
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-STYLE: ITALIC">
	(in thousands)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	0 - 30 Days
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	31 - 60 Days
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	61 - 90 Days
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Over 90 Days
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Total
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 50%; FONT-SIZE: 10PT">
	Medicare
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	116
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	55
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	32
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	16
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	219
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Contracted insurance companies
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	13
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	9
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	16
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	38
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Direct bill
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	101
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	12
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	24
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	14
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	151
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Non-contracted insurance companies
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	336
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	256
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	215
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,244
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,051
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Accounts receivable, gross
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	566
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	323
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	280
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,290
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,459
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Less: contractual allowances
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(347
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(245
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(230
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(1,243
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(2,065
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT; PADDING-LEFT: 10PT">
	Accounts receivable, net
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	219
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	78
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	50
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	47
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	394
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="19" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	December 31, 2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-STYLE: ITALIC">
	(in thousands)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	0 - 30 Days
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	31 - 60 Days
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	61 - 90 Days
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Over 90 Days
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Total
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 50%; FONT-SIZE: 10PT">
	Medicare
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	79
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	44
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	51
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	82
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	256
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Contracted insurance companies
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	12
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	52
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	72
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Direct bill
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	161
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	282
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	67
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	510
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Non-contracted insurance companies
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	182
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	142
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	160
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,216
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,700
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Accounts receivable, gross
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	434
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	472
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	282
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,350
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,538
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Less: contractual allowances
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(162
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(113
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(127
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(1,048
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(1,450
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT; PADDING-LEFT: 10PT">
	Accounts receivable, net
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	272
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	359
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	155
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	302
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,088
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The days sales outstanding (&#8220;DSO&#8221;) was 53 days at December
	31, 2015 compared to 84 days at December 31, 2014. The decrease in DSO is primarily due to improved collection of Medicare and
	non-contracted third party payors during 2015, reflective of improved collection procedures internally. Net revenues from private
	insurance payors was 19% and 7% of total net revenue during 2015 and 2014, respectively. Since these customers are slower to pay,
	we would expect our DSO&#8217;s to increase as net revenues from these customers increase.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Stock-Based Compensation
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We recognize compensation expense in an amount equal to the estimated
	fair value of each stock award over the estimated period of service and vesting. The estimation of the fair value of each stock-based
	grant or issuance involves numerous assumptions by management. The use of different values by management in connection with these
	assumptions could produce substantially different results.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Accounting for Income Taxes
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Deferred income taxes result primarily from temporary differences
	between financial and tax reporting. Deferred tax assets and liabilities are determined based on the difference between the financial
	statement basis and tax basis of assets and liabilities using enacted tax rates. Future tax benefits are subject to a valuation
	allowance when management is unable to conclude that our deferred tax assets will more-likely-than-not be realized from the results
	of operations. Our estimate for the valuation allowance for deferred tax assets requires management to make significant estimates
	and judgments about projected future operating results. If actual results differ from these projections or if management&#8217;s
	expectations of future results change, it may be necessary to adjust the valuation allowance.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 47; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	44
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage48"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Recent Accounting Pronouncements
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We have reviewed all recently issued standards and have determined
	that other than as disclosed in Note 2 to the consolidated financial statements included herein, such standards will not have a
	material impact on our consolidated financial statements or do not otherwise apply to our operations.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Future Accounting Pronouncements
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Section 107 of the JOBS Act provides that an emerging growth company,
	such as our company, can take advantage of an extended transition period for complying with new or revised accounting standards.
	Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply
	to private companies. Although to date, we have not yet taken advantage of this delay, we have elected to avail ourselves of this
	extended transition period for adopting new or revised accounting standards in the future. Therefore, we will not be subject to
	the same new or revised accounting standards as other public companies that are not emerging growth companies. As a result of this
	election, our financial statements may not be comparable to companies that comply with public company effective dates. In the future,
	we may elect to opt out of the extended period for adopting new or revised accounting standards. If we do so, we will be required
	to disclose such decision, which will be irrevocable.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_RESULTS_OF_OPERATIONS>
<A NAME="FIS_RESULTS_OF_OPERATIONS"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Results of Operations
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_5"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Year Ended December 31, 2015 Compared to the Year Ended December 31, 2014
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Net Revenue
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Net revenue was $2.5 million during 2015, a decrease of $1.8 million,
	or 41%, compared to $4.3 million during 2014. Net revenue and tests billed during 2015 and 2014 were as follows:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="15" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Net Revenue
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="15" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Tests Billed
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-STYLE: ITALIC">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-STYLE: ITALIC; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-STYLE: ITALIC">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-STYLE: ITALIC; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-STYLE: ITALIC">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Increase (Decrease)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-STYLE: ITALIC; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-STYLE: ITALIC">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-STYLE: ITALIC; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-STYLE: ITALIC">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Increase (Decrease)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT">
	(dollars in thousands)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2014
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	%
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2014
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	#
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	UAMS-sourced:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 28%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	Research programs
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 6%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	954
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 6%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,114
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 6%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(2,160
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(69
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)%
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,170
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,225
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(2,055
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(64
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	Clinical patient revenue
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	412
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	504
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(92
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(18
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	346
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	448
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(102
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(23
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Other US hospitals and direct billed customers
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,052
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	668
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	384
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	57
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	921
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	511
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	410
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	80
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Pharmaceutical services
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	120
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	34
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	86
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	253
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	59
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	12
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	47
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	392
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT; PADDING-LEFT: 10PT">
	Total
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,538
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,320
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(1,782
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(41
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)%
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,496
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,196
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(1,700
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(41
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)%
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The net revenue recognized and number of tests reported and billed
	under the UAMS research programs decreased 69% and 64% respectively, in 2015 compared to 2014 primarily due to the decrease in
	funds available at UAMS for such programs. We expect continued declining revenue from the UAMS research programs.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The number of tests we reported and billed for UAMS-sourced clinical
	patients decreased 23% in 2015 when compared to 2014 due to the normal fluctuation in patient census. Net revenue recognized for
	such tests billed decreased 18% in 2015 when compared to 2014. The decrease in net revenue related to the decreased test volume,
	offset by $73,000 of net unfavorable prior year adjustments, booked in 2015, related to revenues recorded in the prior year.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The number of tests we billed for other U.S. hospitals and direct
	billed customers increased 80% in 2015 when compared to 2014 due to an increase in new hospital customers, a direct result of the
	ongoing expansion of our commercial organization and our increased marketing efforts. Net revenue recognized for such tests increased
	57% in 2015 when compared to 2014. The increase in net revenue was driven by the increased test volume offset by a reduction in
	test average selling price estimates used to calculate revenue for billings to non-contracted insurance payors. Additionally, a
	net unfavorable prior year adjustment of $120,000 was booked in 2015, relating to revenues recorded in the prior year. The reduction
	in current year pricing estimates for these non-contracted payors was in anticipation of the potential impact of the Affordable
	Care Act on utilization, coupled with a review of our historical collection trends, including non-contracted payors for whom we
	do not have collection experience. We expect the number of new payors to continue to increase, which may affect our collection
	trends and, therefore, revenue estimates for billings to non-contracted insurance payors.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 48; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	45
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage49"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The net revenue recognized and number of tests reported and billed
	under service agreements with pharmaceutical customers increased 253% and 392%, respectively, in 2015 compared to 2014 due to the
	master laboratory service agreements executed with two pharmaceutical companies during 2015. We expect revenue from our pharmaceutical
	services business to grow as testing volume from these two agreements increase. We are pursuing additional agreements with other
	pharmaceutical companies as well as additional projects with our two current collaborators.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Cost of Revenue
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Cost of revenue was $2.5 million or 97% of net revenues, during
	2015, a decrease of $894,000, or 27%, compared to $3.4 million, or 78% of net revenues, during 2014. The decrease was attributable
	to 1) $526,000 in decreased personnel costs, primarily related to $200,000 in decreased stock-based compensation expense, $100,000
	in one-time bonuses paid in 2014, $156,000 in labor costs allocated to research and development projects and $109,000 in reduced
	employee health insurance costs related to changing insurers, and 2) $424,000 in decreased material and supply costs due to a decrease
	in the total tests performed. These decreases were partially offset by a $56,000 increase in other laboratory related expenses,
	including depreciation expense.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Research and Development Expenses
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Research and development expenses were $1.0 million during 2015,
	an increase of $655,000, or 189%, when compared to $347,000 during 2014. The increase is due to $470,000 in our increased usage
	of labor, materials and supplies for research projects, $15,000 in increased consulting services and $170,000 in sponsored research
	programs related to research to further validate the use of MyPRS
<SUP>
	&#174;
</SUP>
	in MM and AMG.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Selling and Marketing Expenses
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Selling and marketing expenses were $2.6 million during 2015, an
	increase of $1.8 million, or 257%, when compared to $717,000 during 2014. The increase was primarily attributed to a $1.4 million
	increase in personnel costs related to expanding our sales and marketing function and establishing our managed care, commercial
	and business development functions, and $432,000 of expense for new marketing projects.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	General and Administrative Expenses
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	General and administrative expenses were $7.7 million during 2015,
	an increase of $835,000, or 12%, when compared to $6.9 million during 2014. The increase was primarily attributable to $1.2 million
	in increased personnel costs related to hiring our chief financial and information officers, and accounting, internal billing,
	information technology and administrative staff, $275,000 in additional costs for an incentive plan, $638,000 of increased legal,
	accounting and insurance expenses related to our being a publicly-traded company for a full year during 2015, partially offset
	by $1.1 million in decreased stock-based compensation expense and $144,000 in decreased bad debt expense.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Gain on Legal Settlement
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	In August 2013, we settled a lawsuit in which we were the plaintiff
	for a tortuous interference claim regarding a potential acquisition, of which $100,000 was recognized as a gain on legal settlement
	during 2014.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Interest Expense
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Interest expense was $141,000 during 2015, compared to $1.0 million
	during 2014. The decrease was primarily attributable to the Debt Conversion that occurred in June 2014.
</P>
</EFX_RESULTS_OF_OPERATIONS>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_LIQUIDITY_CAPITAL>
<A NAME="FIS_LIQUIDITY_CAPITAL"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Liquidity and Capital Resources
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We had cash and cash equivalents of $10.8 million at December 31,
	2015 compared to $5.1 million at December 31, 2014. At December 31, 2015, we had working capital of $9.3 million.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	On July 10, 2015, we filed a prospectus for the offering, issuance
	and sale of securities from time to time in one or more offerings (&#8220;Shelf Registration&#8221;) which was declared effective
	by the SEC on July 28, 2015. The amount of securities to be sold pursuant to the Shelf Registration is limited by our public float.
	Concurrently with filing the Shelf Registration, we entered into a sales agreement with Cantor Fitzgerald &amp; Co., to sell shares
	of our common stock, with aggregate gross sales proceeds of up to $4.45 million, from time to time, through an &#8220;at-the-market&#8221;
	equity offering program (the &#8220;ATM program&#8221;). During September 2015, we sold 2,734,983 shares of common stock pursuant
	to this registration for total cash proceeds of $4.0 million, which is net of $429,000 in underwriter commissions and offering
	expenses. Due to the size of our public float, the current ATM program has been completed, unless and until our public float increases.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	On February 20, 2015, we completed a public offering of 3,214,285
	shares of our common stock, at $2.80 per share, for total cash proceeds of $7.8 million, which is net of $1.2 million in underwriter
	commissions and estimated offering expenses. On February 26, 2015, the underwriters exercised their overallotment option for 482,142
	additional shares of our common stock, for total cash proceeds of $1.3 million, which is net of $95,000 in underwriter commissions.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 49; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	46
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage50"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Prior to our initial public offering (&#8220;IPO&#8221;) in June
	2014, our principal sources of cash consisted primarily of borrowings on our note payable to a related party. We received total
	cash proceeds of $6.1 million from our IPO, which is net of $2.4 million in underwriter commissions and offering expenses.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We expect that as our revenues grow, our operating expenses will
	grow and, as a result, we will need to generate significant additional net revenues to achieve profitability.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We have no material commitments for capital expenditures at this
	time.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Although we are forecasting continued losses and negative cash flows
	as we continue to fund our commercialization activities and research and development programs, we currently expect that we will
	have sufficient cash and cash equivalents on hand to support operations for 12 to 15 months from the date of this report. Going
	forward, as we continue our expansion, we may seek additional financing and/or strategic investments. However, there can be no
	assurance that any additional financing or strategic investments will be available on acceptable terms, if at all. If events or
	circumstances occur such that we do not obtain additional funding, we will most likely be required to reduce our plans and/or certain
	discretionary spending, which could have a material adverse effect on our ability to achieve our intended business objectives.
	Our financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.
	If we cannot continue as a viable entity, our stockholders may lose some or all of their investment in us.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Operating activities
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Cash used by operations during 2015 was $6.9 million, compared to
	$2.2 million during 2014. Our use of cash during 2015 was primarily a result of our higher net loss during 2015, when compared
	to 2014. Changes in operating assets and liabilities during 2015 provided cash of $1.1 million, compared to $282,000 during 2014.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	During 2015, the provision of cash from changes in operating assets
	and liabilities of $1.1 million includes a $694,000 decrease in accounts receivable, which reflects a reduction in our DSO from
	84 days at December 31, 2014 to 53 days at December 31, 2015, a $633,000 increase in accounts payable and accrued liabilities,
	primarily due to higher accrued compensation and related expenses, partially offset by a $248,000 reduction in our lease termination/abandonment
	payable, due to payments made on the terminated lease.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Revenues from non-contracted insurance companies represented 17%
	and 7% of our total revenues during 2015 and 2014, respectively. Since these customers are slower to pay, our accounts receivable
	over 90 days will increase if revenues from these customers increase. We do not know if collections will remain at the levels experienced
	during 2015. Future collections may depend upon our ability to obtain in-network contracts with additional insurance providers.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	During 2014, the provision of cash from changes in operating assets
	and liabilities of $282,000 includes a $383,000 increase in accounts payable and accrued liabilities, primarily due to higher accrued
	compensation and related expenses, a $178,000 decrease in inventory due to the timing of the receipt of laboratory materials and
	supplies and a $191,000 decrease in prepaid expenses and other assets, which were partially offset by a $376,000 reduction in our
	lease termination/abandonment payable due to payments made on the terminated lease. Our DSO at December 31, 2014 remained relatively
	flat at 84 days when compared to December 31, 2013 at 83 days.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Investing activities
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Net cash used by investing activities during 2015 of $95,000 was
	for the purchase of property and equipment, partially offset by a reduction in our security deposit on a lease.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Net cash used by investing activities during 2014 of $274,000 was
	primarily for the purchase of property and equipment.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	As of this time, we plan to focus on our growth strategies and do
	not plan to use a material amount of our cash resources for the purchase of property and equipment during 2016.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Financing activities
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Net cash provided by financing activities during 2015 of $12.7 million
	consisted primarily of the net proceeds from our public offerings of common stock in February and September 2015 of $13.1 million,
	partially offset by $363,000 used to repurchase shares from employees to satisfy tax withholding obligations for restricted stock
	awards.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Net cash provided by financing activities during 2014 of $7.4 million
	consisted primarily of $6.6 million in net proceeds from our IPO and $795,000 in net proceeds from our note payable-related party.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Related Party Transactions
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	During 2014, our then majority member, and current Chairman of our
	board of directors, through various entities controlled by such member, loaned a net amount of $795,000 to us to support our operations.
	The secured note bore interest at 8% compounded quarterly, was due on demand and collateralized by substantially all of our assets.
	Pursuant to the terms of an Exchange Agreement, and prior to the Corporate Conversion, $27.3 million of the Secured Note payable
	as of June 17, 2014 was exchanged for 2,732,629 Class C units of Signal Genetics LLC and recorded to members&#8217; equity. The
	remaining $1.0 million as of that date, along with an additional $45,000, which was advanced to pay for certain offering expenses,
	was reclassified as unsecured amounts due to related party in the consolidated balance sheet. The aggregate amount was non-interest
	bearing and was due on demand.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 50; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	47
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage51"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	On March 6, 2015, our amounts due to related party, aggregating
	$1,045,000, were converted into an unsecured note payable &#8211; related party, bearing interest at 8% per annum and due on demand.
	The principal amount of the note was increased by $60,000 over the amounts due to related party to $1,105,000 to provide the equivalent
	of 8% per annum interest for the period of time the amounts due to related party were held as a payable in exchange for a provision
	that the related party would not call the note prior to June 30, 2015. The increase in the principal amount of the note was deferred
	and amortized to interest expense over the initial term of the note to June 30, 2015. Interest expense related to this note during
	the year ended December 31, 2015 was $132,000. The note balance at December 31, 2015 was $1,105,000 and accrued interest payable
	of $73,000 is included in accrued liabilities in the consolidated balance sheet at December 31, 2015.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Commitments and Contingencies
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	At December 31, 2015, other than our office and laboratory lease,
	a license agreement with UAMS and a services agreement with a third party to assist with collections from customers, we had no
	material commitments other than the liabilities reflected in our financial statements.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	The JOBS Act
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	In April 2012, the JOBS Act was enacted. Section 107 of the JOBS
	Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised
	accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards
	would otherwise apply to private companies. The Company has elected to avail itself of the extended transition period for adopting
	new or revised accounting standards. As a result of this election, our financial statements may not be comparable to companies
	that comply with public company effective dates.
</P>
</EFX_LIQUIDITY_CAPITAL>
</EFX_MANAGEMENTS_DISCUSSION>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<EFX_MARKET_RISK>
<A NAME="FIS_MARKET_RISK"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<A NAME="F10K_032116P_HTM_A_011">
</A>
	Item 7A. Quantitative and Qualitative Disclosures About Market Risk
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	As a &#8220;smaller reporting company,&#8221; we are not required
	to provide the information required by this Item.
</P>
</EFX_MARKET_RISK>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<EFX_FINANCIAL_STATEMENTS>
<A NAME="FIS_FINANCIAL_STATEMENTS"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<A NAME="F10K_032116P_HTM_A_012">
</A>
	Item 8. Financial Statements and Supplementary Data
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The financial statements and supplemental data required by this
	item are set forth at the pages indicated in Part IV, Item 15(a)(1) of this Annual Report.
</P>
</EFX_FINANCIAL_STATEMENTS>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<EFX_ACCOUNTING_CHANGES>
<A NAME="FIS_ACCOUNTING_CHANGES"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<A NAME="F10K_032116P_HTM_A_013">
</A>
<B>
	Item 9. Changes in and Disagreements with Accountants on Accounting and Financial
	Disclosure
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Not applicable.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 51; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	48
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_ACCOUNTING_CHANGES>
<A NAME="eolPage52"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<EFX_CONTROL_AND_PROCEDURES>
<A NAME="FIS_CONTROL_AND_PROCEDURES"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<A NAME="F10K_032116P_HTM_A_014">
</A>
	Item 9A. Controls and Procedures
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Disclosure Controls and Procedures
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	In evaluating the disclosure controls and procedures, management
	recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of
	achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship
	of possible controls and procedures. Our management, with the participation of our Chief Executive Officer and our Chief Financial
	Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Annual
	Report on Form 10-K. Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure
	controls and procedures were effective, at the reasonable assurance level, as of the end of the period covered by this report to
	ensure that information we are required to disclose in reports that we file or submit under the Securities Exchange Act of 1934,
	as amended, (1) is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission
	rules and forms, and (2) is accumulated and communicated to management, including our Chief Executive Officer and our Chief Financial
	Officer as appropriate to allow timely decisions regarding required disclosure.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Management&#8217;s Report on Internal Control Over Financial Reporting
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Internal control over financial reporting refers to the process
	designed by, or under the supervision of, our Chief Executive Officer and Chief Financial Officer, and effected by our board of
	directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and
	the preparation of financial statements for external purposes in accordance with generally accepted accounting principles, and
	includes those policies and procedures that: (1) pertain to the maintenance of records that in reasonable detail accurately and
	fairly reflect the transactions and dispositions of our assets; (2) provide reasonable assurance that transactions are recorded
	as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that
	our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and (3) provide
	reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company&#8217;s
	assets that could have a material effect on the financial statements.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Internal control over financial reporting cannot provide absolute
	assurance of achieving financial reporting objectives because of its inherent limitations. Internal control over financial reporting
	is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human
	failures. Internal control over financial reporting also can be circumvented by collusion or improper management override. Because
	of such limitations, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal
	control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore,
	it is possible to design into the process safeguards to reduce, though not eliminate, this risk.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Management is responsible for establishing and maintaining adequate
	internal control over our financial reporting, as such term is defined in Rule 13a-15(f) under the Exchange Act. Under the supervision
	and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an
	evaluation of the effectiveness of our internal control over financial reporting. Management has used the framework set forth in
	the report entitled &#8220;Internal Control &#8212; Integrated Framework (2013 Framework)&#8221; published by the Committee of
	Sponsoring Organizations of the Treadway Commission to evaluate the effectiveness of our internal control over financial reporting.
	Based on its evaluation, management has concluded that our internal control over financial reporting was effective as of December
	31, 2015, the end of our most recent fiscal year.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Changes in Internal Control Over Financial Reporting
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	There were no changes in our internal control over financial reporting
	that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting during
	the fourth quarter of 2015.
</P>
</EFX_CONTROL_AND_PROCEDURES>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_OTHER_INFORMATION>
<A NAME="FIS_OTHER_INFORMATION"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<A NAME="F10K_032116P_HTM_A_015">
</A>
	Item 9B. Other Information
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	None.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 52; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	49
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_OTHER_INFORMATION>
</EFX_PART_II>
<A NAME="eolPage53"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<EFX_PART_III>
<A NAME="FIS_PART_III"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
<B>
	PART III
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_DIRECTORS_AND_OFFICERS>
<A NAME="FIS_DIRECTORS_AND_OFFICERS"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<A NAME="F10K_032116P_HTM_A_016">
</A>
	Item 10. Directors, Executive Officers and Corporate Governance
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Board of Directors and Executive Officers
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Our business and affairs are organized under the direction of our
	board of directors, which currently consists of five members. Set forth below are our directors and executive officers and their
	respective ages and positions as of the date of this report:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_NAME_AND_TITLE>
<A NAME="FIS_NAME_AND_TITLE"></A>
<TABLE CELLSPACING="0" CELLPADDING="2" STYLE="WIDTH: 70%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD NOWRAP STYLE="VERTICAL-ALIGN: TOP; WIDTH: 39%">
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	Executive
	Officers and Directors
</B>
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 9%; TEXT-ALIGN: LEFT">
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 0PT; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	Age
</B>
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 50%">
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	Position(s)
	Held
</B>
</FONT>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Bennett S. LeBow
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	78
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Chairman of the Board
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Samuel D. Riccitelli
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	57
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	President, Chief Executive Officer and Director
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Tamara A. Seymour
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	57
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Chief Financial Officer
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	David A. Gonyer, R. Ph.
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	52
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Douglas A. Schuling
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	55
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Robin L. Smith, M.D.
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	51
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
</TR>
</TABLE>
</EFX_NAME_AND_TITLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	There are no family relationships among any of our directors or
	executive officers. Set forth below is a summary of the business experience of each of our directors and executive officers identified
	above and our key employees:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
<B>
<I>
	Bennett S. LeBow.
</I>
</B>
	Mr. LeBow has served as the Chairman
	of our board of directors since our inception in January 2010 and was our founding member and the sole manager of Signal Genetics
	LLC, prior to the Corporate Conversion. Mr. LeBow is the sole partner and has sole voting and dispositive power, of our principal
	stockholder, LeBow Alpha. Mr. LeBow is a private investor and currently serves as the Chairman and Chief Executive Officer of BSL
	Capital, Inc. Mr. LeBow also serves as the Chairman of the board of directors of Vector Group, Ltd., where he has been a director
	since 1986 and where he served as Executive Chairman from January 2006 until his retirement in December 2008. Mr. LeBow served
	as the Chairman of the board of directors of Borders Group Inc. from May 2010 until January 2012 and Chief Executive Officer from
	June 2010 until January 2012. In February 2011, Borders Group Inc. filed a petition for protection under Chapter 11 of Title 11
	of the United States Bankruptcy Code. Mr. LeBow received a B.A. in electrical engineering from Drexel University.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We selected Mr. LeBow to serve on our board of directors as Chairman
	due to the perspective and extensive experience he brings as our founder. Mr. LeBow brings to the board of directors significant
	executive leadership and operational experience in both the private and public sector.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
<B>
<I>
	Samuel D. Riccitelli.
</I>
</B>
	Mr. Riccitelli has served as
	our President and Chief Executive Officer since October 2012. He was elected to our board of directors immediately prior to our
	initial public offering in June 2014. From July 2011 to October 2012, Mr. Riccitelli was an independent consultant. From October
	2001 to June 2011, Mr. Riccitelli served as the Executive Vice President and Chief Operating Officer of Genoptix, Inc., a publicly
	traded diagnostic services company focused on the needs of community hematologists and oncologists. From 1995 to 2001, Mr. Riccitelli
	served in a number of positions for Becton, Dickinson and Company, including most recently as a vice president and general manager
	and as a board member for BD Ventures, L.L.C., a venture capital fund. From 1989 to 1994, he served in a number of positions at
	Puritan-Bennett Corporation, including most recently as general manager. Mr. Riccitelli also served on the board of directors of
	Exagen Diagnostics, Inc., from October 2011 through September 2014. Mr. Riccitelli received a B.A. in Biology from Washington and
	Jefferson College and a M.S. Eng. degree from The University of Texas in Mechanical &amp; Biomedical Engineering.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We selected Mr. Riccitelli to serve on our board of directors because
	he brings to the board of directors extensive knowledge of the life sciences and biotechnology industries. He has served in senior
	corporate positions of companies in the biotechnology and diagnostic industries. Mr. Riccitelli has led the successful development
	and commercialization of a broad range of diagnostic services, medical devices, and information based product and services and
	is a named inventor on eight patents. His business experience provides him with a broad understanding of the operational, financial
	and strategic issues facing public companies.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
<B>
<I>
	Tamara A. Seymour.
</I>
</B>
	Ms. Seymour has served as our Chief
	Financial Officer since August 4, 2014. Prior to joining the Company, Ms. Seymour served as Chief Financial Officer of HemaQuest
	Pharmaceuticals, Inc., a biotechnology company, beginning in November 2010. From July 2009 through November 2010, Ms. Seymour served
	as a financial consultant for various life sciences companies. From 2001 to 2009, Ms. Seymour served as Chief Financial Officer
	and Secretary for Favrille, Inc. (now MMRGlobal, Inc.), a publicly traded biotechnology company focused on developing immunotherapies
	for hematological malignancies. While at Favrille, she was responsible for various private and public equity and debt financings,
	including the initial public offering. From 1991 to 2001, Ms. Seymour served as consulting chief financial officer for a number
	of biotechnology companies. From 1988 through 1991, Ms. Seymour was Director of Finance and Controller with Agouron Pharmaceuticals,
	Inc. From 1980 through 1988, she worked with Deloitte &amp; Touche LLP and PricewaterhouseCoopers LLP in various positions including
	audit manager from 1985 &#8211; 1988. Ms. Seymour is a Certified Public Accountant. Ms. Seymour received an M.B.A. with an emphasis
	in Finance from Georgia State University and a bachelor&#8217;s degree in Business Administration with an emphasis in Accounting
	from Valdosta State University.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 53; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	50
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage54"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
<B>
<I>
	David A. Gonyer, R. Ph.
</I>
</B>
	Mr. Gonyer became a member
	of our board of directors immediately prior to the listing of our common stock on The NASDAQ Capital Market in June 2014. Mr. Gonyer
	is a co-founder of Evoke Pharma, Inc., a specialty pharmaceutical company focused primarily on the development of drugs to treat
	gastrointestinal diseases, and has served as its President and Chief Executive Officer and a member of its board of directors since
	March 2007. From January 2004 to June 2007, Mr. Gonyer served as Vice President, Strategic and Product Development of Medgenex,
	Inc., a subsidiary of Victory Pharma, Inc., a biopharmaceutical company focused on acquiring, developing and marketing products
	to treat pain and related conditions. From April 2000 to December 2004, Mr. Gonyer was a founder and Vice President of Sales and
	Marketing at Xcel Pharmaceuticals, Inc., a specialty pharmaceutical company focused on neurological disorders. From December 1996
	to April 2000, Mr. Gonyer served as Director of Marketing at Elan/Dura Pharmaceuticals, Inc. From 1987 to 1996, Mr. Gonyer held
	a broad range of management positions in commercial operations, alliance/partnership management, and regional sales at Eli Lilly
	&amp; Company, a global pharmaceutical company. From 2010 to 2015, Mr. Gonyer served as a member of the board of directors of Neurelis,
	Inc., a privately held neurological specialty pharmaceutical company. Mr. Gonyer is a Registered Pharmacist and holds a B.Sc. in
	Pharmacy from Ferris State University School of Pharmacy.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We selected Mr. Gonyer to serve on our board of directors because
	of his significant management experience, his extensive experience in the pharmaceutical industry and his substantial knowledge
	with respect to developing and marketing pharmaceutical products.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
<B>
<I>
	Douglas A. Schuling.
</I>
</B>
	Mr. Schuling became a member
	of our board of directors immediately prior to the listing of our common stock on The NASDAQ Capital Market in June 2014. From
	April 1999 through May 2011, when he retired, Mr. Schuling held the position of Executive Vice President and Chief Financial Officer
	for Genoptix, Inc., a publicly traded specialized laboratory service provider focused on delivering diagnostic services to hematologists
	and oncologists. Since May 2011, Mr. Schuling has acted as an independent consultant. From 1997 to March 1999, Mr. Schuling held
	the position of Chief Financial and Operating Officer for Point-of-Care Systems, a venture capital backed clinical information
	systems company. From 1985 to 1997, Mr. Schuling held various positions at Nellcor Puritan Bennett, a research, development and
	manufacturing company, specializing in medical equipment and supplies, most recently as Hospital Group Controller. Mr. Schuling
	received his B.S. degree in accounting from Drake University.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We selected Mr. Schuling to serve on our board of directors because
	of his extensive knowledge of the life sciences and biotechnology industries and his substantial financial and accounting background,
	having served as the chief financial officer of two other companies and controller of a third company.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
<B>
<I>
	Dr. Robin L. Smith.
</I>
</B>
	Dr. Robin Smith became a member
	of our board of directors immediately prior to the listing of our common stock on The NASDAQ Capital Market in June 2014. From July 2007 to December 2014, Dr. Smith served as Chief Executive Officer of Caladrius Biosciences, Inc. (formerly
	NeoStem, Inc.). She also served as Chairman of the Board of Caladrius Biosciences, Inc. during that tenure and until December
	2015. During her transition for the first 6 months of 2015, she served as Executive Chairman of the Board of Caladrius Biosciences,
	Inc. Dr.
	Smith currently serves on the board of directors of MYnd Analytics, Inc. and BioXcel Corporation. Dr. Smith is also the president
	and chairman of the board of The Stem for Life Foundation. She was also appointed to the board of directors, Science and Faith
	STOQ Foundation in Rome and the Capital Formation Committee of the Alliance for Regenerative Medicine, and Chief Executive Officer
	from July 2007 to December 2014. Dr. Smith also serves on the board of directors of the Palm Beach Country Club from April 2015
	to the present.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We selected Dr. Smith to serve on our board of directors because
	of her expertise in business development and medicine, which includes her extensive and diversified experience serving in executive
	and board level capacities for various medical enterprises and health care-based entities. Dr. Smith has acted as a senior advisor
	to, and investor in, companies where she has played a significant role in restructuring and/or growth.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Key Employees
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
<B>
<I>
	Michael Cerio.
</I>
</B>
	Mr. Cerio has served as our Chief Commercial
	Officer since January 1, 2016 and as Senior Vice President of Commercial Strategy and Business Development from August 2014 through
	December 2015. Prior to joining us, Mr. Cerio served as an independent consultant building out commercial plans for oncology diagnostics
	startups with the life science venture capital firm, MPM Capital, Inc., since May 2013. From June 2012 to April 2013, Mr. Cerio
	served as Consulting Chief Executive Officer for Modulation Therapeutics, Inc., a company that was developing a novel mechanism
	of action MM drug. From April 2012 to April 2013, Mr. Cerio was the President and Chief Executive Officer of Oncolome Diagnostics,
	Inc., where he built out commercial plans for oncology diagnostics in myelodysplastic syndrome and non-small cell lung cancer.
	From 2005 through 2011, Mr. Cerio led the licensing, early commercial strategy and merger and acquisition teams at Genzyme Genetics
	Corp., the clinical diagnostics business unit of Genzyme Corporation. From 1999 through 2005, Mr. Cerio held business development
	and licensing roles at BG Medicine and Genaissance Pharmaceuticals Inc. Mr. Cerio holds a B.S. in biology from Syracuse University,
	a M.S. in microbiology from the University of Connecticut and a M.B.A. from Columbia University.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 54; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	51
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage55"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
<B>
<I>
	Richard A. Bender MD, FACP.
</I>
</B>
	Dr. Bender has served
	as our Chief Medical Officer since September 2015. Prior to joining us, from 2012 to 2015, Dr. Bender held consulting roles with
	various companies, including serving as a long-term Medical Affairs Consultant for Quest Diagnostics. From 2011 to 2012, Dr. Bender
	served as Senior Vice President, Medical Affairs of Caris Life Sciences. From 2008 to 2011, he held the role of Chief Medical Officer
	and Vice President of Agendia, Inc. where he helped to develop advocacy, adoption and reimbursement of the company's breast cancer
	assays. From 2002 to 2008, Dr. Bender served as the Medical Director of Hematology/Oncology at Quest Diagnostics. From 2000 to
	2002, he served as Senior Director/Strategic Development Leader in Medical Oncology/Hematology at Johnson &amp; Johnson Pharmaceutical
	R&amp;D. From 1982 to 2000, he served as Director of Medical Oncology/Hematology at Permanente Medical Group where he helped to
	manage the second largest cancer center in California. From 1972 to 1978, Dr. Bender served in various roles including Senior Investigator
	and Attending Physician at the National Cancer Institute in Bethesda, Maryland. Dr. Bender received his M.D. from the University
	of California, Los Angeles as a Regents Scholar and has a B.A. in Biology from the University of California, Santa Barbara.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
<B>
<I>
	Sudipto Sur, Ph.D.
</I>
</B>
	Dr. Sur has served as our Chief
	Information Officer since January 2015. Prior to joining us, Dr. Sur was President of Anssur Corp and Founder and Chief Executive
	Officer of Miralex Systems Incorporated from 2007 to 2014, firms involved in modeling, analysis and visualization services for
	large scale scientific, engineering, marketing and business data as well as in the development of complex engineering systems and
	algorithms in areas such as medical robotics and unstructured large scale imaging. From 2004 to 2007, he served as Director of
	R&amp;D: Informatics and Systems for Sequenom, Inc. From 2001 to 2004, Dr. Sur was Associate Director, Control Systems and Software
	for Genoptix, Inc. Dr. Sur holds a Ph.D. in Control Systems and Robotics from the California Institute of Technology and a B.S.
	in Mechanical Engineering from the Indian Institute of Technology, Bombay.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
<B>
<I>
	Ryan Van Laar, Ph.D.
</I>
</B>
	Dr. Van Laar has served as our
	Vice President of Research and Operations since August 2014 and as our Director of Bioinformatics from February 2012 through July
	2014. Prior to joining us, Dr. Van Laar served as the Founder and Chief Scientific Officer of ChipDX from June 2008 to February
	2012. From May 2008 to January 2012, Dr. Van Laar worked at Regeneron Pharmaceuticals, Inc. as a bioinformatics scientist, facilitated
	the expansion of their oncology bioinformatics department and had the responsibility for identifying and developing oncology targets
	and biomarkers. From June 2005 to May 2008, Dr. Van Laar worked as a senior bioinformatician at Agendia where he developed novel
	diagnostic and prognostic multi-gene assays for breast and colon cancer, including the first FDA-cleared multi-gene oncology test,
	Mammaprint. Dr. Van Laar&#8217;s work has been extensively published in more than 20 peer-reviewed journals and has more than 20
	issued patents. Dr. Van Laar received his Ph.D. in molecular biology and bioinformatics from The University of Melbourne, Australia.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Board Composition and Election of Directors
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Our board of directors consists of five members: Messrs. LeBow,
	Riccitelli, Gonyer and Schuling and Dr. Smith. Our board of directors has undertaken a review of its composition and its committees
	and the independence of each director. Based upon information requested from and provided by each director concerning his or her
	background, employment and affiliations, including family relationships, our board of directors has determined that each of Messrs.
	Gonyer and Schuling and Dr. Smith is &#8220;independent&#8221; under the applicable rules of the SEC and NASDAQ and that neither
	Messrs. LeBow nor Riccitelli is &#8220;independent&#8221; as defined under the such rules. In making such determination, our board
	of directors considered the relationship that each such non-employee director has with our company and all other facts and circumstances
	that our board of directors deemed relevant in determining his independence, including the beneficial ownership of our capital
	stock by each non-employee director. Mr. Riccitelli is not an independent director under these rules because he is our President
	and Chief Executive Officer and Mr. LeBow is not an independent director under these rules because of the payments that have been
	made by us to LeBow Alpha and because of his control over LeBow Alpha, our largest stockholder.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Board Committees
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Our board of directors has established an Audit Committee, a Compensation
	Committee and a Nominating and Corporate Governance Committee.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 55; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	52
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage56"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Audit Committee
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The members of our Audit Committee are Mr. Gonyer, Mr. Schuling
	and Dr. Smith, each of whom has been determined by our board of directors to be independent under applicable NASDAQ and SEC rules
	and regulations. Mr. Schuling is the chair of the Audit Committee. Our Audit Committee&#8217;s responsibilities include, among
	others:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
	appointing, approving the compensation of, and assessing the independence of our registered public accounting firm;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
	overseeing the work of our independent registered public accounting firm, including through the receipt and consideration of
	reports from that firm;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
	reviewing and discussing with management and our independent registered public accounting firm our annual and quarterly financial
	statements and related disclosures;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
	monitoring our internal control over financial reporting, disclosure controls and procedures;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
	overseeing our internal audit function;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
	discussing our risk management policies;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
	establishing policies regarding hiring employees from our independent registered public accounting firm and procedures for
	the receipt and retention of accounting related complaints and concerns;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
	meeting independently with our internal auditing staff, if any, our independent registered public accounting firm and management;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
	reviewing and approving or ratifying any related person transactions; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
	preparing the Audit Committee report required by SEC rules.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	All audit and non-audit services, other than de minimis non-audit
	services, to be provided to us by our independent registered public accounting firm must be approved in advance by our Audit Committee.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Our board of directors has determined that Mr. Schuling is an &#8220;audit
	committee financial expert&#8221; as defined in applicable SEC rules.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Compensation Committee
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The members of our Compensation Committee are Mr. Gonyer, Mr. Schuling
	and Dr. Smith, each of whom has been determined by our board of directors to be independent under current NASDAQ and SEC rules
	and regulations. Dr. Smith is the chair of the Compensation Committee. Our Compensation Committee&#8217;s responsibilities include,
	among others:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
	reviewing and approving annually the corporate goals and objectives applicable to the compensation of the Chief Executive Officer,
	evaluating at least annually the Chief Executive Officer&#8217;s performance in light of those goals and objectives, and determining
	and approving the Chief Executive Officer&#8217;s compensation level based on this evaluation;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
	reviewing and approving the compensation of all other executive officers;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
	reviewing and approving and, when appropriate, recommending to the board of directors for approval, incentive compensation
	plans and equity-based plans, and where appropriate or required, recommending for approval by the stockholders of the Company,
	the adoption, amendment or termination of such plans; and administering such plans;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
	reviewing and approving the executive compensation information included in the Company&#8217;s annual report on Form 10-K and
	proxy statement;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
	reviewing and approving or providing recommendations with respect to any employment agreements or severance arrangements or
	plans; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
	reviewing director compensation and recommending any changes to the board of directors.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Nominating and Corporate Governance Committee
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The members of our Nominating and Corporate Governance Committee
	are Mr. Gonyer, Mr. Schuling and Dr. Smith, each of whom has been determined by our board of directors to be independent under
	current NASDAQ rules. Mr. Gonyer is the chair of the Nominating and Corporate Governance Committee. Our Nominating and Corporate
	Governance Committee&#8217;s responsibilities include, among others:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
	identifying and recommending candidates to fill vacancies on the board of directors and for election by the stockholders;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
	recommending committee and chairperson assignments for directors to the board of directors;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
	developing, subject to the board of directors&#8217; approval, a process for an annual evaluation of the board of directors
	and its committees and to oversee the conduct of this annual evaluation;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 56; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	53
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage57"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
	overseeing the Company&#8217;s corporate governance practices, including reviewing and recommending to the board of directors
	for approval any changes to the documents and policies in the Company&#8217;s corporate governance framework, including its certificate
	of incorporation and bylaws; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
	monitoring compliance with the Company&#8217;s Code of Business Conduct and Ethics, investigating alleged breaches or violations
	thereof and enforcing its provisions.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Board of Directors Leadership Structure
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Mr. LeBow serves as the Chairman of our board of directors. Our
	board of directors does not have a lead independent director. Our board of directors has determined its leadership structure is
	appropriate and effective for us, given our stage of development.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Risk Oversight
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Our board of directors monitors our exposure to a variety of risks
	through our Audit Committee. Our Audit Committee charter gives the Audit Committee responsibilities and duties that include discussing
	with management, the internal audit department and the independent auditors our major financial risk exposures and the steps management
	has taken to monitor and control such exposures, including our risk assessment and risk management policies.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Code of Business Conduct and Ethics
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We have adopted a code of business conduct and ethics that applies
	to all of our employees, officers (including our principal executive, financial and accounting officers), and directors, including
	those officers responsible for financial reporting. These standards are designed to deter wrongdoing and to promote honest and
	ethical conduct. The code of business conduct and ethics and the written charter for the audit committee is available on our website.
	The information that appears on our website is not part of, and is not incorporated into, this report.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	None of our directors or executive officers, nor any associate of
	such individual, is involved in a legal proceeding adverse to us or any of our subsidiaries.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The Code of Business Conduct and Ethics is available on our website
	at http://www.signalgenetics.com. Stockholders may request a free copy of our Code of Business Conduct and Ethics from:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Signal Genetics, Inc.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Attention: Investor Relations
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	5740 Fleet Street
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Carlsbad, California 92008
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	(760) 537-4100
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	If we make any substantive amendments to the Code of Business Conduct
	and Ethics or grant any waiver from a provision of the code to any executive officer or director, we will promptly disclose the
	nature of the amendment or waiver on our website. We will promptly disclose on our website (i) the nature of any amendment to the
	policy that applies to our principal executive officer, principal financial officer, principal accounting officer or controller,
	or persons performing similar functions and (ii) the nature of any waiver, including an implicit waiver, from a provision of the
	policy that is granted to one of these specified individuals, the name of such person who is granted the waiver and the date of
	the waiver.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Section 16(a) Beneficial Ownership Reporting Compliance
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Section 16(a) of the 1934 Act requires our directors and executive
	officers, and persons who own more than ten percent of a registered class of our equity securities, to file with the SEC initial
	reports of ownership within 10 days after he or she becomes a beneficial owner, director or officer and reports of changes in ownership
	of our common stock and other equity securities within two business days after the transaction is executed. Our officers, directors
	and greater than ten percent stockholders are required by SEC regulations to furnish us with copies of all Section 16(a) forms
	they file. To our knowledge, based solely on a review of the copies of such reports furnished to us and written representations
	that no other reports were required, during the fiscal year ended December 31, 2015, all Section 16(a) filing requirements applicable
	to our officers, directors and greater than ten percent beneficial owners were complied with.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 57; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	54
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_DIRECTORS_AND_OFFICERS>
<A NAME="eolPage58"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
</B>
</P>
<EFX_COMPENSATION>
<A NAME="FIS_COMPENSATION"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<A NAME="F10K_032116P_HTM_A_017">
</A>
	Item 11. Executive Compensation
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Summary Compensation Table (2015 and 2014)
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The following table sets forth the information as to compensation
	paid to or earned by our President and Chief Executive Officer and our only other executive officer during the fiscal years noted
	below whose total compensation exceeded $100,000. The persons listed in the following table are referred to herein as the &#8220;named
	executive officers.&#8221;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_COMPENSATION_TABLE>
<A NAME="FIS_COMPENSATION_TABLE"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Name and Principal
	Position
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Fiscal
<BR>
	Year
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Salary
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Bonus
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	Stock
</B>
<BR>
<B>
	Award(s)
<SUP>
	(1)
</SUP>
</B>
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	Option
</B>
<BR>
<B>
	Award(s)
<SUP>
	(1)
</SUP>
</B>
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	All
	Other Compensation
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Total
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 30%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Samuel D. Riccitelli
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2015
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	450,000
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 7%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	450,000
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Chief Executive Officer
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2014
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	450,000
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	90,000
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	(2)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7,455,110
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	24,164
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8,019,274
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT; PADDING-LEFT: 10PT">
	&nbsp;and President
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Tamara A. Seymour
<SUP>
	(3)
</SUP>
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	350,000
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	53,070
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	403,070
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Chief Financial Officer
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2014
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	144,712
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	43,414
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	468,280
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,398
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	657,804
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_COMPENSATION_TABLE>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1.1PT SOLID; WIDTH: 15%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)
</TD>
<TD>
	Represents the aggregate grant date fair value of stock awards or options for common stock computed in accordance with FASB
	ASC Topic 718.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT; MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(2)
</TD>
<TD>
	Discretionary bonus granted in March 2015, not made pursuant to any contractual arrangement.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(3)
</TD>
<TD>
	Ms. Seymour has served as Chief Financial Officer since August 4, 2014.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Riccitelli Employment Agreement
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We entered into an amended and restated employment agreement (the
	&#8220;CEO Agreement&#8221;), with Samuel D. Riccitelli, on June 17, 2014 (the effective date of the CEO Agreement) in connection
	with our initial public offering. The CEO Agreement was subsequently amended on July 23, 2014, to bring the agreement into compliance
	with Section 409A of the Internal Revenue Code of 1986, as amended, and the Treasury Regulations and interpretive guidance issued
	thereunder. The CEO Agreement prohibits Mr. Riccitelli from engaging in any competitive activity, as described in the CEO Agreement,
	during his employment with us and for a period of one year following termination of his employment for any reason.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The CEO Agreement continues in effect until October 31, 2015, and
	automatically renews for additional one-year terms on each anniversary of the effective date of the CEO Agreement after October
	31, 2015. The CEO Agreement provides for, among other things, an annual base salary of $450,000, payable on a semi-monthly basis.
	It also provides that Mr. Riccitelli will be reimbursed for all reasonable business expenses, including travel and entertainment
	expenses incurred in the performance of his duties. During the term of his employment, Mr. Riccitelli is entitled to participate
	in any annual performance-based incentive compensation programs and any long-term incentive compensation programs that are established
	by the Company, on the terms established from time to time by the Compensation Committee or the board of directors of the Company.
	Mr. Riccitelli is also entitled to four weeks of paid vacation time and is eligible to receive the same employee benefits as are
	provided by the Company to other executive employees.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The CEO Agreement also provides for certain post-termination benefits.
	See &#8220;Payments Due Upon Termination of Employment or a Change in Control &#8212; Riccitelli Employment Agreement&#8221; below
	for more information.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Seymour Employment Agreement
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We entered into an employment agreement (the &#8220;CFO Agreement&#8221;),
	with Tamara A. Seymour, on August 4, 2014 (the effective date of the CFO Agreement). The CFO Agreement prohibits Ms. Seymour from
	engaging in any competitive activity, as described in the CFO Agreement, during her employment with us.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The CFO Agreement continues in effect until the one year anniversary
	of the effective date of the CFO Agreement, and automatically renews for additional one-year terms on each anniversary of such
	effective date. The CFO Agreement provides for, among other things, an annual base salary of $350,000, payable on a semi-monthly
	basis. It also provides that Ms. Seymour will be reimbursed for all reasonable business expenses, including travel and entertainment
	expenses incurred in the performance of her duties. The CFO Agreement also provides that at the end of each fiscal year of the
	Company, in addition to Ms. Seymour&#8217;s base salary then in effect, she will be eligible to receive a bonus payment of up to
	30% of her base salary then in effect, which bonus payment will be awarded in the sole discretion of the Compensation Committee
	based upon performance goals established by the Compensation Committee during the first ninety (90) days of each fiscal year, which
	goals shall be set after consultation with the Chief Executive Officer. Pursuant to the terms of the CFO Agreement, Ms. Seymour
	received an initial restricted stock unit award for 92,000 shares as of the Effective Date. Ms. Seymour is also entitled to four
	weeks of paid vacation time and is eligible to receive the same employee benefits as are provided by the Company to other executive
	employees.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The CFO Agreement also provides for certain post-termination benefits.
	See &#8220;Payments Due Upon Termination of Employment or a Change in Control&#8221; below for more information.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	2014 Stock Incentive Plan
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Prior to our initial public offering, we adopted a stock incentive
	plan (the &#8220;2014 Plan&#8221;). On March 25, 2015, our Board approved an amendment to the 2014 Plan (the &#8220;2014 Plan Amendment&#8221;),
	which was subsequently approved by our stockholders on June 18, 2015, which increased the number of shares of our Common Stock
	reserved for issuance by 854,601 shares (the &#8220;Additional Shares&#8221;) from 1,245,399 shares to 2,100,000 shares. The 2014
	Plan Amendment also provides for an annual increase to the total number of shares available for issuance under the 2014 Plan, as
	amended, on the first day of each calendar year, beginning with January 1, 2016 and ending with the last January 1 during the initial
	ten-year term of the plan, equal to the lesser of (A) four percent (4%) of the shares of Common Stock outstanding (on an as-converted
	basis) on the last day of the immediately preceding fiscal year, and (B) such smaller number of shares of Common Stock as determined
	by the Board. No other amendments were made to the 2014 Plan.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 58; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	55
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage59"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;The 2014 Plan, as amended, is
	otherwise unchanged from the plan as approved by the stockholders prior to our initial public offering, except for the increase
	in the total authorized shares thereunder and the &#8220;evergreen&#8221; provision. A description of the 2014 Plan, as amended
	by the 2014 Plan Amendment, is included below. This is not a complete statement of the 2014 Plan. The full text of the 2014 Plan
	was attached as Exhibit 10.1 to our Quarterly Report on Form 10-Q, filed on August 14, 2014 with the SEC, which is available at
	the SEC&#8217;s website located at
</FONT>
	&nbsp;
<FONT STYLE="FONT-SIZE: 10PT">
	www.sec.gov. The 2014 Plan Amendment is attached hereto
	as Exhibit 10.15.
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
<I>
	Purpose.
</I>
	We believe that the 2014 Plan promotes our
	long-term growth and profitability by (1) providing key people with incentives to improve stockholder value and to contribute to
	our growth and financial success through their future services, and (2) enabling us to attract, retain and reward the best-available
	personnel.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
<I>
	Eligibility.
</I>
	Selected employees, officers, directors, and
	other individuals providing bona fide services to us or any of our affiliates, are eligible for awards under the 2014 Plan. The
	plan administrator may also grant awards to individuals in connection with hiring, retention, or otherwise before the date the
	individual first performs services for the Company or an affiliate. However, those awards will not become vested or exercisable
	before the date the individual first performs those services for us.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
<I>
	Shares subject to the plan.
</I>
	The number of shares of common
	stock that we may issue pursuant to awards under the 2014 Plan is 2,100,000; provided, however, that no more than 1,680,000 shares
	of common stock may be issued in the form of full-value awards, and no more than 1,000,000 shares of common stock may be issued
	pursuant to incentive stock options intended to qualify under section 422 of the Internal Revenue Code. The maximum number of shares
	of common stock subject to awards of any combination that may be granted under the 2014 Plan during any fiscal year to any one
	individual will be limited to 750,000 shares. These limits will be appropriately adjusted to reflect any stock dividends, split
	ups, recapitalizations, mergers, consolidations, share exchanges, and similar transactions. If any award, or portion of an award,
	under the 2014 Plan expires or terminates unexercised, becomes unexercisable, is settled in cash without delivery of shares, or
	is forfeited or otherwise terminated, surrendered or canceled as to any shares, or if any shares are repurchased by or surrendered
	to us in connection with any award, or if any shares are withheld by us, the shares subject to such award and the repurchased,
	surrendered and withheld shares will thereafter be available for further awards under the 2014 Plan other than incentive stock
	options.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
<I>
	&#8220;Evergreen&#8221; provision.
</I>
	The 2014 Plan Amendment
	also provides for an annual increase to the total number of shares available for issuance under the 2014 Plan, as amended, on the
	first day of each calendar year, beginning with January 1, 2016 and ending with the last January 1 during the initial ten-year
	term of the plan, equal to the lesser of (A) four percent (4%) of the shares of Common Stock outstanding (on an as-converted basis)
	on the last day of the immediately preceding fiscal year, and (B) such smaller number of shares of Common Stock as determined by
	the Board.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
<I>
	Administration.
</I>
	The 2014 Plan is administered by our board
	of directors or by a committee or committees as the board may appoint from time to time. The plan administrator has the full authority
	and discretion to administer the 2014 Plan and to take any action that is necessary or advisable in connection with the administration
	of the plan, including without limitation the authority and discretion to interpret and administer the plan and any instrument
	or agreement relating to the plan or any award made thereunder. The plan administrator&#8217;s determinations will be final and
	conclusive.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
<I>
	Types of awards.
</I>
	The 2014 Plan provides for grants of stock
	options (including incentive stock options qualifying under Code section 422 and nonstatutory stock options), stock appreciation
	rights, restricted or unrestricted stock awards, restricted stock units, performance awards, other stock-based awards, or any combination
	of the foregoing. As of December 31, 2015, 1,404,740 shares have been granted pursuant to awards under the 2014 Plan. Future benefits
	or amounts that will be allocated to any participant or group of participants are indeterminable at this time because participation
	and the types of awards (including options) available under the plan are subject to the discretion of the plan administrator.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 59; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	56
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage60"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
<I>
	Stock options.
</I>
	The 2014 Plan allows the plan administrator
	to grant incentive stock options, as that term is defined in section 422 of the Internal Revenue Code, or nonqualified stock options.
	Only our employees or employees of our subsidiaries or any parent corporation may receive incentive stock option awards. Options
	must have an exercise price at least equal to the fair market value of the underlying shares (110% of the fair market value for
	incentive stock options if the grantee is a 10% holder within the meaning of Code section 422) on the date of grant. The option
	holder may pay the exercise price in cash or by check, by tendering shares of common stock, by a combination of cash and shares,
	or by any other means that the plan administrator approves. Generally, options granted under the 2014 Plan will have a 10 year
	term (five year term in the case of incentive stock options granted to a 10% holder), however, the options will expire earlier
	if the option holder&#8217;s service relationship with us terminates.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
<I>
	Stock appreciation rights.
</I>
	The 2014 Plan allows the plan
	administrator to grant awards of stock appreciation rights, which entitle the holder to receive a payment in cash, in shares of
	common stock, or in a combination of both, having an aggregate value equal to the spread on the date of exercise between the fair
	market value of the underlying shares on that date and the base price of the shares specified in the grant agreement, multiplied
	by the number of shares specified in the award being exercised.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
<I>
	Stock awards.
</I>
	The 2014 Plan allows the plan administrator
	to grant stock awards to eligible participants in such amounts, on such terms and conditions, and for such consideration, including
	no consideration or minimum consideration as may be required by law. A stock award may be denominated in common stock or other
	securities, stock-equivalent units or restricted stock units, securities or debentures convertible into common stock, or any combination
	of the foregoing and may be paid in common stock or other securities, in cash, or in a combination of common stock or other securities
	and cash, all as determined in the sole discretion of the plan administrator.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
<I>
	Performance awards.
</I>
	The 2014 Plan allows the plan administrator
	to grant performance awards which become payable in common stock or other securities, in cash, or in a combination of common stock
	or other securities and cash, on account of attainment of one or more performance goals established by the plan administrator.
	The plan administrator may establish performance goals relating to any of the following, as it may apply to an individual, one
	or more business units, divisions or subsidiaries, or on a Company-wide basis, and in either absolute terms or relative to the
	performance of one or more comparable companies or an index covering multiple companies:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
<I>
	Earnings or profitability metrics:
</I>
	including, but not limited to, earnings/loss (gross, operating, net, or adjusted);
	earnings/loss before interest and taxes (&#8220;EBIT&#8221;); earnings/loss before interest, taxes, depreciation and amortization
	(&#8220;EBITDA&#8221;); profit margins; expense levels or ratios; in each case adjusted to eliminate the effect of any one or more
	of the following: interest expense, asset impairments, early extinguishment of debt, equity incentive compensation expense, changes
	in generally accepted accounting principles or critical accounting policies, or other extraordinary or non-recurring items, as
	specified by the plan administrator when establishing the performance goals;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
<I>
	Return metrics:
</I>
	including, but not limited to, return on investment, assets, equity or capital (total or invested);
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
<I>
	Cash flow metrics:
</I>
	including, but not limited to, operating cash flow; cash flow sufficient to achieve financial ratios
	or a specified cash balance; free cash flow; cash flow return on capital; net cash provided by operating activities; cash flow
	per share; working capital;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
<I>
	Liquidity metrics:
</I>
	including, but not limited to, capital raising; debt reduction; extension of maturity dates of outstanding
	debt; debt leverage (debt to capital, net debt-to-capital, debt-to-EBITDA or other liquidity ratios) or access to capital; debt
	ratings; total or net debt; other similar measures approved by the plan administrator;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
<I>
	Stock Price and Equity Metrics:
</I>
	including, but not limited to, return on stockholders&#8217; equity; total stockholder
	return; revenue (gross, operating or net); revenues from sales; revenues from search model; revenue growth; stock price; stock
	price appreciation; market capitalization; earnings/loss per share (basic or diluted) (before or after taxes); price-to-earnings
	ratio;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
<I>
	Strategic Metrics:
</I>
	including, but not limited to, number of users, site traffic, conversion ratios, product research
	and development; regulatory filings or approvals; patent application or issuance; manufacturing or process development; sales or
	net sales; geographic coverage; market share; market penetration; inventory control; growth in assets; key hires; business expansion;
	acquisitions, divestitures, affiliate agreements, collaborations, licensing or joint ventures; financing; resolution of significant
	litigation; legal compliance or risk reduction.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The plan administrator is authorized to make adjustments in the
	method of calculating attainment of performance measures and performance targets in recognition of: (1) extraordinary or non-recurring
	items; (2) changes in tax laws; (3) changes in generally accepted accounting principles or changes in accounting policies; (4)
	charges related to restructured or discontinued operations; (5) restatement of prior period financial results; and (6) any other
	unusual, non-recurring gain or loss that is separately identified and quantified in our financial statements; provided that the
	plan administrator&#8217;s decision as to whether such adjustments will be made with respect to any covered employee, within the
	meaning of section 162(m) of the Internal Revenue Code, is determined when the performance targets are established for the applicable
	performance period. Notwithstanding the foregoing, the plan administrator may, at its sole discretion, modify the performance results
	upon which awards are based under the 2014 Plan to offset any unintended results arising from events not anticipated when the performance
	measures and performance targets were established; provided, that such modifications may be made with respect to an award granted
	to any covered employee, only to the extent permitted by Section 162(m) of the Internal Revenue Code if the award was intended
	to constitute &#8220;qualified performance-based compensation&#8221; within the meaning of Section 162(m) of the Internal Revenue
	Code.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 60; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	57
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage61"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
<I>
	Change in control.
</I>
	In the event of any transaction resulting
	in a &#8220;change in control&#8221; of the Company (as defined in the 2014 Plan), outstanding stock options and other awards that
	are payable in or convertible into our common stock will terminate upon the effective time of the change in control unless provision
	is made in connection with the transaction for the continuation, assumption, or substitution of the awards by the surviving or
	successor entity or its parent. In the event of such termination the holders of stock options and other awards under the 2014 Plan
	will be permitted immediately before the change in control to exercise or convert all portions of awards that are then exercisable
	or convertible or which become exercisable or convertible upon or prior to the effective time of the change in control. In the
	event that a change in control occurs after a performance-based stock award has been granted but before completion of the applicable
	performance period, a pro rata portion of such award will become payable (or a pro rata portion of the lapse restrictions will
	lapse, as applicable) as of the date of the change in control to the extent otherwise earned on the basis of achievement of the
	pro rata portion of the performance goals and performance targets relating to the portion of the performance period completed as
	of the date of the change in control.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
<I>
	Amendment and termination.
</I>
	The 2014 Plan became effective
	on June 17, 2014. The 2014 Plan Amendment became effective on June 18, 2015. No award will be granted under the 2014 Plan after
	the close of business on the day before the tenth anniversary of the effective date of the plan. Our board of directors may terminate,
	amend or modify the 2014 Plan, or any portion thereof, at any time. Stockholder approval will be required to reprice any options
	or SARs under the 2014 Plan.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
<I>
	U.S. federal income tax consequences.
</I>
	The following is a
	general summary of the U.S. federal income tax treatment of stock options and other awards that are authorized for issuance under
	the 2014 Plan, based upon the provisions of the Internal Revenue Code as of the date of this report. This summary is not intended
	to be exhaustive and the exact tax consequences to any grantee will depend upon his or her particular circumstances and other facts.
	Participants must consult their tax advisors with respect to any state, local and non-U.S. tax considerations or particular federal
	tax implications of awards granted to them under the 2014 Plan.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
<I>
	Treatment of Options.
</I>
	The Code treats incentive stock options
	and nonstatutory stock options differently. However, as to both types of options, no income will be recognized to the optionee
	at the time of the grant of the options under the 2014 Plan.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Generally, upon exercise of a nonstatutory (or non-qualified) stock
	option (including an option intended to be an incentive stock option but which has not continued to so qualify at the time of exercise),
	an optionee will recognize ordinary income tax on the excess of the fair market value of the stock on the exercise date over the
	option price. In general, if an optionee, in exercising a nonstatutory stock option, tenders shares of our common stock in partial
	or full payment of the option price, no gain or loss will be recognized on the tender. However, if the tendered shares were previously
	acquired upon the exercise of an incentive stock option and the tender is within two years after the date of grant or within one
	year after the date of exercise of the incentive stock option, the tender will be a disqualifying disposition of the shares acquired
	upon exercise of the incentive stock option.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	For incentive stock options, there is no taxable income to an optionee
	at the time of exercise. However, the excess of the fair market value of the stock on the date of exercise over the exercise price
	will be taken into account in determining whether the &#8220;alternative minimum tax&#8221; will apply for the year of exercise.
	If the shares acquired upon exercise are held until at least two years from the date of grant and more than one year from the date
	of exercise, any gain or loss upon the sale of such shares, if held as capital assets, will be long-term capital gain or loss (measured
	by the difference between the sales price of the stock and the exercise price). Under current federal income tax law, a long-term
	capital gain will be taxed at a rate which is less than the maximum rate of tax on ordinary income. If the two-year and one-year
	holding period requirements are not met (a &#8220;disqualifying disposition&#8221;), an optionee will recognize ordinary income
	in the year of disposition in an amount equal to the lesser of (1) the fair market value of the stock on the date of exercise minus
	the exercise price or (2) the amount realized on disposition minus the exercise price. The remainder of the gain will be treated
	as long-term capital gain, depending upon whether the stock has been held for more than a year. If an optionee makes a disqualifying
	disposition, he or she will be obligated to notify us.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	In general, if an optionee, in exercising an incentive stock option,
	tenders shares of our common stock in partial or full payment of the option price, no gain or loss will be recognized on the tender.
	However, if the tendered shares were previously acquired upon the exercise of another incentive stock option and the tender is
	within two years after the date of grant or within one year after the date of exercise of the other option, the tender will be
	a disqualifying disposition of the shares acquired upon exercise of the other option.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	As noted above, the exercise of an incentive stock option could
	subject an optionee to the alternative minimum tax. The application of the alternative minimum tax to any particular optionee depends
	upon the particular facts and circumstances which exist with respect to the optionee in the year of exercise. However, as a general
	rule, the amount by which the fair market value of the common stock on the date of exercise of an option exceeds the exercise price
	of the option will constitute an item of &#8220;adjustment&#8221; for purposes of determining the alternative minimum taxable income
	on which the alternative tax may be imposed. As such, this item will enter into the tax base on which the alternative minimum tax
	is computed and may therefore cause the alternative minimum tax to become applicable in any given year.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
<I>
	Treatment of Stock Appreciation Rights.
</I>
	Generally, the recipient
	of a stock appreciation right will not recognize any income upon grant of the stock appreciation right. Upon exercise of a stock
	appreciation right, the holder will recognize ordinary income equal to the fair market value of our common stock at that time.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 61; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	58
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage62"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
<I>
	Treatment of Stock Awards.
</I>
	Generally, absent an election
	to be taxed currently under Section 83(b) of the Code (&#8220;Section 83(b) Election&#8221;), there will be no federal income tax
	consequences to the recipient upon the grant of a restricted stock award. At the expiration of the restriction period and the satisfaction
	of any other restrictions applicable to the restricted shares, the recipient will recognize ordinary income equal to the fair market
	value of our common stock at that time. If a Section 83(b) Election is made within 30 days after the date the restricted stock
	award is granted, the recipient will recognize an amount of ordinary income at the time of the receipt of the restricted shares
	equal to the fair market value (determined without regard to applicable restrictions) of the shares of our common stock at such
	time. If a Section 83(b) Election is made, no additional income will be recognized by the recipient upon the lapse of restrictions
	on the shares (and prior to the sale of such shares), but, if the shares are subsequently forfeited, the recipient may not deduct
	the income that was recognized pursuant to the Section 83(b) Election at the time of the receipt of the shares.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The recipient of an unrestricted stock award will recognize ordinary
	income equal to the fair market value of our common stock that is the subject of the award when the award is made.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The recipient of a restricted stock unit will recognize ordinary
	income as and when the units vest. The amount of the income will be equal to the fair market value of the shares of our common
	stock issued at that time. The recipient of a restricted stock unit will not be permitted to make a Section 83(b) Election with
	respect to such award.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
<I>
	Treatment of Performance Awards and Other Stock-Based Awards.
</I>
	The federal income tax consequences of performance share awards, performance unit awards, other cash-based awards and other stock-based
	awards will depend on the terms and conditions of those awards.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
<I>
	Tax Withholding.
</I>
	We have the right to deduct or withhold,
	or require a participant to remit to us, the amount required to satisfy minimum statutory withholding requirements of federal,
	state and local tax laws and regulations (domestic or foreign) with respect to any taxable event arising as a result of the 2014
	Plan.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
<I>
	Inapplicability of Code Sections and ERISA.
</I>
	Sections 401(a)
	and 401(k) of the Code and the provisions of the Employee Retirement Income Security Act of 1974 are not applicable to the 2014
	Plan.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_6"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Outstanding Equity Awards at Fiscal Year-End 2015
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The following table provides information about the number of outstanding
	equity awards held by our named executive officers at December 31, 2015.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="15" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Option
	Awards
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="15" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Stock
	Awards
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Name
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Number
	of securities underlying unexercised options exercisable
<BR>
	(#)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Number
	of securities underlying unexercised options unexercisable
<BR>
	(#)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Equity
	incentive plan awards: number of securities underlying unexercised unearned options
<BR>
	(#)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Option
	exercise price
<BR>
	($)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Equity
	Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units Or Other Rights That Have
<BR>
	Not Vested
<BR>
	($)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Market
	Value of Shares or Units of Stock That Have Not Vested
<BR>
	($)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Equity
	Incentive Plan Awards: Number of Unearned Shares, Units Or Other Rights That Have Not Vested
<BR>
	(#)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Equity
	Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units Or Other Rights That Have Not Vested
<BR>
	($)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 28%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Samuel D. Riccitelli
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 6%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	93,188
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<SUP>
	(2)
</SUP>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Tamara A Seymour
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	60,000
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<SUP>
	(1)
</SUP>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1.57
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	51,750
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<SUP>
	(3)
</SUP>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1.1PT SOLID; WIDTH: 15%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)
</TD>
<TD>
	The options underlying this award vest as follows: (1) 15,000 options vest on August 12, 2016; and the remaining 45,000 options
	vest in 36 equal monthly installments beginning on September 12, 2016.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT; MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(2)
</TD>
<TD>
	124,251 shares underlying this award vest on June 17, 2016. The remaining shares underlying this June 17, 2014 award previously
	vested as follows: (1) 248,504 shares vested on June 17, 2014; (2) 124,252 shares vested on January 1, 2015; (3) 124,252 shares
	vested on June 17, 2015; and (4) 124,252 shares vested on December 17, 2015. Settlement of 372,756 of the vested shares was made
	on April 8, 2015, with $249,269 paid in cash to Mr. Riccitelli in exchange for 119,842 of the shares to satisfy tax withholding
	requirements. Settlement of 124,252 of the vested shares was made on June 19, 2015, with $69,513 paid in cash to Mr. Riccitelli
	in exchange for 46,036 of the shares to satisfy tax withholding requirements. Settlement of 124,252 vested shares was made on February
	12, 2016, with $24,963 paid in cash to Mr. Riccitelli in exchange for 54,268 of the shares to satisfy tax withholding requirements.
	The remaining 124,251 shares that vest in 2016 will be made on or after the vesting date, as determined by the Company, in a manner
	intended to comply with the terms of the award agreement and applicable law.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(3)
</TD>
<TD>
	23,000 shares underlying this award vest on August 4th in each of 2016, 2017 and 2018. Settlement of 23,000 of the vested shares
	was made on August 4, 2015, with $13,294 paid in cash to Ms. Seymour in exchange for 8,522 of the shares to satisfy tax withholding
	requirements. The remaining shares that vest after 2015 will be made on or after the vesting date, as determined by the Company,
	in a manner intended to comply with the terms of the award agreement and applicable law.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 62; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	59
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage63"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Payments Due Upon Termination of Employment or a Change in Control
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<I>
	Employment Agreement
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Mr. Riccitelli&#8217;s CEO Agreement and Ms. Seymour&#8217;s CFO
	Agreement entitle each of them (each referred to herein as the &#8220;Executive&#8221;) to receive certain payments upon the termination
	of such person&#8217;s employment under certain circumstance as described below.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
<I>
	Termination for Cause
</I>
	&#8212; In the event Executive&#8217;s employment is terminated for &#8220;Cause,&#8221; Executive&#8217;s
	sole remedy will be to collect all unpaid base salary, all accrued personal time off and all unreimbursed expenses payable for
	all periods through the effective date of termination, as well as any amount arising from his participation in, or benefits under,
	any employee benefit plan, program or arrangement, payable in accordance with the terms of such plan, program or arrangement.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.5IN">
	&#8220;Cause&#8221; means (1) expiration of the term of the CEO Agreement or
	CFO Agreement (as applicable), (2) a material breach by Executive of his or her fiduciary duty to the Company that results in material
	harm to the Company; (3) a material breach by Executive of the terms of the CEO Agreement or CFO Agreement (as applicable) or any
	other agreement between Executive and the Company, which remains uncured for a period of 30 days following the receipt of written
	notice specifying the nature of the breach; (4) the willful commission by Executive of any act of embezzlement, fraud, larceny
	or theft on or from the Company; (5) substantial and continuing willful neglect or inattention by Executive of the duties of such
	person&#8217;s employment, refusal to perform the lawful and reasonable directions of the board of directors or the willful misconduct
	or gross negligence of Executive in connection with the performance of such duties which remain uncured for a period of 30 days
	following the receipt of written notice specifying the nature of the breach; (6) the willful commission by Executive of any crime
	involving moral turpitude or a felony; and (7) Executive&#8217;s performance or omission of any act which, in the judgment of the
	board of directors, if known to the customers, clients, stockholders or any regulators of the Company, would have a material adverse
	impact on the business of the Company.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
<I>
	Termination Without Cause
</I>
	&#8212; In the event Mr. Riccitelli&#8217;s employment is terminated without &#8220;Cause,&#8221;
	he will be entitled to receive all unpaid base salary, accrued annual bonus or incentive compensation (including any unpaid, accrued
	annual bonus or incentive compensation from the immediately preceding year), accrued personal time off, and all unreimbursed expenses
	payable for all periods through the effective date of termination (with such amounts to be paid on the date of termination).
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.5IN">
	In addition, Mr. Riccitelli will be entitled to receive a severance payment,
	calculated as follows:
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 45PT">
</TD>
<TD STYLE="WIDTH: 27PT">
	&#8212;
</TD>
<TD>
	should the termination occur after June 23, 2015, Mr. Riccitelli will be entitled to continue to receive his then-current base
	salary for a period of twelve months.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.5IN">
	In the event Ms. Seymour&#8217;s employment is terminated without Cause, Ms.
	Seymour will be entitled to receive a severance payment calculated as follows:
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 45PT">
</TD>
<TD STYLE="WIDTH: 27PT">
	&#8212;
</TD>
<TD>
	should the termination occur anytime during the employment period after the initial one-year term, Ms. Seymour will be entitled
	to continue to receive her then-current base salary for twelve months.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.5IN">
	Neither Executive will be required to mitigate the amount of any severance
	payments received by seeking other employment during the term of the severance period. However, should the Executive obtain other
	employment during the term of the severance period, the Company will pay such person, for the remaining length of the severance
	period, only the difference between such person&#8217;s new salary and base salary (as in effect at the time of termination), if
	the new salary is less than such person&#8217;s base salary (i.e., the Company will not be obligated to make any severance payments
	to Executive if such person&#8217;s new salary is greater than such person&#8217;s applicable base salary). The severance payment
	(less all applicable withholdings) will be paid in equal monthly installments over the applicable period immediately following
	the termination of Executive&#8217;s employment. The Company will also reimburse Executive for premiums for COBRA coverage for
	Executive (and to the extent he or she has family coverage, his family), provided that Executive elects such coverage, during the
	applicable period when such person is receiving severance payments, until such time as Executive obtains other employment and is
	entitled to comparable health coverage from such employer.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
<I>
	Termination After Disability or Death
</I>
	&#8212; In the event that Executive&#8217;s employment is terminated due to disability
	(as described in the CEO Agreement or CFO Agreement (as applicable)) or on account of such person&#8217;s death, then Executive
	(or such person&#8217;s estate or personal representative, as applicable) will be entitled to receive all unpaid base salary, accrued
	annual bonus or incentive compensation (including any unpaid, accrued annual bonus or incentive compensation from the immediately
	preceding year), accrued personal time off, and all unreimbursed expenses payable for all periods through the effective date of
	termination. In the case of disability only, Executive will be entitled to receive, in addition to the amounts specified above,
	for a period of six months, a series of monthly payments equal to such person&#8217;s then-current monthly base salary payments
	such person received during his or her employment if and only if Executive does not receive any payments as a result of the short-term
	and long-term disability insurance benefits that the Company obtains on such person&#8217;s behalf pursuant to the CEO Agreement
	or CFO Agreement (as applicable), which payments will be paid in equal installments over the applicable period. If Executive is
	provided with such insurance payments, then such person will only be entitled to receive the difference between the insurance payments
	and such person&#8217;s base salary, if the payments are less than such person&#8217;s base salary.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 63; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	60
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage64"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
<I>
	Termination by Executive for Good Reason
</I>
	&#8212; In the event that Executive&#8217;s employment is terminated by such
	person for &#8220;Good Reason,&#8221; then Executive will be entitled to receive all unpaid base salary, accrued annual bonus or
	incentive compensation (including any such unpaid, accrued compensation from the immediately preceding year), accrued personal
	time off and all unreimbursed expenses payable for all periods through the effective date of such person&#8217;s termination. In
	addition, Executive will be entitled to receive the same severance payment such person would be entitled to receive if his or her
	employment were terminated by the Company without Cause
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.5IN">
	&#8220;Good Reason&#8221; means (1) the Company has materially breached the
	CEO Agreement or CFO Agreement (as applicable) and the Company has failed to cure or remedy such breach after 30-days written notice
	from Executive (provided that Executive must resign within 30 days after expiration of the 30-day period following written notice
	without cure or remedy by the Company), (2) there has occurred any material and substantial diminution or reduction in duties,
	base salary, title, health care coverage (but only if such diminution is disproportionate to a diminution in health care coverage
	applicable to other employees of the Company), authority or responsibilities of Executive, whether is scope or nature, and the
	Company has failed to cure or remedy such breach after 30-days written notice from Executive; or (3) the Company has required that
	Executive perform any act or refrain from performing any act that would be in violation of applicable law.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
<I>
	Termination by Executive without Good Reason
</I>
	&#8212; In the event Executive terminates his or her employment without
	Good Reason, such person will only be entitled to receive all unpaid base salary, all accrued personal time off and all unreimbursed
	expenses payable for all periods through the effective date of termination and Executive will not be entitled to any compensation
	or other amounts from the Company following the effective date of termination.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Director Compensation
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Prior to our Corporate Conversion and our initial public offering,
	we did not pay compensation to our managers for their service on our board of managers. In connection with our initial public offering,
	our board of directors adopted the following compensation arrangement for our non-employee independent directors, which was in
	effect until August 6, 2015.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<I>
	Annual Compensation
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
	Board retainer/meeting fees &#8212; $25,000 plus $1,000 per meeting
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
	Audit Committee Member Meeting Fees &#8212; $500 per meeting
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
	Audit Committee Chairman Retainer &#8212; $10,000
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
	Compensation Committee Member Meetings Fees &#8212; $500 per meeting
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
	Compensation Committee Chairman Retainer &#8212; $5,000
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
	Nominating and Corporate Governance Committee Member Meeting Fees &#8212; $500 per meeting
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
	Nominating and Corporate Governance Committee Chairman Retainer &#8212; $5,000
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<I>
	Equity Awards granted upon appointment to the Board of Directors
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
	Restricted Stock Unit Award &#8212; 5,500 shares
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
	Stock Option Award &#8212; 6,000 shares
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Our Compensation Committee established the following fees for payment
	to members of our Board of Directors or committees, as the case may be, effective as of August 6, 2015:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<I>
	Annual Compensation
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
	Board Member Retainer &#8212; $40,000
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
	Board Chairman Retainer &#8212; $30,000
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 64; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	61
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage65"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
	Audit Committee Member Retainer &#8212; $10,000
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
	Audit Committee Chairman Retainer &#8212; $20,000
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
	Compensation Committee Member Retainer &#8212; $7,500
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
	Compensation Committee Chairman Retainer &#8212; $15,000
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
	Nominating and Corporate Governance Committee Member Retainer &#8212; $5,000
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
	Nominating and Corporate Governance Committee Chairman Retainer &#8212; $10,000
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<I>
	Equity Awards granted upon appointment to the Board of Directors
</I>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
	Stock Option Award &#8212; 25,000 shares
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	In August 2015, the Compensation Committee and the Board granted
	the acceleration of the vesting of 4,125 remaining unvested restricted stock units previously granted to each non-employee director
	and granted 5,000 restricted stock units, which restricted stock units fully vested on grant. Beginning in 2016, the Chairman and
	each current non-employee director shall receive, subject to Board approval, an annual option grant as of the date of the Company&#8217;s
	annual meeting to purchase 18,000 shares of the Company&#8217;s Common Stock, which grant shall vest monthly over a one-year period
	beginning on the date of grant and shall have an exercise price equal to the fair market value of a share of the Company&#8217;s
	Common Stock as of the date of grant and shall be subject to such other terms and conditions as set forth in the Company&#8217;s
	form of stock option grant agreement.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_7"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	2015 Director Compensation
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The table below sets forth the compensation of our non-employee
	directors for fiscal year 2015.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	Name
<SUP>
	(1)
</SUP>
</B>
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Fees
	Earned or Paid in Cash
<BR>
	($)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	Stock
	Awards
<SUP>
	(2)
</SUP>
</B>
<BR>
	($)
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	Option
	Awards
<SUP>
	(3)
</SUP>
</B>
<BR>
<B>
	($)
</B>
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Total
<BR>
	($)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 44%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	David A. Gonyer, R. Ph.
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	52,750
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8,100
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	16,043
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	76,893
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Bennett S. LeBow
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	35,000
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8,100
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	16,043
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	59,143
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Douglas A. Schuling
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	57,750
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8,100
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	16,043
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	81,893
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Robin L. Smith, M.D.
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	54,000
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8,100
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	16,043
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	78,143
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1.1PT SOLID; WIDTH: 15%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)
</TD>
<TD>
	Mr. Riccitelli, our President and Chief Executive Officer, is also a director on our board of directors. Mr. Riccitelli&#8217;s
	compensation for serving as our President and Chief Executive Officer is reported in the Summary Compensation Table and other compensation
	tables set forth under &#8220;Executive Compensation.&#8221; Mr. Riccitelli does not receive any additional compensation for his
	service on our Board.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT; MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(2)
</TD>
<TD>
	Each of the non-employee directors was granted a restricted stock unit award for 5,000 shares of common stock on August 6,
	2015. Each restricted stock unit vested immediately upon the date of grant. The values set forth in this column are based on the
	aggregate grant date fair value of the awards computed in accordance with FASB ASC Topic 718.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(3)
</TD>
<TD>
	Each of the non-employee directors was granted a stock option to purchase 18,000 shares of common stock on August 6, 2015.
	The stock options vest in ten equal monthly installments beginning on August 31, 2015. The values set forth in this column are
	based on the aggregate grant date fair value of the awards computed in accordance with FASB ASC Topic 718.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 65; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	62
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_COMPENSATION>
<A NAME="eolPage66"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<EFX_SECURITY_OWNERS>
<A NAME="FIS_SECURITY_OWNERS"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<A NAME="F10K_032116P_HTM_A_018">
</A>
	Item 12. Security Ownership of Certain Beneficial Owners and Management and Related
	Stockholder Matters
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_8"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Securities Authorized for Issuance Under Equity Compensation Plans
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	As of December 31, 2015, we had one equity compensation plan in
	place under which shares of our common stock were authorized for issuance:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Plan
	Category
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Number
	of securities to be issued upon exercise of outstanding options, warrants and rights
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Weighted
	average exercise price of outstanding options, warrants and rights
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Number
	of securities
<BR>
	remaining available for
<BR>
	future issuance under equity
<BR>
	compensation plans
<BR>
	(excluding securities
<BR>
	reflected in first column)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 52%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Equity compensation plans approved by stockholders
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	983,325
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<SUP>
	(1)
</SUP>
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2.28
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<SUP>
	(2)
</SUP>
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	695,260
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Equity compensation plans not approved by stockholders
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT; PADDING-LEFT: 10PT">
	Total
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	983,325
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2.28
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	695,260
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1.1PT SOLID; WIDTH: 15%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT; MARGIN-TOP: 3PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)
</TD>
<TD>
	Total includes options to purchase 631,567 of common stock and 351,758 shares that may be issued under outstanding restricted
	stock units.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(2)
</TD>
<TD>
	The weighted-average exercise price does not take into account the restricted stock units.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	A description of our equity compensation plan is set forth in Note
	6 to the consolidated financial statements included elsewhere in this report.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Beneficial Ownership of Our Securities
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The following table sets forth certain information with respect
	to the beneficial ownership of our common stock as of March 15, 2016:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
	each person who is known by us to be the beneficial owner of more than 5% of our outstanding common stock;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
	each of our directors;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
	each of our named executive officers; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#8226;
</TD>
<TD>
	all of our directors and executive officers as a group.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We have determined beneficial ownership in accordance with the rules
	of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power
	or investment power with respect to those securities. In addition, the rules include shares of common stock issuable pursuant to
	the exercise of stock options, warrants or other rights that are either immediately exercisable or exercisable on or before May
	14, 2016, which is 60 days after the date of the information provided. These shares are deemed to be outstanding and beneficially
	owned by the person holding those options or warrants for the purpose of computing the percentage ownership of that person, but
	they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Unless otherwise
	indicated, the persons or entities identified in this table have sole voting and investment power with respect to all shares shown
	as beneficially owned by them, subject to applicable community property laws.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Except as otherwise noted below, the address for each of the individuals
	and entities listed in this table is c/o Signal Genetics, Inc., 5740 Fleet Street, Carlsbad, California 92008.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 66; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	63
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage67"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_BENEFICIAL_OWNERS>
<A NAME="FIS_BENEFICIAL_OWNERS"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Name of Beneficial Owner
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Number of Shares Beneficially Owned
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	Percentage Ownership
<SUP>
	(1)
</SUP>
</B>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC">
	5% Holders
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 52%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	LeBow Alpha, LLLP
<SUP>
	(2)
</SUP>
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 20%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,232,629
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 20%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	20.8
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	E. Jeffrey Peierls
<SUP>
	(3)
</SUP>
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	681,100
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6.4
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; FONT-STYLE: ITALIC; TEXT-ALIGN: LEFT">
	Executive Officers, Directors and Director Nominees
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Bennett S. LeBow
<SUP>
	(2)
</SUP>
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,253,829
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<SUP>
	(4)
</SUP>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	21.0
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Samuel D. Riccitelli
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	415,114
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3.9
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Tamara A. Seymour
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	14,478
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.1
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	David A. Gonyer
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	28,200
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<SUP>
	(5)
</SUP>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.3
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Douglas A. Schuling
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	28,200
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<SUP>
	(6)
</SUP>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.3
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Dr. Robin L. Smith
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	28,200
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<SUP>
	(7)
</SUP>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.3
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	All Executive Officers &amp; Directors, as a group (six persons)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,768,021
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<SUP>
	(8)
</SUP>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	25.7
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
</TABLE>
</EFX_BENEFICIAL_OWNERS>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1.1PT SOLID; WIDTH: 15%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)
</TD>
<TD>
	Based on 10,709,080 common shares outstanding as of March 15, 2016.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT; MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(2)
</TD>
<TD>
	Bennett S. LeBow is the sole partner of LeBow Alpha. By virtue of his position with LeBow Alpha, he is deemed to be the beneficial
	owner of these shares and has sole voting and dispositive power over the shares. The address of LeBow Alpha is 667 Madison Avenue,
	14th Floor, New York, New York 10065.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(3)
</TD>
<TD>
	Based solely on the Schedule 13G filed with the SEC on March 20, 2015, as of March 11, 2015, E. Jeffrey Peierls has sole voting
	and sole dispositive power over 85,500 shares, and shared voting and shared dispositive power over 595,600 shares. Brian E. Peierls
	has sole voting and sole dispositive power over 50,000 shares, and shared voting and shared dispositive power over 595,600 shares.
	E. Jeffrey Peierls, President and a Director of the Peierls Foundation, Inc. (&#8220;Foundation&#8221;) and Brian E. Peierls, Secretary/Treasurer
	of the Foundation, are co-trustees of UD E.S. Peierls for E. F. Peierls; and co-managers of 75 Brian L.L.C., 75 Jeff L.L.C, Life/Brian,
	L.L.C., Life/Jeff L.L.C., Jen/Brian, L.L.C., Jen/Jeff, L.L.C., Bypass 1, L.L.C., Unitrust1, L.L.C.; and, co-trustees of UW E.S.
	Peierls for Brian E. Peierls and UW E.S. Peierls for E. Jeffrey Peierls. Each of E. Jeffrey Peierls and Brian E. Peierls, as co-managers
	and as co-trustees may be deemed to indirectly own the securities owned by each Limited Liability Company and each Trust as well
	as being control persons of the Foundation. In such filing E. Jeffrey Peierls lists his address as 73 South Holman Way, Golden,
	Colorado, 80401 and Brian E. Peierls lists his address as 7808 Harvestman Cove, Austin, Texas, 78731.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT; MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(4)
</TD>
<TD>
	Includes 5,000 shares of common stock owned directly by Mr. LeBow, 2,232,629 shares owned by LeBow Alpha in which Mr. LeBow
	has a beneficial interest, and 16,200 shares that Mr. LeBow has the right to acquire from us upon the exercise of outstanding stock
	options within 60 days after March 15, 2016.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(5)
</TD>
<TD>
	Includes 10,500 shares of common stock owned directly by Mr. Gonyer and 17,700 shares that Mr. Gonyer has the right to acquire
	from us upon the exercise of outstanding stock options within 60 days after March 15, 2016.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT; MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(6)
</TD>
<TD>
	Includes 10,500 shares of common stock owned directly by Mr. Schuling and 17,700 shares that Mr. Schuling has the right to
	acquire from us upon the exercise of outstanding stock options within 60 days after March 15, 2016.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(7)
</TD>
<TD>
	Includes 10,500 shares of common stock owned directly by Dr. Smith and 17,700 shares that Dr. Smith has the right to acquire
	from us upon the exercise of outstanding stock options within 60 days after March 15, 2016.
</TD>
</TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT-SIZE: 10PT; MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(8)
</TD>
<TD>
	Includes 69,300 aggregate shares of common stock that such persons have the right to acquire from us upon the exercise of outstanding
	options within 60 days after March 15, 2016.
</TD>
</TR>
</TABLE>
</EFX_SECURITY_OWNERS>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<EFX_OFFICER_TRANSACTIONS>
<A NAME="FIS_OFFICER_TRANSACTIONS"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<A NAME="F10K_032116P_HTM_A_019">
</A>
	Item 13. Certain Relationships and Related Transactions and Director Independence
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The following is a summary of transactions since January 1, 2015
	to which we have been a party in which the amount involved exceeded the lesser of $120,000 or one percent of the average of our
	total assets at the end of the last two recent fiscal years and in which any of our executive officers, directors, director nominees
	or beneficial holders of more than five percent of our capital stock had or will have a direct or indirect material interest, other
	than compensation arrangements which are described under the section of this report entitled &#8220;Management &#8212; Non-Employee
	Director Compensation&#8221; and &#8220;Management &#8212; Executive Compensation.&#8221;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Note Payable &#8211; Related Party
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	We and our subsidiaries, as borrowers, entered into a Secured Demand
	Promissory Note (the &#8220;Original Promissory Note&#8221;), in the amount of $20,000,000 with LeBow Alpha, as lender, dated November
	3, 2011. Any unpaid principal under the Original Promissory Note bore interest at a rate of 8% per annum, compounded quarterly.
	In addition, interest was payable on any overdue installment of principal for the period overdue, on demand, at a rate equal to
	11% per annum, compounded quarterly as of the last day of each calendar quarter. The Chairman of our board of directors, Bennett
	LeBow, is the sole partner of LeBow Alpha, our principal stockholder, and has sole voting and dispositive power over this entity.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 67; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	64
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage68"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The Original Promissory Note was amended from time to time to increase
	the principal amount of the borrowings thereunder and to include additional amounts owed to other LeBow-controlled entities as
	lenders, namely LeBow Gamma Limited Partnership (&#8220;LeBow Gamma&#8221;), and BSL Capital, Inc. (collectively, the &#8220;LeBow
	Entities&#8221;), from whom we have also borrowed money, from time to time.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	On December 31, 2013, we entered into an Amended and Restated Secured
	Demand Promissory Note (the &#8220;New Promissory Note&#8221;), in the amount of $25,000,000 with LeBow Alpha to include all of
	the principal and interest then owed to LeBow Alpha and the other LeBow-controlled entities under the Original Promissory Note,
	as amended from time to time and to include certain loans that were made to the Company through December of 2013 by LeBow Alpha,
	LeBow Gamma and BSL Capital, Inc. Unpaid principal under the New Promissory Note bore interest at a rate of 8% per annum, compounded
	quarterly. In addition, interest was payable on any overdue installment of principal for the period overdue, on demand, at a rate
	equal to 11% per annum, compounded quarterly as of the last day of each calendar quarter.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The New Promissory Note (like the Old Promissory Note) contained
	customary representations and warranties and events of default, and includes a cross-default provision to any loan documents, as
	such term was defined in the Promissory Note, and included a Security Agreement (defined below).
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	At the time of our initial public offering in June 2014, $28,326,287
	in principal and interest was outstanding under the New Promissory Note. In connection with our initial public offering and pursuant
	to the Exchange Agreement, on June 17, 2014, $27,326,287 was converted into 2,732,629 Class C units of Signal Genetics LLC (2,032,629
	of which were issued to LeBow Alpha and 700,000 of which were issued to unaffiliated trusts). We refer to this conversion as the
	Debt Conversion. These Class C units were then converted into an aggregate of 2,732,629 shares of common stock of Signal Genetics,
	Inc. in the Corporate Conversion which preceded our initial public offering.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	From January 1, 2011 until the New Promissory Note was converted
	in the Debt Conversion, the largest aggregate amount of principal outstanding under the note was $24,433,380, $17,433,380 of which
	was owed to certain entities controlled by Mr. LeBow. From January 1, 2011 to our initial public offering, we repaid approximately
	$9,279,000 in principal and $1,182,000 in interest under the Original Promissory Note and the New Promissory Note.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	An additional $1,000,000 was advanced to us by Mr. LeBow prior to
	our initial public offering to pay for certain offering expenses. Following the offering, this amount, along with an additional
	$45,000, which was advanced to pay for certain additional offering expenses, was reclassified as amounts due to related party on
	our consolidated balance sheet. This aggregate amount was non-interest bearing and due on demand.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	On March 6, 2015, the amounts due to related party were converted
	into an unsecured note payable &#8211; related party bearing interest at 8% per annum and due on demand on or after June 30, 2015.
	The principal amount of the note, $1.1 million, was increased over the amounts due to related party prior to its issuance to provide
	the equivalent of 8% per annum interest for the period of time the amounts due to related party were held as a payable in exchange
	for a provision that the related party would not call the note prior to June 30, 2015. Interest expense related to this note during
	the year ended December 31, 2015 was $132,000. The note balance and accrued interest payable at December 31, 2015 were $1,105,000
	and $73,000, respectively. No interest was paid during 2015 and as of March 15, 2016, the note has not been called.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	Director Independence
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The information included under the heading &#8220;Board Composition
	and Election of Directors&#8221; in Part III, Item 10 is hereby incorporated by reference into this Item 13.
</P>
</EFX_OFFICER_TRANSACTIONS>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_ACCOUNTANT_FEES>
<A NAME="FIS_ACCOUNTANT_FEES"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<A NAME="F10K_032116P_HTM_A_020">
</A>
<B>
	Item 14. Principal Accounting Fees and Services
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	In connection with the audit of our 2015 and 2014 consolidated financial
	statements the Company entered into engagement agreements with BDO USA, LLP, which sets forth the terms by which BDO USA, LLP has
	performed audit services for the Company.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The aggregate fees agreed to by the Company for the annual audits
	for the years ended December 31, 2015 and 2014, and all other audit fees paid by the Company to BDO USA, LLP during 2015 and 2014
	were $225,000 and $222,000, respectively. Audit fees for the years ended December 31, 2015 and 2014 were for professional services
	provided in connection with the annual audits of the Company&#8217;s consolidated financial statements, review of the Company&#8217;s
	quarterly consolidated financial statements, accounting matters directly related to the annual audits, professional services in
	connection with SEC registration statements, and other documents filed with the SEC or other documents issued in connection with
	securities offerings, and professional services provided in connection with other statutory or regulatory filings.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	All audit fees relating to the audit for the year ended December
	31, 2015, were approved in advance by the Audit Committee. All audit and non-audit services to be provided by BDO USA, LLP were,
	and will continue to be, pre-approved by the Audit Committee.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 68; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	65
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_ACCOUNTANT_FEES>
</EFX_PART_III>
<A NAME="eolPage69"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<EFX_PART_IV>
<A NAME="FIS_PART_IV"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<B>
	PART IV
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_EXHIBITS>
<A NAME="FIS_EXHIBITS"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<A NAME="F10K_032116P_HTM_A_021">
</A>
	Item 15. Exhibits and Financial Statement Schedules
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	(a)(1) Financial Statements
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The financial statements required by this item are submitted in
	a separate section beginning on page F-1 of this annual report.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	(a)(2) Financial Statement Schedules
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Financial statement schedules have been omitted because they are
	either not required, not applicable, or the information is otherwise included.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	(a)(3) Exhibits
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The exhibits listed below are required by Item 601 of Regulation
	S-K. Each management contract or compensatory plan or arrangement required to be filed as an exhibit to this report has been identified.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_9"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 9%; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	Exhibit
<BR>
	Number
</B>
</P>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 90%; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Description of Exhibit
</B>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	3.1
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Certificate of Incorporation of Signal Genetics, Inc. (incorporated by reference to Exhibit 3.1 to the Quarterly Report on Form 10-Q (No. 001-36483) filed with the Securities and Exchange Commission on August 14, 2014).
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	3.2
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Bylaws of Signal Genetics, Inc. (incorporated by reference to Exhibit 3.2 to the Quarterly Report on Form 10-Q (No. 001-36483) filed with the Securities and Exchange Commission on August 14, 2014).
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	4.1
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-1 (No. 333-194668) filed with the Securities and Exchange Commission on March 19, 2014).
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;4.2
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Representative&#8217;s Warrant (incorporated by reference to Exhibit 4.2 to the Registration Statement on Form S-1/A (No. 333-201533) filed with the Securities and Exchange Commission on January 29, 2015).
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	4.3
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Representative&#8217;s Warrant (incorporated by reference to Exhibit 10.24 to the Registration Statement on Form S-1/A (No. 333-194668) filed with the Securities and Exchange Commission on June 6, 2014).
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.1&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Assignment of Membership Interests between LeBow Alpha LLLP and Signal Genetics LLC, dated January 1, 2011 (incorporated by reference to Exhibit 10.1 to the Registration Statement on Form S-1 (No. 333-194668) filed with the Securities and Exchange Commission on March 19, 2014).
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.2&#8224;&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	License Agreement, dated April 1, 2010, by and between The Board of Trustees of the University of Arkansas on behalf of the University of Arkansas for Medical Sciences and Myeloma Health LLC (the &#8220;UAMS License Agreement&#8221;) (incorporated by reference to Exhibit 10.2 to the Registration Statement on Form S-1 (No. 333-194668) filed with the Securities and Exchange Commission on April 9, 2014).
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.2.1
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Letter Agreement, dated April 1, 2010, of Signal Genetics LLC (f/k/a Myeloma Health, LLC) (as referenced in the UAMS License Agreement) (incorporated by reference to Exhibit 10.2.1 to the Registration Statement on Form S-1 (No. 333-194668) filed with the Securities and Exchange Commission on March 19, 2014).
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.3&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	First Amendment to License Agreement, dated September 1, 2010, by and between The Board of Trustees of the University of Arkansas on behalf of the University of Arkansas for Medical Sciences and Myeloma Health LLC (the &#8220;First Amendment to UAMS License Agreement&#8221;) (incorporated by reference to Exhibit 10.3 to the Registration Statement on Form S-1 (No. 333-194668) filed with the Securities and Exchange Commission on March 19, 2014).
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.3.1
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Letter Agreement, dated February 25, 2014, of Signal Genetics LLC (f/k/a Myeloma Health, LLC) (as referenced in the First Amendment to UAMS License Agreement) (incorporated by reference to Exhibit 10.3.1 to the Registration Statement on Form S-1 (No. 333-194668) filed with the Securities and Exchange Commission on March 19, 2014).
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.4&#8224;&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Second Amendment to License Agreement, dated September 14, 2010, by and between The Board of Trustees of the University of Arkansas on behalf of the University of Arkansas for Medical Sciences and Myeloma Health LLC (incorporated by reference to Exhibit 10.4 to the Registration Statement on Form S-1 (No. 333-194668) filed with the Securities and Exchange Commission on March 19, 2014).
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.5&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Third Amendment to License Agreement, dated October 2011, by and between The Board of Trustees of the University of Arkansas on behalf of the University of Arkansas for Medical Sciences and Myeloma Health LLC (incorporated by reference to Exhibit 10.5 to the Registration Statement on Form S-1 (No. 333-194668) filed with the Securities and Exchange Commission on March 19, 2014).
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.6&nbsp;&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Fourth Amendment to License Agreement, dated December 1, 2011, by and between The Board of Trustees of the University of Arkansas on behalf of the University of Arkansas for Medical Sciences and Myeloma Health LLC (incorporated by reference to Exhibit 10.6 to the Registration Statement on Form S-1 (No. 333-194668) filed with the Securities and Exchange Commission on March 19, 2014).
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.7&#8224;&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Reference Laboratory Services Agreement, dated March 21, 2011, by and between The Board of Trustees of the University of Arkansas on behalf of the University of Arkansas for Medical Sciences&#8217; Clinical Laboratory and Signal Genetics LLC (incorporated by reference to Exhibit 10.7 to the Registration Statement on Form S-1 (No. 333-194668) filed with the Securities and Exchange Commission on March 19, 2014).
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 69; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	66
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage70"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_10"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<B>
	Exhibit
<BR>
	Number
</B>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Description of Exhibit
</B>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; WIDTH: 9%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.8&#8224;&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 90%">
<FONT STYLE="FONT-SIZE: 10PT">
	Reference Laboratory Services Agreement, dated September 20, 2014, by and between The Board of Trustees of the University of Arkansas on behalf of the University of Arkansas for Medical Sciences and Signal Genetics, Inc. (incorporated by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q (No. 001-36483) filed with the Securities and Exchange Commission on November 11, 2014).
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.9&#8224;&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Reference Laboratory Services Agreement for Research Specimens, dated March 21, 2011, by and between The Board of Trustees of the University of Arkansas on behalf of the University of Arkansas for Medical Sciences&#8217; Myeloma Institute for Research Therapy and Signal Genetics LLC (incorporated by reference to Exhibit 10.8 to the Registration Statement on Form S-1 (No. 333-194668) filed with the Securities and Exchange Commission on March 19, 2014).
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.10&#8224;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Reference Laboratory Services Agreement for Research Specimens, dated September 20, 2014, by and between The Board of Trustees of the University of Arkansas on behalf of the University of Arkansas for Medical Sciences and Signal Genetics, Inc. (incorporated by reference to Exhibit 10.3 to the Quarterly Report on Form 10-Q (No. 001-36483) filed with the Securities and Exchange Commission on November 11, 2014).
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.13&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Indemnification Agreement between Signal Genetics, Inc. and each of its directors and executive officers (incorporated by reference to Exhibit 10.14 to the Registration Statement on Form S-1 (No. 333-194668) filed with the Securities and Exchange Commission on March 19, 2014).
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.14*&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	2014 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q (No. 001-36483) filed with the Securities and Exchange Commission on August 14, 2014).
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.15*&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	First Amendment to the Signal Genetics, Inc. 2014 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K (No. 001-36483) filed with the Securities and Exchange Commission on June 23, 2015).
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.16&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Exchange Agreement, dated June 17, 2014, by and between Signal Genetics LLC, LeBow Alpha LLLP, LeBow Gamma Limited Partnership, BSL Capital, Inc., Bennett S. LeBow, the LeBow 2012 Nevada Trust and the LFIT-A Trust (incorporated by reference to Exhibit 10.8 to the Quarterly Report on Form 10-Q (No. 001-36483) filed with the Securities and Exchange Commission on August 14, 2014).
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.17*
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Amended and Restated Employment Agreement, dated June 17, 2014, by and between Signal Genetics, Inc. and Samuel D. Riccitelli (incorporated by reference to Exhibit 10.4 to the Quarterly Report on Form 10-Q (No. 001-36483) filed with the Securities and Exchange Commission on August 14, 2014).
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.18*
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Restricted Stock Unit Agreement by and between Signal Genetics, Inc. and Samuel D. Riccitelli (incorporated by reference to Exhibit 10.18 to the Registration Statement on Form S-1/A (No. 333-194668) filed with the Securities and Exchange Commission on April 9, 2014).
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.19
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Letter Agreement, dated March 18, 2014, by and between The Board of Trustees of the University of Arkansas on behalf of the University of Arkansas for Medical Sciences and Signal Genetics, Inc. (incorporated by reference to Exhibit 10.19 to the Registration Statement on Form S-1/A (No. 333-194668) filed with the Securities and Exchange Commission on April 9, 2014).
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.20
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	UAMS Bioventures Lease Agreement, dated March 31, 2014, by and between The Board of Trustees of the University of Arkansas for Medical Sciences and Myeloma Health LLC (incorporated by reference to Exhibit 10.20 to the Registration Statement on Form S-1/A (No. 333-194668) filed with the Securities and Exchange Commission on April 9, 2014).
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.21
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Agreement for Termination of Lease and Voluntary Surrender of Premises, dated March 14, 2014, by and between ARE-Acquisitions, LLC and Signal Genetics LLC (incorporated by reference to Exhibit 10.22 to the Registration Statement on Form S-1/A (No. 333-194668) filed with the Securities and Exchange Commission on May 15, 2014).
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.22
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Letter Agreement, dated May 16, 2014, by and between The Board of Trustees of the University of Arkansas on behalf of the University of Arkansas for Medical Sciences and Signal Genetics, Inc. (incorporated by reference to Exhibit 10.23 to the Registration Statement on Form S-1/A (No. 333-194668) filed with the Securities and Exchange Commission on May 27, 2014).
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.23*
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Employment Agreement, dated August 4, 2014, by and between Signal Genetics, Inc. and Tamara A. Seymour (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K (No. 001-36483) filed with the Securities and Exchange Commission on July 23, 2014).
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.24*
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Amendment to Amended and Restated Employment Agreement, dated July 23, 2014, by and between Signal Genetics, Inc. and Samuel D. Riccitelli (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K (No. 001-36483) filed with the Securities and Exchange Commission on July 23, 2014).
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.25
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Office Building Lease Agreement, dated August 18, 2014, by and between OT9 Owner, LLC and Signal Genetics, Inc. (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q (No. 001-36483) filed with the Securities and Exchange Commission on November 11, 2014).
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 70; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	67
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage71"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_11"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<B>
	Exhibit
<BR>
	Number
</B>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Description of Exhibit
</B>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; WIDTH: 9%">
<FONT STYLE="FONT-SIZE: 10PT">
	10.26*
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 90%">
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Stock Option Grant Agreement under the 2014 Stock Incentive Plan (incorporated by reference to Exhibit 4.5 to the Registration Statement on Form S-8 (No. 333-197316) filed with the Securities and Exchange Commission on July 9, 2014).
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.27*
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Form of Restricted Stock Unit Grant Agreement under the 2014 Stock Incentive Plan (incorporated by reference to Exhibit 4.6 to the Registration Statement on Form S-8 (No. 333-197316) filed with the Securities and Exchange Commission on July 9, 2014).
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.28*
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Letter Agreement, dated March 25, 2015, regarding Signal Genetics, Inc. Restricted Stock Unit Grant Agreement dated June 17, 2014, by and between Signal Genetics, Inc. and Samuel D. Riccitelli (incorporated by reference to Exhibit 10.28 to the Annual Report on Form 10-K (No. 001-36483) filed with the Securities and Exchange Commission on March 27, 2015).
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.29
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Unsecured Demand Promissory Note by and between Signal Genetics, Inc. and Bennett LeBow, dated March 6, 2015(incorporated by reference to Exhibit 10.29 to the Annual Report on Form 10-K (No. 001-36483) filed with the Securities and Exchange Commission on March 27, 2015).
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.30
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Controlled Equity Offering
<SUP>
	SM
</SUP>
</FONT>
	&nbsp;
<FONT STYLE="FONT-SIZE: 10PT">
	Sales Agreement, dated July 10, 2015, by and between Signal Genetics, Inc. and Cantor Fitzgerald &amp; Co. (incorporated by reference to Exhibit 1.2 to the Registration Statement on Form S-3 (No. 333-205620) filed with the Securities and Exchange Commission on July 10, 2015).
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	10.31****
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	UAMS Bioventures Lease Agreement, effective as of April 1, 2016, by and between The Board of Trustees of the University of Arkansas for Medical Sciences and Signal Genetics, Inc.
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	23.1
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Consent of BDO USA, LLP.
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	31.1
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Certification of Principal Executive Officer pursuant to Rule13a-14(a) and Rule 15d-14(a) of the Securities and Exchange Act, as amended.
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	31.2
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Certification of Principal Financial Officer pursuant to Rule13a-14(a) and Rule 15d-14(a) of the Securities and Exchange Act, as amended.
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	32.1**
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	101.INS***
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	XBRL Instance Document
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	101.SCH***
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	XBRL Taxonomy Extension Schema
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	101.CAL***
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	XBRL Taxonomy Extension Calculation Linkbase
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	101.DEF***
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	XBRL Taxonomy Extension Definition Linkbase
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	101.LAB***
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	XBRL Taxonomy Extension Label Linkbase
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	101.PRE***
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-SIZE: 10PT">
	XBRL Taxonomy Extension Presentation Linkbase
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1.1PT SOLID; WIDTH: 15%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-SIZE: 10PT">
	&#8224;
</FONT>
</TD>
<TD STYLE="WIDTH: 93%">
<FONT STYLE="FONT-SIZE: 10PT">
	Confidential treatment granted as to portions of the exhibit. Confidential materials omitted and filed separately with the Securities and Exchange Commission.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	*
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Management contract or compensatory plans or arrangements.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	**
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	This certification is being furnished pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	***
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	In accordance with Rule 406T of Regulation S-T, the Interactive Data Files in Exhibit 101 are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Exchange Act of 1934, as amended, and otherwise are not subject to liability under these sections.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD NOWRAP>
<FONT STYLE="FONT-SIZE: 10PT">
	****
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	Filed herewith.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 71; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	68
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
</EFX_EXHIBITS>
</EFX_PART_IV>
<A NAME="eolPage72"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<EFX_SIGNATURES>
<A NAME="FIS_SIGNATURES"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
<A NAME="F10K_032116P_HTM_A_022">
</A>
	SIGNATURES
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 26.4PT; MARGIN: 0PT 0 0PT 9.9PT">
	Pursuant to the requirements of Section&nbsp;13 or 15(d)
	of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
	thereunto duly authorized.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 26.4PT; MARGIN: 0PT 0 0PT 9.9PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 26.4PT; MARGIN: 0PT 0 0PT 9.9PT">
</P>
<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-ALIGN: LEFT">
	Date: March 21, 2016
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; VERTICAL-ALIGN: MIDDLE; TEXT-ALIGN: LEFT">
	SIGNAL GENETICS, INC.
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; WIDTH: 50%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 27%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 20%">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-ALIGN: LEFT">
	By:
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	/
<FONT STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	s/&nbsp;&nbsp;
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
	Samuel
	D. Riccitelli
</FONT>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 8PT">
	Samuel D. Riccitelli, President and Chief
	Executive Officer
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 26.4PT; MARGIN: 0PT 0 0PT 9.9PT">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 26.4PT; MARGIN: 0PT 0 0PT 9.9PT">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Pursuant to the requirements of the Securities Exchange Act of l934,
	this Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 36%; BORDER-BOTTOM: BLACK 1.1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Signature
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 34%; BORDER-BOTTOM: BLACK 1.1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Title
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP; WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 26%; BORDER-BOTTOM: BLACK 1.1PT SOLID; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Date
</B>
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
	Samuel D. Riccitelli
</FONT>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	President, Chief Executive Officer and Director (Principal Executive Officer)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	March 21, 2016
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Samuel D. Riccitelli
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
	Tamara A. Seymour
</FONT>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	March 21, 2016
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Tamara A. Seymour
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
	Bennett S. LeBow
</FONT>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Chairman of the Board of Directors
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	March 21, 2016
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Bennett S. LeBow
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
	David A. Gonyer, R. Ph.
</FONT>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	March 21, 2016
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	David A. Gonyer, R. Ph.
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
	Douglas A. Schuling
</FONT>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	March 21, 2016
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Douglas A. Schuling
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	/s/
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
	Dr. Robin L. Smith
</FONT>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	March 21, 2016
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Dr. Robin L. Smith
</B>
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 72; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	69
<!-- FIELD: /SEQUENCE -->
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage73"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	SIGNAL GENETICS, INC.
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	INDEX
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 91%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%">
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<B>
	Page No.
</B>
</P>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#F10K_032116P_HTM_A_023">
<FONT STYLE="FONT-SIZE: 10PT">
	Report of Independent Registered Public Accounting Firm
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<A HREF="#F10K_032116P_HTM_A_023">
<FONT STYLE="FONT-SIZE: 10PT">
	F-2
</FONT>
</A>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#F10K_032116P_HTM_A_024">
<FONT STYLE="FONT-SIZE: 10PT">
	Consolidated Balance Sheets as of December 31, 2015 and 2014
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<A HREF="#F10K_032116P_HTM_A_024">
<FONT STYLE="FONT-SIZE: 10PT">
	F-3
</FONT>
</A>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#F10K_032116P_HTM_A_025">
<FONT STYLE="FONT-SIZE: 10PT">
	Consolidated Statements of Operations for the Years ended December 31, 2015 and 2014
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<A HREF="#F10K_032116P_HTM_A_025">
<FONT STYLE="FONT-SIZE: 10PT">
	F-4
</FONT>
</A>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
<A HREF="#F10K_032116P_HTM_A_026">
<FONT STYLE="FONT-SIZE: 10PT">
	Consolidated Statements of Changes in Stockholders&#8217; Equity and Members&#8217; Deficiency for the Years ended December 31, 2015 and 2014
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<A HREF="#F10K_032116P_HTM_A_026">
<FONT STYLE="FONT-SIZE: 10PT">
	F-5
</FONT>
</A>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#F10K_032116P_HTM_A_027">
<FONT STYLE="FONT-SIZE: 10PT">
	Consolidated Statements of Cash Flows for the Years ended December 31, 2015 and 2014
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<A HREF="#F10K_032116P_HTM_A_027">
<FONT STYLE="FONT-SIZE: 10PT">
	F-6
</FONT>
</A>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: WHITE">
<TD STYLE="VERTICAL-ALIGN: TOP">
<A HREF="#F10K_032116P_HTM_A_028">
<FONT STYLE="FONT-SIZE: 10PT">
	Notes to the Consolidated Financial Statements
</FONT>
</A>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<A HREF="#F10K_032116P_HTM_A_028">
<FONT STYLE="FONT-SIZE: 10PT">
	F-7
</FONT>
</A>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 73; OPTIONS: NEWSECTION; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	1
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_SIGNATURES>
<A NAME="eolPage74"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
</P>
<EFX_AUDITORS_OPINION>
<A NAME="FIS_AUDITORS_OPINION"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
<A NAME="F10K_032116P_HTM_A_023">
</A>
	Report of Independent Registered Public Accounting Firm
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Board of Directors and Stockholders
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Signal Genetics, Inc.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.55IN; MARGIN: 0PT 0">
	We have audited the accompanying consolidated balance sheets of
	Signal Genetics, Inc. and Subsidiaries (the &#8220;Company&#8221;) as of December 31, 2015 and 2014 and the related consolidated
	statements of operations, changes in stockholders&#8217; equity and members&#8217; deficiency, and cash flows for each of the two
	years in the period ended December 31, 2015. These financial statements are the responsibility of the Company&#8217;s management.
	Our responsibility is to express an opinion on these financial statements based on our audits.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.55IN; MARGIN: 0PT 0">
	We conducted our audits in accordance with the standards of the
	Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain
	reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have,
	nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits included consideration of
	internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances,
	but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting.
	Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and
	disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management,
	as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our
	opinion.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.55IN; MARGIN: 0PT 0">
	In our opinion, the consolidated financial statements referred to
	above present fairly, in all material respects, the financial position of Signal Genetics, Inc. and Subsidiaries at December 31,
	2015 and 2014, and the results of their operations and their cash flows for each of two years in the period ended December 31,
	2015, in conformity with accounting principles generally accepted in the United States of America.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	/s/ BDO USA, LLP
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	San Diego, CA
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	March 21, 2016
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 74; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage75"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	SIGNAL GENETICS, INC.
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<A NAME="F10K_032116P_HTM_A_024">
</A>
<B>
	CONSOLIDATED BALANCE SHEETS
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	(in thousands, except share and par value data)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<DIV DATA-TD-TAGGABLE-TABLE="" DATA-TD-STATEMENT-TYPE="BALANCE-SHEET">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	December 31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2014
</TD>
</TR>
</EFX_AUDITORS_OPINION>
<EFX_BALANCE_SHEET>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<A NAME="FIS_BALANCE_SHEET"></A>
	ASSETS
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Current assets:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 68%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Cash and cash equivalents
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	10,832
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,119
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Accounts receivable, net
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	394
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,088
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; PADDING-LEFT: 10PT">
	Inventory
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	187
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	179
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 10PT">
	Prepaid expenses and other current assets
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	321
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	399
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT">
	Total current assets
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	11,734
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,785
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Property and equipment, net
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,153
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,214
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Deferred offering costs
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	47
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Security deposits
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	15
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	43
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT; PADDING-LEFT: 20PT">
	Total assets
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	12,902
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8,089
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	LIABILITIES AND STOCKHOLDERS&#8217; EQUITY
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Current liabilities:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Accounts payable
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	242
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	255
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Accrued liabilities
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,018
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	361
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Note payable &#8211; related party
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,105
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Amounts due to related party
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,045
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Lease termination/abandonment payable - current portion
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	248
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 10PT">
	Other current liabilities
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	103
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	80
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT">
	Total current liabilities
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,468
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,989
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Other noncurrent liabilities
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	24
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	109
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Commitments and contingencies (Note 7)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Stockholders&#8217; equity:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	Preferred stock, $0.01 par value, 5,000,000 shares authorized, no shares issued or outstanding at December 31, 2015 or 2014
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	Common stock, $0.01 par value, 50,000,000 shares authorized, 10,635,454 and 3,782,629 shares issued and outstanding at December 31, 2015 and 2014, respectively
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	106
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	38
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Additional paid in capital
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	28,272
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	12,593
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 10PT">
	Accumulated deficit
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(17,968
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(6,640
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 20PT">
	Total stockholders&#8217; equity
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	10,410
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,991
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT; PADDING-LEFT: 30PT">
	Total liabilities and stockholders&#8217; equity
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	12,902
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8,089
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</EFX_BALANCE_SHEET>
</TABLE>
</DIV>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	See accompanying notes to consolidated financial statements.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 75; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage76"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_INCOME_STATEMENT>
<A NAME="FIS_INCOME_STATEMENT"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	SIGNAL GENETICS, INC.
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
<A NAME="F10K_032116P_HTM_A_025">
</A>
	CONSOLIDATED STATEMENTS OF OPERATIONS
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	(in thousands, except share and per share data)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<DIV DATA-TD-TAGGABLE-TABLE="" DATA-TD-STATEMENT-TYPE="INCOME">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Years Ended December 31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 68%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Net revenue
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,538
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,320
</TD>
<TD STYLE="WIDTH: 1%; BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Operating expenses:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; PADDING-LEFT: 10PT">
	Cost of revenue
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,472
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,366
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Research and development
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,002
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	347
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Selling and marketing
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,559
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	717
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	General and administrative
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7,692
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,857
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 10PT">
	Gain on legal settlement
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(100
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 20PT">
	Total operating expenses
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	13,725
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	11,187
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 30PT">
	Loss from operations
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(11,187
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(6,867
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 10PT">
	Interest expense
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(141
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(1,023
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 40PT; TEXT-INDENT: -10PT">
	Net loss attributable to members of Signal Genetics LLC
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(1,250
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 40PT; TEXT-INDENT: -10PT">
	Net loss attributable to stockholders of Signal Genetics, Inc.
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(11,328
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(6,640
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT; PADDING-LEFT: 40PT; TEXT-INDENT: -10PT">
	Net loss attributable to stockholders of Signal Genetics, Inc./members of Signal Genetics LLC
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(11,328
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(7,890
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT">
	Net loss per common share, basic and diluted
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(1.40
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(3.50
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Weighted-average number of shares outstanding, basic and diluted
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8,091,899
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,255,864
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_INCOME_STATEMENT>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	See accompanying notes to consolidated financial statements.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 76; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage77"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
</P>
<EFX_STOCKHOLDERS_EQUITY>
<A NAME="FIS_STOCKHOLDERS_EQUITY"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	SIGNAL GENETICS, INC.
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<A NAME="F10K_032116P_HTM_A_026">
</A>
<B>
	CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY
	AND MEMBERS&#8217; DEFICIENCY
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	(in thousands, except share and unit data)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT">
<B>
</B>
</P>
<DIV DATA-TD-TAGGABLE-TABLE="" DATA-TD-STATEMENT-TYPE="STOCKHOLDERS-EQUITY">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-STYLE: ITALIC; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Common Stock
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Additional&nbsp;&nbsp;Paid-in
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Accumulated
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Total Stockholders&#8217;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="11" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Membership Units
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	Members&#8217;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-STYLE: ITALIC">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Shares
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Amount
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Capital
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Deficit
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Equity
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Class A
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Class B
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Class C
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; FONT-STYLE: NORMAL; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" NOWRAP STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; FONT-STYLE: NORMAL; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Deficiency
<FONT STYLE="FONT-SIZE: 10PT; FONT-STYLE: NORMAL">
<B>
<SUP>
	(1)
</SUP>
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 46%; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Balance, December 31, 2013
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	72,500
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	41,088
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 3%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 3%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(23,887
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Conversion of note payable to Class C Units
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,732,629
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	27,326
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Net loss attributable to members of Signal Genetics LLC
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(1,250
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Conversion from Limited Liability Company to Corporation
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,932,629
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	29
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,160
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,189
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(72,500
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(41,088
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(2,732,629
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(2,189
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Initial public offering of common stock, net of costs to issue
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	850,000
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	9
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,835
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,844
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Fair value of warrants and option for overallotment shares to underwriters issued in connection with initial public stock offering
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	300
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	300
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Stock-based compensation
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,298
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,298
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Net loss attributable to stockholders of Signal Genetics, Inc.
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(6,640
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(6,640
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD">
	Balance, December 31, 2014
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,782,629
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	38
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	12,593
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(6,640
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,991
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Public offerings of common stock, net of costs to issue
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,431,410
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	64
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	12,701
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	12,765
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Fair value of warrants and option for overallotment shares to underwriters issued in connection with public stock offering
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	330
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	330
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Stock-based compensation
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,015
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,015
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Shares issued under employee stock incentive plan, net of shares repurchased to satisfy tax withholding obligations
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	421,415
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(367
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	-363
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 10PT; TEXT-INDENT: -10PT">
	Net loss attributable to stockholders of Signal Genetics, Inc.
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(11,328
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(11,328
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 2.25PT">
	Balance, December 31, 2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	10,635,454
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	106
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	28,272
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(17,968
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	10,410
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_STOCKHOLDERS_EQUITY>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1.1PT SOLID; WIDTH: 15%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT">
<B>
</B>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	(1)
</TD>
<TD>
	Members&#8217; deficiency was reclassified to additional paid-in capital upon conversion from the Limited Liability Company
	to the Corporation.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	See accompanying notes to consolidated financial statements.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: PAGE; SEQUENCE: 77; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage78"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
</B>
</P>
<EFX_CASH_FLOW>
<A NAME="FIS_CASH_FLOW"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	SIGNAL GENETICS, INC.
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<A NAME="F10K_032116P_HTM_A_027">
</A>
<B>
	CONSOLIDATED STATEMENTS OF CASH FLOWS
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	(in thousands)
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<DIV DATA-TD-TAGGABLE-TABLE="" DATA-TD-STATEMENT-TYPE="CASH-FLOWS">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Years Ended December 31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	OPERATING ACTIVITIES
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 68%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Net loss
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(11,328
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(7,890
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Adjustments to reconcile net loss to net cash used in operating activities:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Stock-based compensation
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,015
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,298
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Depreciation and amortization
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	184
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	144
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Noncash interest on note payable &#8211; related party
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	132
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,007
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Lease termination
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	46
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Gain on legal settlement
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(100
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Changes in operating assets and liabilities:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT">
	Accounts receivable
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	694
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(94
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; PADDING-LEFT: 20PT">
	Inventory
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(8
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	178
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT">
	Prepaid expenses and other current assets
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	28
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	191
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT">
	Accounts payable and accrued liabilities
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	633
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	383
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 20PT">
	Lease termination/abandonment payable
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(248
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(376
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 30PT">
	Net cash used in operating activities
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(6,898
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(2,213
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	INVESTING ACTIVITIES
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Purchases of property and equipment
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(123
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(266
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	(Increase) decrease in security deposit on lease
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	28
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(8
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 30PT">
	Net cash used in investing activities
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(95
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(274
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	FINANCING ACTIVITIES
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Proceeds from issuances of common stock, net of costs to issue
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	13,095
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,644
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Proceeds from issuance of note payable/amounts due to related party
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	795
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Proceeds from cash released from restricted cash account securing a letter of credit
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	50
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Shares repurchased to satisfy tax withholding obligation for restricted stock awards
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(363
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Repayment of capital lease obligation and note payable
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(76
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(42
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 30PT">
	Net cash provided by financing activities
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	12,706
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7,397
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 40PT">
	Net increase in cash
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,713
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,910
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Cash and cash equivalents, beginning of period
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,119
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	209
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT">
	Cash and cash equivalents, end of period
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	10,832
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,119
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Cash paid for interest
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Noncash investing and financing activities:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	Conversion of amounts due to related party to note payable &#8211; related party
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,045
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	Fair value of warrants and options for overallotment shares to underwriters issued in connection with public stock offerings
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	330
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	300
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Conversion of note payable to Class C Units
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	27,326
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Asset acquired under capital lease
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	164
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_CASH_FLOW>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	See accompanying notes to consolidated financial statements.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 78; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage79"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	SIGNAL GENETICS, INC.
</B>
</P>
<EFX_NOTES_TO_FINANCIAL_STATEMENT>
<A NAME="FIS_NOTES_TO_FINANCIAL_STATEMENT"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
<A NAME="F10K_032116P_HTM_A_028">
</A>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	&nbsp;
</B>
</P>
<DIV DATA-TD-STATEMENT-TYPE="NOTE">
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<B>
	1.
</B>
</TD>
<TD>
<B>
	Basis of Presentation
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Signal Genetics, Inc. (the &#8220;Company&#8221;) is a commercial
	stage, molecular genetic diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed
	decisions concerning the care of their patients suffering from cancer. In 2010, the Company became the exclusive licensee to the
	intellectual property stemming from the renowned research on multiple myeloma (&#8220;MM&#8221;), performed at the University of
	Arkansas for Medical Sciences (&#8220;UAMS&#8221;). Myeloma Prognostic Risk Signature (&#8220;MyPRS
<SUP>
	&#174;
</SUP>
	&#8221;) is
	based upon 30 years of clinical research on over 10,000 MM patients who received their care at UAMS. The Company currently generates
	revenues from the performance of its MyPRS
<SUP>
	&#174;
</SUP>
	diagnostic test, which was launched in April 2011.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Basis of Presentation and Liquidity
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The accompanying consolidated financial statements include the Company
	and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Since its inception, the Company has devoted substantial effort
	in developing its products and services and has incurred losses and negative cash flows from operations. Prior to its IPO, all
	financial support had been provided by the Company&#8217;s majority member. As of December 31, 2015, however, following the ATM
	program, the 2015 Offering, the Debt Conversion, the Corporate Conversion and the IPO, each as defined below, the Company has positive
	working capital and stockholders&#8217; equity. Although the Company is forecasting continued losses and negative cash flows as
	it funds its expanding selling and marketing activities, and research and development programs, the Company believes that it has
	enough cash and cash equivalents on hand to support operations for 12 to 15 months from the date of this report. Going forward,
	as the Company continues its expansion, it may seek additional financing and/or strategic investments. However, there can be no
	assurance that any additional financing or strategic investments will be available to the Company on acceptable terms, if at all.
	If events or circumstances occur such that the Company does not obtain additional funding, it will most likely be required to reduce
	its plans and/or certain discretionary spending, which could have a material adverse effect on the Company&#8217;s ability to achieve
	its intended business objectives.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Public Offerings of Common Stock
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	On July 10, 2015, the Company filed a prospectus for the offering,
	issuance and sale of securities from time to time in one or more offerings (&#8220;Shelf Registration&#8221;) which was declared
	effective by the SEC on July 28, 2015. The amount of securities to be sold pursuant to the Shelf Registration is limited by the
	Company&#8217;s public float. Concurrently with filing the Shelf Registration, the Company entered into a sales agreement with
	Cantor Fitzgerald &amp; Co., to sell shares of its common stock, with aggregate gross sales proceeds of up to $4.45 million, from
	time to time, through an &#8220;at-the-market&#8221; equity offering program (the &#8220;ATM program&#8221;). During the year ended
	December 31, 2015, the Company sold 2,734,983 shares of common stock pursuant to this registration for total cash proceeds of $4.0
	million, which is net of $429,000 in sales agent&#8217;s commissions and offering expenses. Due to the size of the Company&#8217;s
	public float, the current ATM program has been completed, unless and until the Company&#8217;s public float increases.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	On February 20, 2015, the Company completed a public offering (the
	&#8220;2015 Offering&#8221;) of 3,214,285 shares of its common stock, at $2.80 per share, for total cash proceeds of $7.8 million,
	which is net of $1.2 million in underwriter commissions and offering expenses. On February 26, 2015, the underwriters exercised
	their overallotment option for 482,142 additional shares of the Company&#8217;s common stock, for total cash proceeds of $1.3 million,
	which is net of $95,000 in underwriter commissions.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Corporate Conversion and Initial Public Offering
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	On June 17, 2014, the Company completed a corporate conversion and
	Signal Genetics LLC converted from a limited liability company to a Delaware corporation (the &#8220;Corporate Conversion&#8221;).
	Immediately prior to the Corporate Conversion, $27.3 million of the Company&#8217;s note payable &#8212; related party was converted
	into 2,732,629 newly authorized Class C units (the &#8220;Debt Conversion&#8221;). In connection with the Corporate Conversion,
	all outstanding Class A and C units of Signal Genetics LLC were converted into 200,000 and 2,732,629 shares, respectively, for
	an aggregate of 2,932,629 shares of common stock of the Company, the members of Signal Genetics LLC became stockholders of the
	Company and the Company succeeded to the business of Signal Genetics LLC and its consolidated subsidiaries.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	On June 23, 2014, the Company completed an initial public offering
	(the &#8220;IPO&#8221;) of 850,000 shares of its common stock, at $10.00 per share, for net cash proceeds of $6.1 million, which
	is net of $2.4 million in underwriter commissions and offering expenses. The net contribution to additional paid-in capital was
	$5.8 million after deducting the noncash fair values of warrants and the option for overallotment shares issued in connection with
	the IPO.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 79; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage80"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<B>
</B>
</TD>
</TR>
</TABLE>
<DIV DATA-TD-STATEMENT-TYPE="NOTE">
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
<B>
	2.
</B>
</TD>
<TD>
<B>
	Significant Accounting Policies
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Use of Estimates
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The accompanying consolidated financial statements have been prepared
	in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;). The preparation of financial
	statements in conformity with GAAP requires management to make judgments, assumptions and estimates that affect the amounts reported
	in the Company&#8217;s consolidated financial statements and accompanying notes. Significant estimates in the consolidated financial
	statements have been made for revenue, accounts receivable and allowance for doubtful accounts, accounting for income taxes, depreciation
	of property and equipment and stock-based compensation. Actual results could differ materially from those estimates.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Cash and Cash Equivalents
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Cash is comprised of cash on hand and deposits in banks. The Company
	considers all highly liquid investments with a maturity at date of purchase of three months or less to be cash equivalents, which,
	at December 31, 2015, are comprised of money market funds. At December 31, 2014, the Company had $50,000 in a restricted money
	market account that was held as cash collateral against an outstanding letter of credit for security on a lease. The restriction
	was removed during 2015 and the cash balance transferred into the Company&#8217;s money market account.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Accounts Receivable, and Contractual Allowances and Allowance for Doubtful Accounts
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Accounts receivable are recorded net of contractual allowances and
	an allowance for doubtful accounts. At December 31, 2015 and 2014, contractual allowances were $2.1 million and $1.5 million, respectively.
	The Company estimates an allowance for doubtful accounts based on the aging of the accounts receivable and the historical collection
	experience for each type of payor. Account balances are charged-off against the allowance when it is probable the receivable will
	not be recovered.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	During the years ended December 31, 2015 and 2014, the Company recognized
	$33,000 and $177,000 in bad debt expense, respectively. At December 31, 2015 and 2014, there were no allowances for doubtful accounts.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Inventory
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Inventory, which consists entirely of raw materials, and includes
	laboratory materials and supplies, is valued at the lower of cost or market using the first-in, first-out (&#8220;FIFO&#8221;)
	method.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Property and Equipment
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Property and equipment is carried at cost. Expenditures for major
	additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation and amortization
	are calculated using the straight-line method over the estimated useful lives of the assets, which range from three to ten years.
	Upon sale or retirement of property and equipment, the related cost and accumulated depreciation are removed from the accounts
	and any gain or loss is reflected in operations.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Long Lived Assets
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Long-lived assets, consisting of property and equipment, are reviewed
	for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable
	based on undiscounted cash flows. If long-lived assets are impaired, an impairment loss is recognized and is measured as the amount
	by which the carrying value exceeds the estimated fair value of the assets. No impairment charges were recorded during the years
	ended December 31, 2015 or 2014.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Deferred Offering Costs
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	During the year ended December 31, 2014, the Company incurred $47,000
	in direct costs related to its anticipated public offering of common stock. These costs were deferred and recorded as a long-term
	asset at December 31, 2014 and reclassified as a reduction to additional paid-in capital upon completion of the 2015 Offering.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Deferred Rent
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Where rent abatements are made available to the Company under the
	terms of a lease agreement, the abatements are accounted for as a reduction of rent expense over the life of the lease and rent
	expense is recognized on a straight-line basis over the entire term of the lease. The cumulative difference between actual rent
	payments and recognized rental expense is recorded as deferred rent in the consolidated balance sheets.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Revenue Recognition
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Revenues that are derived from testing services are recognized in
	accordance with revenue recognition accounting guidance, which requires that four basic criteria be met before revenue can be recognized:
	(1) persuasive evidence that an arrangement exists; (2) delivery has occurred and title and the risks and rewards of ownership
	have been transferred to the client or services have been rendered; (3) the price is fixed or determinable; and (4) collectability
	is reasonably assured.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 80; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage81"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Revenues are recorded on an accrual basis when the contractual obligations
	are completed as tests are processed through the Company&#8217;s laboratory and test results are delivered to ordering physicians.
	Revenues are billed to various payors, including Medicare, contracted insurance companies, directly billed customers (UAMS, pharmaceutical
	companies, reference laboratories and hospitals) and non-contracted insurance companies. Revenues from Medicare, contracted insurance
	companies and directly billed customers are reported based on the contractual rate. The difference between the amounts billed and
	the contractual rates from Medicare and contracted insurance companies are recorded as contractual allowances at the same time
	the revenue is recognized, to arrive at reported net revenue. The contractual rate is based on established agreed upon rates between
	the Company and the respective payor. Directly billed customers are invoiced at the contractual rate by the Company. Revenues from
	non-contracted insurance companies are reported based on the amount expected to be collected, which is based on the historical
	collection experience of each payor or payor group, as appropriate, and anticipated effects of changes in the healthcare industry,
	if any. The difference between the amount billed and the amount estimated to be collected from non-contracted insurance companies
	is recorded as a contractual allowance at the same time the revenue is recognized, to arrive at reported net revenue. The Company
	does not record revenue from individuals for billings until cash is collected; as collectability is not assured at the time services
	are provided, therefore there are no accounts receivable from self-payors. Gross revenues from individuals have been immaterial
	to date.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The Company&#8217;s estimates of net revenue for non-contracted
	insurance companies are subject to change based on the contractual status and payment policies of the third-party payors with whom
	the Company deals. The Company regularly refines its estimates in order to make estimated revenue as accurate as possible based
	on its most recent collection experience with each third-party payor. The Company regularly reviews its historical collection experience
	for non-contracted payors and anticipated changes in the healthcare industry and adjusts expected revenues for current and subsequent
	periods accordingly. During the year ended December 31, 2015, net unfavorable changes in estimates were recorded to revenue related
	to non-contracted revenues recorded in the prior year of $193,000. During the year ended December 31, 2014, net unfavorable changes
	in estimates were recorded to revenue related to non-contracted revenues recorded in prior years of $380,000, of which $106,000
	and $274,000 related to revenues previously recorded during 2012 and 2013, respectively.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The table below shows the adjustments made to gross revenues to
	arrive at net revenues, the amount reported in the consolidated statements of operations:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_12"></A>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Years Ended December 31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-STYLE: ITALIC">
	(in thousands)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 64%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Gross revenues
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 14%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,706
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 14%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6,484
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Less: contractual allowances
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(3,168
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(2,164
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT; PADDING-LEFT: 10PT">
	Net revenue
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,538
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,320
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Contractual allowances recorded during the years ended December
	31, 2015 and 2014 represented 56% and 33% of gross revenues, respectively. The increase in the contractual allowances is due to
	changes in the Company&#8217;s estimates of net revenue for non-contracted payors based on the contractual status and payment policies
	of the payors, and anticipated changes in the healthcare industry.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Cost of Revenue
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Cost of revenue represents the cost of materials, personnel costs,
	costs associated with processing specimens including pathological review, quality control analyses, and delivery charges necessary
	to render an individualized test result, depreciation, amortization and royalty expense. Costs associated with performing tests
	are recorded as the tests are processed.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Royalties
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The Company licenses technology for patents for uses of a gene expression
	profiling (&#8220;GEP&#8221;) assay called MyPRS
<SUP>
	&#174;
</SUP>
	and its related technology. Under the terms of the license agreement,
	the Company is required to pay royalties to UAMS. The royalties are calculated as a fixed percentage of the net revenue received
	from third parties that the Company generates from using this technology. The Company accrues for such royalties when incurred,
	which is based on when revenue is collected. Such royalties are included in cost of revenue in the accompanying consolidated statements
	of operations.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Research and Development
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Costs associated with research and development activities are expensed
	as incurred. Research and development costs primarily include personnel costs, laboratory supplies, reagents, consulting and sponsored
	research agreements.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Income Taxes
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Prior to the Corporate Conversion, the Company was a limited liability
	company, which is not a tax paying entity at the corporate level. Each member was instead individually responsible for such member&#8217;s
	share of the Company&#8217;s income or loss for income tax reporting purposes. Net operating losses incurred by the Company through
	the date of the Corporate Conversion have been, or will be, used by the members to offset gains on other interests and are, therefore,
	not able to be carried forward to the Company.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 81; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage82"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Effective as of the Corporate Conversion, deferred tax assets and
	liabilities are recorded for the expected future tax consequences of events that have been included in the consolidated financial
	statements or income tax returns. Deferred taxes are determined on the basis of the differences between the carrying amount of
	assets and liabilities for financial statement and income tax purposes, as well as tax credit and net operating loss carryforwards,
	at enacted rates in effect for the years in which the differences are expected to reverse. Valuation allowances are established,
	when necessary, to reduce deferred tax assets to the amounts expected to be realized.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Applicable accounting guidance requires that a position taken or
	expected to be taken in a tax return be recognized in the financial statements when it is more likely than not that the position
	would be sustained upon examination by tax authorities. A recognized tax position is then measured at the largest amount of benefit
	that is greater than 50% likely of being realized upon ultimate settlement. Accounting provisions also require that a change in
	judgment that results in subsequent recognition, derecognition, or change in a measurement of a tax position taken in a prior annual
	period (including any related interest and penalties) be recognized as a discrete item in the period in which the change occurs.
	The Company regularly evaluates the likelihood of recognizing the benefit for income tax positions taken in various federal and
	state filings by considering all relevant facts, circumstances, and information available.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Any interest and penalties related to unrecognized tax benefits
	are classified as a component of income tax expense.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Stock-Based Compensation
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Compensation expense for all stock-based payments made to employees,
	directors, and consultants are measured and recognized based on estimated fair value, net of an estimated forfeiture rate. These
	stock-based awards include stock options and restricted stock units. The Company estimates the fair value of stock options granted
	using the Black-Scholes-Merton (&#8220;BSM&#8221;), option-pricing model, which requires the use of estimates such as stock price
	volatility and expected option lives, as well as expected option forfeiture rates. The fair value of stock options granted to employees
	and directors is estimated at the date of grant.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The fair value of restricted stock units issued to employees and
	directors is based on the market price of the Company&#8217;s common stock on the date of grant and, for nonemployees, at the date
	when performance is complete. For stock-based compensation awards granted to non-employees, the fair value of the awards are remeasured
	at each reporting date until vested, with changes in the estimated fair value recognized as an adjustment to compensation expense
	in the period of change. Upon settlement of all or a portion of the award in cash, the recognized fair value of the corresponding
	amount of awards is reversed from additional paid-in capital and the excess of the cash payment over this amount is recognized
	as additional stock-based compensation expense.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Stock-based compensation cost is recognized on a straight-line basis
	over the requisite service period of the award. Stock-based compensation expense is recognized only for those awards that are ultimately
	expected to vest. The Company estimates forfeitures at the time of grant and revises the estimate, if necessary, in subsequent
	periods if actual forfeitures differ from those estimates. Changes in forfeiture estimates impact compensation cost in the period
	in which the change in estimate occurs.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Due to the Company&#8217;s net loss position, no tax benefits for
	stock-based compensation have been recognized in the statements of cash flows. The Company has not recognized, and does not expect
	to recognize in the near future, any tax benefit related to stock-based compensation cost as a result of its full valuation allowance
	on net deferred tax assets and net operating loss carryforwards.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Fair Value of Financial Instruments
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The Company&#8217;s financial instruments that are measured at fair
	value on a recurring basis consist principally of cash and cash equivalents, restricted cash, accounts receivable, accounts payable
	and note payable-related party.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Fair value is defined as the price that would be received to sell
	an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting
	guidance also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize
	the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure
	fair value:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Level 1&#8212;Observable inputs that reflect quoted prices (unadjusted)
	for identical assets or liabilities in active markets.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Level 2&#8212;Includes other inputs that are directly or indirectly
	observable in the marketplace.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Level 3&#8212;Unobservable inputs that are supported by little or
	no market activities, therefore requiring an entity to develop its own assumptions.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	At December 31, 2015 and 2014, the Company&#8217;s cash equivalent
	instruments consisted of $10.4 million and $0, respectively, in a money market fund which is reported at fair value using Level
	1 inputs. The carrying amounts of financial instruments such as restricted cash, accounts receivable, accounts payable and note
	payable-related party approximate their relative fair values due to the short-term maturities and market rates of interest of these
	instruments.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 82; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage83"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	At December 31, 2014, the fair value of the Company&#8217;s remaining
	lease liability on its vacated facility, which was paid in full during 2015, was measured using estimated net cash flows, discounted
	using a nominal risk-free rate, which are considered Level 3 inputs. The present value of the remaining lease liability at December
	31, 2014 was $248,000.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Net Loss Per Share
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Basic and diluted net loss per common share for the periods presented
	is computed by dividing net loss by the weighted-average number of common shares outstanding during the respective periods, without
	consideration of common stock equivalents. Basic and diluted net loss per common share includes vested, but unissued restricted
	stock units from the date of vesting.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Common stock equivalents, determined on a weighted-average outstanding
	basis, that could potentially reduce net income per common share in the future that were not included in the determination of diluted
	loss per common share as their effects were antidilutive are as follows:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_13"></A>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	December 31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 64%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Unvested restricted stock units
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	431,088
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	655,200
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Options to purchase common stock
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	355,215
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	152,000
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Warrants to purchase common stock
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	180,446
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	42,500
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT; PADDING-LEFT: 10PT">
	Total
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	966,749
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	849,700
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Concentration of Credit Risk, Major Customers and Suppliers
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Financial instruments that potentially subject the Company to concentrations
	of credit risk are primarily cash and cash equivalents. Cash is maintained at two financial institutions and, at times, balances
	may exceed federally insured limits. The Company has not experienced any losses related to these balances. The Company invests
	excess cash in money market funds under the custodianship of a major financial institution. This diversification of risk is consistent
	with the Company's policy to ensure safety of principal and maintain liquidity.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The Company had two major customers, UAMS and H. Lee Moffitt Cancer
	Center and Research Institute (&#8220;Moffitt&#8221;). Revenue sourced either from or through UAMS accounted for 54% and 84% of
	net revenue during the years ended December 31, 2015 and 2014, respectively, and revenue sourced through Moffitt accounted for
	10% and 9% of net revenue during the years ended December 31, 2015 and 2014 respectively. Accounts receivable from UAMS at December
	31, 2015 and 2014 accounted for 19% and 42%, respectively, of total accounts receivable outstanding. At December 31, 2015 and 2014
	the Company had no accounts receivable from Moffitt.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Inventory used in the Company&#8217;s testing process is procured
	from one supplier. Any supply interruption or an increase in demand beyond such supplier&#8217;s capabilities could have an adverse
	impact on the Company&#8217;s business. Management believes it could identify alternative suppliers, if necessary, but it is possible
	such suppliers may not be identified in a timely manner to avoid an adverse impact on the Company&#8217;s business.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 3.3PT 0PT 0">
<B>
<I>
	Reclassifications
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 3.3PT 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Reclassifications of certain operating expenses in the consolidated
	statement of operations have been made to year ended December 31, 2014 to conform to the 2015 presentation.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Recent Accounting Pronouncements
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;)
	issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02, which replaces the existing accounting guidance for leases.
	This standard requires entities that lease assets to recognize the assets and liabilities for the rights and obligations created
	by those leases on the balance sheet. The standard is effective for fiscal years and the interim periods within those fiscal years
	beginning after December 15, 2018. The guidance is required to be applied by the modified retrospective transition approach and
	early adoption is permitted. The Company is currently assessing the impact that adoption of this guidance will have on its consolidated
	financial statements and footnote disclosures.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	In July 2015, the FASB issued ASU 2015-11, which simplifies the
	measurement of inventories valued under most methods, including the Company&#8217;s inventories valued under the FIFO method. Under
	this new guidance, inventories valued under these methods would be valued at the lower of cost and net realizable value, with net
	realizable value defined as the estimated selling price less reasonable costs to sell the inventory. The new guidance is effective
	prospectively for the Company&#8217;s quarterly reporting period beginning January 1, 2017, with early adoption permitted. The
	Company is currently assessing the impact that this standard will have on its consolidated financial statements.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 83; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage84"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts
	with Customers, which outlines a single comprehensive model for entities to use in accounting for revenue from contracts with customers
	and supersedes most current revenue recognition guidance in FASB ASC 605, Revenue Recognition, including industry-specific guidance.
	This standard is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to
	customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or
	services. This standard also requires additional disclosure about the nature, amount, timing and uncertainty of assets recognized
	from costs incurred to fulfill a contract and was originally effective for the Company&#8217;s annual reporting period beginning
	January 1, 2018, including interim periods within that reporting period. In July 2015, the FASB voted to defer the effective date
	of this ASU by one year, which is effective for the Company&#8217;s annual reporting period beginning January 1, 2019, with early
	adoption permitted beginning with the annual reporting period ending December 31, 2017. Entities have the option of using either
	a full retrospective or a modified retrospective approach for the adoption of the new standard. The Company is currently assessing
	the impact that this standard will have on its consolidated financial statements.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	In August 2014, the FASB issued ASU 2014-15, Presentation of Financial
	Statements &#8212; Going Concern, which provides guidance on management&#8217;s responsibility in evaluating whether there is substantial
	doubt about a company&#8217;s ability to continue as a going concern and the related footnote disclosure. For each reporting period,
	management will be required to evaluate whether there are conditions or events that raise substantial doubt about a company&#8217;s
	ability to continue as a going concern within one year from the date the financials are issued. When management identifies conditions
	or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern, this standard also outlines
	disclosures that are required in the company&#8217;s footnotes based on whether or not there are any plans intended to mitigate
	the relevant conditions or events to alleviate the substantial doubt. This standard becomes effective for the Company&#8217;s annual
	reporting period ending December 31, 2016, and for annual and interim periods thereafter. Early application is permitted. The Company
	does not expect the adoption of this standard to have a material impact on its consolidated financial statements.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Future Accounting Pronouncements
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Section 107 of the Jumpstart Our Business Startups Act of 2012 (the
	&#8220;JOBS Act&#8221;) provides that an emerging growth company, such as the Company, may take advantage of an extended transition
	period for complying with new or revised accounting standards. Thus, an emerging growth company may delay the adoption of certain
	accounting standards until those standards would otherwise apply to private companies. Although, to date, the Company has not taken
	advantage of this delay, the Company has elected to avail itself of the extended transition period for adopting new or revised
	accounting standards in the future. As a result of this election, the Company&#8217;s consolidated financial statements may not
	be comparable to companies that comply with public company effective dates.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<DIV DATA-TD-STATEMENT-TYPE="NOTE">
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<B>
	3.
</B>
</TD>
<TD>
<B>
	Balance Sheet Accounts and Supplemental Disclosures
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_14"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 3.3PT 0PT 0">
<B>
<I>
	Property and Equipment
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 3.3PT 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Property and equipment consist of the following:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	December 31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-STYLE: ITALIC">
	(in thousands)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 64%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Laboratory and computer equipment
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 14%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,817
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 14%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,711
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Furniture and fixtures
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	69
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	52
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Leasehold improvements
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,892
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,769
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Less: accumulated depreciation and amortization
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(739
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(555
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT; PADDING-LEFT: 10PT">
	Total property and equipment, net
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,153
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,214
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	An asset with a cost of $300,000 recorded under a capital lease
	is included in the laboratory equipment balance at December 31, 2015 and 2014.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 84; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage85"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_15"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Accrued Expenses
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Accrued expenses consist of the following:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	December 31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-STYLE: ITALIC">
	(in thousands)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 64%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Accrued bonuses
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 14%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	592
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 14%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	183
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Accrued compensation and related expenses
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	234
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	74
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Accrued interest payable &#8211; related party
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	73
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Accrued contract research and development
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	35
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Accrued offering costs
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	42
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	Other
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	84
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	62
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT; PADDING-LEFT: 10PT">
	Total accrued expenses
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,018
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	361
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<DIV DATA-TD-STATEMENT-TYPE="NOTE">
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<B>
	4.
</B>
</TD>
<TD>
<B>
	Amount Due Related Party, Notes Payable and Capital Lease Obligations
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Note Payable &#8212; Related Party and Amounts Due to Related Party
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	On March 6, 2015, the amounts due to related party, aggregating
	$1,045,000, were converted into an unsecured note payable &#8211; related party, bearing interest at 8% per annum and due on demand.
	The principal amount of the note was increased by $60,000 over the amounts due to related party to $1,105,000 to provide the equivalent
	of 8% per annum interest for the period of time the amounts due to related party were held as a payable in exchange for a provision
	that the related party would not call the note prior to June 30, 2015. The increase in the principal amount of the note was deferred
	and amortized to interest expense over the initial term of the note to June 30, 2015. Interest expense related to this note during
	the year ended December 31, 2015 was $132,000. The note balance at December 31, 2015 was $1,105,000 and accrued interest payable
	of $73,000 is included in accrued liabilities in the consolidated balance sheet at December 31, 2015.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	During the year ended December 31, 2014, the Company&#8217;s then
	majority member, through various entities controlled by such member, loaned a net amount of $795,000 to the Company to support
	its operations. Pursuant to the terms of an Exchange Agreement, and prior to the Corporate Conversion, $27.3 million of the Secured
	Note payable as of June 17, 2014 was exchanged for 2,732,629 Class C units of Signal Genetics LLC and recorded to members&#8217;
	equity. The remaining $1.0 million as of that date, along with an additional $45,000, which was advanced to pay for certain offering
	expenses, was reclassified as unsecured amounts due to related party in the consolidate balance sheet. Such amounts due were converted
	into an unsecured note payable &#8211; related party as discussed above.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Prior to the Debt Conversion, the Secured Note bore interest at
	8% compounded quarterly, was due on demand and collateralized by substantially all assets of the Company. The average amount of
	borrowings during the years ended December 31, 2014 (prior to conversion) were $27.4 million. Interest expense related to the note
	during the year ended December 31, 2014 was $1.1 million.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Capital Lease Obligation
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	In December 2014, the Company entered into a new two-year capital
	lease obligation for laboratory equipment which expires in January 2017, and provides for monthly rent of $7,200. The lease obligations
	at December 31, 2015 and 2014 were $88,000 and $164,000, which are net of $6,000 and $8,000, respectively, in unamortized discounts.
	Future maturities of this obligation at December 31, 2015 are $86,000 and $7,000 during 2016 and 2017, respectively. Laboratory
	equipment with a net book value of $270,000 at December 31, 2015 serves as collateral for this obligation.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<DIV DATA-TD-STATEMENT-TYPE="NOTE">
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<B>
	5.
</B>
</TD>
<TD>
<B>
	Stockholders&#8217; Equity
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Preferred Shares
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The Company has authorized 5,000,000 shares of preferred stock,
	of which no shares were issued or outstanding at December 31, 2015 or 2014. The Company&#8217;s board of directors has the authority
	to issue preferred stock in one or more classes or series and to fix the designations, powers, preferences and rights, and the
	qualifications, limitations or restrictions thereof, including dividend rights, conversion right, voting rights, terms of redemption,
	liquidation preferences and the number of shares constituting any class or series, without further vote or action by the stockholders.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 85; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage86"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Common Shares
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The Company has authorized 50,000,000 shares of common stock, of
	which 10,635,454 and 3,782,629 shares were issued and outstanding at December 31, 2015 and 2014, respectively. Common shares reserved
	for future issuance upon the exercise, issuance or conversion of the respective equity instruments at December 31, 2015 is as follows:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_16"></A>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 70%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Issued and Outstanding:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 80%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Restricted stock units
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 16%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	351,758
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Stock options
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	631,567
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; PADDING-LEFT: 10PT">
	Warrants
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	203,214
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Shares reserved for future award grants
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	695,260
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT; PADDING-LEFT: 20PT">
	Total
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,881,799
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0 0PT 0.25IN">
<B>
	&nbsp;
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Public Offerings of Common Stock
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	During September 2015, the Company sold 2,734,983 shares of common
	stock for total cash proceeds of $4.0 million, which is net of $429,000 in sales agent&#8217;s commissions and offering expenses,
	pursuant to its July 2015 ATM program. Due to the size of the Company&#8217;s public float, the current ATM program has been completed,
	unless and until the Company&#8217;s public float increases.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	On February 20, 2015, the Company completed a public offering of
	3,214,285 shares of its common stock, at $2.80 per share, for total cash proceeds of $7.8 million, which is net of $1.2 million
	in underwriter commissions and offering expenses. In connection with the offering, the Company granted a 45-day option to the underwriter
	to purchase up to 482,142 shares of common stock to cover overallotments, with an aggregate grant date fair value of $132,000.
	On February 26, 2015, the underwriters exercised the overallotment option for total cash proceeds of $1.3 million, which is net
	of $95,000 in underwriter commissions. In connection with this offering, as a portion of the underwriting compensation payable
	to the underwriters, the Company issued warrants to purchase 160,714 shares of its common stock to the representative of the underwriters
	with an aggregate grant date fair value of $198,000. The warrants are exercisable at any time from February 2016 through February
	2020 at an exercise price of $3.50 per share. The aggregate fair values of the warrants and overallotment option issued were recorded
	as an increase to additional paid-in capital with an offset to the proceeds from the offering. The net contribution to additional
	paid-in capital was $8.7 million after deducting the noncash fair values of warrants and overallotment option issued in connection
	with the offering.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The estimated fair values of the warrants and overallotment option
	were determined on their respective measurement dates using the BSM option valuation model with the following assumptions:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_17"></A>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Warrants
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Overallotment
	Option
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 64%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Fair value of underlying common stock
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 14%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2.57
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 14%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2.62
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	Exercise price
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3.50
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2.60
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Risk-free interest rate
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1.61
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.02
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	Volatility
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	65.5
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	73.0
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Dividend yield
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Contractual term (in years)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5.0
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.12
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	Weighted-average measurement date fair value per share
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1.23
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.27
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Initial Public Offering
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	On June 23, 2014, the Company completed an IPO of 850,000 shares
	of its common stock, at $10.00 per share, for total net cash proceeds of $6.1 million, which is net of $2.4 million in underwriter
	commissions and offering expenses. The net contribution to additional paid-in capital was $5.8 million after deducting the noncash
	fair values of warrants and option for overallotment shares issued in connection with the IPO.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	In connection with the IPO in June 2014, the Company issued warrants
	to certain designees of the underwriter to purchase an aggregate of 42,500 shares of common stock with an aggregate grant date
	fair value of $143,000. The warrants are exercisable at any time from June 17, 2015 through June 17, 2019. Also, in connection
	with the IPO, the Company granted a 45-day option to the underwriter to purchase up to 127,500 shares of common stock to cover
	overallotments, with an aggregate grant date fair value of $157,000. The aggregate fair values of the warrants and stock option
	issued were recorded as an increase to additional paid-in capital with an offset to the proceeds from the IPO.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 86; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage87"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The estimated fair values of the warrants and stock option award
	were determined on their respective measurement dates using the BSM option valuation model with the following assumptions:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_18"></A>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Warrants
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Options
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 64%; FONT-SIZE: 10PT">
	Fair value of common stock
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 14%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	7.84
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 14%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	10.00
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	Exercise price
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	12.50
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	9.30
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Risk-free interest rate
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1.72
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.035
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	Volatility
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	64.6
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	63.0
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Dividend Yield
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Contractual term (in years)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5.0
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	0.12
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	Weighted-average measurement date fair value per share
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3.38
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1.23
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Corporate Conversion
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Immediately prior to the Corporate Conversion, Signal Genetics LLC
	had issued and outstanding 72,500 Class A units and 41,088 Class B units (23,328 of which were unvested). In connection with the
	Debt Conversion, on June 17, 2014, the note payable &#8212; related party was exchanged for 2,732,629 Class C units of the Company.
	On June 17, 2014, the outstanding Class A and Class C units of Signal Genetics LLC were converted into 200,000 and 2,732,629 shares,
	respectively, for an aggregate of 2,932,629 shares of common stock at $10.00 per share. All outstanding Class B units, which consisted
	of equity incentive units, were cancelled.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
</P>
<DIV DATA-TD-STATEMENT-TYPE="NOTE">
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<B>
	6.
</B>
</TD>
<TD>
<B>
	Stock Compensation Plan
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
<FONT STYLE="FONT-SIZE: 10PT">
	The Company&#8217;s 2014 Stock Incentive
	Plan (the &#8220;Plan&#8221;) provides for stock awards that may be made in the form of incentive or non-statutory stock options,
	stock appreciation rights, restricted or unrestricted stock awards, restricted stock units, performance awards, or other stock-based
	awards. No awards may be granted after June 16, 2024. On June 18, 2015, the Company&#8217;s stockholders approved the First Amendment
	to the Plan which provided for an increase in the number of shares of common stock reserved for issuance under the Plan from 1,245,399
	to 2,100,000,
</FONT>
<FONT STYLE="FONT-SIZE: 10PT">
	and an annual increase on the first day of each calendar year, beginning with
	January 1, 2016 that is equal to the lesser of four percent of the shares of common stock outstanding on the last day of the immediately
	preceding fiscal year or a smaller number of shares as determined by the board of directors. At December 31, 2015, up to 1,678,585
	shares of common stock may be issued under the Plan, of which 983,325 shares are reserved for issuance upon the exercise of outstanding
	options and vesting of outstanding restricted stock units, and 695,260 shares are available for future grants.
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Restricted Stock Units (&#8220;RSUs&#8221;)
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	All of the Company&#8217;s outstanding RSU agreements provide for
	the settlement of the vested RSUs in shares of the Company&#8217;s common stock equal to the number of vested RSUs or an amount
	in cash equal to the product of the fair market value of the common stock on the respective payment date and the number of vested
	RSUs, or some combination of common shares and cash as determined by the plan administrator as of each settlement date.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	RSUs generally vest over a period of one to four years, subject
	to earlier cancellation or forfeiture prior to vesting upon cessation of service to the Company. The total fair value of RSUs that
	vested during the year ended December 31, 2015 was $734,000. A summary of the activity related to RSUs during year ended December
	31, 2015 is as follows:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_19"></A>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Number
	of Shares
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Weighted-Average
	Grant Date Fair Value per Share
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 68%; FONT-SIZE: 10PT">
	Unvested at December 31, 2014
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	655,200
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	9.20
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	Granted
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	20,000
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1.62
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	Vested
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(459,208
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1.1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 1.1PT; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	9.23
</TD>
<TD STYLE="PADDING-BOTTOM: 1.1PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT; PADDING-LEFT: 10PT">
	Unvested at December 31, 2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	215,992
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.25PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 2.25PT; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	8.43
</TD>
<TD STYLE="PADDING-BOTTOM: 2.25PT; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	During the year ended December 31, 2015, the Company issued 421,415
	shares in settlement of RSUs that vested in 2015 and 2014. As permitted under the Plan, the Company repurchased 186,920 shares
	with an aggregate value of $363,000 during the year ended December 31, 2015 to satisfy tax withholding obligations for employees
	in connection with the vesting of restricted stock units previously granted.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 87; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage88"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Stock Options
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Stock options generally vest over a four-year period and have a
	maximum term of ten years from the date of grant, subject to earlier cancellation prior to vesting upon cessation of service to
	the Company. A summary of the activity related to stock option awards during the year ended December 31, 2015 is as follows:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_20"></A>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Shares
	Subject to Options
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Weighted-Average
	Exercise Price per Share
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Weighted-Average
	Remaining Contractual Term
<BR>
	(in years)
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Aggregate
	Intrinsic Value
<BR>
	(in thousands)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 48%; FONT-SIZE: 10PT">
	Outstanding at December 31, 2014
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	152,000
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4.53
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	Granted
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	513,400
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1.60
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Forfeitures and cancellations
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(33,833
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2.14
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT; PADDING-LEFT: 10PT">
	Outstanding at December 31, 2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	631,567
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2.28
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	9.4
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	Options exercisable at December 31, 2015
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	78,009
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3.20
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	9.1
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Options vested and expected to vest as of December 31, 2015
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	631,567
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2.28
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	9.4
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_21"></A>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Stock-Based Compensation Expense
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The estimated fair value of each stock option award was determined
	on the date of grant using the BSM option valuation model with the following assumptions:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Years Ended December 31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Risk-free interest rate
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1.34%
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	1.94%
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1.73%
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	2.03%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Expected volatility
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	58.9%
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	-
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	67.8%
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	65.3%
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	-
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	66.9%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 62%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Weighted-average volatility
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	60.2%
</TD>
<TD STYLE="WIDTH: 6%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 5%; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	66.3%
</TD>
<TD STYLE="WIDTH: 6%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Dividend yield
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	0%
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	0%
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Expected term (in years)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	6.0
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	6.3
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	Weighted-average grant date fair value per share
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	$0.90
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
	$2.81
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The fair value of each stock option is estimated on the date of
	grant using the BSM option pricing model which requires the input of highly subjective assumptions. Because the option-pricing
	model is sensitive to change in the input assumptions, different determinations of the required inputs may result in different
	fair value estimates of the options. The risk-free interest rate is based on the rate currently available on U.S. Treasury issues
	with terms approximating the expected term of the option. Due to the Company&#8217;s limited historical stock data, the estimated
	future stock price volatility is based upon the average historical volatilities of a group of peer companies. The Company has not
	paid any dividends on common stock since the Corporate Conversion and does not anticipate paying dividends on common stock in the
	foreseeable future. The Company did not issue options prior to the IPO and, therefore, has no history of option exercises. As such,
	the &#8216;simplified&#8217; method has been used to estimate the expected term of options.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Stock-based compensation expense is recognized only for those awards
	that are ultimately expected to vest. Forfeitures are required to be estimated at the time of grant and revised, if necessary,
	in subsequent periods if actual forfeitures differ from those estimates.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Total non-cash stock-based compensation expense for all stock awards
	that was recognized in the consolidated statements of operations is as follows:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_22"></A>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Years Ended December 31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-STYLE: ITALIC">
	(in thousands)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 68%; FONT-SIZE: 10PT">
	Cost of revenue
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	57
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	257
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Selling and marketing
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	62
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	16
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Research and development
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	98
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	121
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	General and administrative
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	2,798
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,904
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT; PADDING-LEFT: 10PT">
	Total
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,015
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	4,298
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	At December 31, 2015, there was $1.5 million of unamortized compensation
	cost related to unvested RSUs which is expected to be recognized over a remaining weighted-average vesting period of 1.3 years.
	At December 31, 2015, there was $628,000 of unamortized compensation cost related to unvested stock option awards, which is expected
	to be recognized over a remaining weighted-average vesting period of 2.8 years.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 88; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage89"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<DIV DATA-TD-STATEMENT-TYPE="NOTE">
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<B>
	7.
</B>
</TD>
<TD>
<B>
	Commitments and Contingencies
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Operating Leases
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	During 2014, the Company entered into a new lease for office space
	for its corporate headquarters in California, which expires in October 2017. The lease provides for monthly rent of $14,000, which
	will increase at a rate of 3% annually, and includes three months of rent abatement during the first year with an option to renew
	the lease for one additional 36-month period.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The Company leases a laboratory and office facility under a non-cancellable
	operating lease agreement, which expires on March 31, 2016. Monthly rent expense is $6,400. Subsequent to December 31, 2015, in
	February 2016, the Company extended the lease for one year to March 2017, with monthly rent expense of $6,750.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Rent expense during the years ended December 31, 2015 and 2014 was
	$234,000 and $149,000, respectively. In addition, certain administrative functions were performed at an office location leased
	by the majority stockholder through September of 2014 at no charge to the Company. No amount has been charged for these functions
	as it is not deemed reasonable to estimate.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	At December 31, 2015, the future minimum annual obligations under
	non-cancellable operating lease commitments, excluding the abandoned lease liability described below, are $173,000 and $148,000
	during 2016 and 2017, respectively.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Lease Abandonment
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	In March 2014, the Company entered into a termination agreement
	with the landlord of one of its operating leases and agreed to a termination fee of $565,000, payable in monthly installments of
	$31,400, which were paid in full through August 2015. The present value of the remaining payments under the termination agreement
	at December 31, 2014 and reported in the consolidated balance sheet was $248,000. The termination agreement resulted in a change
	in estimate which is reported as an additional expense of $46,000 during the year ended December 31, 2014 and is included in general
	and administrative expenses in the consolidated statement of operations.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Licensing Agreement
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The Company has a licensing agreement with UAMS for the exclusive
	use of patents used in the GEP assay, MyPRS
<SUP>
	&#174;
</SUP>
	and its related technology through April 2020. The agreement is effective
	through the earlier of the expiration of the related patents or termination of the agreement pursuant to its terms. The Company
	may terminate the agreement for any reason upon 90 days written notice. UAMS may terminate the agreement with 90 days written notice
	upon a material breach of the agreement by the Company or if the Company challenges the validity of any licensed patent in a court
	of competent jurisdiction. Under the terms of the license agreement, the Company is required to pay $30,000 in annual minimum royalties
	on sales to customers other than UAMS unless sales, as defined in the agreement, exceed certain thresholds in which case the additional
	royalties would range from 2% &#8211; 4%. Total royalty expense during each of the years ended December 31, 2015 and 2014 was $30,000.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Services Agreement
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The Company has a services agreement with a third party to assist
	with billing and collections from customers through March 2017. The agreement contains automatic one-year renewals, unless a 90-day
	termination notice is given by either party. Under the terms of the agreement, fees to the third party are based on a percentage
	of cash collections. The Company has a minimum commitment of $10,000 per month. During the years ended December 31, 2015 and 2014,
	the Company paid $126,000 and $142,000, respectively, to this vendor. At December 31, 2015, the future minimum commitments under
	this agreement are $120,000 and $30,000 during the years ended December 31, 2016 and 2017, respectively.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Litigation
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The Company is, from time to time, involved in legal proceedings,
	regulatory actions, claims and litigation arising in the ordinary course of business. Currently, the Company is not a defendant
	in any lawsuit.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
<B>
<I>
	Litigation Settlement
</I>
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	In August 2013, the Company settled a lawsuit in which it was the
	plaintiff for a tortuous interference claim regarding a potential acquisition for a payment of at least $350,000, of which $250,000
	was received in January 2014 and the remaining $100,000 was received in January 2015. At December 31, 2014 the Company recorded
	a receivable for $100,000 in prepaid expenses and other current assets in the consolidated balance sheets, and recognized the related
	gain for $100,000 during the year ended December 31, 2014.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 89; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	F-
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage90"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.25IN">
<B>
</B>
</TD>
</TR>
</TABLE>
<DIV DATA-TD-STATEMENT-TYPE="NOTE">
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
<B>
	8.
</B>
</TD>
<TD>
<B>
	Income Taxes
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT-SIZE: 10PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The principal items accounting for the difference in income taxes
	computed at the federal statutory tax rate of 34% and the effective income tax rate for the Company&#8217;s operations during the
	year ended December 31, 2015 and the period subsequent to the Corporate Conversion on June 17, 2014 through December 31, 2014 are
	as follows:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_23"></A>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-STYLE: ITALIC">
	(in thousands)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	Year Ended
<BR>
	December 31,
<BR>
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	June 17, 2014 to
<BR>
	December 31,
<BR>
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 68%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Federal tax at statutory rate
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(3,851
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(2,682
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; TEXT-INDENT: -10PT; PADDING-LEFT: 10PT">
	Signal Genetics LLC loss, prior to Corporate Conversion, not taxed at corporate level
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	425
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	State taxes, net of federal benefit
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(277
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(141
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Change in valuation allowance
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,625
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,356
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Nondeductible compensation
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	526
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,046
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT">
	Credits and other
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(23
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(4
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT; PADDING-LEFT: 10PT">
	Total provision for income taxes
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Significant components of the Company&#8217;s deferred tax assets
	and liabilities are as follows:
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_24"></A>
<DIV DATA-TD-TAGGABLE-TABLE="">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	December 31,
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; FONT-STYLE: ITALIC; PADDING-BOTTOM: 1.1PT">
	(in thousands)
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1.1PT SOLID">
	2014
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Deferred Tax Assets:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 68%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Net operating loss carryforwards
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	3,913
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	853
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Stock-based compensation
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	810
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	463
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Accrued compensation
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	257
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	74
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Deferred rent
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	14
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 10PT">
	Credit carryforward
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	52
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	6
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT">
	Total deferred tax assets
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	5,046
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	1,396
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 20PT">
	Valuation allowance
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(4,696
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(1,196
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 30PT">
	Deferred tax assets, net of valuation allowance
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	350
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	200
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	Deferred tax liabilities:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1.1PT; PADDING-LEFT: 10PT">
	Depreciation and amortization
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(350
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1.1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	(200
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1.1PT SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.25PT; PADDING-LEFT: 20PT">
	Net deferred tax assets
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2.25PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&#8212;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.25PT DOUBLE; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	A valuation allowance is established when it is more likely than
	not the future realization of all or some of the deferred tax assets will not be achieved. Based on the available evidence at December
	31, 2015 and 2014, the Company was not able to conclude that it is more likely than not certain deferred tax assets will be realized,
	and, therefore, recorded valuation allowances of $4.7 million and $1.2 million, respectively, against deferred tax assets.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	As of December 31, 2015, the Company had operating loss carryforwards
	for federal and state tax purposes of $10.6 million each, which will begin to expire in 2035. In addition, the Company has $52,000
	in federal tax credits at December 31, 2015 that will begin to expire in 2035.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	Internal Revenue Code Sections 382 and 383 limit the availability
	of income tax net operating losses and tax credit carryforwards that arise prior to certain cumulative changes in a corporation's
	ownership resulting in change of control of the Company should such changes in ownership occur. Pursuant to Internal Revenue Code
	Sections 382 and 383, use of the Company's net operating loss and credit carryforwards may be limited if a cumulative change in
	ownership of more than 50% occurs within a three-year period.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	The Company&#8217;s 2015 and 2014 tax years remain open to examination
	by one or more major taxing jurisdictions to which the Company is subject.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
</DIV>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 0.25IN; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
	F-18
</P>
</EFX_NOTES_TO_FINANCIAL_STATEMENT>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 4PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
	&nbsp;
</P>
</EFX_FORM>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage91"></A>
<A NAME="EXH_1031_HTM"></A>
<EFX_EXHIBIT_10>
<A NAME="FIS_EXHIBIT_10"></A>
<P STYLE="MARGIN: 0; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Exhibit 10.31
</B>
</FONT>
</P>
<P STYLE="MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 12PT">
	UAMS
	BIOVENTURES
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 12PT">
<B>
	LEASE
	AGREEMENT
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.05PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	This
	agreement of Lease made and entered into by and between the Board of Trustees of the University of Arkansas acting for and on
	behalf of the University of Arkansas for Medical Sciences (hereinafter referred to as &ldquo;UNIVERSITY&rdquo;) and Signal Genetics,
	Inc., a corporation organized and existing under the laws of the State of Delaware ( hereinafter referred to as &ldquo;CLIENT&rdquo;).
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&#9;WITNESSETH:
	&#9;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.05PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	WHEREAS,
</B>
	the UNIVERSITY has lease authority over certain property in Little Rock, Arkansas known as UAMS Arkansas BioVentures Building
	(hereinafter referred to as the &ldquo;BioVentures Building&rdquo;); and
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.05PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	WHEREAS
</B>
	,
	the UNIVERSITY has a program called UAMS BIOVENTURES which supports the development and growth of entrepreneurial, science and
	technology-based firms, by providing limited space, technical assistance, access to UNIVERSITY laboratories and equipment, and
	certain administrative and maintenance services; and
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.05PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	WHEREAS
</B>
	,
	CLIENT is engaged in genetic testing services; and
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.05PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	WHEREAS,
</B>
	the CLIENT will acquire limited access to laboratory, library, meeting rooms
<I>
	,
</I>
	and research facilities and resources
	located at the UNIVERSITY; and
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.05PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	WHEREAS
</B>
	,
	the business and proposed operation of CLIENT would be enhanced by the facilities at the UNIVERSITY and the projects to be conducted
	by CLIENT offer the prospect of potential economic development for the State of Arkansas;
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.05PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	NOW,
	THEREFORE
</B>
	, for and in consideration of the covenants and agreements hereinafter set forth, the parties do hereby agree as
	follows:
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.05PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	1.
<U>
	PREMISES
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	UNIVERSITY hereby leases unto CLIENT the following described premises, identified as the Entergy Life Sciences Laboratory Rooms
	G09, G11, G13, G15, G17, G19, G21, G23, G25, G27, and G29 located on the ground floor and the Office Rooms 140, 142, and 144 and
	Labs 143 and 145 located on the first floor of the BioVentures Building. The premises shall be furnished with equipment (Appendix
	A) to be used by the CLIENT during the course of this lease. Use of the premises, equipment, and equipment maintenance shall be
	with the approval of and in compliance with the requirements set by the UNIVERSITY&rsquo;s Research Support Center, Quality Assurance
	Unit. The CLIENT also has use of Room G12 (data closet) located on the ground floor for storage of CLIENT&rsquo;s IT equipment.
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	2.
<U>
	TERM
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Term of this lease shall be for a period of twelve months beginning on April 1, 2016 and ending on March 31, 2017. Upon expiration
	of this term, this lease may be renewed for a successive renewal term of one year pending annual reassessment. During this term
	and any renewal term, CLIENT, upon ninety (90) days written notice, may terminate this LEASE. UNIVERSITY may terminate this Lease
	during this term and any renewal term pursuant to the provisions of Sections 11, 12, 13, and 19.
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
	&nbsp;
</DIV>
<A NAME="eolPage92"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	3.
<U>
	RENTAL
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	As
	rental for the said premises, CLIENT shall pay to UNIVERSITY an annual rental of eighty-one thousand dollars ($81,000.00) at a
	rate of six thousand seven hundred fifty dollars ($6,750.00) per calendar month. Rental payment is due on the first day of each
	month. There will be a late charge of 10% of the total amount due each month if rent is not paid by the fifth (5
<SUP>
	th
</SUP>
	)
	business day of the month.
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	4.
<U>
	UTILITIES
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	UNIVERSITY
	shall be responsible for the payment of all charges for water, electricity and gas consumed on the premises. In the event of a
	substantial increase in the cost of utilities with respect to the premises occasioned by the nature of CLIENT's use of the premises,
	CLIENT will reimburse UNIVERSITY for the cost of such utilities reasonably attributed to the premises over and above the cost
	based on current existing rates. A substantial increase in utilities would be an amount in excess of Two Dollars ($2.00) per square
	foot per year. UNIVERSITY is responsible for documentation and metering that the actual rate is above the Two Dollar ($2.00) figure.
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.05PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	5.
<U>
	TAXES
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	premises are part of a facility used for educational purposes by the UNIVERSITY of Arkansas for Medical Sciences and are exempt
	from ad valorem taxes and assessments. In the event ad valorem taxes are assessed against the UNIVERSITY by virtue of or arising
	out of CLIENT's use of the premises, CLIENT shall reimburse UNIVERSITY for any taxes thus paid by UNIVERSITY. UNIVERSITY will
	make reasonable efforts to contest any taxes which might be so assessed. CLIENT shall be responsible for all taxes attributable
	to the property of CLIENT on the premises and for all license, privilege and occupation taxes levied, assessed or charged against
	CLIENT on account of the operation of the business from these premises. If UNIVERSITY or CLIENT determines that a probability
	exists that ad valorem taxes will be assessed against the UNIVERSITY then CLIENT may terminate tenancy at any time provided termination
	will prevent the assessment of taxes.
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	6.
<U>
	HAZARDOUS MATERIAL USE AND DISPOSAL
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	CLIENT shall request from the UNIVERSITY, in writing, approval to use or store any form of hazardous material on the premises.
	The request shall be submitted no later than thirty (30) days prior to the hazardous material being placed on the premises and
	will be approved subject to review by the UNIVERSITY&rsquo;s Department of Occupational Health and Safety. The CLIENT shall abide
	by all federal, state, and local laws and regulations, including UNIVERSITY policies and procedures, in the handling, use and
	storage of hazardous materials. The CLIENT will pay for all costs related to the storage and disposal of CLIENT&rsquo;s hazardous
	materials. The disposal of CLIENT&rsquo;s hazardous wastes shall be handled in accordance with directions from the UNIVERSITY&rsquo;s
	Department of Occupational Health and Safety.
<I>
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 2; OPTIONS: NEWSECTION; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage93"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	7.
<U>
	REPAIRS
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	UNIVERSITY
	agrees that it will keep and maintain the exterior of the building of the premises, including the roof, walls and exterior plumbing
	in good condition and repair, and agrees that if the roof or any part of the exterior walls or exterior plumbing of said building
	shall become defective or damaged at any time during the term thereof, upon notice from the CLIENT, UNIVERSITY will cause repairs
	to be made and restore the defective
<B>
</B>
	portions to good position. UNIVERSITY will be responsible for the maintenance and
	normal operating conditions of all heating, electrical and air conditioning equipment and interior plumbing on the premises. CLIENT
	shall at his own cost and expense maintain and keep the interior of the premises in as good repair as when the premises were received,
	ordinary wear and tear and casualties beyond CLIENT's control alone excepted, and CLIENT shall return the premises and the equipment
	on the premises at the expiration or termination of this lease in good order and condition, excepting only ordinary wear and tear
	and casualties beyond CLIENT's control.
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	8.
<U>
	ALTERATIONS
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	CLIENT
	shall have the right and privilege to make, at CLIENT's expense, ordinary repairs and alterations to the interior of the premises;
	provided, however, no alterations or changes of a structural nature shall be made without prior written consent of UNIVERSITY.
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	9.
<U>
	JANITORIAL SERVICES
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Housekeeping
	and all other normal janitorial services shall be provided by UNIVERSITY. UNIVERSITY shall have the right during the course of
	the initial lease term and any renewal period to impose a nominal fee for janitorial services. CLIENT shall be given thirty (30)
	days written notice by the UNIVERSITY prior to imposition of the fee.
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	10.
<U>
	FIXTURES
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	All
	trade fixtures not integral to the building installed by CLIENT or acquired by CLIENT independently of this agreement shall remain
	CLIENT's property and may be removed by CLIENT at the expiration of this agreement, including any equipment purchased by CLIENT;
	provided, however, CLIENT shall restore the premises and repair any damage thereto caused by such removal. Fixtures not integral
	to the building installed by UNIVERSITY for which UNIVERSITY receives reimbursement from CLIENT shall remain the property of CLIENT.
	Fixtures integral to the building are not removable unless UNIVERSITY agrees.
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	11.
<U>
	UNTENANTABILITY
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Should
	the premises, or any part thereof, be rendered unfit for occupancy for the purposes for which they are hereby let, by reason of
	fire, windstorm, or other act of nature or unavoidable casualty, the rental hereinabove stipulated to be paid by the CLIENT, or
	such proportion thereof as is related to that portion of the improvements on the premises rendered untenantable by reason of such
	damage, shall be remitted and abated by UNIVERSITY while the same remains unfit for occupancy and until the premises involved
	shall have been repaired or returned to tenantable condition. Upon the occurrence of any such casualty
<B>
</B>
	which results in
	major physical damage to the premises and seriously impairs the operations of CLIENT then the tenancy may be terminated by CLIENT.
	If casualty damage is so extensive that UNIVERSITY determines it is not in its best interest to repair or rebuild the premises
	then the UNIVERSITY may terminate the tenancy. UNIVERSITY shall in no way be liable or responsible for any damage to any property
	of the CLIENT in or about the premises by reason of flood, water, fire, windstorm or other casualty or act of nature or by reason
	of theft or vandalism.
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 3; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage94"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	12.
<U>
	CONDUCT OF BUSINESS AND USES
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	premises are leased to CLIENT for the purpose of conducting projects related to business development and research, and CLIENT
	covenants and agrees with and unto UNIVERSITY that the premises will be used for such purposes and those related to them and no
	other except with the prior written consent of UNIVERSITY.
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	CLIENT's
	continued tenancy is contingent upon reasonable progress toward business goals and growth projections consistent with the intent
	of UAMS BIOVENTURES program. Upon reasonable notice and at reasonable times convenient to CLIENT, CLIENT shall make the premises
	available to UNIVERSITY faculty and students and others approved by CLIENT or UNIVERSITY to tour the facilities and observe activities
	conducted therein. Such access to the premises may be subject to limited restriction upon a showing by CLIENT of the need for
	confidentiality of certain proprietary information and visitors to the premises may be required to sign nondisclosure statements
	before access to premises is permitted. CLIENT agrees to permit UNIVERSITY officials or faculty designated by the Vice Chancellor
	for Research to review the operations and procedures of the business, not to exceed two
<I>
</I>
	reviews per year. Said review will
	include number of persons employed, progress towards goals, disclosure of inventions, patents, or other intellectual property,
	financial success, and employment opportunities. Such review will not include personal and confidential information regarding
	any owner, employee, contractor, or subcontractor of the CLIENT such as salary or other form of compensation, benefits provided,
	personnel file, and such related information. If reasonable progress is not made towards meeting goals, then UNIVERSITY may terminate
	tenancy upon ninety (90) days written notice. In making this decision, UNIVERSITY shall take into account the normal course of
	such activities conducted by similarly situated businesses developing similar products and services and shall take into account
	the efforts of CLIENT as described in any reports provided to UNIVERSITY by CLIENT. UNIVERSITY agrees that an extension of time
	may be given for up to an additional ninety (90) days if UNIVERSITY determines that immediate economic harm will occur to the
	CLIENT if this lease is terminated at the end of the initial ninety (90) day notice period.
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	13.&#9;
<U>
	NONDISCLOSURE
	OF INFORMATION
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	CLIENT
	may designate certain information as proprietary and not subject to review. In the event the proprietary information is so restrictive
	as to inhibit the UNIVERSITY's ability to assess the CLIENT&rsquo;s progress, UNIVERSITY may terminate this lease upon ninety
	(90) days written notice. UNIVERSITY agrees that information obtained by the review is to be used for internal purposes, or for
	reporting purposes to any sponsoring agencies, and will not be disclosed without written consent of the CLIENT except pursuant
	to court order or determination by the Attorney General of the State of Arkansas that the information is subject to the State
	Freedom of Information Act. UNIVERSITY shall not disclose any proprietary information or any part thereof to any other person,
	firm, or corporation, and shall, further, restrict circulation of the information within its own organization except to the extent
	necessary to fulfill the purposes of this lease. Upon request, however, CLIENT shall release UNIVERSITY from the confidentiality
	obligations of this section to the extent that any of the proprietary information (a) is or becomes part of the public domain,
	(b) was known to UNIVERSITY prior to the disclosure by CLIENT, (c) is subsequently rightfully received by UNIVERSITY from a third
	party, (d) is independently developed by the UNIVERSITY other than through knowledge or use of the CLIENT&rsquo;s proprietary
	information, or (e) disclosed pursuant to court order or determination by the Attorney General of the State of Arkansas that the
	information is subject to the State Freedom of Information Act.
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 4; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage95"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	14.
<U>
	PATENT RIGHTS
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	UNIVERSITY
	does not have and shall not claim any rights of any nature whatsoever to inventions, patents, or other intellectual property developed
	by CLIENT under this lease; provided that, UNIVERSITY may reserve rights or, as its sole option, negotiate in good faith with
	CLIENT for rights to such inventions, patents or other intellectual property if such developments are created, conceived, and/or
	reduced to practice through the significant or substantial assistance of UNIVERSITY funds, faculty or staff, or UNIVERSITY laboratories
	or equipment. If the UNIVERSITY does not furnish notice of intent to reserve rights to inventions, patents or other intellectual
	property developed by CLIENT under this lease or fails to initiate negotiations for such rights within ninety (90) days after
	disclosure to the UNIVERSITY, the rights to the inventions, patents or other intellectual property remain solely with the CLIENT.
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	15.&#9;
<U>
	FIRE
	AND INSURANCE
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	CLIENT
	covenants and agrees that CLIENT will not do or permit to be done anything in, upon or about the leased premises that increases
	the hazard of fire beyond that which exists by reason of the uses and occupancy of the premises for the purposes mentioned. CLIENT
	agrees to pay to UNIVERSITY, on demand, any increases in fire insurance premiums on the improvements and buildings which the UNIVERSITY
	may be required to pay by reason of any other use by the CLIENT of the premises in excess of a normal increase. CLIENT will not
	do or permit to be done anything within CLIENT&rsquo;s control which would make the premises, or the improvements thereon, uninsurable
	in whole or in part. CLIENT agrees that CLIENT will not commit waste nor permit waste to be committed or done upon the premises.
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	16.
<U>
	SIGNS
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	UNIVERSITY
	may install any sign or directions to be displayed on any part of the outside of the demised premises or on or about the premises.
	No sign, picture, advertisement or notice shall be posted or otherwise displayed on any part of exterior of the demised premises
	or on or about the premises, without express written consent of UNIVERSITY.
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	17.&#9;
<U>
	INDEMNITY
	AGAINST DAMAGE OR INJURY
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	CLIENT
	agrees to defend, indemnify and hold harmless the UNIVERSITY against any claim, expense, loss or liability as a result of any
	breach by CLIENT, CLIENT's agents, servants, employees, customers, visitors or licensees of any covenant or condition of this
	agreement, or as a result of CLIENT's use or occupancy of the premises, or as a result of the carelessness, negligence, or improper
	conduct of CLIENT, CLIENT's agents, servants, employees, customers, visitors or licensees. CLIENT agrees to keep and maintain
	at all times during the term hereof, in full force and effect, with a company or companies acceptable to the UNIVERSITY, insurance
	against third party liability thereon of not less than $500,000 per person, $1,000,000 per accident and $50,000 coverage for property
	damage, and UNIVERSITY shall be named insured in such policies. CLIENT shall name the UNIVERSITY as an additional insured in such
	policies and a Certificate of Insurance shall be provided to the UNIVERSITY as evidence of coverage. Each policy shall contain
	a provision that the policy will not be cancelled or allowed to expire until at least 30 days prior written notice has been given
	to the UNIVERSITY.
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 5; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage96"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	18.&#9;
<U>
	DEFAULT
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	CLIENT
	shall be in default under the provisions of this lease agreement upon the happening of the following events or conditions and,
	in the case of the events and conditions set forth in subparagraph (a) and (b), the failure to cure same within thirty (30) days
	after notification by UNIVERSITY to CLIENT of such default:
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(a)
	Failure to pay the rental provided herein at the time, in the amount and in the manner set forth or within ten (10) days after
	the date the same became due;
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(b)
	Failure to keep or perform any of the covenants on the part of the CLIENT herein to be kept or performed;
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(c)
	Should the CLIENT become insolvent, or become bankrupt, either voluntary or involuntary, or make any assignment for the benefit
	of creditors, or if a receiver be appointed for the benefit of CLIENT's creditors or if a receiver be appointed for CLIENT to
	take charge of and manage CLIENT's affairs.
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	19.&#9;
<U>
	REMEDIES
	IN THE EVENT OF DEFAULT
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	the event of a default by CLIENT during the term hereof, UNIVERSITY may, at UNIVERSITY's option, declare this lease thereupon
	terminated, and UNIVERSITY shall have the right to enter upon and take possession of the premises, within ten (10) days notice,
	and to evict and expel CLIENT and any or all of CLIENT's property, belongings and effects therefrom, without legal process and
	thereby being guilty of any manner of trespass either at law or in equity which remedy is in addition to any other remedies of
	UNIVERSITY either at law or in equity, including, without limitation, the collection of delinquent rents, possession of the premises,
	damages for breach of this agreement by CLIENT, or otherwise. No delay in or failure to exercise any of the options herein granted
	to UNIVERSITY by reason of default in or failure shall be a waiver of UNIVERSITY's right to exercise its remedies by reason of
	the same or similar default at any later occasion.
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	20.&#9;
<U>
	ASSIGNMENT
	AND SUBLETTING
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	CLIENT
	shall not assign this lease, nor sublet the premises or any part thereof, without the prior consent in writing of UNIVERSITY.
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	21.
<U>
	SURRENDER OF POSSESSION
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	At
	the end of the term of this agreement, including the term extended by the exercise of any option of CLIENT, or upon earlier termination
	by UNIVERSITY in accordance with the options herein reserved, CLIENT agrees to surrender possession of the premises without demand.
	Should CLIENT fail to do so, CLIENT shall be responsible in addition to the damages generally recoverable by UNIVERSITY by reason
	of any breach by CLIENT, for all damages UNIVERSITY may sustain, including claims made by any succeeding CLIENT against UNIVERSITY
	which are founded upon delay of failure in delivering possession of the premises to such succeeding CLIENT. CLIENT hereby waives
	any and all notice to which CLIENT may otherwise be entitled under the laws of the State of Arkansas as a prerequisite to a suit
	against CLIENT for the unlawful detention of the premises.
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 6; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage97"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	22.
<U>
	BINDING EFFECT
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	This
	agreement shall inure to benefit of and be binding upon the parties hereto, their respective successors and assigns, except as
	expressly limited otherwise herein.
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	23.
<U>
	TIME OF THE ESSENCE
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	time of making of the payments and of the keeping of the covenants and furnishings of notices herein are of the essence of this
	agreement, and the parties hereto so agree.
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	24
</B>
	.
<B>
<U>
	PAYMENTS, NOTICES AND OTHER COMMUNICATIONS
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Any
	payment, notice or other communication called for or permitted under the terms hereof shall be sufficiently made or given on the
	date of mailing if sent to such Party by certified first class mail, postage prepaid, addressed to it at its address below or
	as it shall designate by written notice given to the other Party:
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_25"></A>
<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD STYLE="WIDTH: 12%">
	CLIENT:
</TD>
<TD STYLE="WIDTH: 88%">
	Signal Genetics, Inc.
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
	5740 Fleet Street.
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
	Carlsbad, CA&nbsp;&nbsp;92008
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD>
	UNIVERSITY:
</TD>
<TD>
	Notices or other communications:
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
	UAMS BioVentures
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
	University of Arkansas for Medical Sciences
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
	4301 West Markham Street, #831
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
	Little Rock, Arkansas&nbsp;&nbsp;72205
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: MIDDLE">
<TD>
	UNIVERSITY:
</TD>
<TD>
	Payments:
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
	University of Arkansas for Medical Sciences
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
	Treasurer&rsquo;s Office
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
	4301 West Markham Street, #560
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
	Little Rock, AR&nbsp;&nbsp;72205
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
	(Checks to be made out to UAMS and referenced as BioVentures rent)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 7; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage98"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	25.
<U>
	MISCELLANEOUS
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	following miscellaneous provisions shall apply to this lease:
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(a)
	This agreement is entered into in the State of Arkansas and is governed by the laws of the State of Arkansas.
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(b)
	CLIENT shall have a separate entrance to the premises and will be given keys for access to such entrance. CLIENT will exercise
	reasonable care in controlling the persons to whom keys are given for access to the premises, and will return all keys at the
	expiration or termination of this agreement. For security purposes of the UNIVERSITY, access to its
<I>
</I>
	several facilities
	from the premises shall be limited according to the door and lock schedule maintained by the UNIVERSITY after normal business
	hours.
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 20PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(c)
	UNIVERSITY shall provide Internet access to CLIENT upon the condition that CLIENT agrees to abide by the UNIVERSITY&rsquo;s Confidentiality
	Policy and computer use-policies and that CLIENT employees sign a Confidentiality Agreement with the UNIVERSITY pursuant to such
	policies.
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	IN
	WITNESS WHEREOF
</B>
	, the Parties hereto have caused this Agreement to be executed by their duly authorized representatives, and
	is effective on the date of the last required signature.
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_26"></A>
<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; VERTICAL-ALIGN: TOP; TEXT-SHADOW: AUTO; TEXT-ALIGN: LEFT">
	Signal Genetics, Inc.
</TD>
<TD>
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; VERTICAL-ALIGN: MIDDLE; TEXT-SHADOW: AUTO; TEXT-ALIGN: LEFT">
	Board of Trustees of the University of Arkansas acting for and on behalf of the University of Arkansas for Medical Sciences
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-SHADOW: AUTO; TEXT-ALIGN: JUSTIFY; WIDTH: 30%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 4%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 30%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 23%">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-SHADOW: AUTO; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	By:
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-SHADOW: AUTO; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.1PT SOLID; PADDING-LEFT: 20PT">
	/s/
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
	Samuel D. Riccitelli
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	By:
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-SHADOW: AUTO; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.1PT SOLID; PADDING-LEFT: 20PT">
	/s/
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
	Teresa Shaddock
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-SHADOW: AUTO; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-SHADOW: AUTO; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	Date:
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-SHADOW: AUTO; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.1PT SOLID; PADDING-LEFT: 20PT">
	&nbsp;February 25, 2016
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	Date:
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-SHADOW: AUTO; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1.1PT SOLID; PADDING-LEFT: 20PT">
	&nbsp;February 26, 2016
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: JUSTIFY; MARGIN: 0PT 0">
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 8; VALUE: 2 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 4PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
</TD>
<TD STYLE="WIDTH: 33%; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage99"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT COURIER; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_27"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&#9;&#9;APPENDIX
	A
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
</FONT>
</P>
<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="TEXT-DECORATION: UNDERLINE; VERTICAL-ALIGN: MIDDLE; TEXT-SHADOW: AUTO; TEXT-ALIGN: LEFT; WIDTH: 10%">
	TAG #
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE; VERTICAL-ALIGN: MIDDLE; TEXT-SHADOW: AUTO; TEXT-ALIGN: LEFT; WIDTH: 23%">
	DESCRIPTION
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE; VERTICAL-ALIGN: MIDDLE; TEXT-SHADOW: AUTO; TEXT-ALIGN: LEFT; WIDTH: 20%">
	SERIAL #
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="TEXT-DECORATION: UNDERLINE; VERTICAL-ALIGN: MIDDLE; TEXT-SHADOW: AUTO; TEXT-ALIGN: LEFT; WIDTH: 44%">
	BLDG/ROOM
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-SHADOW: AUTO; TEXT-ALIGN: LEFT">
	275058
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-SHADOW: AUTO; TEXT-ALIGN: LEFT">
	Upright Refrigerator
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-SHADOW: AUTO; TEXT-ALIGN: LEFT">
	W16N202237WN
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-SHADOW: AUTO; TEXT-ALIGN: LEFT">
	BioV/G13
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-SHADOW: AUTO; TEXT-ALIGN: LEFT">
	275061
</TD>
<TD>
	&nbsp;
</TD>
<TD NOWRAP STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-SHADOW: AUTO; TEXT-ALIGN: LEFT">
	Centrifuge, Sorvall Legend
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-SHADOW: AUTO; TEXT-ALIGN: LEFT">
	40315709
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-SHADOW: AUTO; TEXT-ALIGN: LEFT">
	BioV/G19
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-SHADOW: AUTO; TEXT-ALIGN: LEFT">
	758308
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-SHADOW: AUTO; TEXT-ALIGN: LEFT">
	Fisher Microscrope
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-SHADOW: AUTO; TEXT-ALIGN: LEFT">
	F0303-0521-0013
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-SHADOW: AUTO; TEXT-ALIGN: LEFT">
	BioV/G19
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-SHADOW: AUTO; TEXT-ALIGN: LEFT">
	275062
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-SHADOW: AUTO; TEXT-ALIGN: LEFT">
	Hood ClassII
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-SHADOW: AUTO; TEXT-ALIGN: LEFT">
	78861
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-SHADOW: AUTO; TEXT-ALIGN: LEFT">
	BioV/G19
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-SHADOW: AUTO; TEXT-ALIGN: LEFT">
	275066
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-SHADOW: AUTO; TEXT-ALIGN: LEFT">
	Hood ClassII
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-SHADOW: AUTO; TEXT-ALIGN: LEFT">
	78863
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; TEXT-SHADOW: AUTO; TEXT-ALIGN: LEFT">
	BioV/G17
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN: 0PT 0">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
</FONT>
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	9
</P>
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 4PT SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="MARGIN-TOP: 0; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
</EFX_EXHIBIT_10>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage100"></A>
<A NAME="EXH_231_HTM"></A>
<EFX_EXHIBIT_23>
<A NAME="FIS_EXHIBIT_23"></A>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; MARGIN: 0PT 0">
<B>
	Exhibit 23.1
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_EXPERTS_CONSENT>
<A NAME="FIS_EXPERTS_CONSENT"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	Consent of Independent Registered Public Accounting Firm
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Signal Genetics, Inc.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Carlsbad, California
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	We hereby consent to the incorporation by reference in the Registration Statements
	on Form S-3 (No. 333-205618 and 333-205620) and Form S-8 (No. 333-197316) of Signal Genetics, Inc. of our report dated March 21, 2016,
	relating to the consolidated financial statements which appears in this Annual Report on Form 10-K for the year ended
	December 31, 2015.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	/s/ BDO USA, LLP
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	San Diego, California
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	March 21, 2016
</P>
</EFX_EXPERTS_CONSENT>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_23>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage101"></A>
<A NAME="EXH_311_HTM"></A>
<EFX_EXHIBIT_31>
<A NAME="FIS_EXHIBIT_31"></A>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; MARGIN: 0PT 0">
<B>
	Exhibit 31.1
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	CERTIFICATION
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	I, Samuel D. Riccitelli, certify that:
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
	I have reviewed this Annual Report on Form 10-K of Signal Genetics, Inc.;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based
	on my knowledge, this Annual Report does not contain any untrue statement of a material fact or omit to state a material fact necessary
	to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
	the period covered by this Annual Report;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based
	on my knowledge, the financial statements, and other financial information included in this Annual Report, fairly present in all
	material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented
	in this Annual Report;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The
	registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
	(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 19.8PT; MARGIN: 0PT 0">
	(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
	to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by
	others within those entities, particularly during the period in which this Annual Report is being prepared;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 19.8PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 19.8PT; MARGIN: 0PT 0">
	(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
	Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in the Annual Report our
	conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Annual
	Report based on such evaluation; and
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 19.8PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 19.8PT; MARGIN: 0PT 0">
	(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
	Disclosed in this Annual Report any change in the registrant&rsquo;s internal control over financial reporting that occurred during
	the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report)
	that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
	reporting.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 19.8PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The
	registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over
	financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or
	person performing the equivalent functions):
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 19.8PT; MARGIN: 0PT 0">
	(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
	are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
	and
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 19.8PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 19.8PT; MARGIN: 0PT 0">
	(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
	internal control over financial reporting.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; WIDTH: 50%">
	Date: March 21, 2016
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; BORDER-BOTTOM: BLACK 1PT SOLID; WIDTH: 30%">
	/s/
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
	Samuel
	D. Riccitelli
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 20%">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 8PT">
	Samuel D. Riccitelli
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 8PT">
	President and Chief Executive Officer
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 8PT">
	(Principal Executive Officer)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_31>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage102"></A>
<A NAME="EXH_312_HTM"></A>
<EFX_EXHIBIT_31>
<A NAME="FIS_EXHIBIT_31_2"></A>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; MARGIN: 0PT 0">
<B>
	Exhibit 31.2
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_2"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	CERTIFICATION
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	I, Tamara A. Seymour, certify that:
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; I have
	reviewed this Annual Report on Form 10-K of Signal Genetics, Inc.;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based
	on my knowledge, this Annual Report does not contain any untrue statement of a material fact or omit to state a material fact necessary
	to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
	the period covered by this Annual Report;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based
	on my knowledge, the financial statements, and other financial information included in this Annual Report, fairly present in all
	material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented
	in this Annual Report;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The
	registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
	(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 19.8PT; MARGIN: 0PT 0">
	(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Designed such
	disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
	ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
	within those entities, particularly during the period in which this Annual Report is being prepared;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 19.8PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 19.8PT; MARGIN: 0PT 0">
	(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Evaluated the
	effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in the Annual Report our conclusions about
	the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Annual Report based on
	such evaluation; and
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 19.8PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 19.8PT; MARGIN: 0PT 0">
	(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Disclosed
	in this Annual Report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
	most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
	or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting.
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 19.8PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The
	registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over
	financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or
	persons performing the equivalent functions):
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 19.8PT; MARGIN: 0PT 0">
	(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; All significant
	deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
	likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 19.8PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 19.8PT; MARGIN: 0PT 0">
	(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Any fraud, whether
	or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control
	over financial reporting.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
</P>
<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; WIDTH: 50%">
	Date: March 21, 2016
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; BORDER-BOTTOM: BLACK 1PT SOLID; WIDTH: 30%">
	/s/
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
	Tamara
	A. Seymour
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 20%">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 8PT">
	Tamara A. Seymour
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;Chief Financial Officer
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 8PT">
	(Principal Financial Officer)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_31>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage103"></A>
<A NAME="EXH_321_HTM"></A>
<EFX_EXHIBIT_32>
<A NAME="FIS_EXHIBIT_32"></A>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; MARGIN: 0PT 0">
<B>
	Exhibit 32.1
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_3"></A>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0">
<B>
	CERTIFICATION
</B>
</P>
<P STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Pursuant to the requirement set forth in Rule 13a-14(b) or Rule 15d-14(b) of the Securities
	Exchange Act of 1934, as amended, and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &sect; 1350),
	as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Samuel D. Riccitelli, the President and Chief Executive Officer
	of Signal Genetics, Inc. (the &ldquo;Registrant&rdquo;), and Tamara A. Seymour, the Chief Financial Officer of the Registrant,
	each hereby certifies that, to his/her knowledge:
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 22.5PT">
	1.
</TD>
<TD>
	The Registrant&rsquo;s Annual Report on Form 10-K for the period ended December 31, 2015, (the &ldquo;Form 10-K&rdquo;) to
	which this Certification is attached as Exhibit 32.1, fully complies with the requirements of Section 13(a) or Section 15(d) of
	the Securities Exchange Act of 1934, as amended; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; TEXT-INDENT: 1.5PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 18PT">
</TD>
<TD STYLE="WIDTH: 22.5PT">
	2.
</TD>
<TD>
	The information contained in the Form 10-K fairly presents, in all material respects, the financial condition of the Registrant
	at the end of the period covered by the Form 10-K and results of operations of the registrant for the period covered by the Form
	10-K.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	These certifications accompanying the Form 10-K to which they relate, are not deemed
	filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the registrant
	under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after
	the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	A signed original of this written statement required by Section 906 has been provided
	to the Registrant and will be retained and furnished to the Securities and Exchange Commission or its staff upon request.
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	Dated: March 21, 2016
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
</P>
<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; BORDER-BOTTOM: BLACK 1PT SOLID; WIDTH: 30%">
	/s/
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
	Samuel
	D. Riccitelli
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; WIDTH: 5%">
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE; BORDER-BOTTOM: BLACK 1PT SOLID; WIDTH: 30%">
	/s/
<FONT STYLE="FONT-VARIANT: SMALL-CAPS">
	Tamara
	A. Seymour
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; WIDTH: 35%">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="FONT-WEIGHT: BOLD; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 8PT">
	Samuel D. Riccitelli
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 8PT">
	Tamara A. Seymour
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 8PT">
	President and Chief Executive Officer
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;Chief Financial Officer
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="FONT-WEIGHT: BOLD; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 8PT">
	(Principal Executive Officer)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; VERTICAL-ALIGN: MIDDLE">
<FONT STYLE="FONT-SIZE: 8PT">
	(Principal Financial Officer)
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-RIGHT: 0; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_32>

<!-- FOOTER LOGO -->
</BODY>
</HTML>
